Allergan 10-K 18 Feb 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2019	Feb. 12, 2020	Jun. 30, 2019
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity File Number	001-36867
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1114402
Entity Address, Address Line One	Clonshaugh Business and Technology Park
Entity Address, Address Line Two	Coolock
Entity Address, City or Town	Dublin
Entity Address, Country	IE
Entity Address, Postal Zip Code	E400
City Area Code	862
Local Phone Number	261-7000
Entity Registrant Name	Allergan plc
Entity Central Index Key	0001578845
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		329,002,015
Entity Public Float			$ 54.8
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	Certain information required by Part III of this Annual Report on Form 10-K (“Annual Report”) is incorporated by reference from the Allergan plc proxy statement to be filed pursuant to Regulation 14A with respect to the Registrant’s 2020 Annual General Meeting of Shareholders or, alternatively included in amendment to this Form 10-K which will be filed within 120 days of the Regisrant’s fiscal year ended December 31, 2019.
Allergan plc Ordinary Shares [Member]
Document Information [Line Items]
Trading Symbol	AGN
Title of 12(b) Security	Allergan plc Ordinary Shares, $0.0001 par value
Security Exchange Name	NYSE
Floating Rate Notes Due 2020 [Member]
Document Information [Line Items]
Trading Symbol	AGN20A
Title of 12(b) Security	Floating rate notes due 2020
Security Exchange Name	NYSE
0.500% Notes Due 2021 [Member]
Document Information [Line Items]
Trading Symbol	AGN21
Title of 12(b) Security	0.500% notes due 2021
Security Exchange Name	NYSE
1.500% Notes Due 2023 [Member]
Document Information [Line Items]
Trading Symbol	AGN 23A
Title of 12(b) Security	1.500% notes due 2023
Security Exchange Name	NYSE
1.250% Notes Due 2024 [Member]
Document Information [Line Items]
Trading Symbol	AGN 24A
Title of 12(b) Security	1.250% notes due 2024
Security Exchange Name	NYSE
2.625% Notes Due 2028 [Member]
Document Information [Line Items]
Trading Symbol	AGN28
Title of 12(b) Security	2.625% notes due 2028
Security Exchange Name	NYSE
2.125% Notes Due 2029 [Member]
Document Information [Line Items]
Trading Symbol	AGN29
Title of 12(b) Security	2.125% notes due 2029
Security Exchange Name	NYSE
Warner Chilcott Limited [Member]
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity File Number	001-36887
Entity Incorporation, State or Country Code	D0
Entity Tax Identification Number	98-0496358
Entity Address, Address Line One	Victoria Place
Entity Address, Address Line Two	5th Floor
Entity Address, City or Town	Hamilton
Entity Address, Country	BM
Entity Address, Postal Zip Code	HM 10
City Area Code	441
Local Phone Number	295-2244
Entity Registrant Name	Warner Chilcott Limited
Entity Central Index Key	0001620602
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,503.3	$ 880.4
Marketable securities	3,411.6	1,026.9
Accounts receivable, net	3,192.3	2,868.1
Inventories	1,133.1	846.9
Current assets held for sale		34
Prepaid expenses and other current assets	886.4	819.1
Total current assets	11,126.7	6,475.4
Property, plant and equipment, net	1,926.5	1,787
Right of use asset - operating leases	490.4
Investments and other assets	408	1,970.6
Non current assets held for sale	31.7	882.2
Deferred tax assets	576.9	1,063.7
Product rights and other intangibles	37,890.6	43,695.4
Goodwill	42,248.3	45,913.3
Total assets	94,699.1	101,787.6
Current liabilities:
Accounts payable and accrued expenses	6,348.7	4,787.2
Income taxes payable	65.1	72.4
Current portion of long-term debt and capital leases	4,532.5	868.3
Current portion of lease liability - operating	124.4
Total current liabilities	11,070.7	5,727.9
Long-term debt and capital leases	18,116.5	22,929.4
Lease liability - operating	446.1
Other long-term liabilities	800.9	882
Other taxes payable	1,704.8	1,615.5
Deferred tax liabilities	4,363.7	5,501.8
Total liabilities	36,502.7	36,656.6
Commitments and contingencies (Refer to Note 26)
Equity:
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 328.6 million and 332.6 million shares issued and outstanding, respectively	0	0
Additional paid-in capital	55,974.9	56,510
Retained earnings	991.5	7,258.9
Accumulated other comprehensive income	1,207.2	1,345.2
Total shareholders’ equity	58,173.6	65,114.1
Retained earnings	(991.5)	(7,258.9)
Noncontrolling interest	22.8	16.9
Total equity	58,196.4	65,131
Total liabilities and equity	94,699.1	101,787.6
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	2,497.1	878.6
Marketable securities	3,411.6	1,026.9
Accounts receivable, net	3,192.3	2,868.1
Receivables from Parents	409.3	640.9
Inventories	1,133.1	846.9
Current assets held for sale		34
Prepaid expenses and other current assets	886.4	818.7
Total current assets	11,529.8	7,114.1
Property, plant and equipment, net	1,926.5	1,787
Right of use asset - operating leases	490.4
Investments and other assets	408	1,970.6
Non current assets held for sale	31.7	882.2
Deferred tax assets	576.9	1,063.7
Product rights and other intangibles	37,890.6	43,695.4
Goodwill	42,248.3	45,913.3
Total assets	95,102.2	102,426.3
Current liabilities:
Accounts payable and accrued expenses	6,347	4,787.4
Payables to Parents	2,715.5	2,829.2
Income taxes payable	65.1	72.4
Current portion of long-term debt and capital leases	4,532.5	868.3
Current portion of lease liability - operating	124.4
Total current liabilities	13,784.5	8,557.3
Long-term debt and capital leases	18,116.5	22,929.4
Lease liability - operating	446.1
Other long-term liabilities	801.4	882
Other taxes payable	1,698.6	1,615.5
Deferred tax liabilities	4,363.2	5,501.8
Total liabilities	39,210.3	39,486
Commitments and contingencies (Refer to Note 26)
Equity:
Member's capital	64,023.6	65,797.9
Retained earnings	9,361.7	4,219.7
Accumulated other comprehensive income	1,207.2	1,345.2
Retained earnings	(9,361.7)	(4,219.7)
Noncontrolling interest	22.8	16.9
Total equity	55,891.9	62,940.3
Total liabilities and equity	95,102.2	102,426.3
Total members’ equity	$ 55,869.1	$ 62,923.4

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Ordinary shares, par value	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	328,600,000	332,600,000
Ordinary shares, shares outstanding	328,600,000	332,600,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net revenues	$ 16,088.9	$ 15,787.4	$ 15,940.7
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	2,493.1	2,191.4	2,168
Research and development	1,812	2,266.2	2,100.1
Selling and marketing	3,461.7	3,250.6	3,514.8
General and administrative	2,481.8	1,271.2	1,501.9
Amortization	5,856.6	6,552.3	7,197.1
Goodwill impairments	3,552.8	2,841.1
In-process research and development impairments	436	804.6	1,452.3
Asset sales and impairments, net	440.2	2,857.6	3,927.7
Total operating expenses	20,534.2	22,035	21,861.9
Operating (loss)	(4,445.3)	(6,247.6)	(5,921.2)
Interest income	76.8	45.2	67.7
Interest (expense)	(783)	(911.2)	(1,095.6)
Other income / (expense), net	32.8	256.7	(3,437.3)
Total other income (expense), net	(673.4)	(609.3)	(4,465.2)
Income / (loss) before income taxes and noncontrolling interest	(5,118.7)	(6,856.9)	(10,386.4)
Provision / (Benefit) for income taxes	146.4	(1,770.7)	(6,670.4)
Net income / (loss) from continuing operations, net of tax	(5,265.1)	(5,086.2)	(3,716)
(Loss) / income from discontinued operations, net of tax			(402.9)
Net (loss) / income	(5,265.1)	(5,086.2)	(4,118.9)
(Income) attributable to noncontrolling interest	(5.9)	(10.2)	(6.6)
Net (loss) / income attributable to shareholders	(5,271)	(5,096.4)	(4,125.5)
Dividends on preferred shares		46.4	278.4
Net (loss) / income attributable to ordinary shareholders	$ (5,271)	$ (5,142.8)	$ (4,403.9)
(Loss) / income per share attributable to ordinary shareholders - basic:
Continuing operations	$ (16.02)	$ (15.26)	$ (11.99)
Discontinued operations			(1.20)
Net (loss) / income per share - basic	(16.02)	(15.26)	(13.19)
(Loss) / income per share attributable to ordinary shareholders - diluted:
Continuing operations	(16.02)	(15.26)	(11.99)
Discontinued operations			(1.20)
Net (loss) / income per share - diluted	$ (16.02)	$ (15.26)	$ (13.19)
Weighted average ordinary shares outstanding:
Basic	329	337	333.8
Diluted	329	337	333.8
Warner Chilcott Limited [Member]
Net revenues	$ 16,088.9	$ 15,787.4	$ 15,940.7
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	2,493.1	2,191.4	2,168
Research and development	1,812	2,266.2	2,100.1
Selling and marketing	3,461.7	3,250.6	3,514.8
General and administrative	2,330.8	1,177.5	1,402.3
Amortization	5,856.6	6,552.3	7,197.1
Goodwill impairments	3,552.8	2,841.1
In-process research and development impairments	436	804.6	1,452.3
Asset sales and impairments, net	440.2	2,857.6	3,927.7
Total operating expenses	20,383.2	21,941.3	21,762.3
Operating (loss)	(4,294.3)	(6,153.9)	(5,821.6)
Interest income	76.8	270.1	166.3
Interest (expense)	(783)	(911.2)	(1,095.6)
Other income / (expense), net	32.8	256.7	(3,437.3)
Total other income (expense), net	(673.4)	(384.4)	(4,366.6)
Income / (loss) before income taxes and noncontrolling interest	(4,967.7)	(6,538.3)	(10,188.2)
Provision / (Benefit) for income taxes	146.4	(1,776.4)	(6,670.4)
Net income / (loss) from continuing operations, net of tax	(5,114.1)	(4,761.9)	(3,517.8)
(Loss) / income from discontinued operations, net of tax			(402.9)
Net (loss) / income	(5,114.1)	(4,761.9)	(3,920.7)
(Income) attributable to noncontrolling interest	(5.9)	(10.2)	(6.6)
Net (loss) / income attributable to ordinary shareholders	(5,120)
Net (loss) / income attributable to members	$ (5,120)	$ (4,772.1)	$ (3,927.3)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) / Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net (loss) / income	$ (5,265.1)	$ (5,086.2)	$ (4,118.9)
Other comprehensive (loss) / income
Foreign currency translation (losses) / gains	(151.8)	(474.4)	1,248
Net impact of other-than-temporary loss on investment in Teva securities			1,599.4
Unrealized (losses) / gains, net of tax	13.8	(38.1)	111.7
Total other comprehensive (loss) / income, net of tax	(138)	(512.5)	2,959.1
Comprehensive (loss) / income	(5,403.1)	(5,598.7)	(1,159.8)
Comprehensive (income) attributable to noncontrolling interest	(5.9)	(10.2)	(6.6)
Comprehensive (loss) / income attributable to ordinary shareholders	(5,409)	(5,608.9)	(1,166.4)
Warner Chilcott Limited [Member]
Net (loss) / income	(5,114.1)	(4,761.9)	(3,920.7)
Other comprehensive (loss) / income
Foreign currency translation (losses) / gains	(151.8)	(474.4)	1,248
Net impact of other-than-temporary loss on investment in Teva securities			1,599.4
Unrealized (losses) / gains, net of tax	13.8	(38.1)	111.7
Total other comprehensive (loss) / income, net of tax	(138)	(512.5)	2,959.1
Comprehensive (loss) / income	(5,252.1)	(5,274.4)	(961.6)
Comprehensive (income) attributable to noncontrolling interest	(5.9)	(10.2)	(6.6)
Comprehensive (loss) / income attributable to members	$ (5,258)	$ (5,284.6)	$ (968.2)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Cash Flows From Operating Activities:
Net (loss) / income	$ (5,265.1)	$ (5,086.2)	$ (4,118.9)
Reconciliation to net cash provided by operating activities:
Depreciation	204.5	196.3	171.5
Amortization	5,856.6	6,552.3	7,197.1
Provision for inventory reserve	160.2	96.4	102.2
Share-based compensation	214.3	239.8	293.3
Deferred income tax benefit	(660.9)	(1,255.7)	(7,783.1)
Goodwill impairments	3,552.8	2,841.1
In-process research and development impairments	436	804.6	1,452.3
Loss on asset sales and impairments, net	440.2	2,857.6	3,927.7
Charge to settle Teva related matters			387.4
(Gain) loss on sale of Teva securities, net		(60.9)	62.9
Amortization of inventory step-up			131.7
Gain on sale of businesses		(182.6)
Non-cash extinguishment of debt	0.2	30	(15.7)
Cash (discount) / charge related to extinguishment of debt		(45.6)	205.6
Amortization of deferred financing costs	17.5	22.6	27.8
Amortization of right of use assets	130.9
Contingent consideration adjustments, including accretion	54.1	(106.5)	(133.2)
Other, net	(5.5)	29	(37)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(358.8)	(37)	(188.3)
Decrease / (increase) in inventories	(393.4)	(145.7)	(144.8)
Decrease / (increase) in prepaid expenses and other current assets	(78.1)	4.3	27.9
Increase / (decrease) in accounts payable and accrued expenses	1,434.4	151.6	95.9
Increase / (decrease) in income and other taxes payable	1,697.9	(1,191.6)	1,114.1
Increase / (decrease) in other assets and liabilities	(199.1)	(73.7)	29.1
Net cash provided by operating activities	7,238.7	5,640.1	6,079
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(375.2)	(253.5)	(349.9)
Additions to product rights and other intangibles	(58.3)		(614.3)
Additions to investments	(3,938)	(2,471.7)	(9,783.8)
Proceeds from sale of investments and other assets	1,569.6	6,259.3	15,153.3
Proceeds from sales of property, plant and equipment	23.7	30.4	7.1
Acquisitions of businesses, net of cash acquired	(80.6)		(5,290.4)
Net cash provided by / (used in) investing activities	(2,858.8)	3,098.5	(878)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility	11.9	2,657	3,550
Payments on debt, including capital lease obligations and credit facility	(1,044.9)	(8,804.5)	(6,413.6)
Debt issuance and other financing costs		(10.4)	(20.6)
Cash charge related to extinguishment of debt			(205.6)
Payments of contingent consideration and other financing	(9.3)	(30.9)	(511.6)
Proceeds from stock plans	91.2	102.4	183.4
Proceeds from forward sale of Teva securities		465.5
Repurchase of ordinary shares	(840.6)	(2,775.4)	(493)
Dividends paid	(974.4)	(1,049.8)	(1,218.2)
Net cash (used in) financing activities	(2,766.1)	(9,680.1)	(5,129.2)
Effect of currency exchange rate changes on cash and cash equivalents	9.1	4.7	21.4
Net (decrease) / increase in cash and cash equivalents	1,622.9	(936.8)	93.2
Cash and cash equivalents at beginning of period	880.4	1,817.2	1,724
Cash and cash equivalents at end of period	2,503.3	880.4	1,817.2
Cash paid / (received) during the year for:
Income taxes other, net of refunds	(876.5)	717.4	(5.1)
Interest	784.9	965.7	1,144.4
Schedule of Non-Cash Investing and Financing Activities:
Conversion of mandatory convertible preferred shares		4,929.7
Settlement of secured financing		(465.5)
Dividends accrued	1.1	1.4	24.6
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(5,114.1)	(4,761.9)	(3,920.7)
Reconciliation to net cash provided by operating activities:
Depreciation	204.5	196.3	171.5
Amortization	5,856.6	6,552.3	7,197.1
Provision for inventory reserve	160.2	96.4	102.2
Share-based compensation	214.3	239.8	293.3
Deferred income tax benefit	(660.9)	(1,255.7)	(7,783.1)
Goodwill impairments	3,552.8	2,841.1
In-process research and development impairments	436	804.6	1,452.3
Loss on asset sales and impairments, net	440.2	2,857.6	3,927.7
Net income impact of other-than-temporary loss on investment in Teva securities			3,273.5
Charge to settle Teva related matters			387.4
(Gain) loss on sale of Teva securities, net		(60.9)	62.9
Amortization of inventory step-up			131.7
Gain on sale of businesses		(182.6)
Non-cash extinguishment of debt	0.2	30	(15.7)
Cash (discount) / charge related to extinguishment of debt		(45.6)	205.6
Amortization of deferred financing costs	17.5	22.6	27.8
Amortization of right of use assets	130.9
Contingent consideration adjustments, including accretion	54.1	(106.5)	(133.2)
Other, net	(5.5)	29	(37)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(358.8)	(37)	(188.3)
Decrease / (increase) in inventories	(393.4)	(145.7)	(144.8)
Decrease / (increase) in prepaid expenses and other current assets	(78.5)	4.7	28.8
Increase / (decrease) in accounts payable and accrued expenses	1,436.3	151.4	121.7
Increase / (decrease) in income and other taxes payable	1,697.9	(1,191.6)	1,114.1
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents	305.5	46.3	45.5
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents	(305.5)	(46.3)	(45.5)
Net cash provided by operating activities	7,284.8	5,992	6,229.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(375.2)	(253.5)	(349.9)
Additions to product rights and other intangibles	(58.3)		(614.3)
Additions to investments	(3,938)	(2,471.7)	(9,783.8)
Proceeds from sale of investments and other assets	1,569.6	6,259.3	15,153.3
Payments to settle Teva related matters		(466)
Proceeds from sales of property, plant and equipment	23.7	30.4	7.1
Acquisitions of businesses, net of cash acquired	(80.6)		(5,290.4)
Net cash provided by / (used in) investing activities	(2,858.8)	3,098.5	(878)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility	11.9	2,657	3,550
Payments on debt, including capital lease obligations and credit facility	(1,044.9)	(8,804.5)	(6,413.6)
Debt issuance and other financing costs		(10.4)	(20.6)
Cash charge related to extinguishment of debt			(205.6)
Payments of contingent consideration and other financing	(9.3)	(30.9)	(511.6)
Payments to settle Teva related matters		(234)
Dividend to Parents	(1,774.3)	(4,075.6)	(1,668.2)
Net cash (used in) financing activities	(2,816.6)	(10,032.9)	(5,269.6)
Cash charge related to extinguishment of debt			(205.6)
Effect of currency exchange rate changes on cash and cash equivalents	9.1	4.7	21.4
Net (decrease) / increase in cash and cash equivalents	1,618.5	(937.7)	103.1
Cash and cash equivalents at beginning of period	878.6	1,816.3	1,713.2
Cash and cash equivalents at end of period	2,497.1	878.6	1,816.3
Cash paid / (received) during the year for:
Income taxes other, net of refunds	(876.5)	717.4	(5.1)
Interest	$ 784.9	965.7	1,144.4
Schedule of Non-Cash Investing and Financing Activities:
Settlement of secured financing		(465.5)
Non-cash dividends to Parents		9,344.3	4,203.9
Zeltiq [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance			8.5
Teva [Member]
Reconciliation to net cash provided by operating activities:
Net income impact of other-than-temporary loss on investment in Teva securities			3,273.5
Cash Flows From Investing Activities:
Payments to settle Teva related matters		(466)
Cash Flows From Financing Activities:
Payments to settle Teva related matters		(234)
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance		465.5
Teva [Member] | Warner Chilcott Limited [Member]
Reconciliation to net cash provided by operating activities:
Net income impact of other-than-temporary loss on investment in Teva securities			$ 3,273.5
Cash Flows From Investing Activities:
Payments to settle Teva related matters		(466)
Cash Flows From Financing Activities:
Proceeds from forward sale of Teva securities		465.5
Payments to settle Teva related matters		(234)
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance		$ 465.5

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Teva [Member]	Zeltiq [Member]	Allergan plc Ordinary Shares [Member]	Preferred Shares [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Zeltiq [Member]	Retained Earnings/(Accumulated Deficit) [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]Teva [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2016	$ 76,200.5				$ 4,929.7	$ 53,958.9		$ 18,342.5	$ (1,038.4)		$ 7.8
Balance, shares at Dec. 31, 2016				334,900,000	5,100,000
Comprehensive (loss):
Net (loss) attributable to shareholders	(4,125.5)							(4,125.5)
Other comprehensive income (loss), net of tax	1,359.7								1,359.7
Net impact of other-than-temporary loss on investment in Teva securities		$ 1,599.4								$ 1,599.4
Share-based compensation	293.3					293.3
Ordinary shares issued in connection with acquisition			$ 8.5				$ 8.5
Ordinary shares issued under employee stock plans	183.4					183.4
Ordinary shares issued under employee stock plans, shares				2,200,000
Impact of change in accounting for share- based compensation plans	20.8					62.4		(41.6)
Dividends declared	(1,218.2)							(1,218.2)
Repurchase of ordinary shares under the share repurchase programs	(450)					(450)
Repurchase of ordinary shares under the share repurchase programs, shares				(6,800,000)
Repurchase of ordinary shares	(43)					(43)
Repurchase of ordinary shares, shares				(100,000)
Movement in noncontrolling interest	8.2										8.2
Balance at Dec. 31, 2017	73,837.1				$ 4,929.7	54,013.5		12,957.2	1,920.7		16
Balance, shares at Dec. 31, 2017				330,200,000	5,100,000
Comprehensive (loss):
Net (loss) attributable to shareholders	(5,096.4)							(5,096.4)
Other comprehensive income (loss), net of tax	(512.5)								(512.5)
Share-based compensation	239.8					239.8
Ordinary shares issued under employee stock plans	102.4					102.4
Ordinary shares issued under employee stock plans, shares				1,600,000
Dividends declared	(1,026.6)							(1,026.6)
Issuance of Mandatory Convertible Preferred Shares					$ (4,929.7)	4,929.7
Issuance of Mandatory Convertible Preferred Shares, shares				17,800,000	(5,100,000)
Implementation of new accounting pronouncements at Dec. 31, 2017	361.7							424.7	(63)
Comprehensive (loss):
Repurchase of ordinary shares under the share repurchase programs	(2,740.4)					(2,740.4)
Repurchase of ordinary shares under the share repurchase programs, shares				(16,800,000)
Repurchase of ordinary shares	(35)					(35)
Repurchase of ordinary shares, shares				(200,000)
Movement in noncontrolling interest	0.9										0.9
Balance at Dec. 31, 2018	65,131					56,510		7,258.9	1,345.2		16.9
Balance, shares at Dec. 31, 2018				332,600,000
Adjusted Balance at Dec. 31, 2017									1,857.7
Comprehensive (loss):
Net (loss) attributable to shareholders	(5,271)							(5,271)
Other comprehensive income (loss), net of tax	(138)								(138)
Share-based compensation	214.3					214.3
Ordinary shares issued under employee stock plans	91.2					91.2
Ordinary shares issued under employee stock plans, shares				1,600,000
Dividends declared	(974.4)							(974.4)
Implementation of new accounting pronouncements at Dec. 31, 2018	(22)							(22)
Comprehensive (loss):
Repurchase of ordinary shares under the share repurchase programs	(800)					(800)
Repurchase of ordinary shares under the share repurchase programs, shares				(5,300,000)
Repurchase of ordinary shares	(40.6)					(40.6)
Repurchase of ordinary shares, shares				(300,000)
Movement in noncontrolling interest	5.9										5.9
Balance at Dec. 31, 2019	58,196.4					55,974.9		991.5	1,207.2		22.8
Balance, shares at Dec. 31, 2019				328,600,000
Adjusted Balance at Dec. 31, 2018	$ 65,109			$ 332.6		$ 56,510		$ 7,236.9	$ 1,345.2		$ 16.9

Consolidated Statements of Shar

Consolidated Statements of Shareholders' and Members' Equity - USD ($) $ in Millions	Total	Teva [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]Teva [Member]	Noncontrolling Interest [Member]	Warner Chilcott Limited [Member]	Warner Chilcott Limited [Member]Teva [Member]	Warner Chilcott Limited [Member]Member's Capital [Member]	Warner Chilcott Limited [Member]Retained Earnings [Member]	Warner Chilcott Limited [Member]Accumulated Other Comprehensive Income / (Loss) [Member]	Warner Chilcott Limited [Member]Accumulated Other Comprehensive Income / (Loss) [Member]Teva [Member]	Warner Chilcott Limited [Member]Noncontrolling Interest [Member]
Balance at Dec. 31, 2016	$ 76,200.5		$ 18,342.5	$ (1,038.4)		$ 7.8	$ 88,093.5		$ 72,935.1	$ 16,189	$ (1,038.4)		$ 7.8
Balance, shares at Dec. 31, 2016									100
Comprehensive (loss):
Net (loss) attributable to members							(3,927.3)			(3,927.3)
Other comprehensive income (loss), net of tax	1,359.7			1,359.7			1,359.7				1,359.7
Net impact of other-than-temporary loss on investment in Teva securities		$ 1,599.4			$ 1,599.4			$ 1,599.4				$ 1,599.4
Impact of change in accounting for share- based compensation plans							20.8			20.8
Dividend to Parent							(5,872.1)			(5,872.1)
Movement in noncontrolling interest	8.2					8.2	8.2						8.2
Balance at Dec. 31, 2017	73,837.1		12,957.2	1,920.7		16	81,282.2		$ 72,935.1	6,410.4	1,920.7		16
Balance, shares at Dec. 31, 2017									100
Implementation of new accounting pronouncements at Dec. 31, 2017	361.7		424.7	(63)			361.7			424.7	(63)
Adjusted Balance at Dec. 31, 2017				1,857.7
Comprehensive (loss):
Net (loss) attributable to members							(4,772.1)			(4,772.1)
Other comprehensive income (loss), net of tax	(512.5)			(512.5)			(512.5)				(512.5)
Dividend to Parent							(13,419.9)		$ (7,137.2)	(6,282.7)
Movement in noncontrolling interest	0.9					0.9	0.9						0.9
Balance at Dec. 31, 2018	65,131		7,258.9	1,345.2		16.9	62,940.3		$ 65,797.9	(4,219.7)	1,345.2		16.9
Balance, shares at Dec. 31, 2018									100
Implementation of new accounting pronouncements at Dec. 31, 2018	(22)		(22)				(22)			(22)
Adjusted Balance at Dec. 31, 2018	65,109		7,236.9	1,345.2		16.9	62,918.3		$ 65,797.9	(4,241.7)	1,345.2		16.9
Comprehensive (loss):
Net (loss) attributable to members							(5,120)			(5,120)
Other comprehensive income (loss), net of tax	(138)			(138)			(138)				(138)
Dividend to Parent							(1,774.3)		(1,774.3)
Movement in noncontrolling interest	5.9					5.9	5.9						5.9
Balance at Dec. 31, 2019	$ 58,196.4		$ 991.5	$ 1,207.2		$ 22.8	$ 55,891.9		$ 64,023.6	$ (9,361.7)	$ 1,207.2		$ 22.8
Balance, shares at Dec. 31, 2019									100

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Description of Business	NOTE 1 — Description of Business Allergan plc is a global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. The Company has operations in more than 100 countries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities. On June 25, 2019, the Company announced that it entered into a transaction agreement (the “AbbVie Agreement”) under which AbbVie Inc. (“AbbVie”), a global, research-driven biopharmaceutical company, would acquire Allergan plc in a stock and cash transaction (the “AbbVie Transaction”), valued at $188.24 per Allergan share, or approximately $63.0 billion, based on AbbVie’s then-current stock price at the time the AbbVie Transaction was announced. At the closing of the proposed AbbVie Transaction, Company shareholders will receive 0.8660 shares of AbbVie common stock and $120.30 in cash for each of their existing shares. On October 14, 2019, the Company’s shareholders voted to approve the AbbVie Transaction. The AbbVie Transaction is subject to customary regulatory approvals and other customary closing conditions. On October 25, 2019, in connection with the AbbVie Transaction, AbbVie commenced offers to exchange all Allergan Senior Notes issued by Allergan and maturing from September 15, 2020 through March 15, 2045 for up to approximately $19.6 billion aggregate principal amount of new notes to be issued by AbbVie and cash. In conjunction with the exchange offer, AbbVie solicited and obtained consents from eligible holders of the Allergan Senior Notes to amend each of the indentures governing the Allergan Senior Notes to eliminate substantially all of the restrictive covenants in such indentures and eliminate any guarantees of the related Allergan Senior Notes. Consummation of the exchange offer is conditioned upon, among other things, the closing of the AbbVie Transaction. The exchange offers are expected to close, and such amendments are expected to become operative, on or about the closing date of the AbbVie Transaction. On January 27, 2020, in connection with the AbbVie Transaction, Allergan announced that it entered into definitive agreements to divest (a) brazikumab, an IL-23 inhibitor currently being evaluated in a phase IIb/III study as a potential treatment for Crohn’s Disease and in a phase II study for ulcerative colitis, and (b) Zenpep ® ® ® ® ® ®

Formation of the Company

Formation of the Company	12 Months Ended
	Dec. 31, 2019
Regulated Operations [Abstract]
Formation of the Company	NOTE 2 — Formation of the Company Allergan plc was incorporated in Ireland on May 16, 2013 as a private limited company and re-registered effective September 20, 2013 as a public limited company. It was established for the purpose of facilitating the business combination between Allergan Finance, LLC (formerly known as Actavis, Inc.) and Warner Chilcott plc (“Warner Chilcott”). Following the consummation of the acquisition of Warner Chilcott on October 1, 2013 (the “Warner Chilcott Acquisition”), Allergan Finance, LLC and Warner Chilcott became wholly-owned subsidiaries of Allergan plc. Each of Allergan Finance, LLC’s common shares was converted into one Company ordinary share. Effective October 1, 2013, through a series of related-party transactions, Allergan plc contributed its indirect subsidiaries, including Allergan Finance, LLC, to its subsidiary Warner Chilcott Limited. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, the consolidated financial statements and disclosures are for two separate registrants, Allergan plc and Warner Chilcott Limited. The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the de minimis activity between Allergan plc and Warner Chilcott Limited, references throughout this document relate to both Allergan plc and Warner Chilcott Limited. Refer to “Note 3 —Reconciliation of Warner Chilcott Limited results to Allergan plc results” in the accompanying “Notes to the Consolidated Financial Statements” in this document for a summary of the details on the differences between Allergan plc and Warner Chilcott Limited. Pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Allergan plc “AGN” ordinary shares are deemed to be registered under Section 12(b) of the Exchange Act, are subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder. References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Allergan plc. References to “Warner Chilcott Limited” refer to Warner Chilcott Limited, the Company’s indirect wholly-owned subsidiary, and, unless the context otherwise requires, its subsidiaries. References throughout to “Ordinary Shares” refer to Allergan plc’s ordinary shares, par value $0.0001 per share.

Reconciliation of Warner Chilco

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	12 Months Ended
	Dec. 31, 2019
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	NOTE 3 — Reconciliation of Warner Chilcott Limited results to Allergan plc results Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc, the ultimate parent of the group (together with other direct or indirect parents of Warner Chilcott Limited, the “Parents”). The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the de minimis activity between Warner Chilcott Limited and the Parents (including Allergan plc), content throughout this filing relates to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited disclosures relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions): December 31, 2019 December 31, 2018 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 2,503.3 $ 2,497.1 $ 6.2 $ 880.4 $ 878.6 $ 1.8 Prepaid expenses and other current assets 886.4 886.4 - 819.1 818.7 0.4 Accounts payable and accrued liabilities 6,348.7 6,347.0 1.7 4,787.2 4,787.4 (0.2 ) Other taxes payables 1,704.8 1,698.6 6.2 1,615.5 1,615.5 - Deferred tax liabilities 4,363.7 4,363.2 0.5 5,501.8 5,501.8 - Total Equity 58,196.4 55,891.9 2,304.5 65,131.0 62,940.3 2,190.7 Year Ended December 31, 2019 Year Ended December 31, 2018 Year Ended December 31, 2017 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 2,481.8 $ 2,330.8 $ 151.0 $ 1,271.2 $ 1,177.5 $ 93.7 $ 1,501.9 $ 1,402.3 $ 99.6 Operating (loss) (4,445.3 ) (4,294.3 ) (151.0 ) (6,247.6 ) (6,153.9 ) (93.7 ) (5,921.2 ) (5,821.6 ) (99.6 ) Interest Income 76.8 76.8 - 45.2 270.1 (224.9 ) 67.7 166.3 (98.6 ) Other income / (expense), net 32.8 32.8 - 256.7 256.7 - (3,437.3 ) (3,437.3 ) - (Loss) before income taxes and noncontrolling interest (5,118.7 ) (4,967.7 ) (151.0 ) (6,856.9 ) (6,538.3 ) (318.6 ) (10,386.4 ) (10,188.2 ) (198.2 ) Net (loss) from continuing operations, net of tax (5,265.1 ) (5,114.1 ) (151.0 ) (5,086.2 ) (4,761.9 ) (324.3 ) (3,716.0 ) (3,517.8 ) (198.2 ) Net (loss) / income (5,265.1 ) (5,114.1 ) (151.0 ) (5,086.2 ) (4,761.9 ) (324.3 ) (4,118.9 ) (3,920.7 ) (198.2 ) Dividends on preferred shares - - - 46.4 - 46.4 278.4 - 278.4 Net (loss) / income attributable to ordinary shareholders/members (5,271.0 ) (5,120.0 ) (151.0 ) (5,142.8 ) (4,772.1 ) (370.7 ) (4,403.9 ) (3,927.3 ) (476.6 ) The differences between general and administrative expenses in the years ending December 31, 2019, 2018 and 2017 were due to corporate related expenses incurred at Allergan plc as well as transaction costs. The differences in total equity were due to historical differences in the results of operations of the companies and differences in equity awards.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 4 — Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented. The Company’s consolidated financial statements include the financial results of all acquired companies subsequent to the acquisition date. Implementation of New Guidance In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard established a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. On January 1, 2019, the Company adopted the new standard using the modified retrospective transition approach applied to all leases existing at the effective date of initial application of January 1, 2019. Prior period amounts are not adjusted and continue to be reported in accordance with historical accounting practices and the disclosures under the new standard are not required for dates and periods prior to January 1, 2019. When evaluating whether a contract contains a lease under the new standard, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company does not have the right to use an identified asset if the supplier has the substantive right to substitute the asset throughout the period without the Company’s approval. The new standard provided a number of optional practical expedients in transition, the Company elected the ‘package of practical expedients’ which permits us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter was not applicable to the Company. This standard has a significant impact on our consolidated balance sheet but did not have a significant impact on our consolidated statements of operations. The most significant effects relate to the recognition of ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases. Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as follows ($ in millions): ROU Asset Lease Liability Real estate $ 304.2 $ 370.6 Fleet 100.4 100.4 Other 57.5 77.6 Total operating leases $ 462.1 $ 548.6 The cumulative effective adjustment as of the effective date of $22.0 million was recorded on January 1, 2019 to opening retained earnings. The Company has an immaterial amount of finance leases. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the lease recognition exemption for all leases with lease terms of 12 months or less. For leases that qualify under this exception, the Company will not recognize ROU assets or lease liabilities and did not recognize ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also elected the practical expedient to not separate lease and non-lease components for leases of real estate, fleet, IT and office equipment. Refer to “NOTE 14 – Leases” for further information related to the Company’s leases. In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update allows for the optional reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. The amount of the reclassification is calculated as the difference between the historical and newly enacted tax rates on deferred taxes originally recorded through accumulated other comprehensive income. The Company adopted the standard as of January 1, 2019; however, due to the immaterial amount of the stranded tax effects, the Company elected not to reclassify the income tax effects from accumulated other comprehensive income to retained earnings. Tax effects unrelated to the TCJA are released from accumulated other comprehensive income using either the specific identification approach or the portfolio approach based on the nature of the underlying item. Use of Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to the determination of SRAs (defined below) included within either accounts receivable or accrued liabilities, the valuation of inventory balances, the determination of useful lives for intangible assets, pension and other post-retirement benefit plan assumptions, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment and recognition and measurement of assets acquired and liabilities assumed in business combinations at fair value. The estimation process required to prepare the Company’s consolidated financial statements requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. The Company’s actual results could differ materially from those estimates. Foreign Currency Translation For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive (loss) / income. The translational effects of revaluing non-functional currency assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. The Company realizes foreign currency gains / (losses) in the normal course of business based on movement in the applicable exchange rates. These transactional gains / (losses) are included as a component of general and administrative expenses. Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in banks, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity from the date acquired of three months or less to be cash equivalents. Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, investments, trade accounts payable, and long-term debt, including the current portion. The carrying amounts of cash and cash equivalents, marketable securities, accounts and other receivables and trade accounts payable are representative of their respective fair values due to their relatively short maturities. The fair values of investments in companies that are publicly traded are based on quoted market prices. The Company estimates the fair value of its fixed rate long-term obligations based on quoted market rates. Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventory includes brand and aesthetic products which represent Food and Drug Administration (“FDA”) approved or likely to be approved indications. Inventory valuation reserves are established based on a number of factors/situations including, but not limited to, raw materials, work in process or finished goods not meeting product specifications, product obsolescence, or application of the lower of cost (first-in, first-out method) or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. Assumptions utilized in our quantification of inventory reserves include, but are not limited to, estimates of future product demand, consideration of current and future market conditions, product net selling price, anticipated product launch dates, competition and potential product obsolescence and other events relating to special circumstances surrounding certain products. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Major renewals and improvements are capitalized if they add functionality or extend the life of the asset, while routine maintenance and repairs are expensed as incurred. The Company capitalizes interest on qualified construction projects. At the time property, plant and equipment are retired from service, the cost and accumulated depreciation are removed from the respective accounts. Depreciation expense is computed principally on the straight-line method, over the estimated useful lives of the related assets. The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years The Company assesses property, plant and equipment for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Investments The Company’s equity investments are accounted for under the equity method of accounting when the Company can exert significant influence and the Company’s ownership interest does not exceed 50%. The Company records equity method investments at cost and adjusts for the appropriate share of investee net earnings or losses. Investments in which the Company owns less than a 20% interest and cannot exert significant influence are recorded at fair value and the Company recognizes any changes in fair value in net income. For equity investments without readily determinable fair values, the Company may make a separate election for each eligible investment to use a measurement alternative until the investment’s fair value becomes readily determinable. Under the alternative method, the equity investments are accounted for at cost, less any impairment, plus or minus changes resulting from observable price changes in an orderly transaction for an identical or similar investment of the same issuer. Marketable Securities The Company’s marketable securities consist of U.S. treasury and agency securities and debt and equity securities of publicly-held companies. The Company’s marketable securities are recorded at fair value, based upon quoted market prices with an offset to interest income. Product Rights and Other Definite Lived Intangible Assets Our product rights and other definite lived intangible assets are stated at cost, less accumulated amortization, and are amortized using the economic benefit model or the straight-line method, if results are materially aligned, over their estimated useful lives. We determine amortization periods for product rights and other definite lived intangible assets based on our assessment of various factors impacting estimated cash flows. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in an impairment, a reduction in the intangibles’ useful life or an acceleration of related amortization expense, which could cause our net results to decline. Product rights and other definite lived intangible assets are tested periodically for impairment when events or changes in circumstances indicate that an asset’s carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted pre-tax future cash flows over its useful life, including any salvage value. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in net (loss) / income in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Our projections of discounted cash flows use a discount rate determined by our management to be commensurate with the risk inherent in our business model. Our estimates of future cash flows attributable to our other definite lived intangible assets require significant judgment based on our historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect the calculation of the undiscounted cash flows of the other definite lived intangible assets which could trigger impairment. Goodwill and Intangible Assets with Indefinite Lives The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or an indefinite lived intangible asset below its carrying amount such as those first and second quarter 2019 triggering events relating to the Company’s General Medicine Reporting Unit as discussed in “NOTE 17 — Goodwill, Product Rights and Other Intangible Assets”. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including Reporting Unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a Reporting Unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for some or all of its Reporting Units and perform a quantitative test as of the measurement date of the test . Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Fair value is estimated by management using a discounted cash flow model. Management’s cash flow projections include significant judgments and assumptions related to the discount rate, revenue forecasts, operating margins, impact of research and development pipeline events, and the long-term revenue growth rate. Impairment, if any, would be recorded in operating income / (loss) and this could result in a material impact to net income / (loss) and income / (loss) per share. Prior to Allergan’s 2018 annual impairment test, the Company adopted the new guidance under Accounting Standard Update No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to research and development (“R&D”) projects acquired in a business combination that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that has not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired if there is no future alternative use or ability to sell the asset. Impairment testing requires management to develop significant estimates and assumptions involving the determination of the fair value of the IPR&D asset, including estimated revenues, the probability of success of the project, determination of the appropriate discount rate, assessment of the asset’s life, potential regulatory risks, and net revenue growth curve assumptions. The major risks and uncertainties associated with the timely and successful completion of IPR&D projects include legal risk, market risk and regulatory risk. Changes in our assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of a product, we will make a separate determination of the useful life of the intangible asset, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Contingent Consideration We determine the acquisition date fair value of contingent consideration obligations for business acquisitions based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts defined in ASC Topic 820 “Fair Value Measurement,” (“ASC 820”). The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of future revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge or reduction to operating results. Refer to “NOTE 25 — Fair Value Measurement” for additional details regarding the fair value of contingent consideration. Revenue Recognition General Topic 606 provides that revenues are recognized when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods as specified in the underlying terms with the customer. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, commercial and government rebates, customer loyalty programs, fee-for-service arrangements with certain distributors, returns, and other allowances which we refer to in the aggregate as sales returns and allowances (“SRA”). The Company’s performance obligations are primarily achieved when control of the products is transferred to the customer. Transfer of control is based on contractual performance obligations, but typically occurs upon receipt of the goods by the customer as that is when the customer has obtained control of significantly all of the economic benefits. Prior to the achievement of performance obligations, shipping and handling costs associated with outbound freight for a product to be transferred to a customer are accounted for as a fulfillment cost and are included in selling and marketing expenses. When the Company sells a business and future royalties are considered as part of the consideration, the Company recognizes the royalties as a component of “other income / (expense), net”. Other revenues earned are mainly comprised of royalty income from licensing of intellectual property. Royalty income is recognized when the licensee’s subsequent sale occurs. Refer to “NOTE 22 – Segments” for our revenues disaggregated by product and segment and our revenues disaggregated by geography for our international segment. We believe this level of disaggregation best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Significant Payment Terms A contract with a customer states the final terms of the sale, including the description, quantity, and price of each product purchased. The Company’s payment terms vary by the type and location of the customer and the products offered. A customer agrees to a stated rate and price in the contract and given that most of the products sold contain variable consideration, the amount of revenue recognized incorporates adjustments for SRAs as appropriate. Determining the Transaction Price The Company offers discounts and rebates to certain customers who participate in various programs that are referred to as SRA allowances as described further below in the section “Provisions for SRAs”. Such discounting and rebating activity is included as part of the Company’s estimate of the transaction price and is accounted for as a reduction to gross sales. At time of sale, the Company records the related SRA adjustments. The Company performs validation activities each period to assess the adequacy of the liability or contra receivable estimates recorded to reflect actual activity and will adjust the reserve balances accordingly. Provisions for SRAs As is customary in the pharmaceutical industry, certain customers may receive cash-based incentives or credits, which are variable consideration accounted for as SRAs. The Company estimates SRA amounts based on the expected amount to be provided to customers, which reduces the revenues recognized. The Company believes that there will not be significant changes to our estimates of variable consideration. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. These provisions are estimated based on historical payment experience, the historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provisions has been applied on a consistent basis and no material revenue adjustments to total reported revenues have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by such wholesaler customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback credits. We continually monitor current pricing trends and wholesaler inventory levels to ensure the contra-receivable for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally contractually offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states and authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific time period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for a cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, promotional allowances and loyalty cards. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are generally not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns. Promotional allowances are credits with no discernable benefit offered to Allergan that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Loyalty cards allow end-user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2017 $ 77.2 $ 1,799.2 $ 517.6 $ 36.5 $ 2,430.5 Provision related to sales in 2018 1,117.7 5,464.7 1,725.3 322.2 8,629.9 Credits and payments (1,133.1 ) (5,355.4 ) (1,676.3 ) (328.0 ) (8,492.8 ) Balance at December 31, 2018 $ 61.8 $ 1,908.5 $ 566.6 $ 30.7 $ 2,567.6 Provision related to sales in 2019 1,123.5 6,153.8 1,625.1 337.3 9,239.7 Credits and payments (1,117.5 ) (5,959.0 ) (1,559.3 ) (331.0 ) (8,966.8 ) Balance at December 31, 2019 $ 67.8 $ 2,103.3 $ 632.4 $ 37.0 $ 2,840.5 Contra accounts receivable at December 31, 2019 $ 67.8 $ 101.5 $ 35.7 $ 37.0 $ 242.0 Accounts payable and accrued expenses at December 31, 2019 $ - $ 2,001.8 $ 596.7 $ - $ 2,598.5 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): December 31, 2019 December 31, 2018 Contra accounts receivable $ 242.0 $ 207.7 Accounts payable and accrued expenses 2,598.5 2,359.9 Total $ 2,840.5 $ 2,567.6 The SRA provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Years Ended December 31, 2019 2018 2017 Gross product sales $ 24,968.8 $ 24,056.9 $ 23,688.4 Provisions to reduce gross product sales to net products sales (9,239.7 ) (8,629.9 ) (8,120.0 ) Net product sales $ 15,729.1 $ 15,427.0 $ 15,568.4 Percentage of SRA provisions to gross sales 37.0 % 35.9 % 34.3 % Collectability Assessment At the time of contract inception or customer account set-up, the Company performs a collectability assessment on the creditworthiness of such customer. The Company assesses the probability that the Company will collect the consideration to which it will be entitled in exchange for the goods sold. In evaluating collectability, the Company considers the customer’s ability and intention to pay consideration when it is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectible after sale to the customer to reflect allowances for doubtful accounts. Provision for bad debts, included in general and administrative expenses, were $35.8 million, $18.5 million and $11.6 million in the years ended December 31, 2019, 2018 and 2017, respectively. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period is one year or less. These costs are recorded within selling and marketing expenses. The Company does not adjust the promised amount of consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is equal to one year or less. The Company has chosen not to elect the remaining practical expedients. Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with FASB Accounting Standards Codification (“ASC”) Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts pro

Business Developments

Business Developments	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Business Developments	NOTE 5 — Business Developments 2019 Business Development The following transaction was completed in the year ended December 31, 2019. Envy Medical, Inc. On March 26, 2019, the Company acquired Envy Medical, Inc. (“Envy”), a privately held medical aesthetics company that specializes in non-surgical, non-invasive skin resurfacing systems for an acquisition accounting purchase price of $81.4 million, which includes $67.4 million of product rights and other intangibles, $34.1 million of goodwill and other assets and liabilities. The transaction was treated as a business combination. The acquisition combines Envy’s skin care product portfolio with the Company’s leading medical aesthetics business. 2018 Business Developments The following are the transactions that were completed or announced in the year ended December 31, 2018. Licenses and Asset Acquisitions Bonti, Inc. On October 24, 2018, the Company acquired Bonti, Inc. (“Bonti”), a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications, for $195.0 million upfront plus contingent consideration of up to $90.0 million which may be recorded if the corresponding events become probable. The transaction was accounted for as an asset acquisition as the purchase primarily related to one asset. The aggregate upfront expense of $196.6 million was recorded as a component of R&D expense in the year ended December 31, 2018. Elastagen Pty Ltd On April 6, 2018, the Company completed the acquisition of Elastagen Pty Ltd, a clinical stage medical company developing medical and cosmetic treatments including recombinant human tropoelastin, the precursor of elastin, which will be combined with Allergan's existing fillers product lines. The transaction was accounted for as an asset acquisition as the purchase primarily related to one asset. The aggregate upfront expense of $96.1 million was recorded as a component of R&D expense during the year ended December 31, 2018. Under the terms of the agreement, Elastagen Pty Ltd is eligible to receive additional contingent consideration of up to $165.0 million which may be recorded if the corresponding events become probable. Repros Therapeutics, Inc. On January 31, 2018, the Company completed the acquisition of Repros Therapeutics, Inc., which was accounted for as an asset acquisition as the purchase primarily related to one asset. The aggregate upfront expense of $33.2 million was recorded as a component of R&D expense during the year ended December 31, 2018. Divestitures Aclaris Therapeutics, Inc. On November 30, 2018, the Company divested Rhofade ® Aclaris Therapeutics, Inc. Under the terms of the agreement, the purchase price included an upfront cash payment, a potential development milestone payment for an additional dermatology product, and tiered payments based on annual net sales of ® a fair value estimated to be . Almirall, S.A. On September 20, 2018, the Company completed the sale of five medical dermatology products (Aczone ® ® ® ® ™ Purchase Price $ 550.0 Assets sold Intangible assets $ 205.4 Goodwill 184.0 Other assets 31.0 Net assets sold $ 420.4 Net gain included as a component of Other income / (expense), net $ 129.6 2017 Business Developments The following are the transactions that were completed or announced in the year ended December 31, 2017. Acquisitions Keller Medical, Inc. On June 23, 2017, the Company acquired Keller Medical, Inc. (“Keller”), a privately held medical device company and developer of the Keller Funnel ® ® Zeltiq ® On April 28, 2017, the Company acquired Zeltiq ® ® Assets Acquired and Liabilities Assumed at Fair Value The Zeltiq Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Final Valuation Cash and cash equivalents $ 36.7 Accounts receivable 47.0 Inventories 59.3 Property, plant and equipment 12.4 Intangible assets 1,185.0 Goodwill 1,211.6 Other assets 17.1 Accounts payable and accrued expenses (104.6 ) Deferred revenue (10.6 ) Deferred taxes, net (47.2 ) Other liabilities (1.3 ) Net assets acquired $ 2,405.4 IPR&D and Intangible Assets The estimated fair value of the intangible assets, including customer relationships, was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs, other allocated costs, and working capital/contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream. This technique is referred to herein as the “IPR&D and Intangible Asset Valuation Technique.” The fair value of the intangible assets acquired in the Zeltiq Acquisition was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for these acquired intangible assets ranged from 10.0% to 11.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the Zeltiq Acquisition was driven by the life-cycle stage of the products and the therapeutic indication. For these and other reasons, actual results may vary significantly from estimated results. The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite Lived Assets Consumables $ 985.0 6.7 System 43.0 3.7 Total CMP 1,028.0 Customer Relationships 157.0 6.6 Total Definite Lived Assets $ 1,185.0 Goodwill Among the reasons the Company acquired Zeltiq and the factors that contributed to the recognition of goodwill was the expansion of the Company’s leading medical aesthetics portfolio. Goodwill from the Zeltiq Acquisition of $ 954.7 Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $22.9 million which was recognized as a component of cost of sales as the inventory acquired was sold to the Company’s customers in the year ended December 31, 2017. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. LifeCell Corporation On February 1, 2017, the Company acquired LifeCell Corporation (“LifeCell”), a regenerative medicine company, for an acquisition accounting price of $2,883.1 million (the “LifeCell Acquisition”). The LifeCell Acquisition combined LifeCell's novel, regenerative medicines business, including its high-quality and durable portfolio of dermal matrix products with the Company's leading portfolio of medical aesthetic products, breast implants and tissue expanders. The LifeCell Acquisition expanded the Company’s medical aesthetics portfolio by adding Alloderm ® ® Assets Acquired and Liabilities Assumed at Fair Value The LifeCell Acquisition has been accounted for using the acquisition method of accounting. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Final Valuation Cash and cash equivalents $ 8.7 Accounts receivable 50.8 Inventories 175.4 Property, plant and equipment, net 53.7 Currently marketed products ("CMP") intangible assets 2,010.0 In-process research and development ("IPR&D") intangible assets 10.0 Goodwill 1,449.1 Accounts payable and accrued expenses (149.6 ) Deferred tax liabilities, net (746.2 ) Other 21.2 Net assets acquired $ 2,883.1 IPR&D and Intangible Assets The fair value of the acquired intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for these acquired intangible assets was 7.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections in the LifeCell Acquisition. The discount rate of the LifeCell Acquisition was driven by the life-cycle stage of the products including, the advanced nature of IPR&D projects and the therapeutic indication. For these and other reasons, actual results may vary significantly from estimated results. The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite lived assets Alloderm ® $ 1,385.0 6.9 Revolve ® 80.0 7.1 Strattice ® 320.0 5.1 Artia ® 115.0 8.8 Other 10.0 2.8 Total CMP 1,910.0 Customer Relationships 100.0 6.3 Total definite lived assets 2,010.0 In-process research and development Other 10.0 Total IPR&D 10.0 Total intangible assets $ 2,020.0 Goodwill Among the reasons the Company acquired LifeCell and the factors that contributed to the recognition of goodwill was the expansion of the Company’s leading medical aesthetic portfolio. Goodwill from the LifeCell Acquisition of $ 1,449.1 Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $108.4 million which was recognized as a component of cost of sales as the inventory acquired was sold to the Company’s customers in the year ended December 31, 2017, excluding currency impact. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. Licenses and Other Transactions Accounted for as Asset Acquisitions Lyndra, Inc. On July 31, 2017, the Company entered into a collaboration, option and license agreement with Lyndra, Inc. (“Lyndra”) to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease and an additional, unspecified indication. The total upfront payment of $15.0 million was included as a component of R&D expense in the year ended December 31, 2017. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The future option exercise payments, if any, and any future success based milestones relating to the licensed products of up to $85.0 million will be recorded if the corresponding events become probable. Editas Medicine, Inc. On March 14, 2017, the Company entered into a strategic alliance and option agreement with Editas Medicine, Inc. (“Editas”) for access to early stage, first-in-class eye care programs. Pursuant to the agreement, Allergan made an upfront payment of $90.0 million for the right to license up to five of Editas’ gene-editing programs in eye care, including its lead program for Leber Congenital Amaurosis (“LCA”). Under the terms of the agreement, if an option is exercised, Editas is eligible to receive contingent research and development and commercial milestones plus royalties based on net sales. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The total upfront payment of $90.0 million was included as a component of R&D expense in the year ended December 31, 2017. The future option exercise payments, if any, and any future success based milestones relating to the licensed products will be recorded if the corresponding events become probable. In the year ended December 31, 2018, the Company exercised a $15.0 million option to develop and commercialize EDIT-101 globally for the treatment of LCA10 which was included as a component of R&D expense. Additionally, Editas has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States. Editas received an additional $25.0 million milestone, which was included as a component as R&D expense in the year ended December 31, 2018, as the FDA accepted the investigational new drug application for EDIT-101. Assembly Biosciences, Inc. On January 9, 2017, the Company entered into a licensing agreement with Assembly Biosciences, Inc. (“Assembly”) for the worldwide rights to Assembly’s microbiome gastrointestinal development programs. Under the terms of the agreement, the Company made an upfront payment to Assembly of $50.0 million for the exclusive, worldwide rights to develop and commercialize certain development compounds. Additionally, Assembly will be eligible to receive success-based development and commercial milestone payments plus royalties based on net sales. The Company and Assembly will generally share development costs through proof-of-concept (“POC”) studies, and Allergan will assume all post-POC development costs. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as the lack of certain other inputs and processes that the transaction did not qualify as a business. The total upfront payment of $50.0 million was included as a component of R&D expense in the year ended December 31, 2017 and the future success based milestone payments of up to $2,771.0 million, including amounts for additional development programs not committed to as of December 31, 2017, will be recorded if the corresponding events become probable. Lysosomal Therapeutics, Inc. On January 9, 2017, the Company entered into a definitive agreement for the option to acquire Lysosomal Therapeutics, Inc. (“LTI”). LTI is focused on innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Under the agreement, Allergan acquired an option right directly from LTI shareholders to acquire LTI for $150.0 million plus future milestone payments following completion of a Phase Ib trial for LTI-291 as well as an upfront research and development payment. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The aggregate upfront payment of $145.0 million was recorded as a component of R&D expense in the year ended December 31, 2017. The Company did not exercise its option and on January 2, 2019, the option agreement with LTI was terminated. Other Transactions Saint Regis Mohawk Tribe On September 8, 2017, the Company entered into an agreement with the Saint Regis Mohawk Tribe, under which the Saint Regis Mohawk Tribe obtained the rights to Orange Book-listed patents covering Restasis ® During the years ended December 31, 2019 and 2018, the Company paid royalties to the Saint Regis Mohawk Tribe of $10.1 million and $15.0 million, respectively, which were recorded within cost of sales. As of December 31, 2019, the Company has no future royalty obligations to the Saint Regis Mohawk Tribe.

Assets Held for Sale

Assets Held for Sale	12 Months Ended
	Dec. 31, 2019
Assets Held For Sale Not Part Of Disposal Group [Abstract]
Assets Held for Sale	NOTE 6 — Assets Held for Sale The following represents the assets held for sale ($ in millions): December 31, December 31, 2019 2018 Assets held for sale: Inventories $ - $ 34.0 Property, plant and equipment, net 31.7 32.8 Product rights and other intangibles - 849.4 Total assets held for sale $ 31.7 $ 916.2 As of December 31, 2018, the Company had concluded that its Anti-Infectives business met the criteria for held for sale based on management’s intent and ability to divest the business within the next twelve months. Assets held for sale also include miscellaneous properties. As of June 30, 2019, and as a result of the proposed AbbVie Transaction, the Company concluded that the Anti-Infectives business no longer met the criteria for held for sale. The Anti-Infectives intangible assets and inventory were reclassified to held in use at the lower of their carrying amount before the assets were recorded as held for sale less any amortization that would have been recognized had the assets been continuously classified as held and used or their fair value at the date of the subsequent decision not to sell. As a result of the reclassification, the Company recorded a charge of $129.6 million, primarily related to amortization that would have been recorded if the assets were held and used, within Assets, sales and impairments, net for the nine month period the assets were held for sale.

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborations	NOTE 7 — Collaborations The Company has ongoing transactions with other entities through collaboration agreements. The following represent the material collaboration agreements impacting the years ended December 31, 2019, 2018 and 2017. Ironwood Collaboration In September 2007, Forest entered into a collaboration agreement with Ironwood Pharmaceuticals (“Ironwood”) to jointly develop and commercialize Linzess ® The agreement included contingent milestone payments as well as a contingent equity investment based on the achievement of specific clinical and commercial milestones. The Company may be obligated to pay up to an additional $100.0 million if certain sales milestones are achieved. Based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable guidance, the Company records receipts from and payments to Ironwood in two pools: the “Development pool” which consists of R&D expenses, and the “Commercialization pool,” which consists of revenue, cost of sales and other operating expenses. The net payment to or receipt from Ironwood for the Development pool is recorded in R&D expense and the net payment to or receipt from Ironwood for the Commercialization pool is recorded in cost of goods sold. In the year ended December 31, 2018, the Company recorded a $29.9 million Linzess ® Amgen Collaboration In December 2011, we entered into a collaboration agreement with Amgen Inc. (“Amgen”) to develop and commercialize, on a worldwide basis, biosimilar versions of Herceptin ® ® ® ® ™ ™ ™

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2019
Global Generics [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued Operations	NOTE 8 — Discontinued Operations Global Generics Business On July 27, 2015, the Company announced that it entered into the Teva Transaction, which closed on August 2, 2016. On October 3, 2016, the Company completed the divestiture of the Anda Distribution business to Teva for $500.0 million. The Company recognized a combined gain on the sale of the Anda Distribution business and the sale of the global generics business of $15,932.2 million in the twelve months ended December 31, 2016. In October 2016, pursuant to our agreement with Teva, Teva provided the Company with its proposed estimated adjustment to the closing date working capital balance. The Company disagreed with Teva’s proposed adjustment, and, pursuant to our agreement with Teva, each of the Company’s and Teva’s proposed adjustments were submitted to arbitration (“Working Capital Arbitration”) to determine the working capital amount in accordance with GAAP as applied by the Company consistent with past practice. On January 31, 2018, Allergan plc and Teva entered into a Settlement Agreement and Mutual Releases (the “Agreement”). The Agreement provided that the Company make a one-time payment of $700.0 million to Teva which was paid in the year ended December 31, 2018; the Company and Teva jointly dismissed their working capital dispute arbitration, and the Company and Teva released all actual or potential claims under the Master Purchase Agreement, dated July 26, 2015, by and between the Company and Teva, for breach of any representation, warranty, or covenant (other than any breach of a post-closing covenant not known as of the date of the Agreement). The Company recorded a pre-tax charge of $466.0 million as a component of other (expense) / income, net from discontinued operations relating to the settlement in the year ended December 31, 2017. The fair value of Teva Shares owned were recorded within “Marketable securities” on the Company’s Consolidated Balance Sheet. The closing August 2, 2016 Teva stock price discounted at a rate of 5.9 percent due to the lack of marketability was used to initially value the shares. Teva Share Activity During the year ended December 31, 2018, the Company recorded the following movements in its investment in Teva securities ("Teva Share Activity") ($ in millions except per share information): Shares Carrying Value per Share Market Price Proceeds Received Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income Gain / (Loss) Recognized in Other Income/ (Expense), Net Derivative Instrument (Liability)/ Asset Retained Earnings Teva securities as of December 31, 2017 95.9 $ 17.60 $ 18.95 n.a. $ 1,817.7 $ 129.3 $ - $ (62.9 ) $ - Impact of ASU No. 2016-01 - - - - - (129.3 ) - - 129.3 Settlement of initial accelerated share repurchase ("ASR"), net during the three months ended March 31, 2018 (1) (25.0 ) 18.95 16.53 (2) 413.3 (473.8 ) - 2.5 62.9 - Settlement of forward sale entered into during the three months ended March 31, 2018, net (3) (25.0 ) 17.09 18.61 (4) 465.5 (427.3 ) - 38.2 - - Open market sales during the twelve months ended December 31, 2018 (45.9 ) n.a. (5) 20.41 936.7 (916.6 ) - 20.2 - - Teva securities as of and for the twelve months ended December 31, 2018 - $ - $ - $ 1,815.5 $ - $ - $ 60.9 $ - $ 129.3 (1) (2) (3) (4) (5) During the year ended December 31, 2017, the Company recorded the following movements in its investment in Teva securities ($ in millions except per share information): Shares Carrying Value per Share Market Price Discount Movement in the Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income (Loss) / Gain Recognized in Other Income / (Expense), Net Teva securities as of December 31, 2016 100.3 $ 53.39 $ 36.25 5.4 % $ 3,439.2 $ (1,599.4 ) $ - Other-than-temporary impairment recognized at March 31, 2017 100.3 32.09 32.09 4.9 % (378.6 ) 1,599.4 (1,978.0 ) Other-than-temporary impairment recognized at September 30, 2017 100.3 17.60 17.60 0.0 % (1,295.5 ) - (1,295.5 ) Sales during the twelve months ended December 31, 2017 (4.4 ) n.a. n.a. 0.0 % (76.7 ) - 4.2 Other fair value movements in the twelve months ended December 31, 2017 95.9 17.60 18.95 0.0 % 129.3 129.3 - Teva securities as of and for the twelve months ended December 31, 2017 95.9 $ 17.60 $ 18.95 0.0 % $ 1,817.7 $ 129.3 $ (3,269.3 ) The Teva stock price was discounted due to the lack of marketability. Financial results of the global generics business and the Anda Distribution business are presented as “(Loss) / income from discontinued operations, net of tax” on the Consolidated Statements of Operations for the year ended December 31, 2017. The following table presents key financial results of the global generics business and the Anda Distribution business included in “(Loss) / income from discontinued operations, net of tax” for the year ended December 31, 2017 ($ in millions): 2017 Net revenues $ - Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - Research and development - Selling and marketing - General and administrative 18.8 Amortization - Asset sales and impairments, net 1.2 Total operating expenses 20.0 Operating (loss) / income (20.0 ) Other (expense) / income, net (470.4 ) (Benefit) / provision for income taxes (87.5 ) (Loss) / income from discontinued operations, net of tax $ (402.9 )

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 9 — Share-Based Compensation The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant. A summary of the Company’s share-based compensation plans is presented below. Option award plans require options to be granted at the fair market value of the shares underlying the options at the date of the grant and generally become exercisable over periods ranging from three to five years. Each option granted expires ten years from the date of the grant. Restricted stock awards are grants that entitle the holder to ordinary shares, subject to certain terms. Restricted stock unit awards are grants that entitle the holder the right to receive an ordinary share, subject to certain terms. Restricted stock and restricted stock unit awards (both time-based vesting and performance-based vesting) generally have restrictions that lapse over a one to four year vesting period. Restrictions generally lapse for non-employee directors after one year. Certain restricted stock units are performance-based awards issued at a target number with the actual number of ordinary shares issued ranging based on achievement of the performance criteria. All restricted stock and restricted stock units which remain active under the Company’s equity award plans are eligible to receive cash dividend equivalent payments upon vesting. Fair Value Assumptions All restricted stock and restricted stock units (whether time-based or performance-based) are granted and expensed using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2019 Grants 2018 Grants 2017 Grants Dividend yield 1.7 - 2.2% 1.5% 1.2% Expected volatility 23.5 - 26.4% 27.0% 27.0% Risk-free interest rate 1.9 - 2.6% 2.2-2.9% 2.0-2.3% Expected term (years) 7.0 7.0 7.0 Share-Based Compensation Expense Share-based compensation expense recognized in the Company’s results of operations, including discontinued operations, for the years ended December 31, 2019, 2018 and 2017 was as follows ($ in millions): Years Ended December 31, 2019 2018 2017 Equity-based compensation awards $ 214.3 $ 239.8 $ 293.3 Cash-settled awards in connection with the Zeltiq Acquisition - - 31.5 Non-equity settled awards other - - (16.8 ) Total share-based compensation expense $ 214.3 $ 239.8 $ 308.0 In the years ended December 31, 2019, 2018 and 2017, the related tax benefits were $47.1 million, $53.5 million and $105.0 million, respectively, relating to share-based compensation. In the year ended December 31, 2017, the income in non-equity settled awards other was due to an actuarial reversal of $16.8 million based on the decline of the total shareholder return metrics. These awards are cash-settled and fair valued based on a pre-determined total shareholder return metric. Included in the share-based compensation awards for the years ended December 31, 2019, 2018 and 2017 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Zeltiq Acquisition, the acquisition of Allergan, Inc. (the “Allergan Acquisition”), and the acquisition of Forest Laboratories, Inc. (the “Forest Acquisition”) ($ in millions): Years Ended December 31, 2019 2018 2017 Zeltiq Acquisition $ 4.9 $ 10.1 $ 47.8 Allergan Acquisition 0.5 8.3 47.1 Forest Acquisition - - 10.1 Total $ 5.4 $ 18.4 $ 105.0 Unrecognized future share-based compensation expense was $296.9 million as of December 31, 2019. This amount will be recognized as an expense over a remaining weighted average period of 1.5 years. Share-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis. Share Activity The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2018 through December 31, 2019 (in millions, except per share data): Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2018 2.5 $ 190.27 1.6 $ 472.9 Granted 1.5 140.13 210.7 Vested (0.8 ) 210.08 (159.6 ) Forfeited (0.1 ) 174.29 (31.0 ) Restricted shares / units outstanding at December 31, 2019 3.1 $ 159.74 1.4 $ 493.0 The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2018 through December 31, 2019 (in millions, except per share data): Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2018 6.3 $ 122.74 4.4 $ 69.0 Granted 0.3 140.56 Exercised (0.9 ) 99.71 Cancelled (0.2 ) 224.58 Outstanding, vested and expected to vest at December 31, 2019 5.5 $ 127.27 3.9 $ 352.9 The increase in the aggregate intrinsic value of the options is primarily related to the increase in the Company’s stock from $133.66 as of December 31, 2018 to $191.17 as of December 31, 2019.

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefit Plans	NOTE 10 — Pension and Other Postretirement Benefit Plans Defined Benefit Plan Obligations The Company has numerous defined benefit plans offered to employees around the world. For these plans, retirement benefits are generally based on an employee’s years of service and compensation. Funding requirements are determined on an individual country and plan basis and are subject to local country practices and market circumstances. As of December 31, 2019, all of the Company’s plans were frozen for future enrollment. The service and settlement costs captured as part of the net periodic (benefit) are recorded within general & administrative expenses and the interest costs and expected return on plan assets are recorded within “other income / (expense), net”. Years Ended December 31, 2019 2018 2017 Service cost $ 1.2 $ 2.8 $ 5.5 Interest cost 39.6 38.1 40.7 Expected return on plan assets (56.3 ) (63.8 ) (54.5 ) Settlement (0.6 ) (0.6 ) (0.1 ) Net periodic (benefit) $ (16.1 ) $ (23.5 ) $ (8.4 ) Obligations and Funded Status Benefit obligation and asset data for the defined benefit plans for continuing operations, was as follows ($ in millions): Years Ended December 31, 2019 2018 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,129.6 $ 1,235.2 Employer contribution 12.3 14.8 (Loss) / gain on plan assets 221.3 (53.6 ) Benefits paid (38.6 ) (41.1 ) Settlements - (2.9 ) Effects of exchange rate changes and other (2.9 ) (22.8 ) Fair value of plan assets at end of year $ 1,321.7 $ 1,129.6 Years Ended December 31, 2019 2018 Change in Benefit Obligation Benefit obligation at beginning of the year $ 1,227.2 $ 1,330.0 Service cost 1.2 2.8 Interest cost 39.6 38.1 Actuarial (gain) / loss 143.5 (74.5 ) Settlements and other - (2.9 ) Benefits paid (38.6 ) (41.1 ) Effects of exchange rate changes and other (5.7 ) (25.2 ) Benefit obligation at end of year $ 1,367.2 $ 1,227.2 Funded status at end of year $ (45.5 ) $ (97.6 ) The following table outlines the funded actuarial amounts ($ in millions): Years Ended December 31, 2019 2018 Noncurrent assets $ 57.1 $ 27.6 Current liabilities (0.9 ) (0.9 ) Noncurrent liabilities (101.7 ) (124.3 ) $ (45.5 ) $ (97.6 ) The funding status of pension benefits is primarily a function of the different funding incentives that exist outside of the United States. In certain countries, there are no legal requirements or financial incentives provided to companies to pre-fund pension obligations. In these instances, benefit payments are typically paid directly by the Company as they become due. Plan Assets Companies are required to use a fair value hierarchy as defined in ASC 820 which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value (“Fair Value Leveling”). There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The fair values of the Company’s pension plan assets at December 31, 2019 by asset category are as follows ($ in millions): Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 30.6 $ - $ - $ 30.6 International equities 249.1 - - 249.1 Other equity securities 65.5 - - 65.5 Equity securities $ 345.2 $ - $ - $ 345.2 U.S. Treasury bonds $ - $ 46.2 $ - $ 46.2 Bonds and bond funds - 923.2 - 923.2 Other debt securities - - - - Debt securities $ - $ 969.4 $ - $ 969.4 Other investments Other - 7.1 - 7.1 Total assets $ 345.2 $ 976.5 $ - $ 1,321.7 The fair values of the Company’s pension plan assets at December 31, 2018 by asset category are as follows ($ in millions): Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 20.6 $ - $ - $ 20.6 International equities 205.3 - - 205.3 Other equity securities 49.8 - - 49.8 Equity securities $ 275.7 $ - $ - $ 275.7 U.S. Treasury bonds $ - $ 63.0 $ - $ 63.0 Bonds and bond funds - 787.2 - 787.2 Other debt securities - - - - Debt securities $ - $ 850.2 $ - $ 850.2 Other investments Other - 3.7 - 3.7 Total assets $ 275.7 $ 853.9 $ - $ 1,129.6 The assets of the pension plan are held in separately administered trusts. The investment guidelines for the Company’s pension plans is to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of the plan, given an acceptable level of risk. The target investment portfolio of the Company’s continuing operations pension plans is allocated as follows: Target Allocation as of December 31, 2019 2018 Bonds 74.3 % 70.6 % Equity securities 22.4 % 26.0 % Other investments 3.3 % 3.4 % Expected Contributions Employer contributions to the pension plan during the year ending December 31, 2020 are expected to be $8.5 million for continuing operations. Expected Benefit Payments Total expected benefit payments for the Company’s pension plans are as follows ($ in millions): Expected Benefit Payments 2020 $ 38.6 2021 40.9 2022 43.1 2023 45.2 2024 47.1 Thereafter 1,152.3 Total liability $ 1,367.2 Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service. The majority of the payments will be paid from plan assets and not Company assets. Information for defined benefit plans with an accumulated benefit obligation in excess of plan assets is presented below ($ in millions): Defined Benefit as of December 31, 2019 2018 Projected benefit obligations $ 1,367.2 $ 1,227.2 Accumulated benefit obligations $ 1,362.6 $ 1,223.5 Plan assets $ 1,321.7 $ 1,129.6 Amounts Recognized in Other Comprehensive Income / (Loss) Net (loss) / gain amounts reflect experience differentials primarily relating to differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net pension cost over the average remaining service life of employees. Balances recognized within accumulated other comprehensive income/(loss) excluding the impact of taxes that have not been recognized as components of net periodic benefit costs are as follows ($ in millions): Defined Benefit Balance as of December 31, 2017 $ 58.2 Net actuarial (loss) (44.6 ) Balance as of December 31, 2018 $ 13.6 Net actuarial gain 20.3 Balance as of December 31, 2019 $ 33.9 Actuarial Assumptions The weighted average assumptions used to calculate the projected benefit obligations of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2019 2018 Discount rate 2.4 % 3.3 % Salary growth rate 3.0 % 3.0 % The weighted average assumptions used to calculate the net periodic benefit cost of the C ompany’s defined benefit plans are as follows: As of December 31, 2019 2018 Discount rate 3.3 % 2.9 % Expected rate of return on plan assets 5.1 % 5.2 % Salary growth rate 3.0 % 3.0 % In order to select a discount rate for purposes of valuing the plan obligations the Company uses market returns and adjusts them as needed to fit the estimated duration of the plan liabilities. The expected rate of return represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, long-term historical returns data are considered as well as actual returns on the plan assets and other capital markets experience. Using this reference information, the long-term return expectations for each asset category and a weighted average expected return was developed, according to the allocation among those investment categories. Other Post-Employment Benefit Plans The Company has post-employment benefit plans. Accumulated benefit obligation for the defined benefit plans, were as follows ($ in millions): Accumulated Benefit Obligation Accumulated benefit obligation as of December 31, 2017 $ 46.8 Interest cost 1.6 Actuarial charge (2.6 ) Benefits paid (3.6 ) Accumulated benefit obligation as of December 31, 2018 $ 42.2 Interest cost 1.7 Actuarial charge 2.1 Benefits paid (3.6 ) Accumulated benefit obligation as of December 31, 2019 $ 42.4 Savings Plans The Company also maintains certain defined contribution savings plans covering substantially all U.S.-based employees. The Company contributes to the plans based upon the employee contributions. The Company’s expense for contributions to these retirement plans for amounts included in continuing operations was $150.4 million, $128.9 million and $89.1 million in the years ended December 31, 2019, 2018 and 2017, respectively.

Other Income _ (Expense), Net

Other Income / (Expense), Net	12 Months Ended
	Dec. 31, 2019
Other Income And Expenses [Abstract]
Other Income / (Expense), Net	NOTE 11 — Other Income / (Expense), Net Other income / (expense), net consisted of the following ($ in millions): Years Ended December 31, 2019 2018 2017 Teva Share Activity $ - $ 60.9 $ (3,269.3 ) Sale of businesses - 182.6 - Debt extinguishment costs as part of the debt tender offer - - (161.6 ) Debt extinguishment other (0.2 ) 15.6 (27.6 ) Other-than-temporary impairments - - (26.1 ) Dividend income - - 85.2 Naurex recovery - - 20.0 Forward sale of Teva shares - - (62.9 ) Other (expense) / income, net 33.0 (2.4 ) 5.0 Other income / (expense), net $ 32.8 $ 256.7 $ (3,437.3 ) Teva Share Activity Refer to “NOTE 8 — Discontinued Operations” for the movements that the Company recorded during the years ended December 31, 2018 and 2017 in its investment in Teva securities. Sale of Business During the year ended December 31, 2018, the Company recorded a net gain of $129.6 million as a result of the sale of five medical dermatology products to Almirall, S.A. During the year ended December 31, 2018, the Company completed the sale of a non-strategic asset group held for sale as of December 31, 2017, which was deemed a business based on the applicable guidance at the time, for $55.0 million in cash plus deferred consideration of $20.0 million. As a result of this transaction, the Company recognized a gain of $53.0 million. Debt Extinguishment Costs as Part of the Debt Tender Offer On May 30, 2017, the Company completed the repurchase of certain debt securities issued for cash under a previously announced tender offer. Debt Extinguishment Other During the year ended December 31, 2019, the Company repurchased $249.8 million of senior notes in the open market. The net gain / (loss) on the debt extinguishments was not material. During the year ended December 31, 2018, the Company repurchased $3,939.1 million of senior notes in the open market. As a result of the debt extinguishment, the Company recognized a net gain of $15.6 million within “other income / (expense), net” for the discount received upon repurchase of $45.6 million, offset by the non-cash write-off of premiums and debt fees related to the repaid notes of $30.0 million. During the year ended December 31, 2019, the Company redeemed and retired the following senior notes ($ in millions): Year Ended December 31, 2019 Tranche Face Value Retired Cash Paid for Retirement Remaining Value at December 31, 2019 3.000% due 2020 $ 180.7 $ 180.7 $ 2,526.0 3.450% due 2022 62.3 62.3 2,878.2 3.800% due 2025 6.8 6.8 3,020.7 Total $ 249.8 $ 249.8 $ 8,424.9 In the year ended December 31, 2017, the Company repaid $750.0 million of senior notes due in the year ended December 31, 2019. As a result of the extinguishment, the Company recognized a loss of $27.6 million, within “Other (expense) / income” for the early payment and non-cash write-off of premiums and debt fees related to the repaid notes, including $35.1 million of a make-whole premium. Other-than-temporary Impairments The Company recorded other-than-temporary impairment charges on other equity investments and cost method investments of $26.1 million in the year ended December 31, 2017. Dividend Income During the years ended December 31, 2017, the Company received dividend income of $85.2 million on the 100.3 million Teva ordinary shares acquired as a result of the Teva Transaction. On February 8, 2018, Teva suspended all dividends on ordinary shares. Naurex Recovery On August 28, 2015, the Company acquired certain products in early stage development of Naurex, Inc. (“Naurex”) in an all-cash transaction, which was accounted for as an asset acquisition. The Company received a purchase price reduction of $20.0 million in the year ended December 31, 2017 based on the settlement of an open contract dispute. Forward Sale of Teva Shares Refer to “NOTE 8 — Discontinued Operations” for the movements in the Company’s investment in Teva securities. Other Income, net Other income, net includes the mark-to-market gains of $7.7 million and losses of $13.6 million, respectively, on equity securities held by the Company during the years ended December 31, 2019 and 2018.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	NOTE 12 — Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results. Inventories consisted of the following ($ in millions): December 31, December 31, 2019 2018 Raw materials $ 455.2 $ 303.2 Work-in-process 246.2 145.7 Finished goods 581.7 520.2 1,283.1 969.1 Less: inventory reserves 150.0 122.2 Total Inventories $ 1,133.1 $ 846.9 In connection with the voluntary recall of BIOCELL ®

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 13 — Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following ($ in millions): December 31, December 31, 2019 2018 Accrued expenses: Accrued third-party rebates $ 2,001.8 $ 1,832.1 Litigation-related reserves and legal fees 1,250.7 92.0 Accrued payroll and related benefits 830.3 694.3 Accrued returns and other allowances 596.7 527.8 Accrued R&D expenditures 184.8 215.5 Interest payable 189.5 191.4 Royalties payable 216.9 155.1 Accrued pharmaceutical fees 125.9 145.3 Accrued severance, retention and other shutdown costs 12.7 71.6 Accrued non-provision taxes 64.6 68.5 Accrued selling and marketing expenditures 61.3 61.1 Current portion of contingent consideration obligations 12.1 8.3 Dividends payable 1.1 1.4 Other accrued expenses 409.9 373.0 Total accrued expenses $ 5,958.3 $ 4,437.4 Accounts payable 390.4 349.8 Total accounts payable and accrued expenses $ 6,348.7 $ 4,787.2

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	NOTE 14 — Leases Starting in 2019 leases are accounted for under ASC Topic 842. The Company has entered into various lease contracts, mainly operating leases for the use of real estate, fleet, and operating equipment. The Company leases certain assets to limit exposure to the risks of ownership as well as to reduce administrative burdens inherent in the ownership of assets. Term The remaining terms for leases other than real estate leases are between 1 and 9 years as of December 31, 2019. For real estate leases, the remaining lease terms are between 1 and 13 years as of December 31, 2019. The Company has an option for certain lease contracts, mainly for real estate lease contracts, to renew the lease term beyond the noncancelable lease period. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU asset if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial consequences of a decision to extend or not to extend a lease in determining if the renewal option is reasonably certain to be exercised. Discount Rate The Company is primarily a lessee, not a lessor. The Company discounts future lease payments to calculate the present value when determining the lease classification and measuring the lease liability. The rate utilized is either the implicit rate or the incremental borrowing rate. The incremental borrowing rate is not a commonly quoted rate and is derived through a combination of inputs including the Company’s credit rating and the impact of full collateralization. The incremental borrowing rate is based on the Company’s collateralized borrowing capabilities over a similar term of the lease payments. The Company utilizes the consolidated group incremental borrowing rate for all leases as the Company has centralized treasury operations. Other The Company does not have any material residual value guarantee terms in its lease contracts. The Company does not have material variable leases. The Company has chosen to separate lease and non-lease components for its plant operations and research and development equipment. The Company allocates the contract consideration to the lease component using the standalone price from our supplier. As of December 31, 2019, the Company had the following operating ROU assets and lease liabilities ($ in millions): December 31, 2019 ROU Asset Lease Liability Real estate $ 321.2 $ 386.9 Fleet 115.0 114.9 Other 54.2 68.7 Total operating leases $ 490.4 $ 570.5 December 31, 2019 Current lease liability - operating $ 124.4 Long-term lease liability - operating 446.1 Total lease liability - operating $ 570.5 Finance leases are not material as of December 31, 2019. For the year ended December 31, 2019, the Company noted the following lease expense ($ in millions): Year Ended December 31, 2019 Operating lease expense* $ 151.3 Sublease (income) (14.3 ) Net operating lease expense $ 137.0 * Includes short-term and variable lease expenses of $9.5 million for the year ended December 31, 2019. As of December 31, 2019, the Company had the following lease commitments ($ in millions): Total Payments 2020 $ 131.6 2021 116.6 2022 88.8 2023 58.3 2024 49.7 2025 and after 192.1 Total undiscounted cash flows $ 637.1 Future interest (66.6 ) Total lease liability – operating $ 570.5 As of December 31, 2019, the weighted average remaining lease term for operating leases was 6.6 years with a weighted average discount rate of 2.5%. The ROU assets obtained in exchange for operating lease obligations was $159.9 million for the year ended December 31, 2019. The cash paid for amounts included in the measurement of operating lease liabilities were $137.2 million for the year ended December 31, 2019. As of December 31, 2018, the Company had operating leases for certain facilities, vehicles and equipment. Total property rental expense for operating leases for the year ended December 31, 2018 was $63.2 million. Total fleet rental expense for operating leases for the year ended December 31, 2018 was $41.1 million. The Company also had de minimis capital leases for certain facilities and equipment. As of December 31, 2018, the future anticipated property lease rental payments under both capital and operating leases that had remaining terms in excess of one year were ($ in millions): Total Payments 2019 62.5 2020 52.5 2021 47.9 2022 43.3 2023 39.0 Thereafter 173.8 Total minimum lease payments $ 419.0

Property, plant and equipment,

Property, plant and equipment, net	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Property, plant and equipment, net	NOTE 15 — Property, Plant and Equipment, Net Property, plant and equipment, net consisted of the following as of December 31, 2019 and 2018 ($ in millions): Machinery and Equipment Research and Laboratory Equipment Transportation/ Other Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2018 $ 590.4 $ 67.4 $ 529.6 $ 911.1 $ 466.7 $ 2,565.2 Additions 11.5 20.0 25.6 38.9 279.2 375.2 Disposals/transfers/other 82.5 8.4 89.5 41.4 (302.9 ) (81.1 ) Currency translation (2.4 ) 1.2 (1.2 ) (1.9 ) (0.6 ) (4.9 ) At December 31, 2019 $ 682.0 $ 97.0 $ 643.5 $ 989.5 $ 442.4 $ 2,854.4 Accumulated depreciation At December 31, 2018 $ 284.2 $ 46.3 $ 291.4 $ 156.3 $ - $ 778.2 Additions 67.3 10.9 77.8 48.5 - 204.5 Disposals/transfers/impairments/other (23.2 ) (0.1 ) (9.2 ) (20.8 ) - (53.3 ) Currency translation (1.0 ) 0.8 (0.9 ) (0.5 ) - (1.6 ) At December 31, 2019 $ 327.3 $ 57.9 $ 359.1 $ 183.5 $ - $ 927.8 Property, plant and equipment, net At December 31, 2019 $ 354.7 $ 39.1 $ 284.4 $ 806.0 $ 442.4 $ 1,926.5

Prepaid Expenses, Investments a

Prepaid Expenses, Investments and Other Assets	12 Months Ended
	Dec. 31, 2019
Investments All Other Investments [Abstract]
Prepaid Expenses, Investments and Other Assets	NOTE 16 — Prepaid Expenses, Investments and Other Assets Prepaid expenses and other current assets consisted of the following ($ in millions): December 31, December 31, 2019 2018 Prepaid taxes $ 437.7 $ 403.8 Prepaid insurance 11.5 16.7 Contingent income 83.6 67.7 Sales and marketing 65.0 41.8 Other 288.6 289.1 Total prepaid expenses and other current assets $ 886.4 $ 819.1 Investments in marketable securities, including those classified in cash and cash equivalents due to the maturity term of the instrument, other investments and other assets consisted of the following ($ in millions): December 31, December 31, 2019 2018 Marketable securities: Short-term investments $ 3,411.6 $ 1,026.9 Total marketable securities $ 3,411.6 $ 1,026.9 Investments and other assets: Deferred executive compensation investments $ 89.2 $ 90.8 Equity method investments 7.6 8.4 Other long-term investments 63.3 37.6 Taxes receivable 41.2 1,674.8 Contingent income 51.8 75.3 Other assets 154.9 83.7 Total investments and other assets $ 408.0 $ 1,970.6 The Company’s marketable securities and other long-term investments are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non current, as appropriate, in the Company’s consolidated balance sheets. During the third quarter of 2019, the Company received a one-time $1.6 billion refund of taxes previously paid on capital gains. The tax refund was accrued in a prior year. During the year ended December 31, 2019, the Company entered into a supply arrangement for a diversified brands product which resulted in an upfront payment of $125.0 million and future milestone payments of $120.0 million. The upfront amount was capitalized as an asset and will be amortized through Cost of Sales over the contract term of five years. As of December 31, 2019, $39.2 million is recorded in Prepaid Other and $36.7 million is recorded in Other Assets. Other assets include security and equipment deposits and long-term receivables.

Goodwill, Product Rights and Ot

Goodwill, Product Rights and Other Intangible Assets	12 Months Ended
	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Product Rights and Other Intangible Assets	NOTE 17 — Goodwill, Product Rights and Other Intangible Assets Goodwill Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Specialized Therapeutics US General Medicine International Total Balance as of December 31, 2018 $ 20,675.6 $ 17,936.6 $ 7,301.1 $ 45,913.3 Acquisitions 34.1 - - 34.1 Impairments - (3,552.8 ) - (3,552.8 ) Allocation to current segments (340.0 ) 340.0 - - Foreign exchange and other adjustments - - (146.3 ) (146.3 ) Balance as of December 31, 2019 $ 20,369.7 $ 14,723.8 $ 7,154.8 $ 42,248.3 During the second quarter of 2019, the Company changed the operational and management structure for its in-development CGRP receptors, Ubrogepant and Atogepant. The development products were previously reported within the US Specialized Therapeutics segment and have been transferred to the US General Medicine segment to align these development products with the management structure and reporting. These development products were acquired as part of an asset acquisition and were expensed in prior years. Goodwill of $340.0 million was re-allocated from the US Specialized Therapeutics segment to the US General Medicine segment based on relative fair value as of June 30, 2019. As a result of the transfer of these development projects, the Company performed its annual goodwill impairment test, both prior to and after, transfer. Annual Testing The Company performed its annual goodwill impairment test during the second quarter of 2019 by quantitatively evaluating its five Reporting Units. As of June 30, 2019, the net asset value of the General Medicine Reporting Unit exceeded its fair value prior to the transfer of the products noted above and the Company recorded a $1,085.8 million goodwill impairment charge to its General Medicine Reporting Unit. The charge is due in part to delays in the clinical studies as well as a reduction in the expected value of certain R&D projects. As of June 30, 2019, the fair value of each of the Company’s other four reporting units exceeded its book value by less than five percent except for the U.S. Botox Therapeutic Reporting Unit. The General Medicine Reporting Unit, International Reporting Unit, US Eye Care Reporting Unit and US Medical Aesthetics Reporting Unit were the most sensitive to change in future valuation assumptions. The Company’s US Eye Care Reporting Unit and US Medical Aesthetics Reporting Unit, which are components of its US Specialized Therapeutics Segment, have an allocated goodwill balance of $9,824.8 million and $7,698.8 million, respectively. While management believes the assumptions used are reasonable and commensurate with the views of a market participant, changes in key assumptions for these Reporting Units, including increasing the discount rate, lowering revenue forecasts, lowering the operating margin, R&D pipeline delays, or lowering the long-term growth rate, could result in a future impairment. Other market factors and conditions could also result in downward revisions of the Company’s forecasts on future projected cash flows for these reporting units. Negative events regarding R&D pipeline assets including, but not limited to, Abicipar, Atogepant, Bimatoprost SR, and Ceniciviroc as well as next generation aesthetic products, could lead to further goodwill impairment charges. As a result of the proposed AbbVie Transaction, a component of the Company’s implied enterprise value contemplates the share price of AbbVie as attributed to the Company. If the AbbVie share price were to decline, the overall consideration associated with the AbbVie Transaction could be reduced which could result in a future goodwill impairment triggering event. In performing the annual impairment test, the Company utilized discount rates ranging from 9.5% to 11.0%, which were consistent with the rates utilized in the impairment testing performed in the first quarter of 2019. These rates increased versus the prior year annual testing discount rates of 8.5% to 10.0% to reflect changes in market conditions. The Company also reduced long-term growth rate assumptions consistent with the implied enterprise value. The assumptions used in evaluating goodwill for impairment are significant estimates, are subject to change, are assessed against historical performance by management and could result in additional impairment charges. Non-Annual Testing As of December 31, 2018, the net asset value of the General Medicine Reporting Unit equaled fair value. On March 6, 2019, Allergan announced negative topline results from three pivotal studies of rapastinel as an adjunctive treatment of Major Depressive Disorder (MDD). These results represented a triggering event to perform an impairment test for the Company’s General Medicine Reporting Unit. During the first quarter of 2019, primarily as a result of the impairment test noted above and a delay in clinical studies and anticipated launch of brazikumab, the Company recorded a $2,467.0 million goodwill impairment charge to its General Medicine Reporting Unit. As of December 31, 2019 and 2018, the gross balance of goodwill, prior to the consideration of impairments, was $48,659.4 million and $48,771.7 million, respectively. Product Rights and Other Intangible Assets Product rights and other intangible assets consisted of the following for the years ended December 31, 2019 and 2018 ($ in millions): Cost Basis Balance as of December 31, 2018 Additions Impairments Transfers / Held Sale Foreign Currency Translation Balance as of December 31, 2019 Intangibles with definite lives: Product rights and other intangibles $ 70,235.1 $ 178.4 $ - $ 1,936.6 $ (132.6 ) $ 72,217.5 Trade name 690.0 - - - - 690.0 Total definite lived intangible assets $ 70,925.1 $ 178.4 $ - $ 1,936.6 $ (132.6 ) $ 72,907.5 Intangibles with indefinite lives: IPR&D $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total indefinite lived intangible assets $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total product rights and other intangibles $ 75,973.2 $ 178.4 $ (436.0 ) $ 1,861.0 $ (132.6 ) $ 77,444.0 Accumulated Amortization Balance as of December 31, 2018 Amortization Impairments Transfers / Held for Sale Foreign Currency Translation Balance as of December 31, 2019 Intangibles with definite lives: Product rights and other intangibles $ (31,985.0 ) $ (5,776.7 ) $ (443.6 ) $ (1,011.4 ) $ 36.0 $ (39,180.7 ) Trade name (292.8 ) (79.9 ) - - - (372.7 ) Total definite lived intangible assets $ (32,277.8 ) $ (5,856.6 ) $ (443.6 ) $ (1,011.4 ) $ 36.0 $ (39,553.4 ) Total product rights and other intangibles $ (32,277.8 ) $ (5,856.6 ) $ (443.6 ) $ (1,011.4 ) $ 36.0 $ (39,553.4 ) Net Product Rights and Other Intangibles $ 43,695.4 $ 37,890.6 Year Ended December 31, 2019 Annual Testing During the second quarter of 2019, the Company performed its annual IPR&D impairment test and based on events occurring or decisions made within the quarter ended June 30, 2019, the Company recorded the following impairments: • a $133.0 million impairment as a result of competition and a decline in market opportunities of a facial aesthetic product obtained as part of the acquisition of Allergan, Inc. (the “Allergan Acquisition”); • a $176.0 million impairment as a result of reduced cash flow projections including higher than anticipated clinical trial costs for a GI project obtained as part of the acquisition of Tobira Therapeutics, Inc.; and • a $127.0 million impairment for two pipeline programs that had previously been deprioritized and were subsequently deemed to have no alternative use in the period. Non-Annual Testing The Company noted the following impairments based on triggering events during the year ended December 31, 2019: • a $314.0 million impairment for the intangible asset Carafate as a result of a generic entrant in December 2019 which reduced the expected future cash flows of this product; Product rights and other intangible assets consisted of the following for the years ended December 31, 2018 and 2017 ($ in millions): Cost Basis Balance as of December 31, 2017 Additions Impairments IPR&D CMP Transfers Divested / Held for Sale / Other Foreign Currency Translation Balance as of December 31, 2018 Intangibles with definite lives: Product rights and other intangibles $ 73,892.5 $ 49.0 $ - $ — $ (3,391.0 ) $ (315.4 ) $ 70,235.1 Trade name 690 - - - - - 690.0 Total definite lived intangible assets $ 74,582.5 $ 49.0 $ - $ - $ (3,391.0 ) $ (315.4 ) $ 70,925.1 Intangibles with indefinite lives: IPR&D $ 5,874.1 $ - $ (798.0 ) $ - $ (28.0 ) $ - $ 5,048.1 Total indefinite lived intangible assets $ 5,874.1 $ - $ (798.0 ) $ - $ (28.0 ) $ - $ 5,048.1 Total product rights and other intangibles $ 80,456.6 $ 49.0 $ (798.0 ) $ - $ (3,419.0 ) $ (315.4 ) $ 75,973.2 Accumulated Amortization Balance as of December 31, 2017 Amortization Impairments Divested / Held for Sale / Other Foreign Currency Translation Balance as of December 31, 2018 Intangibles with definite lives: Product rights and other intangibles $ (25,593.6 ) $ (6,474.2 ) $ (2,239.9 ) $ 2,233.4 $ 89.3 $ (31,985.0 ) Trade name (214.7 ) (78.1 ) - - - (292.8 ) Total definite lived intangible assets $ (25,808.3 ) $ (6,552.3 ) $ (2,239.9 ) $ 2,233.4 $ 89.3 $ (32,277.8 ) Total product rights and other intangibles $ (25,808.3 ) $ (6,552.3 ) $ (2,239.9 ) $ 2,233.4 $ 89.3 $ (32,277.8 ) Net Product Rights and Other Intangibles $ 54,648.3 $ 43,695.4 In the year ended December 31, 2018, the Company determined that the Anti-Infectives business was deemed held for sale. Based on the anticipated future cash flows, the Company impaired certain Anti-Infective CMP by $149.7 million. The remaining amount of net product rights and other intangibles which met the held for sale criteria is $849.4 million. Non-Annual Testing In addition to the Company’s annual impairment test performed in the second quarter, the Company noted the following impairments based on triggering events during the year ended December 31, 2018: • In the fourth quarter of 2018, the Company impaired the intangible assets associated with Kybella by $1,643.8 million in “Asset sales and impairments, net” as a result of a decrease in the future sales forecasts based on current performance, in part due to risks relating to supply of the product and the corresponding impact on demand; • In the fourth quarter of 2018, the Company impaired the intangible assets associated with True Tear ® • In the year ended December 31, 2018, the Company divested net product rights and other intangibles of $205.4 million in “Asset sales and impairments, net” and $130.5 million (after intangible asset impairment of $252.0 million) as part of the divestitures of the Medical Dermatology business to Almirall, S.A. and the divestiture of Rhofade ® • In the first quarter of 2018, the Company recorded a $522.0 million impairment as a result of negative clinical data related to the oral psoriasis indication received in March 2018 for its RORyt IPR&D project obtained as part of the acquisition of Vitae Pharmaceuticals, Inc. Annual Testing During the second quarter of 2018, the Company performed its annual IPR&D impairment test and based on events occurring or decisions made within the quarter ended June 30, 2018, the Company recorded the following impairments: • a $164.0 million impairment as a result of changes in launch plans based on clinical results of an eye care project obtained as part of the Allergan Acquisition; • a $40.0 million impairment due to a delay in clinical studies and anticipated approval date of a project obtained as part of the acquisition of Vitae Pharmaceuticals, Inc.; • a $27.0 million impairment due to a delay in clinical studies and anticipated approval date of a medical dermatology project obtained as part of the Allergan Acquisition; • a $20.0 million impairment as a result of a strategic decision to no longer pursue approval internationally of an eye care project obtained as part of the Allergan Acquisition; • a $19.0 million impairment due to a delay in clinical studies and anticipated approval date for a CNS project obtained as part of the Allergan Acquisition; and • a $6.0 million impairment due to a delay in clinical studies and anticipated approval date of an eye care project obtained as part of the Allergan Acquisition. Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of December 31, 2019 over each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2020 $ 5,565.8 2021 $ 4,590.7 2022 $ 4,197.8 2023 $ 3,741.7 2024 $ 2,864.8 The above amortization expense is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, finalization of preliminary fair value estimates, potential impairments, accelerated amortization or other events. Additional amortization may occur as products are approved. In addition, the Company has certain currently marketed products for which operating contribution performance has been below that which was originally assumed in the products’ initial valuations, and certain IPR&D projects which are subject to delays in timing or other events which may negatively impact the asset’s value. The Company, on a quarterly basis, monitors the related intangible assets for these products for potential impairments. It is reasonably possible that impairments may occur in future periods, which may have a material adverse effect on the Company’s results of operations and financial position.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Debt	NOTE 18 — Long-Term Debt Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of Guarantor Issuance Date / Acquisition Date Interest Payments December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due March 12, 2020 (1) (4) March 4, 2015 Quarterly 500.0 500.0 501.0 501.9 500.0 500.0 501.0 501.9 Fixed Rate Notes $3,500.0 million 3.000% notes due March 12, 2020 (4) March 4, 2015 Semi-annually 2,526.0 2,706.7 2,529.5 2,694.8 $650.0 million 3.375% notes due September 15, 2020 (5) March 17, 2015 Semi-annually 650.0 650.0 654.7 648.7 $750.0 million 4.875% notes due February 15, 2021 (6) July 1, 2014 Semi-annually 450.0 450.0 463.4 459.4 $1,200.0 million 5.000% notes due December 15, 2021 (6) July 1, 2014 Semi-annually 1,200.0 1,200.0 1,262.9 1,234.8 $3,000.0 million 3.450% notes due March 15, 2022 (4) March 4, 2015 Semi-annually 2,878.2 2,940.5 2,945.1 2,891.0 $1,700.0 million 3.250% notes due October 1, 2022 (5) October 2, 2012 Semi-annually 1,700.0 1,700.0 1,739.1 1,652.2 $350.0 million 2.800% notes due March 15, 2023 (5) March 17, 2015 Semi-annually 350.0 350.0 352.7 332.8 $1,200.0 million 3.850% notes due June 15, 2024 (4) June 10, 2014 Semi-annually 1,036.7 1,036.7 1,089.9 1,021.0 $4,000.0 million 3.800% notes due March 15, 2025 (4) March 4, 2015 Semi-annually 3,020.7 3,027.5 3,172.4 2,956.0 $2,500.0 million 4.550% notes due March 15, 2035 (4) March 4, 2015 Semi-annually 1,789.0 1,789.0 1,953.4 1,690.7 $1,000.0 million 4.625% notes due October 1, 2042 (5) October 2, 2012 Semi-annually 456.7 456.7 482.8 412.4 $1,500.0 million 4.850% notes due June 15, 2044 (4) June 10, 2014 Semi-annually 1,079.4 1,079.4 1,192.8 1,019.1 $2,500.0 million 4.750% notes due March 15, 2045 (4) March 4, 2015 Semi-annually 881.0 881.0 968.7 836.6 18,017.7 18,267.5 18,807.4 17,849.5 Euro Denominated Notes €700.0 million floating rate notes due June 1, 2019 (2) (4) May 26, 2017 Quarterly - 802.7 - 794.9 €700.0 million floating rate notes due November 15, 2020 (3) (4) November 15, 2018 Quarterly 784.9 802.7 784.4 791.3 €750.0 million 0.500% notes due June 1, 2021 (4) May 26, 2017 Annually 841.0 860.0 846.7 849.7 €500.0 million 1.500% notes due November 15, 2023 (4) November 15, 2018 Annually 560.7 573.4 589.8 572.4 €700.0 million 1.250% notes due June 1, 2024 (4) May 26, 2017 Annually 784.9 802.7 817.7 775.5 €500.0 million 2.625% notes due November 15, 2028 (4) November 15, 2018 Annually 560.7 573.4 648.2 573.4 €550.0 million 2.125% notes due June 1, 2029 (4) May 26, 2017 Annually 616.7 630.7 683.9 594.7 4,148.9 5,045.6 4,370.7 4,951.9 Total Senior Notes Gross 22,666.6 23,813.1 23,679.1 23,303.3 Unamortized premium 39.9 64.3 Unamortized discount (55.4 ) (64.5 ) Total Senior Notes Net 22,651.1 23,812.9 23,679.1 23,303.3 Other Indebtedness Debt Issuance Costs (74.7 ) (92.1 ) Margin Loan - - Other 72.6 69.3 Total Other Borrowings (2.1 ) (22.8 ) Capital Leases - 7.6 Total Indebtedness $ 22,649.0 $ 23,797.7 (1) (2) (3) (4) (5) (6) Fair market value in the table above is determined in accordance with Fair Value Leveling under Level 2 based upon quoted prices for similar items in active markets. The following represents the significant activity during the year ended December 31, 2019 with respect to the Company’s total indebtedness: • The Company repaid scheduled maturities of €700.0 million senior notes; • The Company repurchased and retired $249.8 million of senior notes at approximately face value from open market redemptions. The following represents the significant activity during the year ended December 31, 201 8 with respect to the Company’s total indebtedness: • The Company borrowed $700.0 million, and subsequently repaid $700.0 million, under its revolving credit facility to fund, in part, the repurchase of the Company’s ordinary shares; • The Company repurchased and retired $3,939.1 million of senior notes at face value for a total of $3,893.5 million from open market redemptions. As a result of the debt extinguishment, the Company recognized a net gain of $15.6 million within “other income / (expense), net” for the discount received upon repurchase of $45.6 million, offset by the non-cash write-off of premiums and debt fees related to the repaid notes of $30.0 million; • The Company borrowed €1,700.0 million of senior notes; • The Company repaid scheduled maturities on senior notes of $3,750.0 million; and • The Company prepaid $459.0 million of indebtedness under the Company’s margin loan. Revolving Credit Facility On June 14, 2017, Allergan plc and certain of its subsidiaries entered into a revolving credit and guaranty agreement (the “Revolver Agreement”) among Allergan Capital, as borrower, Allergan plc, as Ultimate Parent; Warner Chilcott Limited, Allergan Finance LLC, and Allergan Funding SCS, as guarantors; the lenders from time to time party thereto (the “Revolving Lenders”); J.P. Morgan Chase Bank as Administrative Agent; J.P. Morgan Europe Limited, as London Agent; and the other financial institutions party thereto. Under the Revolver Agreement, the Revolving Lenders have committed to provide an unsecured five-year The Revolver Agreement provides that loans thereunder would bear interest, at our choice, of a per annum rate equal to either (a) a base rate, plus an applicable margin per annum varying from 0.00% per annum to 1.00% per annum depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from 0.875% per annum to 2.00% per annum depending on the Debt Rating. Additionally, to maintain availability of funds, the Company pays an unused commitment fee varying from 0.070% to 0.250% per annum, depending on the Debt Rating, of the unused portion of the revolver. The obligations under the Revolver Agreement are guaranteed by Warner Chilcott Limited, Allergan Finance, LLC and Allergan Funding SCS. The Revolver Agreement contains customary affirmative covenants for facilities of this type, including, among others, covenants pertaining to the delivery of financial statements, notices of default, maintenance of corporate existence and compliance with laws, as well as customary negative covenants for facilities of this type, including, among others, limitations on secured indebtedness, non-guarantor subsidiary indebtedness, mergers and certain other fundamental changes and passive holding company status. The Revolver Agreement also contains a financial covenant requiring maintenance of a maximum consolidated leverage ratio. In addition, the Revolver Agreement also contains customary events of default (with customary grace periods and materiality thresholds). The Company was subject to, and as of December 31, 2019, was in compliance with all financial covenants under the terms of the Revolver Agreement. At December 31, 2019, there were $33.6 million of outstanding borrowings or letters of credit outstanding under the Revolver Agreement. Annual Debt Maturities As of December 31, 2019, annual debt maturities of senior notes gross were as follows ($ in millions): Total Payments 2020 4,460.9 2021 2,491.0 2022 4,578.2 2023 910.7 2024 1,821.6 2025 and after 8,404.2 Total senior notes gross $ 22,666.6 Amounts represent total anticipated cash payments assuming scheduled repayments.

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	NOTE 19 — Other Long-Term Liabilities Other long-term liabilities consisted of the following ($ in millions): December 31, December 31, 2019 2018 Acquisition related contingent consideration liabilities $ 377.3 $ 336.3 Long-term pension and post retirement liability 144.1 166.5 Legacy Allergan deferred executive compensation 89.2 90.8 Accrued R&D milestone 75.0 75.0 Long-term contractual obligations - 43.2 Deferred revenue 26.6 36.1 Product warranties 29.2 27.9 Long-term severance and restructuring liabilities 10.8 14.2 Other long-term liabilities 48.7 92.0 Total other long-term liabilities $ 800.9 $ 882.0

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 20 — Income Taxes For the years ended December 31, 2019, 2018 and 2017, losses before income taxes consisted of the following ($ in millions): Years Ended December 31, 2019 2018 2017 Irish $ (4,756.0 ) $ (4,285.8 ) $ (1,139.0 ) Non-Irish (362.7 ) (2,571.1 ) (9,247.4 ) Total (loss) / income before taxes $ (5,118.7 ) $ (6,856.9 ) $ (10,386.4 ) The Company’s provision / (benefit) for income taxes consisted of the following ($ in millions): Years Ended December 31, 2019 2018 2017 Current (benefit) / provision: U.S. federal $ 476.5 $ (1,024.5 ) $ 763.1 U.S. state 35.6 34.2 (54.8 ) Non-U.S. 295.2 481.6 410.0 Total current (benefit) / provision 807.3 (508.7 ) 1,118.3 Deferred (benefit) / provision: U.S. federal (635.7 ) (569.9 ) (6,911.9 ) U.S. state (131.7 ) (80.6 ) (252.3 ) Non-U.S. 106.5 (611.5 ) (624.5 ) Total deferred (benefit) / provision (660.9 ) (1,262.0 ) (7,788.7 ) Total (benefit) / provision for income taxes $ 146.4 $ (1,770.7 ) $ (6,670.4 ) The reconciliations for the years ended December 31, 2019, 2018 and 2017 between the statutory Irish income tax rate for Allergan plc and the effective income tax rates were as follows: Allergan plc Years Ended December 31, 2019 2018 2017 Statutory rate (12.5 )% (12.5 )% (12.5 )% Earnings subject to U.S. taxes (1) (2) 1.3 % (1.8 )% (17.4 )% Earnings subject to rates different than the statutory rate (1)(2) (5.3 )% (3.4 )% 2.1 % Impact of U.S. tax reform enactment 0.0 % (0.2 )% (27.2 )% Tax reserves and audit outcomes 2.1 % 2.6 % 0.4 % Non-deductible expenses (3) 12.6 % 7.4 % 0.2 % Impact of acquisitions and reorganizations (4) (2.6 )% (15.3 )% (9.3 )% Tax credits and U.S. special deductions (2.0 )% (0.9 )% (1.5 )% Rate changes (5) 0.3 % 2.2 % (1.2 )% Valuation allowances (6) 8.7 % (3.7 )% 2.2 % Other 0.3 % (0.2 )% 0.0 % Effective income tax rate 2.9 % (25.8 )% (64.2 )% (1) The U.S. rate differential was a detriment of $64.5 million to the 2019 effective tax rate as compared to a benefit of $122.9 million to the 2018 effective tax rate, primarily driven by decreases of approximately $2.9 billion in impairment charges and amortization expense. The remaining rate differential is driven by non-U.S. income subject to rates lower than the Irish statutory rate. (2) The Company recorded amortization expense of $5.9 billion and intangible impairment charges of $0.9 billion, resulting in a tax benefit of $14.1 million to the 2019 effective tax rate. In 2018, the Company recorded amortization expense of $6.6 billion and intangible impairment charges of $3.0 billion, resulting in a tax benefit of $277.5 million, favorably impacting the 2018 effective tax rate as compared to 2019. (3) In 2019, the Company recorded charges of $3.6 billion for goodwill impairment and $1.1 billion for legal settlements with no corresponding tax benefit, resulting in a tax detriment of $581.5 million to the effective tax rate. In 2018, the Company recorded a goodwill impairment charge of $3.5 billion with no corresponding tax benefit, resulting in a tax detriment of $432.9 million. (4) In 2019, the Company recorded a tax benefit of $131.2 million related to the tax effects of integration and the recognition of outside basis differences. In 2018, the Company recorded a tax benefit of $1,047.8 million related to the tax effects of integration and the recognition of outside basis differences. This resulted in a more favorable impact in 2018 as compared to 2019. (5) As a result of statutory and other tax rate changes applied to certain deferred tax assets and liabilities, the Company recorded a detriment of $15.1 million in 2019. In 2018, the Company recorded a detriment of $148.0 million, favorably impacting the 2019 rate as compared to 2018. (6) In 2019, the Company recorded a tax detriment of $444.9 million to establish a valuation allowance on deferred tax assets related to certain tax attributes, which are not expected to be realized. In 2018, the Company recorded a tax benefit of $254.0 million for the full release of a valuation allowance related to the Company’s foreign tax credit and partial release related to non-U.S. net operating loss carryforwards. The reconciliations for the years ended December 31, 2019, 2018 and 2017 between the statutory Bermuda income tax rate for Warner Chilcott Limited and the effective income tax rates were as follows: Warner Chilcott Limited (1) Years Ended December 31, 2019 2018 2017 Statutory rate 0.0 % 0.0 % 0.0 % Earnings subject to U.S. taxes (2.8 )% (10.2 )% (27.4 )% Earnings subject to rates different than the statutory rate (14.2 )% (8.4 )% (0.9 )% Impact of U.S. tax reform enactment 0.0 % (0.2 )% (27.7 )% Tax reserves and audit outcomes 2.1 % 2.6 % 0.5 % Non-deductible expenses 13.0 % 7.7 % 0.2 % Impact of acquisitions and reorganizations (2.6 )% (16.0 )% (9.5 )% Tax credits and U.S. special deductions (2.1 )% (1.0 )% (1.5 )% Rate changes 0.3 % 2.3 % (1.3 )% Valuation allowances 9.0 % (3.9 )% 2.3 % Other 0.3 % (0.1 )% (0.2 )% Effective income tax rate 3.0 % (27.2 )% (65.5 )% (1) The rate reconciliation for Bermuda is largely consistent with the Irish effective tax rate reconciliations presented above. Deferred tax assets and liabilities are measured based on the difference between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The significant components of the Company’s net deferred tax assets and liabilities consisted of the following (in millions): Years Ended December 31, 2019 2018 Benefits from net operating and capital loss carryforwards $ 2,105.2 $ 2,145.8 Benefits from tax credit and other carryforwards 440.4 377.6 Differences in financial statement and tax accounting for: Inventories, receivables and accruals 496.8 231.8 Basis differences in investments 185.5 56.1 Share-based and other compensation 242.8 295.5 Other 183.4 82.4 Total deferred tax asset, gross $ 3,654.1 $ 3,189.2 Less: Valuation allowance (2,079.1 ) (1,637.9 ) Total deferred tax asset, net $ 1,575.0 $ 1,551.3 Differences in financial statement and tax accounting for: Property, equipment and intangible assets (4,725.2 ) (5,487.4 ) Basis differences in investments (525.9 ) (499.9 ) Other (110.7 ) (2.1 ) Total deferred tax liabilities $ (5,361.8 ) $ (5,989.4 ) Total deferred taxes $ (3,786.8 ) $ (4,438.1 ) During the year ended December 31, 2019, the Company’s net deferred tax liability decreased by $651.3 million. This was predominately the result of amortization and impairments related to our intangible assets partially offset by an increase to the Company’s valuation allowance. The Company had the following carryforward tax attributes at December 31, 2019: • $1,095.1 million of U.S. federal net operating losses (“NOL”) and other tax attributes which begin to expire in 2020 • $310.2 million of U.S. tax credits which begin to expire in 2020 • $227.3 million of U.S. state NOLs which begin to expire in 2020 • $4,819.5 million of non-U.S. NOLs which begin to expire in 2020 and $4,120.8 million of non-U.S. NOLs which are not subject to expiration. U.S. net operating loss and tax credit carryforwards of $194.8 million and $4.6 million, respectively, are subject to an annual limitation under Internal Revenue Code Section 382. During the year ended December 31, 2019, the Company recorded a net increase to the valuation allowance of $441.2 million primarily related to deferred tax assets in Ireland. When determining the realizability of these deferred tax assets, the Company weighed all available positive and negative evidence, including future income projections for our Irish subsidiaries and limitations on our ability to utilize tax attributes against certain types of income. As a result, the Company concluded that the more likely than not threshold was not met for realizability and accordingly recorded a valuation allowance. As of December 31, 2019, a valuation allowance balance of $2,079.1 million is recorded due to the uncertainty of realizing tax credits ($56.3 million), net operating and other carryforwards ($1,822.6 million), capital loss carryforwards ($115.3 million) and other deferred tax assets ($84.9 million). At December 31, 2019, Allergan plc (the Irish parent) is permanently reinvested in approximately $17.0 billion of earnings of its non-Irish subsidiaries and therefore has not provided deferred income taxes on these undistributed earnings. The amounts are intended to be indefinitely reinvested in non-Irish operations and would be subject to approximately $194.6 million in taxes if amounts were distributed to Allergan plc. The U.S. subsidiaries of Allergan plc are not permanently reinvested in the earnings of their non-U.S. subsidiaries as the provisions under current U.S. tax law will allow these earnings to be remitted to the U.S. without any significant tax cost. The Company recorded a $67.7 million deferred tax liability for the estimated cost to repatriate the accumulated earnings of these non-U.S. subsidiaries to their U.S. shareholders as of December 31, 2019. On January 1, 2018, the Company adopted ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Previously, GAAP prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. This prohibition on recognition was an exception to the principle of comprehensive recognition of current and deferred income taxes in GAAP. The amendment to the guidance eliminated the exception for an intra-entity transfer of an asset other than inventory and required an entity to recognize the income tax consequences when the transfer occurs. Accounting for Uncertainty in Income Taxes A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in millions): Years Ended December 31, 2019 2018 2017 Balance at the beginning of the year $ 1,186.8 $ 850.3 $ 811.2 Increases for current year tax positions 66.4 164.3 10.1 Increases for prior year tax positions 214.3 193.4 69.2 Increases due to acquisitions 0.0 0.0 19.8 Decreases for prior year tax positions (218.1 ) (5.0 ) (38.7 ) Settlements (23.3 ) (5.4 ) (21.7 ) Lapse of applicable statute of limitations (13.3 ) (5.9 ) (2.9 ) Foreign exchange 1.6 (4.9 ) 3.3 Balance at the end of the year $ 1,214.4 $ 1,186.8 $ 850.3 If these benefits were subsequently recognized, $965.7 million would favorably impact the Company’s effective tax rate. The decrease in prior year tax positions of $218.1 million was primarily driven by audit settlements with taxing authorities and the recognition of previously unrecognized tax benefits resulting from the issuance of new regulations. The Company's continuing policy is to recognize interest and penalties related to uncertain tax positions in tax expense. During the years ended December 31, 2019, 2018 and 2017, the Company recognized approximately $27.7 million, $42.3 million and $45.8 million in interest and penalties, respectively. At December 31, 2019, 2018 and 2017, the Company had accrued $183.0 million (net of tax benefit of $44.1 million), $155.2 million (net of tax benefit of $35.0 million) and $113.7 million (net of tax benefit of $25.9 million) of interest and penalties related to uncertain tax positions, respectively. Although the Company cannot determine the impact with certainty based on specific factors, it is reasonably possible that the unrecognized tax benefits may change by up to approximately $200.0 million within the next twelve months due to the resolution of certain tax examinations. The Company conducts business globally and, as a result, files U.S. federal, state and foreign tax returns. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for amounts it believes are in accordance with the accounting standard, the final outcome with a tax authority may result in a tax liability that is different than that reflected in the consolidated financial statements. Furthermore, the Company may decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations with tax authorities, identification of new issues and issuance of new legislation, regulations or case law. The Company has several concurrent audits open and pending with the Internal Revenue Service (“IRS”) as set forth below: IRS Audits Taxable Years Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc. 2013, 2014, 2015 and 2016 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Allergan, Inc. 2009, 2010, 2011, 2012, 2013, 2014 and 3/17/2015

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Shareholders' Equity	NOTE 21 — Shareholders’ Equity Share Repurchase Programs On January 29, 2019, the Company announced that its Board of Directors approved a separate $2.0 billion share repurchase program. As of December 31, 2019, the Company has not made any repurchases under the program. The Company’s Board of Directors previously approved a $2.0 billion share repurchase program in July 2018 (the “2018 Program”). As of December 31, 2019, the Company had completed the 2018 Program, repurchasing 12.5 million shares, including 5.3 million shares (or $0.8 billion of shares) in the year ended December 31, 2019. In September 2017, the Company’s Board of Directors approved a $2.0 billion share repurchase program. As of December 31, 2017, the Company had repurchased $450.0 million, or 2.6 million shares under the program. The Company completed the share repurchase program in 2018, repurchasing $1.54 billion or 9.6 million shares. Quarterly Dividend During the year ended December 31, 2019 the Company paid a quarterly cash dividend of $0.74 per share for holders of the Company’s ordinary shares in March, June, September and December of 2019. The total amount paid in the year ended December 31, 2019 was $974.4 million. During the year ended December 31, 2018 the Company paid a quarterly cash dividend of $0.72 per share for holders of the Company’s ordinary shares in March, June, September and December of 2018. The total amount paid in the year ended December 31, 2018 was $980.2 million. Preferred Shares In February 2015, the Company completed an offering of 5,060,000 of our 5.500% mandatorily convertible preferred shares, Series A, par value $0.0001 per share (the “Mandatory Convertible Preferred Shares”). Dividends on the Mandatory Convertible Preferred Shares were payable on a cumulative basis when, as and if declared by our board of directors, or an authorized committee thereof, at an annual rate of 5.500% on the liquidation preference of $1,000.00 per Mandatory Convertible Preferred Share. The net proceeds from the Mandatory Convertible Preferred Share issuance of $4,929.7 million were used to fund the Allergan Acquisition. In the year ended December 31, 2018 and 2017, the Company paid $69.6 million and $278.4 million, respectively, of dividends on the preferred shares. Each preferred share automatically converted to approximately 3.53 ordinary shares on March 1, 2018, for a total of 17,876,930 ordinary shares. Accumulated Other Comprehensive Income / (Loss) For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive income / (loss). The effects of converting non-functional currency assets and liabilities into the functional currency are recorded as transaction gains / (losses) in general and administrative expenses in the consolidated statements of operations. Unrealized gain / (losses) net of tax primarily represent experience differentials and other actuarial charges related to the Company’s defined benefit plans. The movements in accumulated other comprehensive income / (loss) for the years ended December 31, 2019 and 2018 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gain / (loss) net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2017 $ 1,782.7 $ 138.0 $ 1,920.7 Amounts reclassed, net of tax, upon adoption of ASU 2016-01 - (63.0 ) (63.0 ) Balance as of January 1, 2018 $ 1,782.7 $ 75.0 $ 1,857.7 Other comprehensive gain / (loss) before reclassifications into general and administrative (474.4 ) (38.1 ) (512.5 ) Balance as of December 31, 2018 $ 1,308.3 $ 36.9 $ 1,345.2 Other comprehensive gain / (loss) before reclassifications into general and administrative (151.8 ) 13.8 (138.0 ) Balance as of December 31, 2019 $ 1,156.5 $ 50.7 $ 1,207.2 As of December 31, 2019 and 2018, unrealized gain / (loss) net of tax included $7.9 million and $36.9 million, respectively,

Segments

Segments	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segments	NOTE 22 — Segments The Company’s businesses are organized into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments. During the second quarter of 2019, the Company changed the operational and management structure for its in-development calcitonin gene-related peptide (“CGRP”) receptors, Ubrogepant and Atogepant. These development products were previously reported within the US Specialized Therapeutics segment and have been transferred to the US General Medicine segment to align these development products with the management structure and reporting. The revenues and cost of sales related to these products in the prior periods were zero and any selling and marketing expenses and general and administrative expenses were de minimis and therefore it was not necessary to recast prior periods. The operating segments are organized as follows: • The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the U.S., including Medical Aesthetics, Medical Dermatology through September 20, 2018, Eye Care and Neuroscience and Urology therapeutic products. • The US General Medicine segment includes sales and expenses relating to branded products within the U.S. that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands. • The International segment includes sales and expenses relating to products sold outside the U.S. The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level: • Revenues and operating expenses within cost of sales, selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, divestitures, acquisitions, certain milestones and other shared costs. • General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States. • Other select revenues and operating expenses including R&D expenses, amortization, IPR&D impairments, goodwill impairments and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments. • Total assets including capital expenditures. The Company defines segment net revenues as product sales and ot her revenue derived from our products or licensing agreements. Cost of sales within segment contribution includes standard production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales within segment contribution excludes non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles. Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs. General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation costs and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Year Ended December 31, 2019 US Specialized US General Therapeutics Medicine International Total Net revenues $ 6,820.0 $ 5,834.9 $ 3,402.0 $ 16,056.9 Operating expenses: Cost of sales (1) 578.2 954.8 548.3 2,081.3 Selling and marketing 1,490.4 978.2 934.7 3,403.3 General and administrative 190.1 160.7 117.0 467.8 Segment contribution $ 4,561.3 $ 3,741.2 $ 1,802.0 $ 10,104.5 Contribution margin 66.9 % 64.1 % 53.0 % 62.9 % Corporate (2) 2,452.2 Research and development 1,812.0 Amortization 5,856.6 Goodwill impairments 3,552.8 In-process research and development impairments 436.0 Asset sales and impairments, net 440.2 Operating (loss) $ (4,445.3 ) Operating margin (27.7 )% (1) (2) Year Ended December 31, 2018 US Specialized US General Therapeutics Medicine International Total Net revenues $ 6,920.3 $ 5,322.9 $ 3,504.7 $ 15,747.9 Operating expenses: Cost of sales (1) 565.2 799.1 537.1 1,901.4 Selling and marketing 1,348.3 924.6 928.7 3,201.6 General and administrative 205.3 156.4 141.7 503.4 Segment contribution $ 4,801.5 $ 3,442.8 $ 1,897.2 $ 10,141.5 Contribution margin 69.4 % 64.7 % 54.1 % 64.4 % Corporate (2) 1,067.3 Research and development 2,266.2 Amortization 6,552.3 Goodwill impairments 2,841.1 In-process research and development impairments 804.6 Asset sales and impairments, net 2,857.6 Operating (loss) $ (6,247.6 ) Operating margin (39.7 )% (1) (2) Year Ended December 31, 2017 US Specialized US General Therapeutics Medicine International Total Net revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 15,919.3 Operating expenses: Cost of sales (1) 495.4 843.9 478.7 1,818.0 Selling and marketing 1,369.5 1,084.1 913.8 3,367.4 General and administrative 208.2 177.3 120.6 506.1 Segment contribution $ 4,730.5 $ 3,690.9 $ 1,806.4 $ 10,227.8 Contribution margin 69.5 % 63.7 % 54.4 % 64.2 % Corporate (2) 1,471.8 Research and development 2,100.1 Amortization 7,197.1 In-process research and development impairments 1,452.3 Asset sales and impairments, net 3,927.7 Operating (loss) $ (5,921.2 ) Operating margin (37.2 )% (1) (2) No country outside of the United States represents ten percent or more of net revenues. The US Specialized Therapeutics and US General Medicine segments are comprised solely of sales within the United States. The following table presents our net revenue disaggregated by geography for our international segment for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Years Ended December 31, 2019 2018 2017 Europe $ 1,471.7 $ 1,482.6 $ 1,439.2 Asia Pacific, Middle East and Africa 1,075.1 1,089.9 929.9 Latin America and Canada 772.9 862.4 863.3 Other* 82.3 69.8 87.1 Total International $ 3,402.0 $ 3,504.7 $ 3,319.5 *Includes royalty and other revenue The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Year Ended December 31, 2019 US Specialized Therapeutics US General Medicine International Total Botox® $ 2,730.5 $ - $ 1,060.8 $ 3,791.3 Restasis® 1,138.4 - 50.2 1,188.6 Juvederm® Collection 587.5 - 656.1 1,243.6 Lumigan®/Ganfort® 269.2 - 360.8 630.0 Linzess®/Constella® - 803.2 23.8 827.0 Bystolic® /Byvalson® - 600.6 2.1 602.7 Alphagan®/Combigan® 360.0 - 162.0 522.0 Lo Loestrin® - 588.9 - 588.9 Breast Implants 254.4 - 0.6 255.0 Viibryd®/Fetzima® - 412.1 11.4 423.5 Eye Drops 230.4 - 235.8 466.2 Asacol®/Delzicol® - 76.7 36.1 112.8 Coolsculpting® Consumables 185.3 - 76.3 261.6 Coolsculpting® Systems & Add On Applicators 62.8 - 42.4 105.2 Alloderm® 395.9 - 7.9 403.8 Ozurdex ® 125.5 - 274.6 400.1 Carafate ® /Sulcrate ® - 212.5 3.0 215.5 Aczone® 9.3 - - 9.3 Zenpep® - 288.0 1.2 289.2 Canasa®/Salofalk® - 31.5 16.8 48.3 Vraylar ® - 857.5 - 857.5 Saphris® - 135.3 - 135.3 Viberzi® - 187.9 1.6 189.5 Teflaro® - 147.0 6.0 153.0 Namzaric® - 88.6 - 88.6 Rapaflo® 23.5 - 6.0 29.5 Skin Care 158.0 - 14.6 172.6 Kybella® /Belkyra® 27.4 - 3.3 30.7 Dalvance® - 81.9 6.0 87.9 Avycaz® - 116.7 - 116.7 Liletta® - 79.1 - 79.1 Namenda® - 22.8 - 22.8 Armour Thyroid - 218.5 - 218.5 Savella® - 88.5 - 88.5 Other Products Revenues 261.9 797.6 342.6 1,402.1 Total segment revenues $ 6,820.0 $ 5,834.9 $ 3,402.0 $ 16,056.9 Corporate revenues 32.0 Total net revenues $ 16,088.9 Year Ended December 31, 2018 US Specialized Therapeutics US General Medicine International Total Botox ® $ 2,545.8 $ - $ 1,031.6 $ 3,577.4 Restasis ® 1,197.0 - 64.5 1,261.5 Juvederm ® 548.2 - 614.8 1,163.0 Linzess ® ® - 761.1 24.1 785.2 Lumigan ® ® 291.8 - 392.6 684.4 Bystolic ® ® - 583.8 2.0 585.8 Alphagan ® ® 375.4 - 176.0 551.4 Lo Loestrin ® - 527.7 - 527.7 Vraylar ® - 487.1 - 487.1 Eye Drops 202.7 - 279.7 482.4 Alloderm ® 407.3 - 8.0 415.3 Breast Implants 263.0 - 130.1 393.1 Viibryd ® ® - 342.4 7.2 349.6 Coolsculpting ® 235.3 - 64.2 299.5 Ozurdex ® 111.0 - 187.7 298.7 Zenpep ® - 237.3 0.4 237.7 Carafate ® ® - 217.8 2.8 220.6 Armour Thyroid - 198.8 - 198.8 Canasa ® ® - 169.2 17.6 186.8 Viberzi ® - 176.5 1.3 177.8 Asacol ® ® - 130.8 45.7 176.5 Coolsculpting ® 126.3 - 43.3 169.6 Skin Care 138.8 - 15.2 154.0 Saphris ® - 139.7 - 139.7 Teflaro ® - 128.0 0.3 128.3 Namzaric ® - 115.8 - 115.8 Avycaz ® - 94.6 - 94.6 Rapaflo ® 81.9 - 6.4 88.3 Savella ® - 85.0 - 85.0 Namenda ® - 71.0 - 71.0 Dalvance ® - 56.1 2.3 58.4 Aczone ® 55.1 - 0.4 55.5 Liletta ® - 50.9 - 50.9 Kybella ® ® 31.8 - 6.3 38.1 Other 308.9 749.3 380.2 1,438.4 Total segment revenues $ 6,920.3 $ 5,322.9 $ 3,504.7 $ 15,747.9 Corporate revenues 39.5 Total net revenues $ 15,787.4 Year Ended December 31, 2017 US Specialized Therapeutics US General Medicine International Total Botox ® $ 2,254.4 $ - $ 914.5 $ 3,168.9 Restasis ® 1,412.3 - 61.3 1,473.6 Juvederm ® 501.1 - 540.7 1,041.8 Linzess ® ® - 701.1 21.9 723.0 Lumigan ® ® 317.5 - 371.5 689.0 Bystolic ® ® - 612.2 2.2 614.4 Alphagan ® ® 377.3 - 175.1 552.4 Eye Drops 199.5 - 281.0 480.5 Lo Loestrin ® - 459.3 - 459.3 Namenda ® - 452.9 - 452.9 Breast Implants 242.6 - 156.9 399.5 Viibryd ® ® - 333.2 3.1 336.3 Alloderm ® 321.2 - 7.5 328.7 Ozurdex ® 98.4 - 213.4 311.8 Vraylar ® - 287.8 - 287.8 Asacol ® ® - 195.5 50.2 245.7 Carafate ® ® - 235.8 2.9 238.7 Zenpep ® - 212.3 - 212.3 Coolsculpting ® 150.1 - 41.6 191.7 Canasa ® ® - 162.7 18.3 181.0 Armour Thyroid - 169.1 - 169.1 Aczone ® 166.3 - 0.5 166.8 Skin Care 153.2 - 12.0 165.2 Viberzi ® - 156.6 0.5 157.1 Saphris ® - 155.2 - 155.2 Coolsculpting ® 106.6 - 32.1 138.7 Namzaric ® - 130.8 - 130.8 Teflaro ® - 121.9 - 121.9 Rapaflo ® 108.1 - 7.3 115.4 Savella ® - 98.2 - 98.2 Avycaz ® - 61.2 - 61.2 Kybella ® ® 49.5 - 6.8 56.3 Dalvance ® - 53.9 2.4 56.3 Liletta ® - 37.6 - 37.6 Other 345.5 1,158.9 395.8 1,900.2 Total segment revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 15,919.3 Corporate revenues 21.4 Total net revenues $ 15,940.7 On July 24, 2019, the Company announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders as a precaution following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provided by the U.S. Food and Drug Administration (“FDA”). In connection with the voluntary recall, the Company recorded an unfavorable adjustment to operating income of $118.0 million. Of this amount, $37.9 million related to estimated customer returns of product previously sold and was recorded as a reduction of net revenues, $68.1 million related to write-offs of inventory and other costs and was recorded in cost of sales, and $12.0 million related to the estimated penalties and costs to undertake the voluntary recall was recorded in selling, general and administrative expense. On January 27, 2020 the Company announced it has entered into a contingent agreement to divest Zenpep in connection with the proposed AbbVie Transaction with any such divestiture contingent on the closing of the AbbVie Transaction.

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Dec. 31, 2019
Restructuring And Related Activities [Abstract]
Business Restructuring Charges	NOTE 23 — Business Restructuring Charges Restructuring activities for the year ended December 31, 2019 were as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2018 $ 71.4 $ - $ 14.4 $ 85.8 Charged to expense Cost of sales 1.4 - - 1.4 Research and development - - - - Selling and marketing 0.7 - - 0.7 General and administrative 3.7 - 2.3 6.0 Total expense 5.8 - 2.3 8.1 Cash payments (64.8 ) - (3.5 ) (68.3 ) Non-cash adjustments (2.1 ) - - (2.1 ) Reserve balance at December 31, 2019 $ 10.3 $ - $ 13.2 $ 23.5 Restructuring activities for the year ended December 31, 2018 is as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2017 $ 166.0 $ - $ 19.9 $ 185.9 Charged to expense Cost of sales 7.3 - - 7.3 Research and development 1.0 - - 1.0 Selling and marketing 31.2 4.1 - 35.3 General and administrative 4.3 4.1 - 8.4 Total expense 43.8 8.2 - 52.0 Cash payments (138.4 ) - (5.5 ) (143.9 ) Non-cash adjustments - (8.2 ) - (8.2 ) Reserve balance at December 31, 2018 $ 71.4 $ - $ 14.4 $ 85.8 In the year ended December 31, 2018, the Company recorded severance and other employee related charges of $52.0 million, which includes $8.2 million of share-based compensation related to this program. In the year ended December 31, 2018, the Company incurred $14.1 million in severance and other employee related charges and $8.2 million of share-based compensation related to the restructuring program announced in December 2017. In the year ended December 31, 2018, the Company initiated a new restructuring program of its international commercial operations. As a result of the program, the Company eliminated approximately 200 selling and marketing positions which streamlined the Company’s operations and focusing on key growth markets and products. The Company paid the majority of the severance costs during the 2019 fiscal year.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2019
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	NOTE 24 — Derivative Instruments and Hedging Activities The Company’s revenue, earnings, cash flows and fair value of its assets and liabilities can be impacted by fluctuations in foreign exchange risks and interest rates, as applicable. The Company manages the impact of foreign exchange risk and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency derivatives. As of December 31, 2019, the Company had outstanding third-party foreign currency forward instruments, excluding debt, of $49.7 million. As of December 31, 2018, the Company had outstanding third-party foreign currency forward instruments, excluding debt, of $42.1 million. Internationally, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect the Company’s consolidated revenues and favorably impact operating expenses in U.S. dollars. Derivatives Not Designated as Hedging Instruments In November 2018, the Company entered into a 700 million Euro forward contract to buy Euros while selling USD. The derivative matured on May 31, 2019. The derivative instrument was marked-to-market to the P&L offsetting the revaluation (P&L) impact on the Euro 700 million variable interest debt. For the year ended December 31, 2019, the Company recorded a loss of $29.8 million relating to this instrument in general and administrative expenses. Derivatives Designated as Hedging Instruments Cash Flow Hedge In January 2019, the Company entered into $500.0 million notional floating to fixed interest rate swaps maturing on March 12, 2020 whereby it fixed the interest rates on $500.0 million floating rate notes due March 12, 2020 to an average interest rate of 3.98%. The swaps are being accounted for using hedge accounting treatment. As of December December Net Investment Hedge In the normal course of business, we manage certain foreign exchange risks through a variety of strategies, including hedging. Our hedging strategies include the use of derivatives, as well as net investment hedges. For net investment hedges, the effective portion of the gains and losses on the instruments arising from the effects of foreign exchange are recorded in the currency translation adjustment component of accumulated other comprehensive income / (loss), consistent with the underlying hedged item. Hedging transactions are limited to an underlying exposure. As a result, any change in the value of our hedging instruments would be substantially offset by an opposite change in the value of the underlying hedged items. We do not use derivative instruments for trading or speculative purposes. The Company is exposed to foreign exchange risk in its international operations from foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business, including the Euro Denominated Notes. In the years ended December 31, 2019 and 2018, we used effective net investment hedges to partially offset the effects of foreign currency on our investments in certain of our foreign subsidiaries. The total notional amount of our instruments designated as net investment hedges was $5.0 billion as of December 31, 2019 and $5.1 billion as of December 31, 2018. During the year ended December 31, 2019, the impact of the net investment hedges recorded in other comprehensive loss was a gain of $113.0 million, which primarily offset the impact of the Euro denominated notes. During the year ended December 31, 2018, the impact of the net investment hedges recorded in other comprehensive loss was a gain of $144.5 million.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 25 — Fair Value Measurement Assets and liabilities that are measured at fair value using Fair Value Leveling or that are disclosed at fair value on a recurring basis as of December 31, 2019 and 2018 consisted of the following ($ in millions): Fair Value Measurements as of December 31, 2019 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 1,535.4 $ 1,535.4 $ - $ - Short-term investments 3,411.6 - 3,411.6 - Deferred executive compensation investments 89.2 77.0 12.2 - Contingent income 51.8 - - 51.8 Investments and other 70.9 38.2 32.6 - Total assets $ 5,158.9 $ 1,650.6 $ 3,456.4 $ 51.8 Liabilities: Deferred executive compensation liabilities 89.2 77.0 12.2 - Contingent consideration obligations 389.4 - - 389.4 Total liabilities $ 478.6 $ 77.0 $ 12.2 $ 389.4 * Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents. Fair Value Measurements as of December 31, 2018 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 207.1 $ 207.1 $ - $ - Short-term investments 1,026.9 - 1,026.9 - Deferred executive compensation investments 90.8 73.8 17.0 - Contingent income 50.3 - - 50.3 Investments and other 46.0 38.5 7.5 - Total assets $ 1,421.1 $ 319.4 $ 1,051.4 $ 50.3 Liabilities: Deferred executive compensation liabilities 90.8 73.8 17.0 - Contingent consideration obligations 344.6 - - 344.6 Total liabilities $ 435.4 $ 73.8 $ 17.0 $ 344.6 * Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents. Investments in securities as of December 31, 2019 and 2018 included the following ($ in millions): Investments in Securities as of December 31, 2019 Level 1 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 1,535.4 $ 1,535.4 $ 1,535.4 $ - Total $ 1,535.4 $ 1,535.4 $ 1,535.4 $ - Level 2 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Other investments $ 3,411.6 $ 3,411.6 $ - $ 3,411.6 Total $ 3,411.6 $ 3,411.6 $ - $ 3,411.6 Investments in Securities as of December 31, 2018 Level 1 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 207.1 $ 207.1 $ 207.1 $ - Total $ 207.1 $ 207.1 $ 207.1 $ - Level 2 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Other investments $ 1,026.9 $ 1,026.9 $ - $ 1,026.9 Total $ 1,026.9 $ 1,026.9 $ - $ 1,026.9 Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values are determined based on Fair Value Leveling. Marketable securities and investments consist of money market securities, U.S. treasury and agency securities, and equity and debt securities of publicly traded companies for which market prices are readily available. Unrealized gains or losses on marketable debt securities are recorded in interest income beginning January 1, 2018. Unrealized gains or losses on long-term equity investments are recorded in other income / (expense), net beginning on January 1, 2018. These amounts were recorded within accumulated other comprehensive (loss) / income as of December 31, 2017. The Company’s marketable securities and other long-term investments are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and maturity management. Contingent Consideration Obligations The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity, and is based on our own assumptions. Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Years Ended December 31, Expense / (income) 2019 2018 2017 Cost of sales $ 44.6 $ (111.7 ) $ (183.2 ) Research and development 9.5 5.1 50.0 Total $ 54.1 $ (106.6 ) $ (133.2 ) In the year ended December 31, 2019, the expense in cost of sales primarily related to an increase in commercial sales forecasts for Liletta ® During the year ended December 31, 2018, cost of sales primarily relates to the Company’s True Tear ® . During the year ended December 31, 2017, the Company had net contingent consideration income in cost of sales of $183.2 million due to declines in forecasted revenues for select products, including Rhofade ® ® The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2019 and 2018 ($ in millions): Balance as of December 31, 2018 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2019 Liabilities: Contingent consideration obligations $ 344.6 $ - $ (9.3 ) $ 54.1 $ 389.4 Balance as of December 31, 2017 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2018 Liabilities: Contingent consideration obligations $ 476.9 $ - $ (25.7 ) $ (106.6 ) $ 344.6 The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate to reflect the internal rate of return and incremental commercial uncertainty, major risks and uncertainties associated with the successful completion of the events triggering the contingent obligation. At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. Accretion expense related to the increase in the net present value of the contingent liability is included in operating income for the period. During the year ended December 31, 2019, the following activity in contingent consideration obligations by acquisition was incurred ($ in millions): Business Acquisition Balance as of December 31, 2018 Fair Value Adjustments and Accretion Payments and Other Balance as of December 31, 2019 Tobira acquisition $ 255.0 $ 9.3 $ - $ 264.3 Medicines 360 acquisition 43.1 43.3 (6.7 ) 79.7 AqueSys acquisition 5.4 0.2 - 5.6 Oculeve acquisition 1.7 - - 1.7 ForSight acquisition 24.1 0.3 - 24.4 Forest acquisition 13.6 1.2 (2.3 ) 12.5 Other 1.7 (0.2 ) (0.3 ) 1.2 Total $ 344.6 $ 54.1 $ (9.3 ) $ 389.4 Contingent Income The fair value measurement of the contingent income is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity, and is based on our own assumptions. Changes in the fair value of the contingent income are recorded in our consolidated statements of operations as follows ($ in millions): Balance as of December 31, 2018 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2019 Asset: Contingent income $ 50.3 $ - $ (1.1 ) $ 2.6 $ 51.8

Commitments & Contingencies

Commitments & Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments & Contingencies	NOTE 26 — Commitments & Contingencies The Company and its affiliates are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that is accrued. As of December 31, 2019, the Company’s consolidated balance sheet includes accrued loss contingencies of approximately $1,190.0 million. As of December 31, 2018, the Company’s consolidated balance sheet included accrued loss contingencies of approximately $65.0 million. The Company’s legal proceedings range from cases brought by a single plaintiff to mass tort actions and class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including, but not limited to, qui tam In matters involving the assertion or defense of the Company’s intellectual property, the Company believes it has meritorious claims and intends to vigorously assert or defend the patents or other intellectual property at issue in such litigation. Similarly, in matters where the Company is a defendant, the Company believes it has meritorious defenses and intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation or, in the case of patent enforcement matters, that a generic version of the product at issue will not be launched or enjoined. Failing to prevail in a litigation could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Intellectual Property Litigation Patent Enforcement Matters Bystolic ® . On July 2, 2019, subsidiaries of the Company brought an action for infringement of U.S. Patent No. 6,545,040 in the United States District Court for the District of Delaware against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, “Ajanta”) in connection with an abbreviated new drug application filed with the FDA by Ajanta seeking approval to market a generic version of Bystolic ® and challenging said patent. The Company entered into a settlement agreement with Ajanta on December 17, 2019, and the case was dismissed on January 2, 2020 Combigan ® ® ® Fetzima ® In April 2019, subsidiaries of the Company and Pierre Fabre Medicament S.A.S. brought an action for infringement of the ‘879, ‘598 and ‘937 Patents against Micro Labs Ltd. and Micro Labs USA, Inc. (“Micro”) in connection with Micro’s abbreviated new drug application seeking approval to market a generic version of Fetzima ® Juvéderm ® On January 2 3, 2020, subsidiaries of the Company filed a complaint for infringement of U.S. Patent Nos. 10,391,202 (the “‘ 202 Patent”) , and 10,485,896 (the “‘ 896 Patent”) in the U.S. District Court for the District of Delaware against Prollenium. The complaint seeks, among other things, a judgment that Defendants have infringed these patents by making, selling, offering to sell, and importing Prollenium’s Revanesse® Versa+TM product s within and into the United States. Plaintiffs seek injunctive relief and damages for Defendants’ infringement. Juvéderm ® . In August, September and October 2019, Prollenium US Inc. (“Prollenium”) submitted Inter Partes Review (“IPR”) petitions to the USPTO regarding U.S. Patent Nos. 8,450,475 (the “‘475 Patent), 9,238,013 (the “‘013 patent”), 9,358,322 (the “‘322 patent”), 8,822,676 (the “‘676 patent”), 8,357,795 (the “‘795 patent”) and 9,089,519 (the “‘519 patent”). Prollenium’s IPR petitions seek review of all claims of the ‘013, ‘322, 676, and ‘519patents, claims 1-9, 18, and 27-37 of the ‘475 patent, and claims 1-11, 22, 26-39, and 40-41 of the ‘795 patent. Patent owner’s preliminary responses for these petitions are due on December 19, 2019, or later. The Company filed patent owner's preliminary responses in December 2019 and January 2020 for petitions related to the ‘475, ‘013, ‘322, ‘676, and ‘795 patents. The patent owner's preliminary response for the petition related to the ‘519 patent is due on January 29, 2020. On January 17, 2020, Prollenium filed a consolidated reply to the patent owner's preliminary responses with respect to the ‘475, ‘013, ‘322, ‘676, and ‘795 patents, and on January 24, 2020, the Company filed a consolidated sur-reply. Latisse ® . In December 2016, Sandoz announced the U.S. market launch of its generic copy of Latisse ® ® Latisse ® . On September 19, 2018, subsidiaries of the Company and Duke University brought an action for infringement of U.S. Patent No. 9,579,270 (the “‘270 Patent”) against Akorn, Inc. and Hi-Tech Pharmacal Co., Inc. (collectively, “Akorn”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Akorn seeking approval to market a generic version of Latisse® and challenging the ‘270 patent. The Company subsidiaries and Duke entered into a settlement agreement with Akorn and the case was dismissed on October 15, 2019. Linzess ® . Beginning in November 2016 subsidiaries of the Company and Ironwood Pharmaceuticals, Inc. (collectively, “Plaintiffs”), brought multiple actions for infringement of some or all of U.S. Patent Nos. 7,304,036 (the “‘036 Patent”); 7,371,727 (the “‘727 Patent”); 7,704,947 (the “‘947 Patent”); 7,745,409 (the “‘409 Patent”); 8,080,526 (the “‘526 Patent”); 8,110,553 (the “‘553 Patent”); 8,748,573 (the “‘573 Patent”); 8,802,628 (the “‘628 Patent”); and 8,933,030 (the “‘030 Patent”) against Teva Pharmaceuticals USA, Inc. (“Teva”), Aurobindo Pharma Ltd. (“Aurobindo”), Mylan Pharmaceuticals Inc. (“Mylan”), Sandoz Inc. (“Sandoz”) and Sun Pharma Global FZE (“Sun”) in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva, Aurobindo, Mylan, Sandoz and Sun, each seeking approval to market generic versions of Linzess ® On October 20, 2017, November 30, 2017 and January 20, 2018, Plaintiffs brought actions for infringement of U.S. Patent No. 9,708,371 (the “‘371 Patent”) in the U.S. District Court for the District of Delaware against Teva, Mylan and Sandoz, respectively. The ‘371 Patent expires in 2033. The ‘371 patent actions have been consolidated with the November 2016 Action. On February 2, 2018 and March 29, 2018, Plaintiffs brought actions for infringement of some or all of the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553, ‘030 and ‘371 Patents against Teva and Mylan in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva and Mylan, each seeking approval to market generic versions generic versions of Linzess ® In May and August 2018, the district court granted joint stipulations and orders to dismiss without prejudice all claims, counterclaims, and defenses in the November 2016 Action with respect to the ‘371 Patent and the ‘030 Patent, respectively, as between Plaintiffs, Teva, Mylan and Sandoz. On September 4, 2018, Plaintiffs filed an amended complaint as to Mylan to assert the ‘628 patent against Mylan’s 72 mcg ANDA product. Plaintiffs entered into a settlement agreement with Sun and certain Sun affiliates and the case against Sun was dismissed on January 18, 2018. Plaintiffs entered into a settlement agreement with Aurobindo and the case against Aurobindo was dismissed on May 7, 2018. Plaintiffs entered into a settlement agreement with Mylan and the case against Mylan was dismissed on December 27, 2018. Under the terms of the settlement agreement, Plaintiffs will provide a license to Mylan to market its generic versions of Linzess ® ® Plaintiffs entered into a settlement agreement with Sandoz on January 3, 2020, and the cases against Sandoz were dismissed on January 7, 2020. Under the terms of the settlement agreement, Plaintiffs will provide a license to Sandoz to market its generic versions of Linzess ® On January 17, 2020, upon the parties' request, the district court dismissed without prejudice the litigations relating only to Teva's 72 mcg version of Linzess ® ® ® Saphris ® . Between September 2014 and May 2015, subsidiaries of the Company brought actions for infringement of some or all of U.S. Patent Nos. 5,763,476 (the “‘476 patent”), 7,741,358 (the “‘358 patent”) and 8,022,228 (the “‘228 patent”) against Sigmapharm Laboratories, LLC (“Sigmapharm”), Hikma Pharmaceuticals, LLC (“Hikma”), Breckenridge Pharmaceutical, Inc. (“Breckenridge”), Alembic Pharmaceuticals, Ltd. (“Alembic”) and Amneal Pharmaceuticals, LLC (“Amneal”), and related subsidiaries and affiliates thereof in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug applications respectively filed with FDA by Sigmapharm, Hikma, Breckenridge, Alembic and Amneal, each seeking approval to market a generic versions of Saphris ® On March 14, 2019, the Federal Circuit vacated the district court’s July 2017 judgment that claims 1 and 4 are not invalid and remanded for the district court to consider a fact question and its impact on the obviousness analysis. On April 15, 2019, Plaintiffs filed a combined petition for panel rehearing and rehearing en banc with respect to this issue, which was denied on May 15, 2019. In its March 14, 2019 order, the Federal Circuit also vacated the judgment of non-infringement of claims 4, 9 and 10 as to Alembic and Breckenridge and remanded for the district court to consider their infringement under a revised claim construction. In a joint stipulation entered by the district court on November 5, 2019, Alembic stipulated that its ANDA infringed claims 4, 9 and 10 of the '476 patent. On December 17, 2019, the district court entered a schedule for briefing on the remanded issues, with the parties' opening briefs due on February 10, 2020, and responsive briefs due on March 26, 2020. Oral argument is scheduled for April 2, 2020. A separate bench trial concerning Sigmapharm’s infringement of claim 1 of the ‘476 patent began on June 20, 2018, and on November 16, 2018, the court held that Sigmapharm’s proposed ANDA product would infringe claim 1 of the ‘476 patent On November 26, 2018, Sigmapharm sought relief from the November 16, 2018 decision. On November 30, 2018, the Company moved for entry of final judgment. On August 6, 2019, the district court denied Sigmapharm’s motion to reconsider its November 2018 Order, and denied without prejudice the Company’s motion for entry of final judgment. On August 22, 2019, the district court entered Plaintiffs and Sigmapharm’s stipulated final judgment finding that Sigmapharm infringed claims 1, 2, 5, and 6 of the ‘476 patent and ordering, among other things, that Sigmapharm’s ANDA be converted to tentative approval and not be granted final approval by FDA earlier than the date of expiration of the ‘476 patent inclusive of any applicable adjustments, extensions or exclusivities. Viberzi ® . On September 6, 2019, subsidiaries of the Company and Janssen Pharmaceutica NV brought an action for infringement of U.S. Patent Nos. 7,741,356 ("the '356 patent"), 7,786,158 ("the '158 patent"), 8,344,011 ("the '011 patent"), 8,609,709 ("the '709 patent"), 8,772,325 ("the '325 patent"), 9,205,076 ("the '076 patent"), 9,700,542 ("the '542 patent"), and 10,213,415 ("the '415 patent") in the United States District Court for the District of Delaware against Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, “ Aurobindo ”) in connection with an abbreviated new drug application filed with the FDA by Aurobindo seeking approval to market a generic version of Viberzi ® and challenging said patent s . No trial date or case schedule has been set. On September 13, 2019, subsidiaries of the Company brought an action for infringement of United States Patent Nos. 8,691,860 ("the '860 patent"), 9,115,091 ("the '091 patent"), 9,364,489 ("the '489 patent"), 9,675,587 ("the '587 patent"), 9,789,125 ("the '125 patent"), and 10,188,632 ("the '632 patent") in the United States District Court for the District of Delaware against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. (collectively, “Aurobindo”), Alkem Laboratories Limited (“Alkem”), Hetero Labs Limited and Hetero USA Inc. (collectively, “Hetero”), MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, “MSN”), Sun Pharmaceutical Industries Limited (“Sun”), and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) in connection with abbreviated new drug applications, respectively filed with the FDA by Aurobindo, Alkem, Hetero, MSN, Sun and Zydus, each seeking approval to market generic versions of Viberzi® and challenging said patents. Vraylar ® On December 20, 2019, subsidiaries of the Company and Gedeon Richter Plc. brought an action for infringement of U.S. Patent Nos. 7,737,142 ("the '142 patent"), and 7,943,621 ("the '621 patent") in the United States District Court for the District of Delaware against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE (collectively, "Sun"), Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. (collectively, "Aurobindo"), and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited (collectively, "Zydus") in connection with abbreviated new drug applications, respectively filed with the FDA by Sun, Aurobindo, and Zydus, seeking approval to market generic versions of Vraylar ® and challenging said patents. No trial date or case schedule has been set. Trade Secret Matters Botulinum Neurotoxin ITC Investigation . On January 30, 2019, subsidiaries of the Company and Medytox Inc. (collectively, “Complainants”) filed a complaint with the United States International Trade Commission (“ITC”) against Daewoong Pharmaceuticals Co., Ltd., Daewoong Co., Ltd., and Evolus Inc. (collectively, “Respondents”) requesting the ITC commence an investigation with respect to the Respondents’ importation into the United States of Respondents’ botulinum neurotoxin products, including DWP-450 (also known as Jeuveau TM TM TM Trademark Enforcement Matters Juvéderm ® . On April 5, 2017, a subsidiary of the Company brought an action for unfair competition, false advertising, dilution, conspiracy and infringement of Allergan’s Juvéderm ® ® Subsidiaries of the Company requested a preliminary injunction against Dermavita, Dima Corp, Aesthetic Services & Development, Jacqueline Sillam and Dimitri Sillam in the High Court of Paris, France. During June 2017, the Paris Court preliminarily enjoined the defendants, inter alia, to refrain from promoting or selling in France its Juvederm products, to transfer various domain names and to pay provisional damages to Allergan, on the basis that such use would infringe Allergan’s EU and French Juvéderm ® On January 22, 2019, subsidiaries of the Company brought a related action for infringement of the Company’s Juvéderm ® Furthermore, more than 150 trademark opposition and cancellation actions between Allergan and Dermavita have been filed in front of the USPTO, EUIPO and various other national and regional trademark offices around the world. Most of these actions remain pending; however, Allergan has received favorable decisions in more than thirty (30) such actions. Antitrust Litigation Asacol ® . Class action complaints have been filed against certain subsidiaries of the Company on behalf of putative classes of direct and indirect purchasers. The lawsuits have been consolidated in the U.S. District Court for the District of Massachusetts. The complaints allege that plaintiffs paid higher prices for Asacol ® ® ® Loestrin ® . Putative classes of direct and indirect purchasers as well as opt-out direct purchasers have filed complaints that have been consolidated in the U.S. District Court for the District of Rhode Island. The lawsuits allege that subsidiaries of the Company engaged in anticompetitive conduct, including when settling patent lawsuits related to Loestrin ® Namenda ® . In 2014, the State of New York filed a lawsuit in the U.S. District Court for the Southern District of New York alleging that Forest was acting to prevent or delay generic competition to Namenda® in violation of federal and New York antitrust laws and committed other fraudulent acts in connection with its commercial plans for Namenda ® Restasis ® Competitor Litigation . Shire, which offers the dry-eye disease drug Xiidra ® , sued subsidiaries of the Company in U.S. District Court for the District of New Jersey alleging that defendants unlawfully harmed competition by foreclosing Xiidra ® from sales to Medicare Part D plans (and the members of such plans) through the use of discounts (a) contingent on Restasis® receiving preferential formulary treatment; and/or (b) across a bundle of Allergan’s products, including Restasis ® . The complaint seeks injunctive relief and damages under federal and state law. The court issued a decision on March 22, 2019 granting the defendants’ motion to dismiss the complaint. On April 25, 2019, Shire filed an amended complaint. Defendants have moved to dismiss the amended complaint. At the request of the parties, the court entered an Order on June 28, 2019, staying the action through December 27, 2019. The stay has since been extended through February 18, 2020. Restasis ® . Several class actions were filed on behalf of putative classes of direct and indirect purchasers of Restasis ® ® The Company intends to vigorously defend its conduct and the patents or other intellectual property at issue in what remains of this litigation Commercial Litigation Celexa ® ® . Certain subsidiaries of the Company were named in federal court actions relating to the promotion of Celexa ® ® Warner Chilcott Marketing Practices . A Generic Drug Pricing Securities and ERISA Litigation . Putative classes of shareholders and two individual opt-out plaintiffs filed class action lawsuits against the Company and certain of its current and former officers alleging that defendants made materially false and misleading statements between February 2014 and November 2016 regarding the Company’s internal controls over its financial reporting and that it failed to disclose that its former Actavis generics unit had engaged in illegal, anticompetitive price-fixing with its generic industry peers. These lawsuits have been consolidated in the U.S. District Court for the District of New Jersey. The complaints seek unspecified monetary damages. The Company filed a motion to dismiss the complaint, but the court denied the motion in a ruling on August 6, 2019. The parties are now engaging in discovery in these cases. In addition, class action complaints have been filed premised on the same alleged underlying conduct that is at issue in the securities litigation but that assert claims under the Employee Retirement Income Security Act of 1974 (“ERISA”). These complaints have been consolidated in the district court in New Jersey. The court granted the Company’s motion to dismiss this complaint. The ERISA plaintiffs have appealed this decision to the Third Circuit Court of Appeals Prescription Opioid Drug Abuse Litigation . The Company has been named as a defendant, along with several other manufacturers and distributors of opioid products, in over 2,000 discussions with plaintiffs in the MDL proceeding, state attorneys general and other plaintiff stakeholders. The Company continues to examine the possibility of broader resolutions in these actions . Testosterone Replacement Therapy Class Action . Subsidiaries of the Company were named in a class action complaint filed on behalf a putative class of third-party payers in the U.S. District Court for the Northern District of Illinois. The suit alleges that the Company’s subsidiaries violated various laws including the federal RICO statute and state consumer protection laws in connection with the sale and marketing of Androderm ® Breast Implant Securities Class Action. In December 2018, two plaintiffs filed class action lawsuits against the Company and certain of its current and former officers alleging that defendants made materially false and misleading statements regarding the Company’s textured breast implants and their association with an uncommon cancer known as breast implant associated anaplastic large cell lymphoma. These lawsuits have been consolidated in the U.S. District Court for the Southern District of New York. The complaints seek unspecified monetary damages. The Company filed a motion to dismiss the amended complaint, which the court granted in part and denied in part in a ruling on September 20, 2019. The Company filed its answer on October 18, 2019 and the parties are now engaging in discovery. Oculeve Shareholder Dispute . On February 26, 2019, Fortis Advisors LLC, as a representative of the former stockholders of Oculeve, Inc., filed a lawsuit against a subsidiary of the Company in state court in Delaware. The lawsuit centers on a claim that the Company breached the terms of a July 2015 merger agreement. The court recently denied the Company subsidiary’s motion to dismiss the complaint. AbbVie Transaction Shareholder Action . On June 25, 2019, the Company and AbbVie Inc. announced that the companies had entered into a definitive transaction agreement whereby AbbVie will acquire the Company in a cash and stock transaction. On September 20, 2019, a putative class action lawsuit was filed against the Company by one of its shareholders alleging that the Company and its Board of Directors violated the Securities laws by omitting or misrepresenting material information in the proxy statement the Company filed on September 16, 2019 seeking shareholder approval of the transaction with AbbVie. The Company has not yet responded to this complaint. In addition to the complaint in this action, the Company received a shareholder demand letter from a shareholder following the issuance of the preliminary proxy statement filed with the Securities and Exchange Commission on August 12, 2019. Product Liability Litigation Actonel ® . A subsidiary of the Company is a defendant in over 500 filed cases in federal and various state courts, relating to the bisphosphonate prescription drug Actonel ® ® Breast Implant Litigation . Certain Company subsidiaries are defendants in approximately 38 cases, including several class actions and individual cases filed on behalf of multiple plaintiffs, alleging that Allergan’s textured breast implants caused women to develop an uncommon cancer known as breast implant associated anaplastic large cell lymphoma (“BIA-ALCL”). Some of the lawsuits include claims that the defendants failed to properly warn against this risk and failed to promptly and properly report the results of the post-marketing studies relating to these products and that plaintiffs suffered injuries as a result. Other lawsuits seek to recover costs related to medical monitoring and damages for fear of developing BIA-ALCL. The federal product liability and “fear of” cases have been consolidated in an MDL in the U.S. District Court for New Jersey. There are several additional cases filed in state courts in the United States and well as provincial courts in Canada. On July 24, 2019, Allergan announced a voluntary worldwide recall of unused BIOCELL textured breast implants and tissue expanders. This announcement may impact the number of lawsuits related to BIA-ALCL filed moving forward Benicar ® Litigation . A subsidiary of the Company has been named in a number of lawsuits involving allegations that Benicar ® caused certain gastrointestinal injuries. Under a co-promotion agreement, Daiichi Sankyo is defending the Company subsidiary in these lawsuits and has announced that it has agreed to enter into a program to settle all of the pending cases on behalf of all defendants, including the Company subsidiary. Celexa ® ® . Certain Company subsidiaries are defendants in over 150 actions alleging that Celexa® or Lexapro ® RepliForm ® . A Company subsidiary has been named as a defendant in over 300 cases alleging that its biologic mesh product RepliForm ® Testosterone Litigation . A number of product liability suits were filed against certain Company subsidiaries as well as other manufacturers and distributors of testosterone products, for personal injuries including but not limited to cardiovascular events allegedly arising out of the use of Androderm ® Government Investigations, Government Litigation and Qui Tam Litigation The Company and its subsidiaries are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings that could result in litigation, and other litigation matters that arise from time to time. Company subsidiaries have received subpoenas and/or Civil Investigative Demands (“CID”) from the United States Department of Justice, the United States Health and Human Services, Office of Inspector General, United States Congressional Committees as well as various state regulatory and enforcement authorities. Each of the subpoenas and CIDs seek documents and information relating to discrete topics, including but not limited to: the calculation and reporting by certain Company subsidiaries of their Average Manufacturer Prices, Average Wholesale Prices and Best Prices for several of their products; sales and marketing practices of Botox to urology practices; the promotion and sale of two gastroenterology products; the Saint Regis Mohawk Tribe’s acquisition of six Restasis patents and the granting of exclusive licenses to the Restasis product to the Company; and, the promotion and sale of opioid products. In each case, the Company and its subsidiaries are cooperating fully with the governmental authority’s requests. Certain states have initiated lawsuits and qui tam lawsuits have been filed by private parties, also known as relators, on behalf of the federal or state governments. Certain Company subsidiaries have been named as defendants in lawsuits that allege generally that state Medicaid agencies were overcharged for their share of Medicaid drug reimbursement costs due to inflated Average Wholesale Prices (“AWP”) reported by the Company subsidiaries. AWP lawsuits are currently pending in Illinois, Utah and Wisconsin. Namenda XR ® ® . A relator filed a qui tam lawsuit on behalf of the United States government and several individual states against the Company and certain of its subsidiaries along with Adamas Pharma LLC and Adamas Pharmaceuticals, Inc. (collectively, “Adamas”). The lawsuit, filed in the U.S. District Court for the Northern District of California, was unsealed on February 6, 2019. The federal and state governments have declined to intervene in this action. The complaint alleges generally that the Adamas and Allergan defendants each engaged in conduct that delayed generic versions of Namenda XR ® ® Medical Aesthetics Qui Tam . A subsidiary of the Company was served with a qui tam lawsuit that was filed in the U.S. District Court for the Central District of California on behalf of the United States and several individual states. The federal and state governments have declined to intervene in this action. The complaint alleges that certain promotional programs and sampling practices of the Company’s Medical Aesthetics business result in price reporting violations and violate anti-kickback statutes. The court recently denied the Company subsidiary’s motion to dismiss this complaint. Lumigan ® . A relator filed a qui tam lawsuit on behalf of the United States government and several individual states against a subsidiary of the Company in the U.S. District Court for the Southern District of New York, which was unsealed on October 1, 2019. The federal and state governments have declined to intervene in this action. The complaint alleges generally that Allergan failed to disclose certain side effects of Lumigan ® Pricing Qui Tam. A relator filed a qui tam lawsuit on behalf of the United States government and several individual states against certain subsidiaries of the Company in the U.S. District Court for the District of Maryland , which was unsealed on September 17 , 2019. The federal and state government s have d eclined to intervene in this action. The complaint alleges generally that the Company misreported its Best Price and Average Manufacturer Price for a number of products, thereby causing overpayment by the government. Matters Relating to the Company’s Divested Generics Business The following matters relate to the former generics business of the Company or the transaction pursuant to which that business was sold to Teva, effective August 2, 2016. Teva has agreed to indemnify and defend the Company against all matters asserted in litigation against the Company arising out of the former generics business, including litigations and investigations relating to generic opioid products including, without limitation, the actions described below. Lidoderm ® . The U.S. Federal Trade Commission filed a lawsuit in federal district court in the Eastern District of Pennsylvania against the Company and one of its former global generics business subsidiaries and others alleging that patent litigation settlements relating to Lidoderm were anticompetitive. The FTC voluntarily withdrew its complaint in Pennsylvania and filed a similar complaint in the U.S. District Court for the Northern District California where similar lawsuits filed by private plaintiffs were already pending and where the State of California filed a similar complaint against the same defendants. Defendants in the Pennsylvania action filed a declaratory judgment action against the FTC in the Pennsylvania federal court but the court granted the FTC’s motion to dismiss this lawsuit. The FTC and State of California’s actions were stayed pending the declaratory judgment action in the Eastern District of Pennsylvania. The Actavis entities reached agreements with the government and private plaintiffs to resolve this action in its entirety, including with respect to any claims against the Company. Hydrocortisone Investigation . In 2016, the Company received notice from the UK Competition and Markets Authority (“CMA”) that it would be included within the scope of the CMA’s formal investigation under Section 25 of the Competition Act of 1998 (“CA98”) into suspected abuse of dominance by a former generics business subsidiary of the Company in relation to the supply of 10mg and 20mg hydrocortisone tablets. The CMA is investigating: (i) alleged excessive and unfair prices with respect to hydrocortisone tablets and (ii) whether the former generics business subsidiary entered into anti-competitive agreements with a potential competitor for this product. The CMA has issued statements of objection with respect to both parts of its investigation. The Company intends to cooperate fully with the investigation. Teva Shareholder Derivative Litigation . In 2017, the Company was named as defendant in a proposed Teva shareholder derivative litigation filed in the Economic Division of the Tel Aviv District Court in Israel. The lawsuit contains allegations that the Company aided and abetted Teva’s board of directors’ violations of Israeli securities laws. Recently, the plaintiffs have sought to assert additional claims against the Company. To date, the court has not determined whether it will allow plaintiffs to proceed with this action.

Warner Chilcott Limited ("WCL")

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	NOTE 27 — Warner Chilcott Limited (“WCL”) Guarantor and Non-Guarantor Condensed Consolidating Financial Information The following financial information is presented to segregate the financial results of WCL, Allergan Funding SCS, and Allergan Finance, LLC (the issuers of the long-term notes), the guarantor subsidiaries for the long-term notes and the non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guarantee the Company’s obligation under the long-term notes. The information includes elimination entries necessary to consolidate the guarantor and the non-guarantor subsidiaries. Investments in subsidiaries are accounted for using the equity method of accounting. The principal elimination entries eliminate investments in subsidiaries, equity and intercompany balances and transactions. WCL, Allergan Capital S.a.r.l. and Allergan Finance, LLC are guarantors of the long-term notes. The Company anticipates future legal entity structure changes which may impact the presentation of this footnote in the near future. WCL has revised its consolidating balance sheets as previously presented in its balance sheet in Footnote 25 of the December 31, 2018 Annual Report on Form 10-K due to a change in the Company’s legal entity structure and other reclassifications that occurred during the year ended December 31, 2019. As a result, prior period information has been recast to conform to the current period presentation. The following financial information presents the consolidating balance sheets as of December 31, 2019 and 2018, the related statements of operations and comprehensive income / (loss) for the years ended December 31, 2019, 2018 and 2017 and the statements of cash flows for the years ended December 31, 2019, 2018 and 2017. Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2019 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 1.6 $ 0.1 $ - $ 2,495.3 $ - $ 2,497.1 Marketable securities - - - - 3,411.6 - 3,411.6 Accounts receivable, net - - - - 3,192.3 - 3,192.3 Receivables from Parents - - - 409.3 - 409.3 Inventories - - - - 1,133.1 - 1,133.1 Intercompany receivables - 6,508.0 154.0 40.5 14,930.1 (21,632.6 ) - Current assets held for sale - - - - - - - Prepaid expenses and other current assets - - - 33.3 853.1 - 886.4 Total current assets 0.1 6,509.6 154.1 73.8 26,424.8 (21,632.6 ) 11,529.8 Property, plant and equipment, net - - - - 1,926.5 - 1,926.5 Right of use asset - operating leases - - - - 490.4 490.4 Investments and other assets - - - - 408.0 - 408.0 Investment in subsidiaries 55,891.8 76,855.8 21,016.7 83,155.2 - (236,919.5 ) - Non current intercompany receivables - - - - 1,156.6 (1,156.6 ) - Non current receivables from Parents - - - - - Non current assets held for sale - - - - 31.7 - 31.7 Deferred tax assets - 49.6 - - 527.3 - 576.9 Product rights and other intangibles - - - - 37,890.6 - 37,890.6 Goodwill - - - - 42,248.3 - 42,248.3 Total assets $ 55,891.9 $ 83,415.0 $ 21,170.8 $ 83,229.0 $ 111,104.2 $ (259,708.7 ) $ 95,102.2 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 155.2 97.3 6,094.4 - 6,347.0 Intercompany payables - 3,544.4 930.6 10,455.1 6,702.5 (21,632.6 ) - Payables to Parents - - - - 2,715.5 - 2,715.5 Income taxes payable - - 2.4 - 62.7 - 65.1 Current portion of long-term debt and capital leases - - 3,008.2 - 1,524.3 - 4,532.5 Current portion of lease liability - operating - - - - 124.4 - 124.4 Total current liabilities - 3,544.5 4,096.4 10,552.4 17,223.8 (21,632.6 ) 13,784.5 Long-term debt and capital leases - - 14,742.1 2,142.8 1,231.6 - 18,116.5 Lease liability - operating - - - - 446.1 - 446.1 Other long-term liabilities - - - - 801.4 - 801.4 Long-term intercompany payables - - - 1,156.6 - (1,156.6 ) - Other taxes payable - - - - 1,698.6 - 1,698.6 Deferred tax liabilities - - - - 4,363.2 - 4,363.2 Total liabilities - 3,544.5 18,838.5 13,851.8 25,764.7 (22,789.2 ) 39,210.3 Total equity / (deficit) 55,891.9 79,870.5 2,332.3 69,377.2 85,339.5 (236,919.5 ) 55,891.9 Total liabilities and equity $ 55,891.9 $ 83,415.0 $ 21,170.8 $ 83,229.0 $ 111,104.2 $ (259,708.7 ) $ 95,102.2 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2018 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 1.8 $ 0.8 $ - $ 875.9 $ - $ 878.6 Marketable securities - 489.9 - - 537.0 - 1,026.9 Accounts receivable, net - - - - 2,868.1 - 2,868.1 Receivables from Parents - - - - 640.9 - 640.9 Inventories - - - - 846.9 - 846.9 Intercompany receivables - 3,534.7 961.0 16.7 24,779.3 (29,291.7 ) - Current assets held for sale - - - - 34.0 - 34.0 Prepaid expenses and other current assets - - - 33.3 785.4 - 818.7 Total current assets 0.1 4,026.4 961.8 50.0 31,367.5 (29,291.7 ) 7,114.1 Property, plant and equipment, net - - - - 1,787.0 - 1,787.0 Investments and other assets - - - - 1,970.6 - 1,970.6 Investment in subsidiaries 62,940.2 73,846.0 22,656.5 86,628.2 - (246,070.9 ) - Non current intercompany receivables - 28,239.4 18,090.2 - 19,674.2 (66,003.8 ) - Non current assets held for sale - - - - 882.2 - 882.2 Deferred tax assets - 43.6 - - 1,020.1 - 1,063.7 Product rights and other intangibles - - - - 43,695.4 - 43,695.4 Goodwill - - - - 45,913.3 - 45,913.3 Total assets $ 62,940.3 $ 106,155.4 $ 41,708.5 $ 86,678.2 $ 146,310.3 $ (341,366.4 ) $ 102,426.3 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 156.3 92.9 4,538.1 - 4,787.4 Intercompany payables - 14,315.0 21.7 10,442.6 4,512.4 (29,291.7 ) - Payables to Parents - - - - 2,829.2 - 2,829.2 Income taxes payable - - - - 72.4 - 72.4 Current portion of long-term debt and capital leases - - 779.6 - 88.7 - 868.3 Total current liabilities - 14,315.1 957.6 10,535.5 12,040.8 (29,291.7 ) 8,557.3 Long-term debt and capital leases - - 18,090.2 2,135.9 2,703.3 - 22,929.4 Other long-term liabilities - - - - 882.0 - 882.0 Long-term intercompany payables - 18,597.4 - 1,076.8 46,329.6 (66,003.8 ) - Other taxes payable - - - - 1,615.5 - 1,615.5 Deferred tax liabilities - - - - 5,501.8 - 5,501.8 Total liabilities - 32,912.5 19,047.8 13,748.2 69,073.0 (95,295.5 ) 39,486.0 Total equity / (deficit) 62,940.3 73,242.9 22,660.7 72,930.0 77,237.3 (246,070.9 ) 62,940.3 Total liabilities and equity $ 62,940.3 $ 106,155.4 $ 41,708.5 $ 86,678.2 $ 146,310.3 $ (341,366.4 ) $ 102,426.3 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive (Loss) / Income For the Year Ended December 31, 2019 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 16,088.9 $ - $ 16,088.9 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,493.1 - 2,493.1 Research and development - - - - 1,812.0 - 1,812.0 Selling and marketing - - - - 3,461.7 - 3,461.7 General and administrative - - - - 2,330.8 - 2,330.8 Amortization - - - - 5,856.6 - 5,856.6 Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Asset sales and impairments, net - - - - 440.2 - 440.2 Total operating expenses - - - - 20,383.2 - 20,383.2 Operating (loss) - - - - (4,294.3 ) - (4,294.3 ) Interest income / (expense), net - 3.8 (598.3 ) (79.8 ) (31.9 ) - (706.2 ) Other income, net - - (0.1 ) - 32.9 - 32.8 Total other income / (expense), net - 3.8 (598.4 ) (79.8 ) 1.0 - (673.4 ) Income / (loss) before income taxes and noncontrolling interest - 3.8 (598.4 ) (79.8 ) (4,293.3 ) - (4,967.7 ) (Benefit) / provision for income taxes - 1.8 - - 144.6 - 146.4 Losses / (earnings) of equity interest subsidiaries 5,120.0 5,070.0 533.6 (251.3 ) - (10,472.3 ) - Net (loss) / income from continuing operations, net of tax (5,120.0 ) (5,068.0 ) (1,132.0 ) 171.5 (4,437.9 ) 10,472.3 (5,114.1 ) (Loss) from discontinued operations, net of tax - - - - - - - Net (loss) / income (5,120.0 ) (5,068.0 ) (1,132.0 ) 171.5 (4,437.9 ) 10,472.3 (5,114.1 ) (Income) attributable to noncontrolling interest - - - - (5.9 ) - (5.9 ) Net (loss) / income attributable to members (5,120.0 ) (5,068.0 ) (1,132.0 ) 171.5 (4,443.8 ) 10,472.3 (5,120.0 ) Other comprehensive (loss) / income, net of tax (138.0 ) (400.0 ) (1,106.2 ) (3,724.3 ) (138.0 ) 5,368.5 (138.0 ) Comprehensive (loss) / income attributable to members $ (5,258.0 ) $ (5,468.0 ) $ (2,238.2 ) $ (3,552.8 ) $ (4,581.8 ) $ 15,840.8 $ (5,258.0 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive (Loss) / Income For the Year Ended December 31, 2018 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 15,787.4 $ - $ 15,787.4 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,191.4 - 2,191.4 Research and development - - - - 2,266.2 - 2,266.2 Selling and marketing - - - - 3,250.6 - 3,250.6 General and administrative - - - - 1,177.5 - 1,177.5 Amortization - - - - 6,552.3 - 6,552.3 Goodwill impairments - - - - 2,841.1 - 2,841.1 In-process research and development impairments - - - - 804.6 - 804.6 Asset sales and impairments, net - - - - 2,857.6 - 2,857.6 Total operating expenses - - - - 21,941.3 - 21,941.3 Operating (loss) - - - - (6,153.9 ) - (6,153.9 ) Interest income / (expense), net - 1,101.1 (8.8 ) (82.8 ) (1,650.6 ) - (641.1 ) Other (expense), net - - 15.6 - 241.1 - 256.7 Total other income / (expense), net - 1,101.1 6.8 (82.8 ) (1,409.5 ) - (384.4 ) Income / (loss) before income taxes and noncontrolling interest - 1,101.1 6.8 (82.8 ) (7,563.4 ) - (6,538.3 ) Provision / (benefit) for income taxes - (23.8 ) 3.5 (50.7 ) (1,705.4 ) - (1,776.4 ) Losses / (earnings) of equity interest subsidiaries 4,772.1 5,719.1 280.7 250.1 - (11,022.0 ) - Net (loss) / income from continuing operations, net of tax (4,772.1 ) (4,594.2 ) (277.4 ) (282.2 ) (5,858.0 ) 11,022.0 (4,761.9 ) (Loss) from discontinued operations, net of tax - - - - - - - Net (loss) / income (4,772.1 ) (4,594.2 ) (277.4 ) (282.2 ) (5,858.0 ) 11,022.0 (4,761.9 ) (Income) attributable to noncontrolling interest - - - - (10.2 ) - (10.2 ) Net (loss) / income attributable to members (4,772.1 ) (4,594.2 ) (277.4 ) (282.2 ) (5,868.2 ) 11,022.0 (4,772.1 ) Other comprehensive income / (loss), net of tax (512.5 ) (599.3 ) 587.2 2,013.0 (512.5 ) (1,488.4 ) (512.5 ) Comprehensive (loss) / income attributable to members $ (5,284.6 ) $ (5,193.5 ) $ 309.8 $ 1,730.8 $ (6,380.7 ) $ 9,533.6 $ (5,284.6 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive (Loss) / Income For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 15,940.7 - 15,940.7 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,168.0 - 2,168.0 Research and development - - - - 2,100.1 - 2,100.1 Selling and marketing - - - - 3,514.8 - 3,514.8 General and administrative - - 8.6 1.1 1,392.6 - 1,402.3 Amortization - - - - 7,197.1 - 7,197.1 In-process research and development impairments - - - - 1,452.3 - 1,452.3 Asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Total operating expenses - - 8.6 1.1 21,752.6 - 21,762.3 Operating (loss) - - (8.6 ) (1.1 ) (5,811.9 ) - (5,821.6 ) Interest income / (expense), net - 845.5 116.6 (131.2 ) (1,760.2 ) - (929.3 ) Other income, net - - (110.4 ) (66.7 ) (3,260.2 ) - (3,437.3 ) Total other income / (expense), net - 845.5 6.2 (197.9 ) (5,020.4 ) - (4,366.6 ) Income / (loss) before income taxes and noncontrolling interest - 845.5 (2.4 ) (199.0 ) (10,832.3 ) - (10,188.2 ) Provision / (benefit) for income taxes - 5.0 0.3 (177.3 ) (6,498.4 ) - (6,670.4 ) (Earnings) / losses of equity interest subsidiaries 3,927.3 4,517.5 1,958.1 752.7 - (11,155.6 ) - Net income / (loss) from continuing operations, net of tax (3,927.3 ) (3,677.0 ) (1,960.8 ) (774.4 ) (4,333.9 ) 11,155.6 (3,517.8 ) Income from discontinued operations, net of tax - - - - (402.9 ) - (402.9 ) Net income / (loss) (3,927.3 ) (3,677.0 ) (1,960.8 ) (774.4 ) (4,736.8 ) 11,155.6 (3,920.7 ) (Income) attributable to noncontrolling interest - - - - (6.6 ) - (6.6 ) Net income / (loss) attributable to members (3,927.3 ) (3,677.0 ) (1,960.8 ) (774.4 ) (4,743.4 ) 11,155.6 (3,927.3 ) Other comprehensive (loss) / income, net of tax 2,959.1 3,001.5 (643.8 ) (2,203.7 ) 2,959.1 (3,113.1 ) 2,959.1 Comprehensive income / (loss) attributable to members $ (968.2 ) $ (675.5 ) $ (2,604.6 ) $ (2,978.1 ) $ (1,784.3 ) $ 8,042.5 $ (968.2 ) Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2019 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (5,120.0 ) $ (5,068.0 ) $ (1,132.0 ) $ 171.5 $ (4,437.9 ) $ 10,472.3 $ (5,114.1 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 5,120.0 5,070.0 533.6 (251.3 ) - (10,472.3 ) - Depreciation - - - - 204.5 - 204.5 Amortization - - - - 5,856.6 - 5,856.6 Provision for inventory reserve - - - - 160.2 - 160.2 Share-based compensation - - - - 214.3 - 214.3 Deferred income tax benefit - - - - (660.9 ) - (660.9 ) Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Loss on asset sales and impairments, net - - - - 440.2 - 440.2 Non-cash extinguishment of debt - - 0.2 - 0.2 Amortization of deferred financing costs - - 15.9 1.6 - - 17.5 Amortization of right of use assets - - - - 130.9 - 130.9 Contingent consideration adjustments, including accretion - - - - 54.1 - 54.1 Dividends from subsidiaries 1,774.3 - - - - (1,774.3 ) - Other, net - - (5.2 ) (1.7 ) 1.4 - (5.5 ) Changes in assets and liabilities (net of effects of acquisitions) - (291.6 ) 1,618.6 79.9 591.1 - 1,998.0 Net cash provided by / (used in) operating activities 1,774.3 (289.6 ) 1,030.9 - 6,543.5 (1,774.3 ) 7,284.8 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (375.2 ) - (375.2 ) Additions to product rights and other intangibles - - - - (58.3 ) - (58.3 ) Additions to investments - (100.0 ) - - (3,838.0 ) - (3,938.0 ) Proceeds from sale of investments and other assets - 389.4 - - 1,180.2 - 1,569.6 Proceeds from sales of property, plant and equipment - - - - 23.7 - 23.7 Acquisitions of business, net of cash acquired - - - - (80.6 ) - (80.6 ) Net cash (used in) / provided by investing activities - 289.4 - - (3,148.2 ) - (2,858.8 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - - - 11.9 - 11.9 Payments on debt, including capital lease obligations and credit facility - - (1,031.6 ) - (13.3 ) - (1,044.9 ) Debt issuance and other financing costs - - - - - - - Payments of contingent consideration and other financing - - - - (9.3 ) - (9.3 ) Dividends to Parents (1,774.3 ) - - - (1,774.3 ) 1,774.3 (1,774.3 ) Net cash (used in) / provided by financing activities (1,774.3 ) - (1,031.6 ) - (1,785.0 ) 1,774.3 (2,816.6 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 9.1 - 9.1 Net (decrease) / increase in cash and cash equivalents - (0.2 ) (0.7 ) - 1,619.4 - 1,618.5 Cash and cash equivalents at beginning of period 0.1 1.8 0.8 - 875.9 - 878.6 Cash and cash equivalents at end of period $ 0.1 $ 1.6 $ 0.1 $ - $ 2,495.3 $ - $ 2,497.1 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2018 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (4,772.1 ) $ (4,594.2 ) $ (277.4 ) $ (282.2 ) $ (5,858.0 ) $ 11,022.0 $ (4,761.9 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 4,772.1 5,719.1 280.7 250.1 - (11,022.0 ) - Depreciation - - - - 196.3 - 196.3 Amortization - - - - 6,552.3 - 6,552.3 Provision for inventory reserve - - - - 96.4 - 96.4 Share-based compensation - - - - 239.8 - 239.8 Deferred income tax benefit - - - - (1,255.7 ) - (1,255.7 ) Goodwill impairments - - - - 2,841.1 - 2,841.1 In-process research and development impairments - - - - 804.6 - 804.6 Loss on asset sales and impairments, net - - - - 2,857.6 - 2,857.6 Gain on sale of Teva securities, net - - - - (60.9 ) - (60.9 ) Gain on sale of businesses - - (182.6 ) - (182.6 ) Non-cash extinguishment of debt - - 30.0 - - - 30.0 Cash charge related to extinguishment of debt - - (45.6 ) - - - (45.6 ) Amortization of deferred financing costs - - 21.0 1.6 - - 22.6 Contingent consideration adjustments, including accretion - - - - (106.5 ) - (106.5 ) Dividends from subsidiaries 4,075.6 - - - - (4,075.6 ) - Other, net - - (5.6 ) (1.7 ) 36.3 - 29.0 Changes in assets and liabilities (net of effects of acquisitions) - (1,626.3 ) 5,482.0 32.2 (5,152.4 ) - (1,264.5 ) Net cash provided by / (used in) operating activities 4,075.6 (501.4 ) 5,485.1 - 1,008.3 (4,075.6 ) 5,992.0 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (253.5 ) - (253.5 ) Additions to investments - (889.9 ) - - (1,581.8 ) - (2,471.7 ) Proceeds from sale of investments and other assets - 800.0 - - 5,459.3 - 6,259.3 Payments to settle Teva related matters - - - - (466.0 ) - (466.0 ) Proceeds from sales of property, plant and equipment - - - - 30.4 - 30.4 Net cash provided by / (used in) investing activities - (89.9 ) - - 3,188.4 - 3,098.5 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 700.0 1,919.7 - 37.3 - 2,657.0 Payments on debt, including capital lease obligations and credit facility - (700.0 ) (7,393.7 ) - (710.8 ) - (8,804.5 ) Debt issuance and other financing costs - - (10.4 ) - - - (10.4 ) Payments of contingent consideration and other financing - - - - (30.9 ) - (30.9 ) Proceeds from forward sale of Teva securities - - - - 465.5 - 465.5 Payments to settle Teva related matters - - - - (234.0 ) - (234.0 ) Dividends to Parents (4,075.6 ) - - - (4,075.6 ) 4,075.6 (4,075.6 ) Net cash (used in) / provided by financing activities (4,075.6 ) - (5,484.4 ) - (4,548.5 ) 4,075.6 (10,032.9 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 4.7 - 4.7 Net increase in cash and cash equivalents - (591.3 ) 0.7 - (347.1 ) - (937.7 ) Cash and cash equivalents at beginning of period 0.1 593.1 0.1 - 1,223.0 - 1,816.3 Cash and cash equivalents at end of period $ 0.1 $ 1.8 $ 0.8 $ - $ 875.9 $ - $ 878.6 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ (3,927.3 ) $ (3,677.0 ) $ (1,960.8 ) $ (774.4 ) $ (4,736.8 ) $ 11,155.6 $ (3,920.7 ) Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries 3,927.3 4,517.5 1,958.1 752.7 - (11,155.6 ) - Depreciation - - - - 171.5 - 171.5 Amortization - - - - 7,197.1 - 7,197.1 Provision for inventory reserve - - - - 102.2 - 102.2 Share-based compensation - - - - 293.3 - 293.3 Deferred income tax benefit - - - - (7,783.1 ) - (7,783.1 ) In-process research and development impairments - - - - 1,452.3 - 1,452.3 Loss on asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Net income impact of other-than-temporary loss on investment in Teva securities - - - - 3,273.5 - 3,273.5 Charge to settle Teva related matters - - - - 387.4 - 387.4 Loss on forward sale of Teva shares - - - - 62.9 - 62.9 Amortization of inventory step-up - - - - 131.7 - 131.7 Non-cash extinguishment of debt - - 17.6 12.2 (45.5 ) - (15.7 ) Cash charge related to extinguishment of debt - - 91.6 52.9 61.1 - 205.6 Amortization of deferred financing costs - - 23.3 4.5 - - 27.8 Contingent consideration adjustments, including accretion - - - - (133.2 ) - (133.2 ) Dividends from subsidiaries 1,668.2 - - - - (1,668.2 ) - Other, net - (10.0 ) - - (27.0 ) - (37.0 ) Changes in assets and liabilities (net of effects of acquisitions) - (4,228.1 ) (241.5 ) 2,148.3 3,207.3 - 886.0 Net cash provided by / (used in) operating activities 1,668.2 (3,397.6 ) (111.7 ) 2,196.2 7,542.4 (1,668.2 ) 6,229.3 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (349.9 ) - (349.9 ) Additions to product rights and other intangibles - - - - (614.3 ) - (614.3 ) Additions to investments - (4,389.6 ) - - (5,394.2 ) - (9,783.8 ) Proceeds from sale of investments and other assets - 7,866.4 - - 7,286.9 - 15,153.3 Proceeds from sales of property, plant and equipment - - - - 7.1 - 7.1 Acquisitions of businesses, net of cash acquired - - - - (5,290.4 ) - (5,290.4 ) Net cash (used in) / provided by investing activities - 3,476.8 - - (4,354.8 ) - (878.0 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - 3,020.9 - 529.1 - 3,550.0 Payments on debt, including capital lease obligations and credit facility - - (2,800.0 ) (2,143.3 ) (1,470.3 ) - (6,413.6 ) Debt issuance and other financing costs - - (17.5 ) - (3.1 ) - (20.6 ) Cash charge related to extinguishment of debt - - (91.6 ) (52.9 ) (61.1 ) - (205.6 ) Payments of contingent consideration and other financing - - - - (511.6 ) - (511.6 ) Dividends to Parents (1,668.2 ) - - - (1,668.2 ) 1,668.2 (1,668.2 ) Net cash (used in) / provided by financing activities (1,668.2 ) - 111.8 (2,196.2 ) (3,185.2 ) 1,668.2 (5,269.6 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 21.4 - 21.4 Net increase / (decrease) in cash and cash equivalents - 79.2 0.1 - 23.8 - 103.1 Cash and cash equivalents at beginning of period 0.1 513.9 - - 1,199.2 - 1,713.2 Cash and cash equivalents at end of period $ 0.1 $ 593.1 $ 0.1 $ - $ 1,223.0 $ - $ 1,816.3

Compensation

Compensation	12 Months Ended
	Dec. 31, 2019
Compensation Related Costs [Abstract]
Compensation	NOTE 28 — Compensation The following table represents compensation costs for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Years Ended December 31, 2019 2018 2017 Wages and salaries $ 2,193.2 $ 1,994.9 $ 1,892.8 Share-based compensation 214.3 239.8 308.0 Retirement plans 136.0 107.0 82.7 Social welfare (taxes) 143.3 163.1 150.4 Other benefits 152.5 175.2 265.1 Total $ 2,839.3 $ 2,680.0 $ 2,699.0

Concentration

Concentration	12 Months Ended
	Dec. 31, 2019
Risks And Uncertainties [Abstract]
Concentration	NOTE 29 — Concentration The Company considers there to be a concentration risk for customers that account for 10% or more of their third-party revenues. The following table illustrates any customer which accounted for 10% or more of our annual revenues within the U.S. and Canada in any of the past three fiscal years and the respective percentage of our revenues for which they account for each of the last three years: Customer 2019 2018 2017 McKesson Corporation 25 % 25 % 23 % Cardinal Health, Inc. 24 % 23 % 19 % AmerisourceBergen Corporation 22 % 22 % 19 % No other country outside the U.S. and Canada had 10% or more of global sales. The Company’s accounts receivable primarily arise from product sales in North America and primarily represent amounts due from wholesalers, distributors, drug store chains and service providers in the health care and pharmaceutical industries, public hospitals and other government entities. Approximately 66% and 62% of the gross accounts receivable balance are concentrated among the Company’s three largest customers as of December 31, 2019 and 2018, respectively. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential uncollectible accounts. Actual losses from uncollectible accounts have been minimal. Outside of the U.S., concentrations of credit risk with respect to accounts receivable are limited due to the wide variety of customers and markets using the Company’s products, as well as their dispersion across many different geographic areas. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The Company does not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on its financial position, liquidity or results of operations. Certain of the Company’s finished products and raw materials are obtained from single source suppliers. Although the Company seeks to identify more than one source for its various finished products and raw materials, loss of a single source supplier could have an adverse effect on the Company’s results of operations, financial condition and cash flows. Further, a second source supplier may not be able to produce the same volumes of inventory as the Company’s primary supplier. No third party manufacturer accounted for 10% or more of the Company’s products sold based on third-party revenues for the year ended December 31, 2019.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2019
Valuation And Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II Allergan plc Warner Chilcott Limited Valuation and Qualifying Accounts Years Ended December 31, 2019, 2018 and 2017 ($ in millions) Balance at Beginning of Period Charged to Costs and Expenses Deductions / Write-offs Other* Balance at End of Period Allowance for doubtful accounts: Year Ended December 31, 2019 $ 101.7 $ 35.8 $ (26.7 ) $ - $ 110.8 Year Ended December 31, 2018 $ 93.0 $ 18.5 $ (9.8 ) $ - $ 101.7 Year Ended December 31, 2017 $ 75.7 $ 11.6 $ (1.7 ) $ 7.4 $ 93.0 Tax valuation allowance: Year Ended December 31, 2019 $ 1,637.9 $ 443.4 $ - $ (2.2 ) $ 2,079.1 Year Ended December 31, 2018 $ 403.8 $ 1,237.9 $ - $ (3.8 ) $ 1,637.9 Year Ended December 31, 2017 $ 183.9 $ 230.1 $ - $ (10.2 ) $ 403.8 *Includes opening balances of businesses acquired in the period and reclasses to assets held for sale.

Supplementary Data

Supplementary Data	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Supplementary Data	SUPPLEMENTARY DATA (UNAUDITED) Selected unaudited quarterly consolidated financial data and market price information are shown below ($ in millions except per share data): For Three Month Periods Ended Year Ended 12/31/2019 Dec. 31, 2019 Sept. 30, 2019 June 30, 2019 Mar. 31, 2019 Net revenues $ 16,088.9 $ 4,351.0 $ 4,050.7 $ 4,090.1 $ 3,597.1 Net (loss) $ (5,265.1 ) $ (317.3 ) $ (785.6 ) $ (1,754.9 ) $ (2,407.3 ) Basic earnings per share (16.02 ) (0.97 ) (2.40 ) (5.37 ) (7.25 ) Diluted earnings per share (16.02 ) (0.97 ) (2.40 ) (5.37 ) (7.25 ) Market price per share: High $ 191.58 $ 169.61 $ 167.43 $ 160.79 Low $ 165.40 $ 156.34 $ 115.73 $ 132.09 For Three Month Periods Ended Year Ended 12/31/2018 Dec. 31, 2018 Sept. 30, 2018 June 30, 2018 Mar. 31, 2018 Net revenues $ 15,787.4 $ 4,079.7 $ 3,911.4 $ 4,124.2 $ 3,672.1 Net (loss) / income $ (5,086.2 ) $ (4,295.9 ) $ (36.3 ) $ (470.1 ) $ (283.9 ) Basic earnings per share (15.26 ) (12.83 ) (0.11 ) (1.39 ) (0.99 ) Diluted earnings per share (15.26 ) (12.83 ) (0.11 ) (1.39 ) (0.99 ) Market price per share: High $ 193.46 $ 192.51 $ 175.19 $ 188.15 Low $ 129.82 $ 167.21 $ 143.80 $ 144.02

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented. The Company’s consolidated financial statements include the financial results of all acquired companies subsequent to the acquisition date.
Implementation of New Guidance	Implementation of New Guidance In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard established a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. On January 1, 2019, the Company adopted the new standard using the modified retrospective transition approach applied to all leases existing at the effective date of initial application of January 1, 2019. Prior period amounts are not adjusted and continue to be reported in accordance with historical accounting practices and the disclosures under the new standard are not required for dates and periods prior to January 1, 2019. When evaluating whether a contract contains a lease under the new standard, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company does not have the right to use an identified asset if the supplier has the substantive right to substitute the asset throughout the period without the Company’s approval. The new standard provided a number of optional practical expedients in transition, the Company elected the ‘package of practical expedients’ which permits us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter was not applicable to the Company. This standard has a significant impact on our consolidated balance sheet but did not have a significant impact on our consolidated statements of operations. The most significant effects relate to the recognition of ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases. Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as follows ($ in millions): ROU Asset Lease Liability Real estate $ 304.2 $ 370.6 Fleet 100.4 100.4 Other 57.5 77.6 Total operating leases $ 462.1 $ 548.6 The cumulative effective adjustment as of the effective date of $22.0 million was recorded on January 1, 2019 to opening retained earnings. The Company has an immaterial amount of finance leases. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the lease recognition exemption for all leases with lease terms of 12 months or less. For leases that qualify under this exception, the Company will not recognize ROU assets or lease liabilities and did not recognize ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also elected the practical expedient to not separate lease and non-lease components for leases of real estate, fleet, IT and office equipment. Refer to “NOTE 14 – Leases” for further information related to the Company’s leases. In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update allows for the optional reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. The amount of the reclassification is calculated as the difference between the historical and newly enacted tax rates on deferred taxes originally recorded through accumulated other comprehensive income. The Company adopted the standard as of January 1, 2019; however, due to the immaterial amount of the stranded tax effects, the Company elected not to reclassify the income tax effects from accumulated other comprehensive income to retained earnings. Tax effects unrelated to the TCJA are released from accumulated other comprehensive income using either the specific identification approach or the portfolio approach based on the nature of the underlying item.
Use of Estimates	Use of Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to the determination of SRAs (defined below) included within either accounts receivable or accrued liabilities, the valuation of inventory balances, the determination of useful lives for intangible assets, pension and other post-retirement benefit plan assumptions, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment and recognition and measurement of assets acquired and liabilities assumed in business combinations at fair value. The estimation process required to prepare the Company’s consolidated financial statements requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. The Company’s actual results could differ materially from those estimates.
Foreign Currency Translation	Foreign Currency Translation For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive (loss) / income. The translational effects of revaluing non-functional currency assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. The Company realizes foreign currency gains / (losses) in the normal course of business based on movement in the applicable exchange rates. These transactional gains / (losses) are included as a component of general and administrative expenses.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in banks, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity from the date acquired of three months or less to be cash equivalents.
Fair Value of Other Financial Instruments	Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, investments, trade accounts payable, and long-term debt, including the current portion. The carrying amounts of cash and cash equivalents, marketable securities, accounts and other receivables and trade accounts payable are representative of their respective fair values due to their relatively short maturities. The fair values of investments in companies that are publicly traded are based on quoted market prices. The Company estimates the fair value of its fixed rate long-term obligations based on quoted market rates.
Inventories	Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventory includes brand and aesthetic products which represent Food and Drug Administration (“FDA”) approved or likely to be approved indications. Inventory valuation reserves are established based on a number of factors/situations including, but not limited to, raw materials, work in process or finished goods not meeting product specifications, product obsolescence, or application of the lower of cost (first-in, first-out method) or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. Assumptions utilized in our quantification of inventory reserves include, but are not limited to, estimates of future product demand, consideration of current and future market conditions, product net selling price, anticipated product launch dates, competition and potential product obsolescence and other events relating to special circumstances surrounding certain products. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Major renewals and improvements are capitalized if they add functionality or extend the life of the asset, while routine maintenance and repairs are expensed as incurred. The Company capitalizes interest on qualified construction projects. At the time property, plant and equipment are retired from service, the cost and accumulated depreciation are removed from the respective accounts. Depreciation expense is computed principally on the straight-line method, over the estimated useful lives of the related assets. The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years The Company assesses property, plant and equipment for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable.
Investments	Investments The Company’s equity investments are accounted for under the equity method of accounting when the Company can exert significant influence and the Company’s ownership interest does not exceed 50%. The Company records equity method investments at cost and adjusts for the appropriate share of investee net earnings or losses. Investments in which the Company owns less than a 20% interest and cannot exert significant influence are recorded at fair value and the Company recognizes any changes in fair value in net income. For equity investments without readily determinable fair values, the Company may make a separate election for each eligible investment to use a measurement alternative until the investment’s fair value becomes readily determinable. Under the alternative method, the equity investments are accounted for at cost, less any impairment, plus or minus changes resulting from observable price changes in an orderly transaction for an identical or similar investment of the same issuer.
Marketable Securities	Marketable Securities The Company’s marketable securities consist of U.S. treasury and agency securities and debt and equity securities of publicly-held companies. The Company’s marketable securities are recorded at fair value, based upon quoted market prices with an offset to interest income.
Product Rights and Other Definite Lived Intangible Assets	Product Rights and Other Definite Lived Intangible Assets Our product rights and other definite lived intangible assets are stated at cost, less accumulated amortization, and are amortized using the economic benefit model or the straight-line method, if results are materially aligned, over their estimated useful lives. We determine amortization periods for product rights and other definite lived intangible assets based on our assessment of various factors impacting estimated cash flows. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in an impairment, a reduction in the intangibles’ useful life or an acceleration of related amortization expense, which could cause our net results to decline. Product rights and other definite lived intangible assets are tested periodically for impairment when events or changes in circumstances indicate that an asset’s carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted pre-tax future cash flows over its useful life, including any salvage value. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in net (loss) / income in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Our projections of discounted cash flows use a discount rate determined by our management to be commensurate with the risk inherent in our business model. Our estimates of future cash flows attributable to our other definite lived intangible assets require significant judgment based on our historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect the calculation of the undiscounted cash flows of the other definite lived intangible assets which could trigger impairment.
Goodwill and Intangible Assets with Indefinite Lives	Goodwill and Intangible Assets with Indefinite Lives The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or an indefinite lived intangible asset below its carrying amount such as those first and second quarter 2019 triggering events relating to the Company’s General Medicine Reporting Unit as discussed in “NOTE 17 — Goodwill, Product Rights and Other Intangible Assets”. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including Reporting Unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a Reporting Unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for some or all of its Reporting Units and perform a quantitative test as of the measurement date of the test . Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Fair value is estimated by management using a discounted cash flow model. Management’s cash flow projections include significant judgments and assumptions related to the discount rate, revenue forecasts, operating margins, impact of research and development pipeline events, and the long-term revenue growth rate. Impairment, if any, would be recorded in operating income / (loss) and this could result in a material impact to net income / (loss) and income / (loss) per share. Prior to Allergan’s 2018 annual impairment test, the Company adopted the new guidance under Accounting Standard Update No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to research and development (“R&D”) projects acquired in a business combination that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that has not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired if there is no future alternative use or ability to sell the asset. Impairment testing requires management to develop significant estimates and assumptions involving the determination of the fair value of the IPR&D asset, including estimated revenues, the probability of success of the project, determination of the appropriate discount rate, assessment of the asset’s life, potential regulatory risks, and net revenue growth curve assumptions. The major risks and uncertainties associated with the timely and successful completion of IPR&D projects include legal risk, market risk and regulatory risk. Changes in our assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of a product, we will make a separate determination of the useful life of the intangible asset, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life.
Contingent Consideration	Contingent Consideration We determine the acquisition date fair value of contingent consideration obligations for business acquisitions based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts defined in ASC Topic 820 “Fair Value Measurement,” (“ASC 820”). The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of future revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge or reduction to operating results. Refer to “NOTE 25 — Fair Value Measurement” for additional details regarding the fair value of contingent consideration.
Revenue Recognition	Revenue Recognition General Topic 606 provides that revenues are recognized when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods as specified in the underlying terms with the customer. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, commercial and government rebates, customer loyalty programs, fee-for-service arrangements with certain distributors, returns, and other allowances which we refer to in the aggregate as sales returns and allowances (“SRA”). The Company’s performance obligations are primarily achieved when control of the products is transferred to the customer. Transfer of control is based on contractual performance obligations, but typically occurs upon receipt of the goods by the customer as that is when the customer has obtained control of significantly all of the economic benefits. Prior to the achievement of performance obligations, shipping and handling costs associated with outbound freight for a product to be transferred to a customer are accounted for as a fulfillment cost and are included in selling and marketing expenses. When the Company sells a business and future royalties are considered as part of the consideration, the Company recognizes the royalties as a component of “other income / (expense), net”. Other revenues earned are mainly comprised of royalty income from licensing of intellectual property. Royalty income is recognized when the licensee’s subsequent sale occurs. Refer to “NOTE 22 – Segments” for our revenues disaggregated by product and segment and our revenues disaggregated by geography for our international segment. We believe this level of disaggregation best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Significant Payment Terms A contract with a customer states the final terms of the sale, including the description, quantity, and price of each product purchased. The Company’s payment terms vary by the type and location of the customer and the products offered. A customer agrees to a stated rate and price in the contract and given that most of the products sold contain variable consideration, the amount of revenue recognized incorporates adjustments for SRAs as appropriate. Determining the Transaction Price The Company offers discounts and rebates to certain customers who participate in various programs that are referred to as SRA allowances as described further below in the section “Provisions for SRAs”. Such discounting and rebating activity is included as part of the Company’s estimate of the transaction price and is accounted for as a reduction to gross sales. At time of sale, the Company records the related SRA adjustments. The Company performs validation activities each period to assess the adequacy of the liability or contra receivable estimates recorded to reflect actual activity and will adjust the reserve balances accordingly.
Provisions for SRAs	Provisions for SRAs As is customary in the pharmaceutical industry, certain customers may receive cash-based incentives or credits, which are variable consideration accounted for as SRAs. The Company estimates SRA amounts based on the expected amount to be provided to customers, which reduces the revenues recognized. The Company believes that there will not be significant changes to our estimates of variable consideration. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. These provisions are estimated based on historical payment experience, the historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provisions has been applied on a consistent basis and no material revenue adjustments to total reported revenues have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by such wholesaler customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback credits. We continually monitor current pricing trends and wholesaler inventory levels to ensure the contra-receivable for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally contractually offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states and authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific time period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for a cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, promotional allowances and loyalty cards. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are generally not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns. Promotional allowances are credits with no discernable benefit offered to Allergan that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Loyalty cards allow end-user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2017 $ 77.2 $ 1,799.2 $ 517.6 $ 36.5 $ 2,430.5 Provision related to sales in 2018 1,117.7 5,464.7 1,725.3 322.2 8,629.9 Credits and payments (1,133.1 ) (5,355.4 ) (1,676.3 ) (328.0 ) (8,492.8 ) Balance at December 31, 2018 $ 61.8 $ 1,908.5 $ 566.6 $ 30.7 $ 2,567.6 Provision related to sales in 2019 1,123.5 6,153.8 1,625.1 337.3 9,239.7 Credits and payments (1,117.5 ) (5,959.0 ) (1,559.3 ) (331.0 ) (8,966.8 ) Balance at December 31, 2019 $ 67.8 $ 2,103.3 $ 632.4 $ 37.0 $ 2,840.5 Contra accounts receivable at December 31, 2019 $ 67.8 $ 101.5 $ 35.7 $ 37.0 $ 242.0 Accounts payable and accrued expenses at December 31, 2019 $ - $ 2,001.8 $ 596.7 $ - $ 2,598.5 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): December 31, 2019 December 31, 2018 Contra accounts receivable $ 242.0 $ 207.7 Accounts payable and accrued expenses 2,598.5 2,359.9 Total $ 2,840.5 $ 2,567.6 The SRA provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Years Ended December 31, 2019 2018 2017 Gross product sales $ 24,968.8 $ 24,056.9 $ 23,688.4 Provisions to reduce gross product sales to net products sales (9,239.7 ) (8,629.9 ) (8,120.0 ) Net product sales $ 15,729.1 $ 15,427.0 $ 15,568.4 Percentage of SRA provisions to gross sales 37.0 % 35.9 % 34.3 % Collectability Assessment At the time of contract inception or customer account set-up, the Company performs a collectability assessment on the creditworthiness of such customer. The Company assesses the probability that the Company will collect the consideration to which it will be entitled in exchange for the goods sold. In evaluating collectability, the Company considers the customer’s ability and intention to pay consideration when it is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectible after sale to the customer to reflect allowances for doubtful accounts. Provision for bad debts, included in general and administrative expenses, were $35.8 million, $18.5 million and $11.6 million in the years ended December 31, 2019, 2018 and 2017, respectively. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period is one year or less. These costs are recorded within selling and marketing expenses. The Company does not adjust the promised amount of consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is equal to one year or less. The Company has chosen not to elect the remaining practical expedients.
Litigation and Contingencies	Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with FASB Accounting Standards Codification (“ASC”) Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Refer to “NOTE 26 — Commitments and Contingencies” for more information.
R&D Activities	R&D Activities R&D activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any. As of December 31, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including but not limited to the following: Product Therapeutic Area Indication Expected Launch Year Phase Bimatoprost SR Eye Care Glaucoma 2020 Review Abicipar Eye Care Age Related Macular Degeneration 2020 Review Atogepant Central Nervous System Prophylaxis Migraine 2021 III Presbysol Eye Care Presbyopia 2021 III Cenicriviroc Gastrointestinal NASH 2022 III Brimonidine DDS Eye Care Geographic Atrophy 2023 II Relamorelin Gastrointestinal Gastroparesis 2024 III Botox Medical Aesthetics Platysma/Masseter 2025/2024 II Abicipar Eye Care Diabetic Macular Edema 2025 II In addition to the projects listed in the table above, the Company continues to develop brazikumab, a gastrointestinal development project for indications of Crohn’s disease and ulcerative colitis. On January 27, 2020, in connection with the AbbVie Transaction, Allergan announced that it entered into a definitive agreement to divest brazikumab. This agreement was made in conjunction with the ongoing regulatory approval process for a AbbVie Transaction. AstraZeneca plc will acquire brazikumab, including global development and commercial rights. The closing of the divestiture of brazikumab is contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, closing of the AbbVie Transaction and the satisfaction of other customary closing conditions.
Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed	Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed We account for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values as determined using a market participant concept. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The most material line items impacted by the allocation of acquisition fair values are: • Intangible assets (including IPR&D assets upon successful completion of the project and approval of the product) which are amortized to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected future net cash flow streams, the timing of approvals and the probability of success for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the future useful lives. For these and other reasons, actual results may vary significantly from estimated results. • Inventory is recorded at fair market value factoring in selling price and costs to dispose. Inventory acquired is typically valued higher than replacement cost.
Income Taxes	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company’s effective tax rate on future earnings. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first financial reporting period in which that threshold is no longer met. Inherent in these tax positions are various assumptions, including management’s judgments as to the interpretation of tax law, management’s expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the consolidated statements of operations as income tax expense. The TCJA introduced an additional U.S. tax on certain non-U.S. subsidiaries’ earnings which are considered to be Global Intangible Low Taxed Income (referred to as “GILTI”). Under this provision, the amount of GILTI included by a U.S. shareholder will be taxed at a rate of 10.5% for tax years beginning after December 31, 2017 (increasing to 13.125% for tax years beginning after December 31, 2025) with a partial offset for foreign tax credits. After consideration of the relevant guidance and completing the accounting for the tax effects of the TCJA, the Company has elected to treat GILTI as a period cost.
Comprehensive Income / (Loss)	Comprehensive Income / (Loss) Comprehensive income / (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income / (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income / (loss), but excluded from net income / (loss) as these amounts are recorded directly as an adjustment to shareholders’ equity. The Company’s other comprehensive income / (loss) is primarily comprised of actuarial gains / (losses), the impact of hedging transactions, pension liabilities and foreign currency translation adjustments.
Earnings Per Share ("EPS")	Earnings Per Share (“EPS”) The Company computes EPS in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) / income by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Diluted EPS also includes the impact of ordinary share equivalents issued (or issuable in 2017) upon the mandatory conversion of the Company’s preferred shares which occurred on March 1, 2018. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive to continuing operations. A reconciliation of the numerators and denominators of basic and diluted EPS follows ($ in millions, except per share amounts): Years Ended December 31, 2019 2018 2017 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding (loss) / income from discontinued operations, net of tax $ (5,271.0 ) $ (5,142.8 ) $ (4,001.0 ) (Loss) / income from discontinued operations, net of tax - - (402.9 ) Net (loss) / income attributable to ordinary shareholders $ (5,271.0 ) $ (5,142.8 ) $ (4,403.9 ) Basic weighted average ordinary shares outstanding 329.0 337.0 333.8 Basic EPS: Continuing operations $ (16.02 ) $ (15.26 ) $ (11.99 ) Discontinued operations $ - $ - $ (1.20 ) Net (loss) / income per share $ (16.02 ) $ (15.26 ) $ (13.19 ) Dividends per ordinary share $ 2.96 $ 2.88 $ 2.80 Diluted weighted average ordinary shares outstanding 329.0 337.0 333.8 Diluted EPS: Continuing operations $ (16.02 ) $ (15.26 ) $ (11.99 ) Discontinued operations $ - $ - $ (1.20 ) Net (loss) / income per share $ (16.02 ) $ (15.26 ) $ (13.19 ) Stock awards to purchase 2.1 million, 2.3 million, and 3.8 million ordinary shares for the years ended December 31, 2019, 2018 and 2017, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations was also anti-dilutive. The Company’s preferred shares were converted to ordinary shares on March 1, 2018. The weighted average impact of ordinary share equivalents of 2.9 million for the year ended December 31, 2018, which would result from the mandatory conversion of the Company’s preferred shares at the beginning of the period, were not included in the calculation of diluted EPS as their impact would be anti-dilutive. Similarly, the anti-diluted weighted average impact of ordinary share equivalents upon mandatory conversion of the preferred shares for the year ended December 31, 2017 were excluded from in the calculation of diluted EPS. Refer to “NOTE 21 –Shareholders’ Equity” for further discussion on the Company’s share repurchase programs.
Employee Benefits	Employee Benefits Defined Contribution Plans The Company has defined contribution plans that are post-employment benefit plans under which the Company pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to the defined contribution plans are recognized as an employee benefit expense in the consolidated statement of operations in the periods during which the related services were rendered. Defined Benefit Plans The Company recognizes the overfunded or underfunded status of each of its defined benefit plans as an asset or liability on its consolidated balance sheets. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. The estimates of the obligation and related expense of these plans recorded in the financial statements are based on certain assumptions. The most significant assumptions relate to discount rate and expected return on plan assets. Other assumptions used may include employee demographic factors such as compensation rate increases, retirement patterns, expected employee turnover and participant mortality rates. The difference between these assumptions and actual experience results in the recognition of an asset or liability based upon a net actuarial (gain) / loss. If the total net actuarial (gain) / loss included in accumulated other comprehensive income / (loss) exceeds a threshold of 10% of the greater of the projected benefit obligation or the market related value of plan assets, it is subject to amortization and recorded as a component of net periodic pension cost over the average remaining service lives of the employees participating in the pension plan. Net periodic benefit costs are recognized in the consolidated statement of operations.
Share-based Compensation	Share-Based Compensation The Company has adopted several equity award plans which authorize the granting of options, restricted shares, restricted stock units and other forms of equity awards of the Company’s ordinary shares, subject to certain conditions. The Company grants awards with the following features: • Time-based restricted stock and restricted stock unit awards (including, in certain foreign jurisdictions, cash-settled restricted stock unit awards, which are recorded as a liability); • Performance-based restricted stock unit awards measured against performance-based targets defined by the Company, including, but not limited to, total shareholder return metrics and R&D milestones, as defined by the Company; and • Non-qualified options to purchase outstanding shares. The Company recognizes share-based compensation expense for granted awards over the applicable vesting period. Cash-settled performance-based awards are recorded as a liability. These cash-settled performance-based awards were measured against pre-established total shareholder returns metrics.
Restructuring Costs	Restructuring Costs The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also incurs costs with contract terminations and costs of transferring products as part of restructuring activities. Refer to “NOTE 23 — Business Restructuring Charges” for more information.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. It also provides a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. The ASU provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants and only allows a company to present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. The amendments in ASU No. 2018-18 are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company evaluated the impact of this pronouncement and concluded that the guidance does not have a material impact on our financial position and results of operations. In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (i.e. a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application is permitted. The Company will adopt the new guidance prospectively to eligible costs incurred on or after the date this guidance is first applied. The Company evaluated the impact of this pronouncement. The guidance is not expected to have a material impact on our financial position and results of operations. In August 2018, the FASB issued ASU No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20) – Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The revisions to the disclosure requirements affect only the year-end financial statements of plan sponsors, as there are no changes related to interim financial statements. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted. The ASU provisions will be applied on a retrospective basis to all periods presented. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which removes, adds and modifies certain disclosure requirements for fair value measurements The Company will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, and the valuation processes of Level 3 fair value measurements. However, the Company will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. permitted to early adopt either the entire ASU or only the provisions that eliminate or modify the requirements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company evaluated the impact of this pronouncement and concluded that the guidance does not have a material impact on our financial position and results of operations.

Reconciliation of Warner Chil_2

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results (Tables)	12 Months Ended
	Dec. 31, 2019
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc	In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions): December 31, 2019 December 31, 2018 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 2,503.3 $ 2,497.1 $ 6.2 $ 880.4 $ 878.6 $ 1.8 Prepaid expenses and other current assets 886.4 886.4 - 819.1 818.7 0.4 Accounts payable and accrued liabilities 6,348.7 6,347.0 1.7 4,787.2 4,787.4 (0.2 ) Other taxes payables 1,704.8 1,698.6 6.2 1,615.5 1,615.5 - Deferred tax liabilities 4,363.7 4,363.2 0.5 5,501.8 5,501.8 - Total Equity 58,196.4 55,891.9 2,304.5 65,131.0 62,940.3 2,190.7
Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc	Year Ended December 31, 2019 Year Ended December 31, 2018 Year Ended December 31, 2017 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 2,481.8 $ 2,330.8 $ 151.0 $ 1,271.2 $ 1,177.5 $ 93.7 $ 1,501.9 $ 1,402.3 $ 99.6 Operating (loss) (4,445.3 ) (4,294.3 ) (151.0 ) (6,247.6 ) (6,153.9 ) (93.7 ) (5,921.2 ) (5,821.6 ) (99.6 ) Interest Income 76.8 76.8 - 45.2 270.1 (224.9 ) 67.7 166.3 (98.6 ) Other income / (expense), net 32.8 32.8 - 256.7 256.7 - (3,437.3 ) (3,437.3 ) - (Loss) before income taxes and noncontrolling interest (5,118.7 ) (4,967.7 ) (151.0 ) (6,856.9 ) (6,538.3 ) (318.6 ) (10,386.4 ) (10,188.2 ) (198.2 ) Net (loss) from continuing operations, net of tax (5,265.1 ) (5,114.1 ) (151.0 ) (5,086.2 ) (4,761.9 ) (324.3 ) (3,716.0 ) (3,517.8 ) (198.2 ) Net (loss) / income (5,265.1 ) (5,114.1 ) (151.0 ) (5,086.2 ) (4,761.9 ) (324.3 ) (4,118.9 ) (3,920.7 ) (198.2 ) Dividends on preferred shares - - - 46.4 - 46.4 278.4 - 278.4 Net (loss) / income attributable to ordinary shareholders/members (5,271.0 ) (5,120.0 ) (151.0 ) (5,142.8 ) (4,772.1 ) (370.7 ) (4,403.9 ) (3,927.3 ) (476.6 )

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Recognized Lease Liabilities and Corresponding Right of Use Assets	Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as follows ($ in millions): ROU Asset Lease Liability Real estate $ 304.2 $ 370.6 Fleet 100.4 100.4 Other 57.5 77.6 Total operating leases $ 462.1 $ 548.6
Property and Equipment	The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years
Provisions for Sales Returns and Allowances from Continuing Operations Activity	The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2017 $ 77.2 $ 1,799.2 $ 517.6 $ 36.5 $ 2,430.5 Provision related to sales in 2018 1,117.7 5,464.7 1,725.3 322.2 8,629.9 Credits and payments (1,133.1 ) (5,355.4 ) (1,676.3 ) (328.0 ) (8,492.8 ) Balance at December 31, 2018 $ 61.8 $ 1,908.5 $ 566.6 $ 30.7 $ 2,567.6 Provision related to sales in 2019 1,123.5 6,153.8 1,625.1 337.3 9,239.7 Credits and payments (1,117.5 ) (5,959.0 ) (1,559.3 ) (331.0 ) (8,966.8 ) Balance at December 31, 2019 $ 67.8 $ 2,103.3 $ 632.4 $ 37.0 $ 2,840.5 Contra accounts receivable at December 31, 2019 $ 67.8 $ 101.5 $ 35.7 $ 37.0 $ 242.0 Accounts payable and accrued expenses at December 31, 2019 $ - $ 2,001.8 $ 596.7 $ - $ 2,598.5
Schedule of Balance Sheet Classification of SRA Reserves	The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): December 31, 2019 December 31, 2018 Contra accounts receivable $ 242.0 $ 207.7 Accounts payable and accrued expenses 2,598.5 2,359.9 Total $ 2,840.5 $ 2,567.6
Summary of Activity in Gross-to-Net Revenue Excluding Discontinued Operations	The SRA provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Years Ended December 31, 2019 2018 2017 Gross product sales $ 24,968.8 $ 24,056.9 $ 23,688.4 Provisions to reduce gross product sales to net products sales (9,239.7 ) (8,629.9 ) (8,120.0 ) Net product sales $ 15,729.1 $ 15,427.0 $ 15,568.4 Percentage of SRA provisions to gross sales 37.0 % 35.9 % 34.3 %
Summary of Products Which Utilize Novel Drug Delivery Systems through Combination of Internal and Collaborative Programs	As of December 31, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including but not limited to the following: Product Therapeutic Area Indication Expected Launch Year Phase Bimatoprost SR Eye Care Glaucoma 2020 Review Abicipar Eye Care Age Related Macular Degeneration 2020 Review Atogepant Central Nervous System Prophylaxis Migraine 2021 III Presbysol Eye Care Presbyopia 2021 III Cenicriviroc Gastrointestinal NASH 2022 III Brimonidine DDS Eye Care Geographic Atrophy 2023 II Relamorelin Gastrointestinal Gastroparesis 2024 III Botox Medical Aesthetics Platysma/Masseter 2025/2024 II Abicipar Eye Care Diabetic Macular Edema 2025 II
Earnings Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS follows ($ in millions, except per share amounts): Years Ended December 31, 2019 2018 2017 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding (loss) / income from discontinued operations, net of tax $ (5,271.0 ) $ (5,142.8 ) $ (4,001.0 ) (Loss) / income from discontinued operations, net of tax - - (402.9 ) Net (loss) / income attributable to ordinary shareholders $ (5,271.0 ) $ (5,142.8 ) $ (4,403.9 ) Basic weighted average ordinary shares outstanding 329.0 337.0 333.8 Basic EPS: Continuing operations $ (16.02 ) $ (15.26 ) $ (11.99 ) Discontinued operations $ - $ - $ (1.20 ) Net (loss) / income per share $ (16.02 ) $ (15.26 ) $ (13.19 ) Dividends per ordinary share $ 2.96 $ 2.88 $ 2.80 Diluted weighted average ordinary shares outstanding 329.0 337.0 333.8 Diluted EPS: Continuing operations $ (16.02 ) $ (15.26 ) $ (11.99 ) Discontinued operations $ - $ - $ (1.20 ) Net (loss) / income per share $ (16.02 ) $ (15.26 ) $ (13.19 )

Business Developments (Tables)

Business Developments (Tables)	12 Months Ended
	Dec. 31, 2019
Business Acquisition [Line Items]
Summary of Products Sale Transaction and Key Financial Results of Business	The following represents the assets held for sale ($ in millions): December 31, December 31, 2019 2018 Assets held for sale: Inventories $ - $ 34.0 Property, plant and equipment, net 31.7 32.8 Product rights and other intangibles - 849.4 Total assets held for sale $ 31.7 $ 916.2
Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Final Valuation Cash and cash equivalents $ 36.7 Accounts receivable 47.0 Inventories 59.3 Property, plant and equipment 12.4 Intangible assets 1,185.0 Goodwill 1,211.6 Other assets 17.1 Accounts payable and accrued expenses (104.6 ) Deferred revenue (10.6 ) Deferred taxes, net (47.2 ) Other liabilities (1.3 ) Net assets acquired $ 2,405.4
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite Lived Assets Consumables $ 985.0 6.7 System 43.0 3.7 Total CMP 1,028.0 Customer Relationships 157.0 6.6 Total Definite Lived Assets $ 1,185.0
LifeCell Corporation [Member]
Business Acquisition [Line Items]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Final Valuation Cash and cash equivalents $ 8.7 Accounts receivable 50.8 Inventories 175.4 Property, plant and equipment, net 53.7 Currently marketed products ("CMP") intangible assets 2,010.0 In-process research and development ("IPR&D") intangible assets 10.0 Goodwill 1,449.1 Accounts payable and accrued expenses (149.6 ) Deferred tax liabilities, net (746.2 ) Other 21.2 Net assets acquired $ 2,883.1
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite lived assets Alloderm ® $ 1,385.0 6.9 Revolve ® 80.0 7.1 Strattice ® 320.0 5.1 Artia ® 115.0 8.8 Other 10.0 2.8 Total CMP 1,910.0 Customer Relationships 100.0 6.3 Total definite lived assets 2,010.0 In-process research and development Other 10.0 Total IPR&D 10.0 Total intangible assets $ 2,020.0
Sale of Aczone, Tazorac, Azelex, Cordran Tape and Seysara Products [Member]
Business Acquisition [Line Items]
Summary of Products Sale Transaction and Key Financial Results of Business	As a result of this transaction, the Company recorded the following ($ in millions): Purchase Price $ 550.0 Assets sold Intangible assets $ 205.4 Goodwill 184.0 Other assets 31.0 Net assets sold $ 420.4 Net gain included as a component of Other income / (expense), net $ 129.6

Assets Held for Sale (Tables)

Assets Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2019
Assets Held For Sale Not Part Of Disposal Group [Abstract]
Summary of Products Sale Transaction and Key Financial Results of Business	The following represents the assets held for sale ($ in millions): December 31, December 31, 2019 2018 Assets held for sale: Inventories $ - $ 34.0 Property, plant and equipment, net 31.7 32.8 Product rights and other intangibles - 849.4 Total assets held for sale $ 31.7 $ 916.2

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2019
Summary of Products Sale Transaction and Key Financial Results of Business	The following represents the assets held for sale ($ in millions): December 31, December 31, 2019 2018 Assets held for sale: Inventories $ - $ 34.0 Property, plant and equipment, net 31.7 32.8 Product rights and other intangibles - 849.4 Total assets held for sale $ 31.7 $ 916.2
Global Generics [Member]
Summary of Teva Share Activity	During the year ended December 31, 2018, the Company recorded the following movements in its investment in Teva securities ("Teva Share Activity") ($ in millions except per share information): Shares Carrying Value per Share Market Price Proceeds Received Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income Gain / (Loss) Recognized in Other Income/ (Expense), Net Derivative Instrument (Liability)/ Asset Retained Earnings Teva securities as of December 31, 2017 95.9 $ 17.60 $ 18.95 n.a. $ 1,817.7 $ 129.3 $ - $ (62.9 ) $ - Impact of ASU No. 2016-01 - - - - - (129.3 ) - - 129.3 Settlement of initial accelerated share repurchase ("ASR"), net during the three months ended March 31, 2018 (1) (25.0 ) 18.95 16.53 (2) 413.3 (473.8 ) - 2.5 62.9 - Settlement of forward sale entered into during the three months ended March 31, 2018, net (3) (25.0 ) 17.09 18.61 (4) 465.5 (427.3 ) - 38.2 - - Open market sales during the twelve months ended December 31, 2018 (45.9 ) n.a. (5) 20.41 936.7 (916.6 ) - 20.2 - - Teva securities as of and for the twelve months ended December 31, 2018 - $ - $ - $ 1,815.5 $ - $ - $ 60.9 $ - $ 129.3 (1) (2) (3) (4) (5) During the year ended December 31, 2017, the Company recorded the following movements in its investment in Teva securities ($ in millions except per share information): Shares Carrying Value per Share Market Price Discount Movement in the Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income (Loss) / Gain Recognized in Other Income / (Expense), Net Teva securities as of December 31, 2016 100.3 $ 53.39 $ 36.25 5.4 % $ 3,439.2 $ (1,599.4 ) $ - Other-than-temporary impairment recognized at March 31, 2017 100.3 32.09 32.09 4.9 % (378.6 ) 1,599.4 (1,978.0 ) Other-than-temporary impairment recognized at September 30, 2017 100.3 17.60 17.60 0.0 % (1,295.5 ) - (1,295.5 ) Sales during the twelve months ended December 31, 2017 (4.4 ) n.a. n.a. 0.0 % (76.7 ) - 4.2 Other fair value movements in the twelve months ended December 31, 2017 95.9 17.60 18.95 0.0 % 129.3 129.3 - Teva securities as of and for the twelve months ended December 31, 2017 95.9 $ 17.60 $ 18.95 0.0 % $ 1,817.7 $ 129.3 $ (3,269.3 ) The Teva stock price was discounted due to the lack of marketability.
Summary of Products Sale Transaction and Key Financial Results of Business	The following table presents key financial results of the global generics business and the Anda Distribution business included in “(Loss) / income from discontinued operations, net of tax” for the year ended December 31, 2017 ($ in millions): 2017 Net revenues $ - Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - Research and development - Selling and marketing - General and administrative 18.8 Amortization - Asset sales and impairments, net 1.2 Total operating expenses 20.0 Operating (loss) / income (20.0 ) Other (expense) / income, net (470.4 ) (Benefit) / provision for income taxes (87.5 ) (Loss) / income from discontinued operations, net of tax $ (402.9 )

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model	Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2019 Grants 2018 Grants 2017 Grants Dividend yield 1.7 - 2.2% 1.5% 1.2% Expected volatility 23.5 - 26.4% 27.0% 27.0% Risk-free interest rate 1.9 - 2.6% 2.2-2.9% 2.0-2.3% Expected term (years) 7.0 7.0 7.0
Share-Based Compensation Expense Recognized in Company's Results of Operations	Share-based compensation expense recognized in the Company’s results of operations, including discontinued operations, for the years ended December 31, 2019, 2018 and 2017 was as follows ($ in millions): Years Ended December 31, 2019 2018 2017 Equity-based compensation awards $ 214.3 $ 239.8 $ 293.3 Cash-settled awards in connection with the Zeltiq Acquisition - - 31.5 Non-equity settled awards other - - (16.8 ) Total share-based compensation expense $ 214.3 $ 239.8 $ 308.0
Summary of Impact of Accelerations and Step-ups Relating to Acquisition Accounting Treatment of Outstanding Awards	Included in the share-based compensation awards for the years ended December 31, 2019, 2018 and 2017 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Zeltiq Acquisition, the acquisition of Allergan, Inc. (the “Allergan Acquisition”), and the acquisition of Forest Laboratories, Inc. (the “Forest Acquisition”) ($ in millions): Years Ended December 31, 2019 2018 2017 Zeltiq Acquisition $ 4.9 $ 10.1 $ 47.8 Allergan Acquisition 0.5 8.3 47.1 Forest Acquisition - - 10.1 Total $ 5.4 $ 18.4 $ 105.0
Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units	The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2018 through December 31, 2019 (in millions, except per share data): Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2018 2.5 $ 190.27 1.6 $ 472.9 Granted 1.5 140.13 210.7 Vested (0.8 ) 210.08 (159.6 ) Forfeited (0.1 ) 174.29 (31.0 ) Restricted shares / units outstanding at December 31, 2019 3.1 $ 159.74 1.4 $ 493.0
Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares	The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2018 through December 31, 2019 (in millions, except per share data): Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2018 6.3 $ 122.74 4.4 $ 69.0 Granted 0.3 140.56 Exercised (0.9 ) 99.71 Cancelled (0.2 ) 224.58 Outstanding, vested and expected to vest at December 31, 2019 5.5 $ 127.27 3.9 $ 352.9

Pension and Other Postretirem_2

Pension and Other Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Summary of Net Periodic (Benefit) of Defined Benefit Plans for Continuing Operations	The service and settlement costs captured as part of the net periodic (benefit) are recorded within general & administrative expenses and the interest costs and expected return on plan assets are recorded within “other income / (expense), net”. Years Ended December 31, 2019 2018 2017 Service cost $ 1.2 $ 2.8 $ 5.5 Interest cost 39.6 38.1 40.7 Expected return on plan assets (56.3 ) (63.8 ) (54.5 ) Settlement (0.6 ) (0.6 ) (0.1 ) Net periodic (benefit) $ (16.1 ) $ (23.5 ) $ (8.4 )
Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations	Benefit obligation and asset data for the defined benefit plans for continuing operations, was as follows ($ in millions): Years Ended December 31, 2019 2018 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,129.6 $ 1,235.2 Employer contribution 12.3 14.8 (Loss) / gain on plan assets 221.3 (53.6 ) Benefits paid (38.6 ) (41.1 ) Settlements - (2.9 ) Effects of exchange rate changes and other (2.9 ) (22.8 ) Fair value of plan assets at end of year $ 1,321.7 $ 1,129.6 Years Ended December 31, 2019 2018 Change in Benefit Obligation Benefit obligation at beginning of the year $ 1,227.2 $ 1,330.0 Service cost 1.2 2.8 Interest cost 39.6 38.1 Actuarial (gain) / loss 143.5 (74.5 ) Settlements and other - (2.9 ) Benefits paid (38.6 ) (41.1 ) Effects of exchange rate changes and other (5.7 ) (25.2 ) Benefit obligation at end of year $ 1,367.2 $ 1,227.2 Funded status at end of year $ (45.5 ) $ (97.6 )
Schedule of Funded Status Amount in Consolidated Balance Sheet	The following table outlines the funded actuarial amounts ($ in millions): Years Ended December 31, 2019 2018 Noncurrent assets $ 57.1 $ 27.6 Current liabilities (0.9 ) (0.9 ) Noncurrent liabilities (101.7 ) (124.3 ) $ (45.5 ) $ (97.6 )
Schedule of Fair Values of Pension Plan Assets by Asset Category	The fair values of the Company’s pension plan assets at December 31, 2019 by asset category are as follows ($ in millions): Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 30.6 $ - $ - $ 30.6 International equities 249.1 - - 249.1 Other equity securities 65.5 - - 65.5 Equity securities $ 345.2 $ - $ - $ 345.2 U.S. Treasury bonds $ - $ 46.2 $ - $ 46.2 Bonds and bond funds - 923.2 - 923.2 Other debt securities - - - - Debt securities $ - $ 969.4 $ - $ 969.4 Other investments Other - 7.1 - 7.1 Total assets $ 345.2 $ 976.5 $ - $ 1,321.7 The fair values of the Company’s pension plan assets at December 31, 2018 by asset category are as follows ($ in millions): Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 20.6 $ - $ - $ 20.6 International equities 205.3 - - 205.3 Other equity securities 49.8 - - 49.8 Equity securities $ 275.7 $ - $ - $ 275.7 U.S. Treasury bonds $ - $ 63.0 $ - $ 63.0 Bonds and bond funds - 787.2 - 787.2 Other debt securities - - - - Debt securities $ - $ 850.2 $ - $ 850.2 Other investments Other - 3.7 - 3.7 Total assets $ 275.7 $ 853.9 $ - $ 1,129.6
Schedule of Allocated Target Investment Portfolio of Pension Plans for Continuing Operations	The target investment portfolio of the Company’s continuing operations pension plans is allocated as follows: Target Allocation as of December 31, 2019 2018 Bonds 74.3 % 70.6 % Equity securities 22.4 % 26.0 % Other investments 3.3 % 3.4 %
Schedule of Expected Benefit Payments of Pension Plans	Total expected benefit payments for the Company’s pension plans are as follows ($ in millions): Expected Benefit Payments 2020 $ 38.6 2021 40.9 2022 43.1 2023 45.2 2024 47.1 Thereafter 1,152.3 Total liability $ 1,367.2
Schedule of Defined Benefit Plans with Accumulated Benefit Obligation in Excess of Plan Assets	Information for defined benefit plans with an accumulated benefit obligation in excess of plan assets is presented below ($ in millions): Defined Benefit as of December 31, 2019 2018 Projected benefit obligations $ 1,367.2 $ 1,227.2 Accumulated benefit obligations $ 1,362.6 $ 1,223.5 Plan assets $ 1,321.7 $ 1,129.6
Schedule of Balances Recognized within Accumulated Other Comprehensive Income / (Loss) Excluding the Impact of Taxes	Balances recognized within accumulated other comprehensive income/(loss) excluding the impact of taxes that have not been recognized as components of net periodic benefit costs are as follows ($ in millions): Defined Benefit Balance as of December 31, 2017 $ 58.2 Net actuarial (loss) (44.6 ) Balance as of December 31, 2018 $ 13.6 Net actuarial gain 20.3 Balance as of December 31, 2019 $ 33.9
Weighted Average Assumptions Used to Calculate Projected Benefit Obligations and Net Periodic Benefit Cost	The weighted average assumptions used to calculate the projected benefit obligations of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2019 2018 Discount rate 2.4 % 3.3 % Salary growth rate 3.0 % 3.0 % The weighted average assumptions used to calculate the net periodic benefit cost of the C ompany’s defined benefit plans are as follows: As of December 31, 2019 2018 Discount rate 3.3 % 2.9 % Expected rate of return on plan assets 5.1 % 5.2 % Salary growth rate 3.0 % 3.0 %
Schedule of Accumulated Benefit Obligation for Defined Benefit Plans	Accumulated benefit obligation for the defined benefit plans, were as follows ($ in millions): Accumulated Benefit Obligation Accumulated benefit obligation as of December 31, 2017 $ 46.8 Interest cost 1.6 Actuarial charge (2.6 ) Benefits paid (3.6 ) Accumulated benefit obligation as of December 31, 2018 $ 42.2 Interest cost 1.7 Actuarial charge 2.1 Benefits paid (3.6 ) Accumulated benefit obligation as of December 31, 2019 $ 42.4

Other Income _ (Expense), Net (

Other Income / (Expense), Net (Tables)	12 Months Ended
	Dec. 31, 2019
Other Income And Expenses [Abstract]
Components of Other Income / (Expense), Net	Other income / (expense), net consisted of the following ($ in millions): Years Ended December 31, 2019 2018 2017 Teva Share Activity $ - $ 60.9 $ (3,269.3 ) Sale of businesses - 182.6 - Debt extinguishment costs as part of the debt tender offer - - (161.6 ) Debt extinguishment other (0.2 ) 15.6 (27.6 ) Other-than-temporary impairments - - (26.1 ) Dividend income - - 85.2 Naurex recovery - - 20.0 Forward sale of Teva shares - - (62.9 ) Other (expense) / income, net 33.0 (2.4 ) 5.0 Other income / (expense), net $ 32.8 $ 256.7 $ (3,437.3 )
Summary of Redeemed and Retired Senior Notes	During the year ended December 31, 2019, the Company redeemed and retired the following senior notes ($ in millions): Year Ended December 31, 2019 Tranche Face Value Retired Cash Paid for Retirement Remaining Value at December 31, 2019 3.000% due 2020 $ 180.7 $ 180.7 $ 2,526.0 3.450% due 2022 62.3 62.3 2,878.2 3.800% due 2025 6.8 6.8 3,020.7 Total $ 249.8 $ 249.8 $ 8,424.9

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following ($ in millions): December 31, December 31, 2019 2018 Raw materials $ 455.2 $ 303.2 Work-in-process 246.2 145.7 Finished goods 581.7 520.2 1,283.1 969.1 Less: inventory reserves 150.0 122.2 Total Inventories $ 1,133.1 $ 846.9

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following ($ in millions): December 31, December 31, 2019 2018 Accrued expenses: Accrued third-party rebates $ 2,001.8 $ 1,832.1 Litigation-related reserves and legal fees 1,250.7 92.0 Accrued payroll and related benefits 830.3 694.3 Accrued returns and other allowances 596.7 527.8 Accrued R&D expenditures 184.8 215.5 Interest payable 189.5 191.4 Royalties payable 216.9 155.1 Accrued pharmaceutical fees 125.9 145.3 Accrued severance, retention and other shutdown costs 12.7 71.6 Accrued non-provision taxes 64.6 68.5 Accrued selling and marketing expenditures 61.3 61.1 Current portion of contingent consideration obligations 12.1 8.3 Dividends payable 1.1 1.4 Other accrued expenses 409.9 373.0 Total accrued expenses $ 5,958.3 $ 4,437.4 Accounts payable 390.4 349.8 Total accounts payable and accrued expenses $ 6,348.7 $ 4,787.2

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Summary of Operating ROU Assets and liabilities	As of December 31, 2019, the Company had the following operating ROU assets and lease liabilities ($ in millions): December 31, 2019 ROU Asset Lease Liability Real estate $ 321.2 $ 386.9 Fleet 115.0 114.9 Other 54.2 68.7 Total operating leases $ 490.4 $ 570.5 December 31, 2019 Current lease liability - operating $ 124.4 Long-term lease liability - operating 446.1 Total lease liability - operating $ 570.5
Schedule of Lease Expense	For the year ended December 31, 2019, the Company noted the following lease expense ($ in millions): Year Ended December 31, 2019 Operating lease expense* $ 151.3 Sublease (income) (14.3 ) Net operating lease expense $ 137.0 * Includes short-term and variable lease expenses of $9.5 million for the year ended December 31, 2019.
Schedule of Lease Commitments	As of December 31, 2019, the Company had the following lease commitments ($ in millions): Total Payments 2020 $ 131.6 2021 116.6 2022 88.8 2023 58.3 2024 49.7 2025 and after 192.1 Total undiscounted cash flows $ 637.1 Future interest (66.6 ) Total lease liability – operating $ 570.5
Schedule of Future Minimum Property Lease Rental Payments under Capital and Operating Leases	As of December 31, 2018, the future anticipated property lease rental payments under both capital and operating leases that had remaining terms in excess of one year were ($ in millions): Total Payments 2019 62.5 2020 52.5 2021 47.9 2022 43.3 2023 39.0 Thereafter 173.8 Total minimum lease payments $ 419.0

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net consisted of the following as of December 31, 2019 and 2018 ($ in millions): Machinery and Equipment Research and Laboratory Equipment Transportation/ Other Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2018 $ 590.4 $ 67.4 $ 529.6 $ 911.1 $ 466.7 $ 2,565.2 Additions 11.5 20.0 25.6 38.9 279.2 375.2 Disposals/transfers/other 82.5 8.4 89.5 41.4 (302.9 ) (81.1 ) Currency translation (2.4 ) 1.2 (1.2 ) (1.9 ) (0.6 ) (4.9 ) At December 31, 2019 $ 682.0 $ 97.0 $ 643.5 $ 989.5 $ 442.4 $ 2,854.4 Accumulated depreciation At December 31, 2018 $ 284.2 $ 46.3 $ 291.4 $ 156.3 $ - $ 778.2 Additions 67.3 10.9 77.8 48.5 - 204.5 Disposals/transfers/impairments/other (23.2 ) (0.1 ) (9.2 ) (20.8 ) - (53.3 ) Currency translation (1.0 ) 0.8 (0.9 ) (0.5 ) - (1.6 ) At December 31, 2019 $ 327.3 $ 57.9 $ 359.1 $ 183.5 $ - $ 927.8 Property, plant and equipment, net At December 31, 2019 $ 354.7 $ 39.1 $ 284.4 $ 806.0 $ 442.4 $ 1,926.5

Prepaid Expenses, Investments_2

Prepaid Expenses, Investments and Other Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Investments All Other Investments [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following ($ in millions): December 31, December 31, 2019 2018 Prepaid taxes $ 437.7 $ 403.8 Prepaid insurance 11.5 16.7 Contingent income 83.6 67.7 Sales and marketing 65.0 41.8 Other 288.6 289.1 Total prepaid expenses and other current assets $ 886.4 $ 819.1
Marketable Securities, Including Cash and Cash Equivalents, Other Investments and Other Assets	Investments in marketable securities, including those classified in cash and cash equivalents due to the maturity term of the instrument, other investments and other assets consisted of the following ($ in millions): December 31, December 31, 2019 2018 Marketable securities: Short-term investments $ 3,411.6 $ 1,026.9 Total marketable securities $ 3,411.6 $ 1,026.9 Investments and other assets: Deferred executive compensation investments $ 89.2 $ 90.8 Equity method investments 7.6 8.4 Other long-term investments 63.3 37.6 Taxes receivable 41.2 1,674.8 Contingent income 51.8 75.3 Other assets 154.9 83.7 Total investments and other assets $ 408.0 $ 1,970.6

Goodwill, Product Rights and _2

Goodwill, Product Rights and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Specialized Therapeutics US General Medicine International Total Balance as of December 31, 2018 $ 20,675.6 $ 17,936.6 $ 7,301.1 $ 45,913.3 Acquisitions 34.1 - - 34.1 Impairments - (3,552.8 ) - (3,552.8 ) Allocation to current segments (340.0 ) 340.0 - - Foreign exchange and other adjustments - - (146.3 ) (146.3 ) Balance as of December 31, 2019 $ 20,369.7 $ 14,723.8 $ 7,154.8 $ 42,248.3
Schedule of Cost Basis on Product Rights and Other Intangible Assets	Product rights and other intangible assets consisted of the following for the years ended December 31, 2019 and 2018 ($ in millions): Cost Basis Balance as of December 31, 2018 Additions Impairments Transfers / Held Sale Foreign Currency Translation Balance as of December 31, 2019 Intangibles with definite lives: Product rights and other intangibles $ 70,235.1 $ 178.4 $ - $ 1,936.6 $ (132.6 ) $ 72,217.5 Trade name 690.0 - - - - 690.0 Total definite lived intangible assets $ 70,925.1 $ 178.4 $ - $ 1,936.6 $ (132.6 ) $ 72,907.5 Intangibles with indefinite lives: IPR&D $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total indefinite lived intangible assets $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total product rights and other intangibles $ 75,973.2 $ 178.4 $ (436.0 ) $ 1,861.0 $ (132.6 ) $ 77,444.0 Accumulated Amortization Balance as of December 31, 2018 Amortization Impairments Transfers / Held for Sale Foreign Currency Translation Balance as of December 31, 2019 Intangibles with definite lives: Product rights and other intangibles $ (31,985.0 ) $ (5,776.7 ) $ (443.6 ) $ (1,011.4 ) $ 36.0 $ (39,180.7 ) Trade name (292.8 ) (79.9 ) - - - (372.7 ) Total definite lived intangible assets $ (32,277.8 ) $ (5,856.6 ) $ (443.6 ) $ (1,011.4 ) $ 36.0 $ (39,553.4 ) Total product rights and other intangibles $ (32,277.8 ) $ (5,856.6 ) $ (443.6 ) $ (1,011.4 ) $ 36.0 $ (39,553.4 ) Net Product Rights and Other Intangibles $ 43,695.4 $ 37,890.6 Product rights and other intangible assets consisted of the following for the years ended December 31, 2018 and 2017 ($ in millions): Cost Basis Balance as of December 31, 2017 Additions Impairments IPR&D CMP Transfers Divested / Held for Sale / Other Foreign Currency Translation Balance as of December 31, 2018 Intangibles with definite lives: Product rights and other intangibles $ 73,892.5 $ 49.0 $ - $ — $ (3,391.0 ) $ (315.4 ) $ 70,235.1 Trade name 690 - - - - - 690.0 Total definite lived intangible assets $ 74,582.5 $ 49.0 $ - $ - $ (3,391.0 ) $ (315.4 ) $ 70,925.1 Intangibles with indefinite lives: IPR&D $ 5,874.1 $ - $ (798.0 ) $ - $ (28.0 ) $ - $ 5,048.1 Total indefinite lived intangible assets $ 5,874.1 $ - $ (798.0 ) $ - $ (28.0 ) $ - $ 5,048.1 Total product rights and other intangibles $ 80,456.6 $ 49.0 $ (798.0 ) $ - $ (3,419.0 ) $ (315.4 ) $ 75,973.2 Accumulated Amortization Balance as of December 31, 2017 Amortization Impairments Divested / Held for Sale / Other Foreign Currency Translation Balance as of December 31, 2018 Intangibles with definite lives: Product rights and other intangibles $ (25,593.6 ) $ (6,474.2 ) $ (2,239.9 ) $ 2,233.4 $ 89.3 $ (31,985.0 ) Trade name (214.7 ) (78.1 ) - - - (292.8 ) Total definite lived intangible assets $ (25,808.3 ) $ (6,552.3 ) $ (2,239.9 ) $ 2,233.4 $ 89.3 $ (32,277.8 ) Total product rights and other intangibles $ (25,808.3 ) $ (6,552.3 ) $ (2,239.9 ) $ 2,233.4 $ 89.3 $ (32,277.8 ) Net Product Rights and Other Intangibles $ 54,648.3 $ 43,695.4
Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of December 31, 2019 over each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2020 $ 5,565.8 2021 $ 4,590.7 2022 $ 4,197.8 2023 $ 3,741.7 2024 $ 2,864.8

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Capital Leases	Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of Guarantor Issuance Date / Acquisition Date Interest Payments December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due March 12, 2020 (1) (4) March 4, 2015 Quarterly 500.0 500.0 501.0 501.9 500.0 500.0 501.0 501.9 Fixed Rate Notes $3,500.0 million 3.000% notes due March 12, 2020 (4) March 4, 2015 Semi-annually 2,526.0 2,706.7 2,529.5 2,694.8 $650.0 million 3.375% notes due September 15, 2020 (5) March 17, 2015 Semi-annually 650.0 650.0 654.7 648.7 $750.0 million 4.875% notes due February 15, 2021 (6) July 1, 2014 Semi-annually 450.0 450.0 463.4 459.4 $1,200.0 million 5.000% notes due December 15, 2021 (6) July 1, 2014 Semi-annually 1,200.0 1,200.0 1,262.9 1,234.8 $3,000.0 million 3.450% notes due March 15, 2022 (4) March 4, 2015 Semi-annually 2,878.2 2,940.5 2,945.1 2,891.0 $1,700.0 million 3.250% notes due October 1, 2022 (5) October 2, 2012 Semi-annually 1,700.0 1,700.0 1,739.1 1,652.2 $350.0 million 2.800% notes due March 15, 2023 (5) March 17, 2015 Semi-annually 350.0 350.0 352.7 332.8 $1,200.0 million 3.850% notes due June 15, 2024 (4) June 10, 2014 Semi-annually 1,036.7 1,036.7 1,089.9 1,021.0 $4,000.0 million 3.800% notes due March 15, 2025 (4) March 4, 2015 Semi-annually 3,020.7 3,027.5 3,172.4 2,956.0 $2,500.0 million 4.550% notes due March 15, 2035 (4) March 4, 2015 Semi-annually 1,789.0 1,789.0 1,953.4 1,690.7 $1,000.0 million 4.625% notes due October 1, 2042 (5) October 2, 2012 Semi-annually 456.7 456.7 482.8 412.4 $1,500.0 million 4.850% notes due June 15, 2044 (4) June 10, 2014 Semi-annually 1,079.4 1,079.4 1,192.8 1,019.1 $2,500.0 million 4.750% notes due March 15, 2045 (4) March 4, 2015 Semi-annually 881.0 881.0 968.7 836.6 18,017.7 18,267.5 18,807.4 17,849.5 Euro Denominated Notes €700.0 million floating rate notes due June 1, 2019 (2) (4) May 26, 2017 Quarterly - 802.7 - 794.9 €700.0 million floating rate notes due November 15, 2020 (3) (4) November 15, 2018 Quarterly 784.9 802.7 784.4 791.3 €750.0 million 0.500% notes due June 1, 2021 (4) May 26, 2017 Annually 841.0 860.0 846.7 849.7 €500.0 million 1.500% notes due November 15, 2023 (4) November 15, 2018 Annually 560.7 573.4 589.8 572.4 €700.0 million 1.250% notes due June 1, 2024 (4) May 26, 2017 Annually 784.9 802.7 817.7 775.5 €500.0 million 2.625% notes due November 15, 2028 (4) November 15, 2018 Annually 560.7 573.4 648.2 573.4 €550.0 million 2.125% notes due June 1, 2029 (4) May 26, 2017 Annually 616.7 630.7 683.9 594.7 4,148.9 5,045.6 4,370.7 4,951.9 Total Senior Notes Gross 22,666.6 23,813.1 23,679.1 23,303.3 Unamortized premium 39.9 64.3 Unamortized discount (55.4 ) (64.5 ) Total Senior Notes Net 22,651.1 23,812.9 23,679.1 23,303.3 Other Indebtedness Debt Issuance Costs (74.7 ) (92.1 ) Margin Loan - - Other 72.6 69.3 Total Other Borrowings (2.1 ) (22.8 ) Capital Leases - 7.6 Total Indebtedness $ 22,649.0 $ 23,797.7 (1) (2) (3) (4) (5) (6)
Schedule of Annual Debt Maturities	As of December 31, 2019, annual debt maturities of senior notes gross were as follows ($ in millions): Total Payments 2020 4,460.9 2021 2,491.0 2022 4,578.2 2023 910.7 2024 1,821.6 2025 and after 8,404.2 Total senior notes gross $ 22,666.6

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Summary of Other Long-Term Liabilities	Other long-term liabilities consisted of the following ($ in millions): December 31, December 31, 2019 2018 Acquisition related contingent consideration liabilities $ 377.3 $ 336.3 Long-term pension and post retirement liability 144.1 166.5 Legacy Allergan deferred executive compensation 89.2 90.8 Accrued R&D milestone 75.0 75.0 Long-term contractual obligations - 43.2 Deferred revenue 26.6 36.1 Product warranties 29.2 27.9 Long-term severance and restructuring liabilities 10.8 14.2 Other long-term liabilities 48.7 92.0 Total other long-term liabilities $ 800.9 $ 882.0

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule of Losses Before Income Taxes	For the years ended December 31, 2019, 2018 and 2017, losses before income taxes consisted of the following ($ in millions): Years Ended December 31, 2019 2018 2017 Irish $ (4,756.0 ) $ (4,285.8 ) $ (1,139.0 ) Non-Irish (362.7 ) (2,571.1 ) (9,247.4 ) Total (loss) / income before taxes $ (5,118.7 ) $ (6,856.9 ) $ (10,386.4 )
Schedule of Provision / (Benefit)for Income Taxes	The Company’s provision / (benefit) for income taxes consisted of the following ($ in millions): Years Ended December 31, 2019 2018 2017 Current (benefit) / provision: U.S. federal $ 476.5 $ (1,024.5 ) $ 763.1 U.S. state 35.6 34.2 (54.8 ) Non-U.S. 295.2 481.6 410.0 Total current (benefit) / provision 807.3 (508.7 ) 1,118.3 Deferred (benefit) / provision: U.S. federal (635.7 ) (569.9 ) (6,911.9 ) U.S. state (131.7 ) (80.6 ) (252.3 ) Non-U.S. 106.5 (611.5 ) (624.5 ) Total deferred (benefit) / provision (660.9 ) (1,262.0 ) (7,788.7 ) Total (benefit) / provision for income taxes $ 146.4 $ (1,770.7 ) $ (6,670.4 )
Schedule of Components Company's Net Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities are measured based on the difference between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The significant components of the Company’s net deferred tax assets and liabilities consisted of the following (in millions): Years Ended December 31, 2019 2018 Benefits from net operating and capital loss carryforwards $ 2,105.2 $ 2,145.8 Benefits from tax credit and other carryforwards 440.4 377.6 Differences in financial statement and tax accounting for: Inventories, receivables and accruals 496.8 231.8 Basis differences in investments 185.5 56.1 Share-based and other compensation 242.8 295.5 Other 183.4 82.4 Total deferred tax asset, gross $ 3,654.1 $ 3,189.2 Less: Valuation allowance (2,079.1 ) (1,637.9 ) Total deferred tax asset, net $ 1,575.0 $ 1,551.3 Differences in financial statement and tax accounting for: Property, equipment and intangible assets (4,725.2 ) (5,487.4 ) Basis differences in investments (525.9 ) (499.9 ) Other (110.7 ) (2.1 ) Total deferred tax liabilities $ (5,361.8 ) $ (5,989.4 ) Total deferred taxes $ (3,786.8 ) $ (4,438.1 )
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in millions): Years Ended December 31, 2019 2018 2017 Balance at the beginning of the year $ 1,186.8 $ 850.3 $ 811.2 Increases for current year tax positions 66.4 164.3 10.1 Increases for prior year tax positions 214.3 193.4 69.2 Increases due to acquisitions 0.0 0.0 19.8 Decreases for prior year tax positions (218.1 ) (5.0 ) (38.7 ) Settlements (23.3 ) (5.4 ) (21.7 ) Lapse of applicable statute of limitations (13.3 ) (5.9 ) (2.9 ) Foreign exchange 1.6 (4.9 ) 3.3 Balance at the end of the year $ 1,214.4 $ 1,186.8 $ 850.3
Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS	The Company has several concurrent audits open and pending with the Internal Revenue Service (“IRS”) as set forth below: IRS Audits Taxable Years Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc. 2013, 2014, 2015 and 2016 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Allergan, Inc. 2009, 2010, 2011, 2012, 2013, 2014 and 3/17/2015
Irish Income Tax Authority [Member]
Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate	The reconciliations for the years ended December 31, 2019, 2018 and 2017 between the statutory Irish income tax rate for Allergan plc and the effective income tax rates were as follows: Allergan plc Years Ended December 31, 2019 2018 2017 Statutory rate (12.5 )% (12.5 )% (12.5 )% Earnings subject to U.S. taxes (1) (2) 1.3 % (1.8 )% (17.4 )% Earnings subject to rates different than the statutory rate (1)(2) (5.3 )% (3.4 )% 2.1 % Impact of U.S. tax reform enactment 0.0 % (0.2 )% (27.2 )% Tax reserves and audit outcomes 2.1 % 2.6 % 0.4 % Non-deductible expenses (3) 12.6 % 7.4 % 0.2 % Impact of acquisitions and reorganizations (4) (2.6 )% (15.3 )% (9.3 )% Tax credits and U.S. special deductions (2.0 )% (0.9 )% (1.5 )% Rate changes (5) 0.3 % 2.2 % (1.2 )% Valuation allowances (6) 8.7 % (3.7 )% 2.2 % Other 0.3 % (0.2 )% 0.0 % Effective income tax rate 2.9 % (25.8 )% (64.2 )% (1) The U.S. rate differential was a detriment of $64.5 million to the 2019 effective tax rate as compared to a benefit of $122.9 million to the 2018 effective tax rate, primarily driven by decreases of approximately $2.9 billion in impairment charges and amortization expense. The remaining rate differential is driven by non-U.S. income subject to rates lower than the Irish statutory rate. (2) The Company recorded amortization expense of $5.9 billion and intangible impairment charges of $0.9 billion, resulting in a tax benefit of $14.1 million to the 2019 effective tax rate. In 2018, the Company recorded amortization expense of $6.6 billion and intangible impairment charges of $3.0 billion, resulting in a tax benefit of $277.5 million, favorably impacting the 2018 effective tax rate as compared to 2019. (3) In 2019, the Company recorded charges of $3.6 billion for goodwill impairment and $1.1 billion for legal settlements with no corresponding tax benefit, resulting in a tax detriment of $581.5 million to the effective tax rate. In 2018, the Company recorded a goodwill impairment charge of $3.5 billion with no corresponding tax benefit, resulting in a tax detriment of $432.9 million. (4) In 2019, the Company recorded a tax benefit of $131.2 million related to the tax effects of integration and the recognition of outside basis differences. In 2018, the Company recorded a tax benefit of $1,047.8 million related to the tax effects of integration and the recognition of outside basis differences. This resulted in a more favorable impact in 2018 as compared to 2019. (5) As a result of statutory and other tax rate changes applied to certain deferred tax assets and liabilities, the Company recorded a detriment of $15.1 million in 2019. In 2018, the Company recorded a detriment of $148.0 million, favorably impacting the 2019 rate as compared to 2018. (6) In 2019, the Company recorded a tax detriment of $444.9 million to establish a valuation allowance on deferred tax assets related to certain tax attributes, which are not expected to be realized. In 2018, the Company recorded a tax benefit of $254.0 million for the full release of a valuation allowance related to the Company’s foreign tax credit and partial release related to non-U.S. net operating loss carryforwards.
Bermuda Income Tax Authority [Member] | Warner Chilcott Limited [Member]
Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate	The reconciliations for the years ended December 31, 2019, 2018 and 2017 between the statutory Bermuda income tax rate for Warner Chilcott Limited and the effective income tax rates were as follows: Warner Chilcott Limited (1) Years Ended December 31, 2019 2018 2017 Statutory rate 0.0 % 0.0 % 0.0 % Earnings subject to U.S. taxes (2.8 )% (10.2 )% (27.4 )% Earnings subject to rates different than the statutory rate (14.2 )% (8.4 )% (0.9 )% Impact of U.S. tax reform enactment 0.0 % (0.2 )% (27.7 )% Tax reserves and audit outcomes 2.1 % 2.6 % 0.5 % Non-deductible expenses 13.0 % 7.7 % 0.2 % Impact of acquisitions and reorganizations (2.6 )% (16.0 )% (9.5 )% Tax credits and U.S. special deductions (2.1 )% (1.0 )% (1.5 )% Rate changes 0.3 % 2.3 % (1.3 )% Valuation allowances 9.0 % (3.9 )% 2.3 % Other 0.3 % (0.1 )% (0.2 )% Effective income tax rate 3.0 % (27.2 )% (65.5 )% (1) The rate reconciliation for Bermuda is largely consistent with the Irish effective tax rate reconciliations presented above.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Summary of Movements in Accumulated Other Comprehensive (Loss)	Unrealized gain / (losses) net of tax primarily represent experience differentials and other actuarial charges related to the Company’s defined benefit plans. The movements in accumulated other comprehensive income / (loss) for the years ended December 31, 2019 and 2018 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gain / (loss) net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2017 $ 1,782.7 $ 138.0 $ 1,920.7 Amounts reclassed, net of tax, upon adoption of ASU 2016-01 - (63.0 ) (63.0 ) Balance as of January 1, 2018 $ 1,782.7 $ 75.0 $ 1,857.7 Other comprehensive gain / (loss) before reclassifications into general and administrative (474.4 ) (38.1 ) (512.5 ) Balance as of December 31, 2018 $ 1,308.3 $ 36.9 $ 1,345.2 Other comprehensive gain / (loss) before reclassifications into general and administrative (151.8 ) 13.8 (138.0 ) Balance as of December 31, 2019 $ 1,156.5 $ 50.7 $ 1,207.2

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment	Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Year Ended December 31, 2019 US Specialized US General Therapeutics Medicine International Total Net revenues $ 6,820.0 $ 5,834.9 $ 3,402.0 $ 16,056.9 Operating expenses: Cost of sales (1) 578.2 954.8 548.3 2,081.3 Selling and marketing 1,490.4 978.2 934.7 3,403.3 General and administrative 190.1 160.7 117.0 467.8 Segment contribution $ 4,561.3 $ 3,741.2 $ 1,802.0 $ 10,104.5 Contribution margin 66.9 % 64.1 % 53.0 % 62.9 % Corporate (2) 2,452.2 Research and development 1,812.0 Amortization 5,856.6 Goodwill impairments 3,552.8 In-process research and development impairments 436.0 Asset sales and impairments, net 440.2 Operating (loss) $ (4,445.3 ) Operating margin (27.7 )% (1) (2) Year Ended December 31, 2018 US Specialized US General Therapeutics Medicine International Total Net revenues $ 6,920.3 $ 5,322.9 $ 3,504.7 $ 15,747.9 Operating expenses: Cost of sales (1) 565.2 799.1 537.1 1,901.4 Selling and marketing 1,348.3 924.6 928.7 3,201.6 General and administrative 205.3 156.4 141.7 503.4 Segment contribution $ 4,801.5 $ 3,442.8 $ 1,897.2 $ 10,141.5 Contribution margin 69.4 % 64.7 % 54.1 % 64.4 % Corporate (2) 1,067.3 Research and development 2,266.2 Amortization 6,552.3 Goodwill impairments 2,841.1 In-process research and development impairments 804.6 Asset sales and impairments, net 2,857.6 Operating (loss) $ (6,247.6 ) Operating margin (39.7 )% (1) (2) Year Ended December 31, 2017 US Specialized US General Therapeutics Medicine International Total Net revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 15,919.3 Operating expenses: Cost of sales (1) 495.4 843.9 478.7 1,818.0 Selling and marketing 1,369.5 1,084.1 913.8 3,367.4 General and administrative 208.2 177.3 120.6 506.1 Segment contribution $ 4,730.5 $ 3,690.9 $ 1,806.4 $ 10,227.8 Contribution margin 69.5 % 63.7 % 54.4 % 64.2 % Corporate (2) 1,471.8 Research and development 2,100.1 Amortization 7,197.1 In-process research and development impairments 1,452.3 Asset sales and impairments, net 3,927.7 Operating (loss) $ (5,921.2 ) Operating margin (37.2 )% (1) (2)
Schedule of Net Revenue Disaggregated by Geography for International Segment	The following table presents our net revenue disaggregated by geography for our international segment for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Years Ended December 31, 2019 2018 2017 Europe $ 1,471.7 $ 1,482.6 $ 1,439.2 Asia Pacific, Middle East and Africa 1,075.1 1,089.9 929.9 Latin America and Canada 772.9 862.4 863.3 Other* 82.3 69.8 87.1 Total International $ 3,402.0 $ 3,504.7 $ 3,319.5 *Includes royalty and other revenue
Schedule of Global Net Revenues for Top Products and Reconciliation of Segment Revenues to Total Net Revenues	The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Year Ended December 31, 2019 US Specialized Therapeutics US General Medicine International Total Botox® $ 2,730.5 $ - $ 1,060.8 $ 3,791.3 Restasis® 1,138.4 - 50.2 1,188.6 Juvederm® Collection 587.5 - 656.1 1,243.6 Lumigan®/Ganfort® 269.2 - 360.8 630.0 Linzess®/Constella® - 803.2 23.8 827.0 Bystolic® /Byvalson® - 600.6 2.1 602.7 Alphagan®/Combigan® 360.0 - 162.0 522.0 Lo Loestrin® - 588.9 - 588.9 Breast Implants 254.4 - 0.6 255.0 Viibryd®/Fetzima® - 412.1 11.4 423.5 Eye Drops 230.4 - 235.8 466.2 Asacol®/Delzicol® - 76.7 36.1 112.8 Coolsculpting® Consumables 185.3 - 76.3 261.6 Coolsculpting® Systems & Add On Applicators 62.8 - 42.4 105.2 Alloderm® 395.9 - 7.9 403.8 Ozurdex ® 125.5 - 274.6 400.1 Carafate ® /Sulcrate ® - 212.5 3.0 215.5 Aczone® 9.3 - - 9.3 Zenpep® - 288.0 1.2 289.2 Canasa®/Salofalk® - 31.5 16.8 48.3 Vraylar ® - 857.5 - 857.5 Saphris® - 135.3 - 135.3 Viberzi® - 187.9 1.6 189.5 Teflaro® - 147.0 6.0 153.0 Namzaric® - 88.6 - 88.6 Rapaflo® 23.5 - 6.0 29.5 Skin Care 158.0 - 14.6 172.6 Kybella® /Belkyra® 27.4 - 3.3 30.7 Dalvance® - 81.9 6.0 87.9 Avycaz® - 116.7 - 116.7 Liletta® - 79.1 - 79.1 Namenda® - 22.8 - 22.8 Armour Thyroid - 218.5 - 218.5 Savella® - 88.5 - 88.5 Other Products Revenues 261.9 797.6 342.6 1,402.1 Total segment revenues $ 6,820.0 $ 5,834.9 $ 3,402.0 $ 16,056.9 Corporate revenues 32.0 Total net revenues $ 16,088.9 Year Ended December 31, 2018 US Specialized Therapeutics US General Medicine International Total Botox ® $ 2,545.8 $ - $ 1,031.6 $ 3,577.4 Restasis ® 1,197.0 - 64.5 1,261.5 Juvederm ® 548.2 - 614.8 1,163.0 Linzess ® ® - 761.1 24.1 785.2 Lumigan ® ® 291.8 - 392.6 684.4 Bystolic ® ® - 583.8 2.0 585.8 Alphagan ® ® 375.4 - 176.0 551.4 Lo Loestrin ® - 527.7 - 527.7 Vraylar ® - 487.1 - 487.1 Eye Drops 202.7 - 279.7 482.4 Alloderm ® 407.3 - 8.0 415.3 Breast Implants 263.0 - 130.1 393.1 Viibryd ® ® - 342.4 7.2 349.6 Coolsculpting ® 235.3 - 64.2 299.5 Ozurdex ® 111.0 - 187.7 298.7 Zenpep ® - 237.3 0.4 237.7 Carafate ® ® - 217.8 2.8 220.6 Armour Thyroid - 198.8 - 198.8 Canasa ® ® - 169.2 17.6 186.8 Viberzi ® - 176.5 1.3 177.8 Asacol ® ® - 130.8 45.7 176.5 Coolsculpting ® 126.3 - 43.3 169.6 Skin Care 138.8 - 15.2 154.0 Saphris ® - 139.7 - 139.7 Teflaro ® - 128.0 0.3 128.3 Namzaric ® - 115.8 - 115.8 Avycaz ® - 94.6 - 94.6 Rapaflo ® 81.9 - 6.4 88.3 Savella ® - 85.0 - 85.0 Namenda ® - 71.0 - 71.0 Dalvance ® - 56.1 2.3 58.4 Aczone ® 55.1 - 0.4 55.5 Liletta ® - 50.9 - 50.9 Kybella ® ® 31.8 - 6.3 38.1 Other 308.9 749.3 380.2 1,438.4 Total segment revenues $ 6,920.3 $ 5,322.9 $ 3,504.7 $ 15,747.9 Corporate revenues 39.5 Total net revenues $ 15,787.4 Year Ended December 31, 2017 US Specialized Therapeutics US General Medicine International Total Botox ® $ 2,254.4 $ - $ 914.5 $ 3,168.9 Restasis ® 1,412.3 - 61.3 1,473.6 Juvederm ® 501.1 - 540.7 1,041.8 Linzess ® ® - 701.1 21.9 723.0 Lumigan ® ® 317.5 - 371.5 689.0 Bystolic ® ® - 612.2 2.2 614.4 Alphagan ® ® 377.3 - 175.1 552.4 Eye Drops 199.5 - 281.0 480.5 Lo Loestrin ® - 459.3 - 459.3 Namenda ® - 452.9 - 452.9 Breast Implants 242.6 - 156.9 399.5 Viibryd ® ® - 333.2 3.1 336.3 Alloderm ® 321.2 - 7.5 328.7 Ozurdex ® 98.4 - 213.4 311.8 Vraylar ® - 287.8 - 287.8 Asacol ® ® - 195.5 50.2 245.7 Carafate ® ® - 235.8 2.9 238.7 Zenpep ® - 212.3 - 212.3 Coolsculpting ® 150.1 - 41.6 191.7 Canasa ® ® - 162.7 18.3 181.0 Armour Thyroid - 169.1 - 169.1 Aczone ® 166.3 - 0.5 166.8 Skin Care 153.2 - 12.0 165.2 Viberzi ® - 156.6 0.5 157.1 Saphris ® - 155.2 - 155.2 Coolsculpting ® 106.6 - 32.1 138.7 Namzaric ® - 130.8 - 130.8 Teflaro ® - 121.9 - 121.9 Rapaflo ® 108.1 - 7.3 115.4 Savella ® - 98.2 - 98.2 Avycaz ® - 61.2 - 61.2 Kybella ® ® 49.5 - 6.8 56.3 Dalvance ® - 53.9 2.4 56.3 Liletta ® - 37.6 - 37.6 Other 345.5 1,158.9 395.8 1,900.2 Total segment revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 15,919.3 Corporate revenues 21.4 Total net revenues $ 15,940.7

Business Restructuring Charges

Business Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2019
Restructuring And Related Activities [Abstract]
Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities	Restructuring activities for the year ended December 31, 2019 were as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2018 $ 71.4 $ - $ 14.4 $ 85.8 Charged to expense Cost of sales 1.4 - - 1.4 Research and development - - - - Selling and marketing 0.7 - - 0.7 General and administrative 3.7 - 2.3 6.0 Total expense 5.8 - 2.3 8.1 Cash payments (64.8 ) - (3.5 ) (68.3 ) Non-cash adjustments (2.1 ) - - (2.1 ) Reserve balance at December 31, 2019 $ 10.3 $ - $ 13.2 $ 23.5 Restructuring activities for the year ended December 31, 2018 is as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2017 $ 166.0 $ - $ 19.9 $ 185.9 Charged to expense Cost of sales 7.3 - - 7.3 Research and development 1.0 - - 1.0 Selling and marketing 31.2 4.1 - 35.3 General and administrative 4.3 4.1 - 8.4 Total expense 43.8 8.2 - 52.0 Cash payments (138.4 ) - (5.5 ) (143.9 ) Non-cash adjustments - (8.2 ) - (8.2 ) Reserve balance at December 31, 2018 $ 71.4 $ - $ 14.4 $ 85.8

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or Disclosed at Fair Value on Recurring Basis	Assets and liabilities that are measured at fair value using Fair Value Leveling or that are disclosed at fair value on a recurring basis as of December 31, 2019 and 2018 consisted of the following ($ in millions): Fair Value Measurements as of December 31, 2019 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 1,535.4 $ 1,535.4 $ - $ - Short-term investments 3,411.6 - 3,411.6 - Deferred executive compensation investments 89.2 77.0 12.2 - Contingent income 51.8 - - 51.8 Investments and other 70.9 38.2 32.6 - Total assets $ 5,158.9 $ 1,650.6 $ 3,456.4 $ 51.8 Liabilities: Deferred executive compensation liabilities 89.2 77.0 12.2 - Contingent consideration obligations 389.4 - - 389.4 Total liabilities $ 478.6 $ 77.0 $ 12.2 $ 389.4 * Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents. Fair Value Measurements as of December 31, 2018 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 207.1 $ 207.1 $ - $ - Short-term investments 1,026.9 - 1,026.9 - Deferred executive compensation investments 90.8 73.8 17.0 - Contingent income 50.3 - - 50.3 Investments and other 46.0 38.5 7.5 - Total assets $ 1,421.1 $ 319.4 $ 1,051.4 $ 50.3 Liabilities: Deferred executive compensation liabilities 90.8 73.8 17.0 - Contingent consideration obligations 344.6 - - 344.6 Total liabilities $ 435.4 $ 73.8 $ 17.0 $ 344.6 * Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents.
Investments In Securities	Investments in securities as of December 31, 2019 and 2018 included the following ($ in millions): Investments in Securities as of December 31, 2019 Level 1 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 1,535.4 $ 1,535.4 $ 1,535.4 $ - Total $ 1,535.4 $ 1,535.4 $ 1,535.4 $ - Level 2 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Other investments $ 3,411.6 $ 3,411.6 $ - $ 3,411.6 Total $ 3,411.6 $ 3,411.6 $ - $ 3,411.6 Investments in Securities as of December 31, 2018 Level 1 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 207.1 $ 207.1 $ 207.1 $ - Total $ 207.1 $ 207.1 $ 207.1 $ - Level 2 Carrying amount Estimated fair value Cash & cash equivalents Marketable securities Other investments $ 1,026.9 $ 1,026.9 $ - $ 1,026.9 Total $ 1,026.9 $ 1,026.9 $ - $ 1,026.9
Change in Fair Value of Contingent Consideration Obligations	Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Years Ended December 31, Expense / (income) 2019 2018 2017 Cost of sales $ 44.6 $ (111.7 ) $ (183.2 ) Research and development 9.5 5.1 50.0 Total $ 54.1 $ (106.6 ) $ (133.2 )
Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2019 and 2018 ($ in millions): Balance as of December 31, 2018 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2019 Liabilities: Contingent consideration obligations $ 344.6 $ - $ (9.3 ) $ 54.1 $ 389.4 Balance as of December 31, 2017 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2018 Liabilities: Contingent consideration obligations $ 476.9 $ - $ (25.7 ) $ (106.6 ) $ 344.6
Schedule of Contingent Consideration Obligations by Acquisitions	During the year ended December 31, 2019, the following activity in contingent consideration obligations by acquisition was incurred ($ in millions): Business Acquisition Balance as of December 31, 2018 Fair Value Adjustments and Accretion Payments and Other Balance as of December 31, 2019 Tobira acquisition $ 255.0 $ 9.3 $ - $ 264.3 Medicines 360 acquisition 43.1 43.3 (6.7 ) 79.7 AqueSys acquisition 5.4 0.2 - 5.6 Oculeve acquisition 1.7 - - 1.7 ForSight acquisition 24.1 0.3 - 24.4 Forest acquisition 13.6 1.2 (2.3 ) 12.5 Other 1.7 (0.2 ) (0.3 ) 1.2 Total $ 344.6 $ 54.1 $ (9.3 ) $ 389.4
Changes in Fair Value of Royalty Receivable Recorded in Consolidated Statements of Operations	Balance as of December 31, 2018 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2019 Asset: Contingent income $ 50.3 $ - $ (1.1 ) $ 2.6 $ 51.8

Warner Chilcott Limited ("WCL_2

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables)	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidating Balance Sheets	Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2019 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 1.6 $ 0.1 $ - $ 2,495.3 $ - $ 2,497.1 Marketable securities - - - - 3,411.6 - 3,411.6 Accounts receivable, net - - - - 3,192.3 - 3,192.3 Receivables from Parents - - - 409.3 - 409.3 Inventories - - - - 1,133.1 - 1,133.1 Intercompany receivables - 6,508.0 154.0 40.5 14,930.1 (21,632.6 ) - Current assets held for sale - - - - - - - Prepaid expenses and other current assets - - - 33.3 853.1 - 886.4 Total current assets 0.1 6,509.6 154.1 73.8 26,424.8 (21,632.6 ) 11,529.8 Property, plant and equipment, net - - - - 1,926.5 - 1,926.5 Right of use asset - operating leases - - - - 490.4 490.4 Investments and other assets - - - - 408.0 - 408.0 Investment in subsidiaries 55,891.8 76,855.8 21,016.7 83,155.2 - (236,919.5 ) - Non current intercompany receivables - - - - 1,156.6 (1,156.6 ) - Non current receivables from Parents - - - - - Non current assets held for sale - - - - 31.7 - 31.7 Deferred tax assets - 49.6 - - 527.3 - 576.9 Product rights and other intangibles - - - - 37,890.6 - 37,890.6 Goodwill - - - - 42,248.3 - 42,248.3 Total assets $ 55,891.9 $ 83,415.0 $ 21,170.8 $ 83,229.0 $ 111,104.2 $ (259,708.7 ) $ 95,102.2 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 155.2 97.3 6,094.4 - 6,347.0 Intercompany payables - 3,544.4 930.6 10,455.1 6,702.5 (21,632.6 ) - Payables to Parents - - - - 2,715.5 - 2,715.5 Income taxes payable - - 2.4 - 62.7 - 65.1 Current portion of long-term debt and capital leases - - 3,008.2 - 1,524.3 - 4,532.5 Current portion of lease liability - operating - - - - 124.4 - 124.4 Total current liabilities - 3,544.5 4,096.4 10,552.4 17,223.8 (21,632.6 ) 13,784.5 Long-term debt and capital leases - - 14,742.1 2,142.8 1,231.6 - 18,116.5 Lease liability - operating - - - - 446.1 - 446.1 Other long-term liabilities - - - - 801.4 - 801.4 Long-term intercompany payables - - - 1,156.6 - (1,156.6 ) - Other taxes payable - - - - 1,698.6 - 1,698.6 Deferred tax liabilities - - - - 4,363.2 - 4,363.2 Total liabilities - 3,544.5 18,838.5 13,851.8 25,764.7 (22,789.2 ) 39,210.3 Total equity / (deficit) 55,891.9 79,870.5 2,332.3 69,377.2 85,339.5 (236,919.5 ) 55,891.9 Total liabilities and equity $ 55,891.9 $ 83,415.0 $ 21,170.8 $ 83,229.0 $ 111,104.2 $ (259,708.7 ) $ 95,102.2 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2018 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 1.8 $ 0.8 $ - $ 875.9 $ - $ 878.6 Marketable securities - 489.9 - - 537.0 - 1,026.9 Accounts receivable, net - - - - 2,868.1 - 2,868.1 Receivables from Parents - - - - 640.9 - 640.9 Inventories - - - - 846.9 - 846.9 Intercompany receivables - 3,534.7 961.0 16.7 24,779.3 (29,291.7 ) - Current assets held for sale - - - - 34.0 - 34.0 Prepaid expenses and other current assets - - - 33.3 785.4 - 818.7 Total current assets 0.1 4,026.4 961.8 50.0 31,367.5 (29,291.7 ) 7,114.1 Property, plant and equipment, net - - - - 1,787.0 - 1,787.0 Investments and other assets - - - - 1,970.6 - 1,970.6 Investment in subsidiaries 62,940.2 73,846.0 22,656.5 86,628.2 - (246,070.9 ) - Non current intercompany receivables - 28,239.4 18,090.2 - 19,674.2 (66,003.8 ) - Non current assets held for sale - - - - 882.2 - 882.2 Deferred tax assets - 43.6 - - 1,020.1 - 1,063.7 Product rights and other intangibles - - - - 43,695.4 - 43,695.4 Goodwill - - - - 45,913.3 - 45,913.3 Total assets $ 62,940.3 $ 106,155.4 $ 41,708.5 $ 86,678.2 $ 146,310.3 $ (341,366.4 ) $ 102,426.3 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 156.3 92.9 4,538.1 - 4,787.4 Intercompany payables - 14,315.0 21.7 10,442.6 4,512.4 (29,291.7 ) - Payables to Parents - - - - 2,829.2 - 2,829.2 Income taxes payable - - - - 72.4 - 72.4 Current portion of long-term debt and capital leases - - 779.6 - 88.7 - 868.3 Total current liabilities - 14,315.1 957.6 10,535.5 12,040.8 (29,291.7 ) 8,557.3 Long-term debt and capital leases - - 18,090.2 2,135.9 2,703.3 - 22,929.4 Other long-term liabilities - - - - 882.0 - 882.0 Long-term intercompany payables - 18,597.4 - 1,076.8 46,329.6 (66,003.8 ) - Other taxes payable - - - - 1,615.5 - 1,615.5 Deferred tax liabilities - - - - 5,501.8 - 5,501.8 Total liabilities - 32,912.5 19,047.8 13,748.2 69,073.0 (95,295.5 ) 39,486.0 Total equity / (deficit) 62,940.3 73,242.9 22,660.7 72,930.0 77,237.3 (246,070.9 ) 62,940.3 Total liabilities and equity $ 62,940.3 $ 106,155.4 $ 41,708.5 $ 86,678.2 $ 146,310.3 $ (341,366.4 ) $ 102,426.3
Consolidating Statements of Operations and Comprehensive (Loss) / Income	Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive (Loss) / Income For the Year Ended December 31, 2019 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 16,088.9 $ - $ 16,088.9 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,493.1 - 2,493.1 Research and development - - - - 1,812.0 - 1,812.0 Selling and marketing - - - - 3,461.7 - 3,461.7 General and administrative - - - - 2,330.8 - 2,330.8 Amortization - - - - 5,856.6 - 5,856.6 Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Asset sales and impairments, net - - - - 440.2 - 440.2 Total operating expenses - - - - 20,383.2 - 20,383.2 Operating (loss) - - - - (4,294.3 ) - (4,294.3 ) Interest income / (expense), net - 3.8 (598.3 ) (79.8 ) (31.9 ) - (706.2 ) Other income, net - - (0.1 ) - 32.9 - 32.8 Total other income / (expense), net - 3.8 (598.4 ) (79.8 ) 1.0 - (673.4 ) Income / (loss) before income taxes and noncontrolling interest - 3.8 (598.4 ) (79.8 ) (4,293.3 ) - (4,967.7 ) (Benefit) / provision for income taxes - 1.8 - - 144.6 - 146.4 Losses / (earnings) of equity interest subsidiaries 5,120.0 5,070.0 533.6 (251.3 ) - (10,472.3 ) - Net (loss) / income from continuing operations, net of tax (5,120.0 ) (5,068.0 ) (1,132.0 ) 171.5 (4,437.9 ) 10,472.3 (5,114.1 ) (Loss) from discontinued operations, net of tax - - - - - - - Net (loss) / income (5,120.0 ) (5,068.0 ) (1,132.0 ) 171.5 (4,437.9 ) 10,472.3 (5,114.1 ) (Income) attributable to noncontrolling interest - - - - (5.9 ) - (5.9 ) Net (loss) / income attributable to members (5,120.0 ) (5,068.0 ) (1,132.0 ) 171.5 (4,443.8 ) 10,472.3 (5,120.0 ) Other comprehensive (loss) / income, net of tax (138.0 ) (400.0 ) (1,106.2 ) (3,724.3 ) (138.0 ) 5,368.5 (138.0 ) Comprehensive (loss) / income attributable to members $ (5,258.0 ) $ (5,468.0 ) $ (2,238.2 ) $ (3,552.8 ) $ (4,581.8 ) $ 15,840.8 $ (5,258.0 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive (Loss) / Income For the Year Ended December 31, 2018 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 15,787.4 $ - $ 15,787.4 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,191.4 - 2,191.4 Research and development - - - - 2,266.2 - 2,266.2 Selling and marketing - - - - 3,250.6 - 3,250.6 General and administrative - - - - 1,177.5 - 1,177.5 Amortization - - - - 6,552.3 - 6,552.3 Goodwill impairments - - - - 2,841.1 - 2,841.1 In-process research and development impairments - - - - 804.6 - 804.6 Asset sales and impairments, net - - - - 2,857.6 - 2,857.6 Total operating expenses - - - - 21,941.3 - 21,941.3 Operating (loss) - - - - (6,153.9 ) - (6,153.9 ) Interest income / (expense), net - 1,101.1 (8.8 ) (82.8 ) (1,650.6 ) - (641.1 ) Other (expense), net - - 15.6 - 241.1 - 256.7 Total other income / (expense), net - 1,101.1 6.8 (82.8 ) (1,409.5 ) - (384.4 ) Income / (loss) before income taxes and noncontrolling interest - 1,101.1 6.8 (82.8 ) (7,563.4 ) - (6,538.3 ) Provision / (benefit) for income taxes - (23.8 ) 3.5 (50.7 ) (1,705.4 ) - (1,776.4 ) Losses / (earnings) of equity interest subsidiaries 4,772.1 5,719.1 280.7 250.1 - (11,022.0 ) - Net (loss) / income from continuing operations, net of tax (4,772.1 ) (4,594.2 ) (277.4 ) (282.2 ) (5,858.0 ) 11,022.0 (4,761.9 ) (Loss) from discontinued operations, net of tax - - - - - - - Net (loss) / income (4,772.1 ) (4,594.2 ) (277.4 ) (282.2 ) (5,858.0 ) 11,022.0 (4,761.9 ) (Income) attributable to noncontrolling interest - - - - (10.2 ) - (10.2 ) Net (loss) / income attributable to members (4,772.1 ) (4,594.2 ) (277.4 ) (282.2 ) (5,868.2 ) 11,022.0 (4,772.1 ) Other comprehensive income / (loss), net of tax (512.5 ) (599.3 ) 587.2 2,013.0 (512.5 ) (1,488.4 ) (512.5 ) Comprehensive (loss) / income attributable to members $ (5,284.6 ) $ (5,193.5 ) $ 309.8 $ 1,730.8 $ (6,380.7 ) $ 9,533.6 $ (5,284.6 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive (Loss) / Income For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 15,940.7 - 15,940.7 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,168.0 - 2,168.0 Research and development - - - - 2,100.1 - 2,100.1 Selling and marketing - - - - 3,514.8 - 3,514.8 General and administrative - - 8.6 1.1 1,392.6 - 1,402.3 Amortization - - - - 7,197.1 - 7,197.1 In-process research and development impairments - - - - 1,452.3 - 1,452.3 Asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Total operating expenses - - 8.6 1.1 21,752.6 - 21,762.3 Operating (loss) - - (8.6 ) (1.1 ) (5,811.9 ) - (5,821.6 ) Interest income / (expense), net - 845.5 116.6 (131.2 ) (1,760.2 ) - (929.3 ) Other income, net - - (110.4 ) (66.7 ) (3,260.2 ) - (3,437.3 ) Total other income / (expense), net - 845.5 6.2 (197.9 ) (5,020.4 ) - (4,366.6 ) Income / (loss) before income taxes and noncontrolling interest - 845.5 (2.4 ) (199.0 ) (10,832.3 ) - (10,188.2 ) Provision / (benefit) for income taxes - 5.0 0.3 (177.3 ) (6,498.4 ) - (6,670.4 ) (Earnings) / losses of equity interest subsidiaries 3,927.3 4,517.5 1,958.1 752.7 - (11,155.6 ) - Net income / (loss) from continuing operations, net of tax (3,927.3 ) (3,677.0 ) (1,960.8 ) (774.4 ) (4,333.9 ) 11,155.6 (3,517.8 ) Income from discontinued operations, net of tax - - - - (402.9 ) - (402.9 ) Net income / (loss) (3,927.3 ) (3,677.0 ) (1,960.8 ) (774.4 ) (4,736.8 ) 11,155.6 (3,920.7 ) (Income) attributable to noncontrolling interest - - - - (6.6 ) - (6.6 ) Net income / (loss) attributable to members (3,927.3 ) (3,677.0 ) (1,960.8 ) (774.4 ) (4,743.4 ) 11,155.6 (3,927.3 ) Other comprehensive (loss) / income, net of tax 2,959.1 3,001.5 (643.8 ) (2,203.7 ) 2,959.1 (3,113.1 ) 2,959.1 Comprehensive income / (loss) attributable to members $ (968.2 ) $ (675.5 ) $ (2,604.6 ) $ (2,978.1 ) $ (1,784.3 ) $ 8,042.5 $ (968.2 )
Consolidating Statements of Cash Flows	Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2019 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (5,120.0 ) $ (5,068.0 ) $ (1,132.0 ) $ 171.5 $ (4,437.9 ) $ 10,472.3 $ (5,114.1 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 5,120.0 5,070.0 533.6 (251.3 ) - (10,472.3 ) - Depreciation - - - - 204.5 - 204.5 Amortization - - - - 5,856.6 - 5,856.6 Provision for inventory reserve - - - - 160.2 - 160.2 Share-based compensation - - - - 214.3 - 214.3 Deferred income tax benefit - - - - (660.9 ) - (660.9 ) Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Loss on asset sales and impairments, net - - - - 440.2 - 440.2 Non-cash extinguishment of debt - - 0.2 - 0.2 Amortization of deferred financing costs - - 15.9 1.6 - - 17.5 Amortization of right of use assets - - - - 130.9 - 130.9 Contingent consideration adjustments, including accretion - - - - 54.1 - 54.1 Dividends from subsidiaries 1,774.3 - - - - (1,774.3 ) - Other, net - - (5.2 ) (1.7 ) 1.4 - (5.5 ) Changes in assets and liabilities (net of effects of acquisitions) - (291.6 ) 1,618.6 79.9 591.1 - 1,998.0 Net cash provided by / (used in) operating activities 1,774.3 (289.6 ) 1,030.9 - 6,543.5 (1,774.3 ) 7,284.8 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (375.2 ) - (375.2 ) Additions to product rights and other intangibles - - - - (58.3 ) - (58.3 ) Additions to investments - (100.0 ) - - (3,838.0 ) - (3,938.0 ) Proceeds from sale of investments and other assets - 389.4 - - 1,180.2 - 1,569.6 Proceeds from sales of property, plant and equipment - - - - 23.7 - 23.7 Acquisitions of business, net of cash acquired - - - - (80.6 ) - (80.6 ) Net cash (used in) / provided by investing activities - 289.4 - - (3,148.2 ) - (2,858.8 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - - - 11.9 - 11.9 Payments on debt, including capital lease obligations and credit facility - - (1,031.6 ) - (13.3 ) - (1,044.9 ) Debt issuance and other financing costs - - - - - - - Payments of contingent consideration and other financing - - - - (9.3 ) - (9.3 ) Dividends to Parents (1,774.3 ) - - - (1,774.3 ) 1,774.3 (1,774.3 ) Net cash (used in) / provided by financing activities (1,774.3 ) - (1,031.6 ) - (1,785.0 ) 1,774.3 (2,816.6 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 9.1 - 9.1 Net (decrease) / increase in cash and cash equivalents - (0.2 ) (0.7 ) - 1,619.4 - 1,618.5 Cash and cash equivalents at beginning of period 0.1 1.8 0.8 - 875.9 - 878.6 Cash and cash equivalents at end of period $ 0.1 $ 1.6 $ 0.1 $ - $ 2,495.3 $ - $ 2,497.1 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2018 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (4,772.1 ) $ (4,594.2 ) $ (277.4 ) $ (282.2 ) $ (5,858.0 ) $ 11,022.0 $ (4,761.9 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 4,772.1 5,719.1 280.7 250.1 - (11,022.0 ) - Depreciation - - - - 196.3 - 196.3 Amortization - - - - 6,552.3 - 6,552.3 Provision for inventory reserve - - - - 96.4 - 96.4 Share-based compensation - - - - 239.8 - 239.8 Deferred income tax benefit - - - - (1,255.7 ) - (1,255.7 ) Goodwill impairments - - - - 2,841.1 - 2,841.1 In-process research and development impairments - - - - 804.6 - 804.6 Loss on asset sales and impairments, net - - - - 2,857.6 - 2,857.6 Gain on sale of Teva securities, net - - - - (60.9 ) - (60.9 ) Gain on sale of businesses - - (182.6 ) - (182.6 ) Non-cash extinguishment of debt - - 30.0 - - - 30.0 Cash charge related to extinguishment of debt - - (45.6 ) - - - (45.6 ) Amortization of deferred financing costs - - 21.0 1.6 - - 22.6 Contingent consideration adjustments, including accretion - - - - (106.5 ) - (106.5 ) Dividends from subsidiaries 4,075.6 - - - - (4,075.6 ) - Other, net - - (5.6 ) (1.7 ) 36.3 - 29.0 Changes in assets and liabilities (net of effects of acquisitions) - (1,626.3 ) 5,482.0 32.2 (5,152.4 ) - (1,264.5 ) Net cash provided by / (used in) operating activities 4,075.6 (501.4 ) 5,485.1 - 1,008.3 (4,075.6 ) 5,992.0 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (253.5 ) - (253.5 ) Additions to investments - (889.9 ) - - (1,581.8 ) - (2,471.7 ) Proceeds from sale of investments and other assets - 800.0 - - 5,459.3 - 6,259.3 Payments to settle Teva related matters - - - - (466.0 ) - (466.0 ) Proceeds from sales of property, plant and equipment - - - - 30.4 - 30.4 Net cash provided by / (used in) investing activities - (89.9 ) - - 3,188.4 - 3,098.5 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 700.0 1,919.7 - 37.3 - 2,657.0 Payments on debt, including capital lease obligations and credit facility - (700.0 ) (7,393.7 ) - (710.8 ) - (8,804.5 ) Debt issuance and other financing costs - - (10.4 ) - - - (10.4 ) Payments of contingent consideration and other financing - - - - (30.9 ) - (30.9 ) Proceeds from forward sale of Teva securities - - - - 465.5 - 465.5 Payments to settle Teva related matters - - - - (234.0 ) - (234.0 ) Dividends to Parents (4,075.6 ) - - - (4,075.6 ) 4,075.6 (4,075.6 ) Net cash (used in) / provided by financing activities (4,075.6 ) - (5,484.4 ) - (4,548.5 ) 4,075.6 (10,032.9 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 4.7 - 4.7 Net increase in cash and cash equivalents - (591.3 ) 0.7 - (347.1 ) - (937.7 ) Cash and cash equivalents at beginning of period 0.1 593.1 0.1 - 1,223.0 - 1,816.3 Cash and cash equivalents at end of period $ 0.1 $ 1.8 $ 0.8 $ - $ 875.9 $ - $ 878.6 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ (3,927.3 ) $ (3,677.0 ) $ (1,960.8 ) $ (774.4 ) $ (4,736.8 ) $ 11,155.6 $ (3,920.7 ) Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries 3,927.3 4,517.5 1,958.1 752.7 - (11,155.6 ) - Depreciation - - - - 171.5 - 171.5 Amortization - - - - 7,197.1 - 7,197.1 Provision for inventory reserve - - - - 102.2 - 102.2 Share-based compensation - - - - 293.3 - 293.3 Deferred income tax benefit - - - - (7,783.1 ) - (7,783.1 ) In-process research and development impairments - - - - 1,452.3 - 1,452.3 Loss on asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Net income impact of other-than-temporary loss on investment in Teva securities - - - - 3,273.5 - 3,273.5 Charge to settle Teva related matters - - - - 387.4 - 387.4 Loss on forward sale of Teva shares - - - - 62.9 - 62.9 Amortization of inventory step-up - - - - 131.7 - 131.7 Non-cash extinguishment of debt - - 17.6 12.2 (45.5 ) - (15.7 ) Cash charge related to extinguishment of debt - - 91.6 52.9 61.1 - 205.6 Amortization of deferred financing costs - - 23.3 4.5 - - 27.8 Contingent consideration adjustments, including accretion - - - - (133.2 ) - (133.2 ) Dividends from subsidiaries 1,668.2 - - - - (1,668.2 ) - Other, net - (10.0 ) - - (27.0 ) - (37.0 ) Changes in assets and liabilities (net of effects of acquisitions) - (4,228.1 ) (241.5 ) 2,148.3 3,207.3 - 886.0 Net cash provided by / (used in) operating activities 1,668.2 (3,397.6 ) (111.7 ) 2,196.2 7,542.4 (1,668.2 ) 6,229.3 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (349.9 ) - (349.9 ) Additions to product rights and other intangibles - - - - (614.3 ) - (614.3 ) Additions to investments - (4,389.6 ) - - (5,394.2 ) - (9,783.8 ) Proceeds from sale of investments and other assets - 7,866.4 - - 7,286.9 - 15,153.3 Proceeds from sales of property, plant and equipment - - - - 7.1 - 7.1 Acquisitions of businesses, net of cash acquired - - - - (5,290.4 ) - (5,290.4 ) Net cash (used in) / provided by investing activities - 3,476.8 - - (4,354.8 ) - (878.0 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - 3,020.9 - 529.1 - 3,550.0 Payments on debt, including capital lease obligations and credit facility - - (2,800.0 ) (2,143.3 ) (1,470.3 ) - (6,413.6 ) Debt issuance and other financing costs - - (17.5 ) - (3.1 ) - (20.6 ) Cash charge related to extinguishment of debt - - (91.6 ) (52.9 ) (61.1 ) - (205.6 ) Payments of contingent consideration and other financing - - - - (511.6 ) - (511.6 ) Dividends to Parents (1,668.2 ) - - - (1,668.2 ) 1,668.2 (1,668.2 ) Net cash (used in) / provided by financing activities (1,668.2 ) - 111.8 (2,196.2 ) (3,185.2 ) 1,668.2 (5,269.6 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 21.4 - 21.4 Net increase / (decrease) in cash and cash equivalents - 79.2 0.1 - 23.8 - 103.1 Cash and cash equivalents at beginning of period 0.1 513.9 - - 1,199.2 - 1,713.2 Cash and cash equivalents at end of period $ 0.1 $ 593.1 $ 0.1 $ - $ 1,223.0 $ - $ 1,816.3

Compensation (Tables)

Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Compensation Related Costs [Abstract]
Schedule of Compensation Charges	The following table represents compensation costs for the years ended December 31, 2019, 2018 and 2017 ($ in millions): Years Ended December 31, 2019 2018 2017 Wages and salaries $ 2,193.2 $ 1,994.9 $ 1,892.8 Share-based compensation 214.3 239.8 308.0 Retirement plans 136.0 107.0 82.7 Social welfare (taxes) 143.3 163.1 150.4 Other benefits 152.5 175.2 265.1 Total $ 2,839.3 $ 2,680.0 $ 2,699.0

Concentration (Tables)

Concentration (Tables)	12 Months Ended
	Dec. 31, 2019
Risks And Uncertainties [Abstract]
Schedule of Concentration on Revenues	The following table illustrates any customer which accounted for 10% or more of our annual revenues within the U.S. and Canada in any of the past three fiscal years and the respective percentage of our revenues for which they account for each of the last three years: Customer 2019 2018 2017 McKesson Corporation 25 % 25 % 23 % Cardinal Health, Inc. 24 % 23 % 19 % AmerisourceBergen Corporation 22 % 22 % 19 %

Supplementary Data (Tables)

Supplementary Data (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Consolidated Financial Data and Market Price Information	Selected unaudited quarterly consolidated financial data and market price information are shown below ($ in millions except per share data): For Three Month Periods Ended Year Ended 12/31/2019 Dec. 31, 2019 Sept. 30, 2019 June 30, 2019 Mar. 31, 2019 Net revenues $ 16,088.9 $ 4,351.0 $ 4,050.7 $ 4,090.1 $ 3,597.1 Net (loss) $ (5,265.1 ) $ (317.3 ) $ (785.6 ) $ (1,754.9 ) $ (2,407.3 ) Basic earnings per share (16.02 ) (0.97 ) (2.40 ) (5.37 ) (7.25 ) Diluted earnings per share (16.02 ) (0.97 ) (2.40 ) (5.37 ) (7.25 ) Market price per share: High $ 191.58 $ 169.61 $ 167.43 $ 160.79 Low $ 165.40 $ 156.34 $ 115.73 $ 132.09 For Three Month Periods Ended Year Ended 12/31/2018 Dec. 31, 2018 Sept. 30, 2018 June 30, 2018 Mar. 31, 2018 Net revenues $ 15,787.4 $ 4,079.7 $ 3,911.4 $ 4,124.2 $ 3,672.1 Net (loss) / income $ (5,086.2 ) $ (4,295.9 ) $ (36.3 ) $ (470.1 ) $ (283.9 ) Basic earnings per share (15.26 ) (12.83 ) (0.11 ) (1.39 ) (0.99 ) Diluted earnings per share (15.26 ) (12.83 ) (0.11 ) (1.39 ) (0.99 ) Market price per share: High $ 193.46 $ 192.51 $ 175.19 $ 188.15 Low $ 129.82 $ 167.21 $ 143.80 $ 144.02

Description of Business - Addit

Description of Business - Additional Information (Detail) $ / shares in Units, $ in Billions	Oct. 25, 2019USD ($)	Jun. 25, 2019USD ($)$ / sharesshares	Dec. 31, 2019Country
Segment Reporting Information [Line Items]
Number of operating countries | Country			100
AbbVie, Inc. [Member]
Segment Reporting Information [Line Items]
Sale of Stock, Price Per Share | $ / shares		$ 188.24
Business Acquisition, consideration to be transferred | $		$ 63
Business acquisition, equity interest issuable, number of shares | shares		0.8660
Business acquisition, share price | $ / shares		$ 120.30
Aggregate principal amount of new notes to be issued | $	$ 19.6
Debt instrument, maturity date range, start	Sep. 15, 2020
Debt instrument, maturity date range, end	Mar. 15, 2045

Formation of the Company - Addi

Formation of the Company - Additional Information (Detail)	Oct. 01, 2013Ratio	Dec. 31, 2019$ / shares	Dec. 31, 2018$ / shares
Business Acquisition [Line Items]
Date of incorporation as a private limited company		May 16, 2013
Effective date of re-registration as a public limited company		Sep. 20, 2013
Ordinary shares, par value | $ / shares		$ 0.0001	$ 0.0001
Allergan Finance, LLC [Member]
Business Acquisition [Line Items]
Ordinary share, conversion ratio | Ratio	1

Reconciliation of Warner Chil_3

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	$ 2,503.3	$ 880.4
Prepaid expenses and other current assets	886.4	819.1
Accounts payable and accrued liabilities	6,348.7	4,787.2
Other taxes payables	1,704.8	1,615.5
Deferred tax liabilities	4,363.7	5,501.8
Total Equity	58,196.4	65,131	$ 73,837.1	$ 76,200.5
Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	2,497.1	878.6	1,816.3	1,713.2
Prepaid expenses and other current assets	886.4	818.7
Accounts payable and accrued liabilities	6,347	4,787.4
Other taxes payables	1,698.6	1,615.5
Deferred tax liabilities	4,363.2	5,501.8
Total Equity	55,891.9	62,940.3	$ 81,282.2	$ 88,093.5
Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	6.2	1.8
Prepaid expenses and other current assets		0.4
Accounts payable and accrued liabilities	1.7	(0.2)
Other taxes payables	6.2
Deferred tax liabilities	0.5
Total Equity	$ 2,304.5	$ 2,190.7

Reconciliation of Warner Chil_4

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									$ 2,481.8	$ 1,271.2	$ 1,501.9
Operating (loss)									(4,445.3)	(6,247.6)	(5,921.2)
Interest Income									76.8	45.2	67.7
Other income / (expense), net									32.8	256.7	(3,437.3)
(Loss) before income taxes and noncontrolling interest									(5,118.7)	(6,856.9)	(10,386.4)
Net (loss) from continuing operations, net of tax									(5,265.1)	(5,086.2)	(3,716)
Net (loss) / income	$ (317.3)	$ (785.6)	$ (1,754.9)	$ (2,407.3)	$ (4,295.9)	$ (36.3)	$ (470.1)	$ (283.9)	(5,265.1)	(5,086.2)	(4,118.9)
Dividends on preferred shares										46.4	278.4
Net (loss) / income attributable to ordinary shareholders/members									(5,271)	(5,142.8)	(4,403.9)
Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									2,330.8	1,177.5	1,402.3
Operating (loss)									(4,294.3)	(6,153.9)	(5,821.6)
Interest Income									76.8	270.1	166.3
Other income / (expense), net									32.8	256.7	(3,437.3)
(Loss) before income taxes and noncontrolling interest									(4,967.7)	(6,538.3)	(10,188.2)
Net (loss) from continuing operations, net of tax									(5,114.1)	(4,761.9)	(3,517.8)
Net (loss) / income									(5,114.1)	(4,761.9)	(3,920.7)
Net (loss) / income attributable to ordinary shareholders/members									(5,120)
Net (loss) / income attributable to ordinary shareholders/members									(5,120)	(4,772.1)	(3,927.3)
Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									151	93.7	99.6
Operating (loss)									(151)	(93.7)	(99.6)
Interest Income										(224.9)	(98.6)
(Loss) before income taxes and noncontrolling interest									(151)	(318.6)	(198.2)
Net (loss) from continuing operations, net of tax									(151)	(324.3)	(198.2)
Net (loss) / income									(151)	(324.3)	(198.2)
Dividends on preferred shares										46.4	278.4
Net (loss) / income attributable to ordinary shareholders/members									$ (151)	$ (370.7)	$ (476.6)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Recognized Lease Liabilities and Corresponding Righ of use Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019
Right of use asset - operating leases	$ 490.4	$ 462.1
Lease Liability	570.5	548.6
Real Estate [Member]
Right of use asset - operating leases	321.2	304.2
Lease Liability	$ 386.9	370.6
Fleet [Member]
Right of use asset - operating leases		100.4
Lease Liability		100.4
Other [Member]
Right of use asset - operating leases		57.5
Lease Liability		$ 77.6

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	Jan. 02, 2019	Jan. 02, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Summary Of Significant Accounting Policies [Line Items]
Maximum percentage of ownership for equity method accounting			50.00%
Ownership percentage in cost method investments			20.00%
Tax rate for global intangible low taxed income including foreign credits		10.50%
Estimated increase tax rate for global intangible low taxed income including foreign credits for beginning after December 31, 2025			13.125%
Maximum percentage of actuarial gain or loss in excess of greater of projected benefit obligation or market related value of plan assets			10.00%
Allergan plc Ordinary Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS				2.9
Stock Awards [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS			2.1	2.3	3.8
ASU 2016-02 [Member] | Adjustment [Member]
Summary Of Significant Accounting Policies [Line Items]
Implementation of new accounting pronouncement	$ 22
ASC 606 [Member]
Summary Of Significant Accounting Policies [Line Items]
Practical expedients and exemptions, description			The Company does not adjust the promised amount of consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is equal to one year or less.
ASC 606 [Member] | General and Administrative Expense [Member]
Summary Of Significant Accounting Policies [Line Items]
Provision for bad debts			$ 35.8	$ 18.5	$ 11.6

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2019
Computer Software / Hardware (Including Internally Developed) [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Computer Software / Hardware (Including Internally Developed) [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	15 years
Research and Laboratory Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Research and Laboratory Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	10 years
Buildings, Improvements, Leasehold Improvements and Other [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	4 years
Buildings, Improvements, Leasehold Improvements and Other [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	50 years
Transportation Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Transportation Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	20 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Provisions for Sales Returns and Allowances from Continuing Operations Activity (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Valuation And Qualifying Accounts Disclosure [Line Items]
Accounts payable and accrued expenses	$ 6,348.7	$ 4,787.2
Chargebacks [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	61.8	77.2
Provision related to sales	1,123.5	1,117.7
Credits and payments	(1,117.5)	(1,133.1)
Balance at end of period	67.8	61.8
Contra accounts receivable at December 31, 2019	67.8
Rebates [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	1,908.5	1,799.2
Provision related to sales	6,153.8	5,464.7
Credits and payments	(5,959)	(5,355.4)
Balance at end of period	2,103.3	1,908.5
Contra accounts receivable at December 31, 2019	101.5
Accounts payable and accrued expenses	2,001.8
Returns and Other Allowances [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	566.6	517.6
Provision related to sales	1,625.1	1,725.3
Credits and payments	(1,559.3)	(1,676.3)
Balance at end of period	632.4	566.6
Contra accounts receivable at December 31, 2019	35.7
Accounts payable and accrued expenses	596.7
Cash Discounts [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	30.7	36.5
Provision related to sales	337.3	322.2
Credits and payments	(331)	(328)
Balance at end of period	37	30.7
Contra accounts receivable at December 31, 2019	37
Allowance for Sales Returns [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	2,567.6	2,430.5
Provision related to sales	9,239.7	8,629.9
Credits and payments	(8,966.8)	(8,492.8)
Balance at end of period	2,840.5	2,567.6
Contra accounts receivable at December 31, 2019	242	207.7
Accounts payable and accrued expenses	$ 2,598.5	$ 2,359.9

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Summarizes The Balance Sheet Classification of Our SRA Reserves (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Sales Return Allowance Reserve [Line Items]
Accounts payable and accrued expenses	$ 6,348.7	$ 4,787.2
Allowance for Sales Returns [Member]
Sales Return Allowance Reserve [Line Items]
Contra accounts receivable	242	207.7
Accounts payable and accrued expenses	2,598.5	2,359.9
Total	$ 2,840.5	$ 2,567.6

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Summary of Activity in Gross-to-Net Revenue Excluding Discontinued Operations (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Net product sales	$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Product [Member]
Disaggregation Of Revenue [Line Items]
Gross product sales									24,968.8	24,056.9	23,688.4
Provisions to reduce gross product sales to net products sales									(9,239.7)	(8,629.9)	(8,120)
Net product sales									$ 15,729.1	$ 15,427	$ 15,568.4
Percentage of SRA provisions to gross sales									37.00%	35.90%	34.30%

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net (loss) / income:
Net (loss) attributable to ordinary shareholders excluding (loss) / income from discontinued operations, net of tax									$ (5,271)	$ (5,142.8)	$ (4,001)
(Loss) / income from discontinued operations, net of tax											(402.9)
Net (loss) / income attributable to ordinary shareholders									$ (5,271)	$ (5,142.8)	$ (4,403.9)
Basic weighted average ordinary shares outstanding									329	337	333.8
Basic EPS:
Continuing operations									$ (16.02)	$ (15.26)	$ (11.99)
Discontinued operations											(1.20)
Net (loss) / income per share - basic	$ (0.97)	$ (2.40)	$ (5.37)	$ (7.25)	$ (12.83)	$ (0.11)	$ (1.39)	$ (0.99)	(16.02)	(15.26)	(13.19)
Dividends per ordinary share									$ 2.96	$ 2.88	$ 2.80
Diluted weighted average ordinary shares outstanding									329	337	333.8
Diluted EPS:
Continuing operations									$ (16.02)	$ (15.26)	$ (11.99)
Discontinued operations											(1.20)
Net (loss) / income per share - diluted	$ (0.97)	$ (2.40)	$ (5.37)	$ (7.25)	$ (12.83)	$ (0.11)	$ (1.39)	$ (0.99)	$ (16.02)	$ (15.26)	$ (13.19)

Business Developments - Additio

Business Developments - Additional Information (Detail) $ in Millions

Mar. 26, 2019USD ($)

Nov. 30, 2018USD ($)

Oct. 24, 2018USD ($)

Sep. 20, 2018USD ($)Product

Apr. 06, 2018USD ($)

Jan. 31, 2018USD ($)

Sep. 08, 2017USD ($)

Jul. 31, 2017USD ($)

Jun. 23, 2017

Apr. 28, 2017USD ($)

Mar. 14, 2017USD ($)

Feb. 01, 2017USD ($)

Jan. 09, 2017USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Feb. 28, 2017USD ($)

Business Acquisition [Line Items]

Product rights and other intangibles

$ 37,890.6

$ 43,695.4

$ 54,648.3

Goodwill

42,248.3

45,913.3

Gain(loss) on sale of business

182.6

Research and development

1,812

2,266.2

2,100.1

Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)

2,493.1

2,191.4

2,168

Saint Regis Mohawk Tribe [Member]

Business Acquisition [Line Items]

Patent rights, agreement entered date

Sep. 8, 2017

Percentage of rights obtained in the patent

0.05%

Upfront payment of agreement

$ 13.8

Annual royalties payable

10.1

15

License [Member] | Saint Regis Mohawk Tribe [Member]

Business Acquisition [Line Items]

Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)

13.8

US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

20,369.7

20,675.6

International [Member]

Business Acquisition [Line Items]

Goodwill

$ 7,154.8

7,301.1

Sale of Aczone, Tazorac, Azelex, Cordran Tape and Seysara Products [Member]

Business Acquisition [Line Items]

Fair value of purchase price on net sales

$ 0

Gain(loss) on sale of business

$ 129.6

Number of products | Product

5

Cash consideration received on sale

$ 550

Maximum [Member] | Sale of Aczone, Tazorac, Azelex, Cordran Tape and Seysara Products [Member]

Business Acquisition [Line Items]

Eligible to receive additional contingent consideration

$ 100

Envy Medical, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition, consideration transferred

$ 81.4

Product rights and other intangibles

67.4

Goodwill

$ 34.1

Bonti, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 24, 2018

Payments to acquire business, cash

$ 195

Aggregate upfront expense for acquisition

196.6

Bonti, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Additional consideration payable

$ 90

Elastagen Pty Ltd [Member]

Business Acquisition [Line Items]

Aggregate upfront expense for acquisition

$ 96.1

Business acquisition date

Apr. 6, 2018

Elastagen Pty Ltd [Member] | Maximum [Member]

Business Acquisition [Line Items]

Additional consideration payable

$ 165

Repros Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Payments to acquire business, cash

$ 33.2

Aggregate upfront expense for acquisition

$ 33.2

Business acquisition date

Jan. 31, 2018

Aclaris Therapeutics, Inc [Member]

Business Acquisition [Line Items]

Fair value of purchase price on net sales

$ 51.8

Aclaris Therapeutics, Inc [Member] | Asset Sales and Impairments, Net [Member]

Business Acquisition [Line Items]

Gain(loss) on sale of business

$ 266.2

Keller Medical, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Jun. 23, 2017

Zeltiq Aesthetics, Inc. [Member]

Business Acquisition [Line Items]

Goodwill

$ 1,211.6

Business acquisition date

Apr. 28, 2017

Payments to acquire business, cash

$ 2,405.4

Step-up in the value of inventories

22.9

Amortization of inventory step-up to cost of sales

22.9

Zeltiq Aesthetics, Inc. [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

954.7

Zeltiq Aesthetics, Inc. [Member] | International [Member]

Business Acquisition [Line Items]

Goodwill

$ 256.9

Zeltiq Aesthetics, Inc. [Member] | Maximum [Member] | Discount Rate [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

0.110

Zeltiq Aesthetics, Inc. [Member] | Minimum [Member] | Discount Rate [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

0.100

LifeCell Corporation [Member]

Business Acquisition [Line Items]

Business acquisition, consideration transferred

$ 2,883.1

Goodwill

$ 1,449.1

Business acquisition date

Feb. 1, 2017

Step-up in the value of inventories

$ 108.4

LifeCell Corporation [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

$ 1,449.1

LifeCell Corporation [Member] | Discount Rate [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

0.075

Lyndra, Inc [Member] | Ultra-long-acting Oral Products [Member]

Business Acquisition [Line Items]

Business acquisition date

Jul. 31, 2017

Payment for license upfront fees

$ 15

Research and development

15

Lyndra, Inc [Member] | Maximum [Member] | Ultra-long-acting Oral Products [Member]

Business Acquisition [Line Items]

Research and development

85

Editas Medicine Inc [Member]

Business Acquisition [Line Items]

Research and development

25

Exercised option, value

$ 15

Editas Medicine Inc [Member] | Eye Care [Member]

Business Acquisition [Line Items]

Business acquisition date

Mar. 14, 2017

Payment for license upfront fees

$ 90

Research and development

90

Assembly Biosciences, Inc [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 9, 2017

Payment for license upfront fees

$ 50

Research and development

50

Assembly Biosciences, Inc [Member] | Maximum [Member]

Business Acquisition [Line Items]

Research and development

2,771

Lysosomal Therapeutics, Inc [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 9, 2017

Research and development

$ 145

Lysosomal Therapeutics, Inc [Member] | Option Right [Member]

Business Acquisition [Line Items]

Research and development

$ 150

Business Developments - Summary

Business Developments - Summary of Medical Dermatology Products Sale Transaction (Detail) - USD ($) $ in Millions	Sep. 20, 2018	Dec. 31, 2018	Dec. 31, 2019
Assets sold
Intangible assets		$ 849.4
Net assets sold		916.2	$ 31.7
Net gain included as a component of Other income / (expense), net		$ 182.6
Sale of Aczone, Tazorac, Azelex, Cordran Tape and Seysara Products [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Purchase Price	$ 550
Assets sold
Intangible assets	205.4
Goodwill	184
Other assets	31
Net assets sold	420.4
Net gain included as a component of Other income / (expense), net	$ 129.6

Business Developments - Summa_2

Business Developments - Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Apr. 28, 2017	Feb. 28, 2017	Feb. 01, 2017
Business Acquisition [Line Items]
Goodwill	$ 42,248.3	$ 45,913.3
Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			$ 36.7
Accounts receivable			47
Inventories			59.3
Property, plant and equipment			12.4
Intangible assets			1,185
Goodwill			1,211.6
Other assets			17.1
Accounts payable and accrued expenses			(104.6)
Deferred revenue			(10.6)
Deferred taxes, net			(47.2)
Other liabilities			(1.3)
Net assets acquired			2,405.4
Other			$ 1.3
LifeCell Corporation [Member]
Business Acquisition [Line Items]
Cash and cash equivalents				$ 8.7
Accounts receivable				50.8
Inventories				175.4
Property, plant and equipment				53.7
Intangible assets					$ 2,020
Goodwill				1,449.1
Accounts payable and accrued expenses				(149.6)
Deferred taxes, net				(746.2)
Other liabilities				(21.2)
Net assets acquired				2,883.1
Other				21.2
LifeCell Corporation [Member] | Currently Marketed Products ("CMP") [Member]
Business Acquisition [Line Items]
Intangible assets				2,010
LifeCell Corporation [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Intangible assets				$ 10

Business Developments - Summa_3

Business Developments - Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets (Detail) - USD ($) $ in Millions	Apr. 28, 2017	Feb. 01, 2017	Feb. 28, 2017
Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 1,185
Intangible Assets, Amount recognized as of the acquisition date	1,185
LifeCell Corporation [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 2,010
Intangible Assets, Amount recognized as of the acquisition date		2,020
LifeCell Corporation [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date		10
Intangible Assets, Amount recognized as of the acquisition date			$ 10
LifeCell Corporation [Member] | Other Products [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date		10
CMP [Member] | Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	1,028
CMP [Member] | Zeltiq Aesthetics, Inc. [Member] | Consumables [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 985
Weighted average useful lives (years)	6 years 8 months 12 days
CMP [Member] | Zeltiq Aesthetics, Inc. [Member] | System [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 43
Weighted average useful lives (years)	3 years 8 months 12 days
CMP [Member] | LifeCell Corporation [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		1,910
CMP [Member] | LifeCell Corporation [Member] | Alloderm [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 1,385
Weighted average useful lives (years)		6 years 10 months 24 days
CMP [Member] | LifeCell Corporation [Member] | Revolve [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 80
Weighted average useful lives (years)		7 years 1 month 6 days
CMP [Member] | LifeCell Corporation [Member] | Strattice [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 320
Weighted average useful lives (years)		5 years 1 month 6 days
CMP [Member] | LifeCell Corporation [Member] | Artia [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 115
Weighted average useful lives (years)		8 years 9 months 18 days
CMP [Member] | LifeCell Corporation [Member] | Other Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 10
Weighted average useful lives (years)		2 years 9 months 18 days
Customer Relationships [Member] | Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 157
Weighted average useful lives (years)	6 years 7 months 6 days
Customer Relationships [Member] | LifeCell Corporation [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 100
Weighted average useful lives (years)		6 years 3 months 18 days

Assets Held for Sale - Summary

Assets Held for Sale - Summary of Assets Held For Sale (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Assets sold
Inventories		$ 34
Property, plant and equipment, net	$ 31.7	32.8
Product rights and other intangibles		849.4
Net assets sold	$ 31.7	$ 916.2

Assets Held for Sale - Addition

Assets Held for Sale - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)
Assets Held For Sale Not Part Of Disposal Group [Abstract]
Impairment, assets held for sale	$ 129.6

Collaborations - Additional Inf

Collaborations - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Sep. 30, 2007	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborations And License Agreements [Line Items]
Cost of sales		$ 2,493.1	$ 2,191.4	$ 2,168
Amgen, Inc. [Member] | Collaborative Arrangement [Member]
Collaborations And License Agreements [Line Items]
Milestone revenue		$ 25	25
Linzess [Member]
Collaborations And License Agreements [Line Items]
Cost of sales			$ 29.9
Ironwood Collaboration Agreement [Member]
Collaborations And License Agreements [Line Items]
Acquisition related contingent milestone payments	$ 100

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Millions	Oct. 03, 2016	Aug. 02, 2016	Dec. 31, 2017	Dec. 31, 2016	Jan. 31, 2018
Anda Distribution Business and Global Generics Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business				$ 15,932.2
Teva [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Working capital one-time settlement payable					$ 700
Pre-tax charge sale of business			$ 466
Teva [Member] | Allergan Global Generic Pharmaceuticals Business and Certain Other Assets [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discounted rate due to lack of marketability in divestiture of business		5.90%
Teva [Member] | Anda Distribution Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued operations definite sale agreement date	Oct. 3, 2016
Consideration amount on sale of business	$ 500

Discontinued Operations - Summa

Discontinued Operations - Summary of Teva Share Activity (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	May 07, 2018	Feb. 13, 2018	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Retained earnings						$ 7,258.9			$ 991.5
Teva [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares							95.9	100.3
Carrying Value per Share							$ 17.60	$ 53.39
Market Price							$ 18.95	$ 36.25
Discount							0.00%	5.40%
Proceeds Received	$ 465.5	$ 372				1,815.5
Movement in the Value of Marketable Securities							$ 1,817.7	$ 3,439.2
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income							129.3	$ (1,599.4)
Gain / (Loss) Recognized in Other Income/ (Expense), Net						60.9	(3,269.3)
Derivative Instrument (Liability)/ Asset							$ (62.9)
Retained earnings						$ 129.3
Teva [Member] | Accounting Standards Update No. 2016-01 [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			$ (129.3)
Retained earnings			$ 129.3
Teva [Member] | Settlement of Initial Accelerated Share Repurchase ("ASR"), Net [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares			(25)
Carrying Value per Share			$ 18.95
Market Price			$ 16.53
Proceeds Received			$ 413.3
Movement in the Value of Marketable Securities			(473.8)
Gain / (Loss) Recognized in Other Income/ (Expense), Net			2.5
Derivative Instrument (Liability)/ Asset			$ 62.9
Teva [Member] | Settlement of Forward Sale, Net [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares			(25)
Carrying Value per Share			$ 17.09
Market Price			$ 18.61
Proceeds Received			$ 465.5
Movement in the Value of Marketable Securities			(427.3)
Gain / (Loss) Recognized in Other Income/ (Expense), Net			$ 38.2
Teva [Member] | Open Market Sales [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares						(45.9)
Market Price						$ 20.41
Proceeds Received						$ 936.7
Movement in the Value of Marketable Securities						(916.6)
Gain / (Loss) Recognized in Other Income/ (Expense), Net						$ 20.2
Teva [Member] | Other-than-temporary Impairment [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares				100.3	100.3
Carrying Value per Share				$ 32.09	$ 17.60
Market Price				$ 32.09	$ 17.60
Discount				4.90%	0.00%
Movement in the Value of Marketable Securities				$ (378.6)	$ (1,295.5)
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income				1,599.4
Gain / (Loss) Recognized in Other Income/ (Expense), Net				$ (1,978)	$ (1,295.5)
Teva [Member] | Sales [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares							(4.4)
Discount							0.00%
Movement in the Value of Marketable Securities							$ (76.7)
Gain / (Loss) Recognized in Other Income/ (Expense), Net							$ 4.2
Teva [Member] | Other Fair Value [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Shares							95.9
Carrying Value per Share							$ 17.60
Market Price							$ 18.95
Discount							0.00%
Movement in the Value of Marketable Securities							$ 129.3
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income							$ 129.3

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Teva Share Activity (Parenthetical) (Detail) - USD ($) $ / shares in Units, shares in Millions, U_xbrlipure in Millions, $ in Millions	May 07, 2018	Feb. 13, 2018	Jan. 12, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Jan. 17, 2018
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Closing stock price of securities	$ 18.62			$ 133.66		$ 191.17
Teva [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Loss on forward sale of investment			$ 413.3		$ 62.9
Accelerated share repurchases settlement date				Jan. 12, 2018
Acelerated share repurchase transaction					25
Closing stock price of securities							$ 21.48
Forward sale of Investment Shares		25
Percentage of proceeds from forward sale received					8000.00%
Proceeds from forward sale received	$ 465.5	$ 372		$ 1,815.5
Teva [Member] | Open Market Sales [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from forward sale received				$ 936.7
Average carrying value per share						$ 19.97

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Key Financial Results of Global Generics Business Income from Discontinued Operations , Net of Tax (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Operating expenses:
General and administrative	$ 18.8
Asset sales and impairments, net	1.2
Total operating expenses	20
Operating (loss) / income	(20)
Other (expense) / income, net	(470.4)
(Benefit) / provision for income taxes	(87.5)
(Loss) / income from discontinued operations, net of tax	$ (402.9)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	May 07, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	10 years
Restricted stock awards restrictions eliminated period	After one year
Share-based compensation and related tax benefits	$ 47.1	$ 53.5	$ 105
Income in non-equity settled awards other due to actuarial reversal based on total shareholder return metrics			$ (16.8)
Unrecognized future share-based compensation expense	$ 296.9
Remaining weighted average period (years)	1 year 6 months
Closing stock price of securities	$ 191.17	$ 133.66		$ 18.62
Minimum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period	3 years
Minimum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	1 year
Maximum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period	5 years
Maximum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	4 years

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Two Thousand Nineteen Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, minimum	23.50%
Expected volatility, maximum	26.40%
Risk-free interest rate, Minimum	1.90%
Risk-free interest rate, Maximum	2.60%
Expected term	7 years
Two Thousand Nineteen Grants [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	1.70%
Two Thousand Nineteen Grants [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	2.20%
Two Thousand Eighteen Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield		1.50%
Expected volatility		27.00%
Risk-free interest rate, Minimum		2.20%
Risk-free interest rate, Maximum		2.90%
Expected term		7 years
Two Thousand Seventeen Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield			1.20%
Expected volatility			27.00%
Risk-free interest rate, Minimum			2.00%
Risk-free interest rate, Maximum			2.30%
Expected term			7 years

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense Recognized in Company's Results of Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 214.3	$ 239.8	$ 308
Total stock-based compensation expense (benefit)			(16.8)
Equity Based Compensation Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 214.3	$ 239.8	293.3
Cash-Settled Equity Awards [Member] | Zeltiq Aesthetics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense			31.5
Non Equity-Settled Awards Other [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)			$ (16.8)

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Impact of Accelerations and Step-ups Relating to Acquisition Accounting Treatment of Outstanding Awards (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 5.4	$ 18.4	$ 105
Zeltiq Aesthetics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	4.9	10.1	47.8
Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 0.5	$ 8.3	47.1
Forest Laboratories, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired			$ 10.1

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units (Detail) - Restricted Stock [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares / units outstanding, beginning balance	2.5
Shares, Granted	1.5
Shares, Vested	(0.8)
Shares, Forfeited	(0.1)
Restricted shares / units outstanding, ending balance	3.1	2.5
Weighted Average Grant Date Fair Value, outstanding, beginning balance	$ 190.27
Weighted Average Grant Date Fair Value, Granted	140.13
Weighted Average Grant Date Fair Value, Vested	210.08
Weighted Average Grant Date Fair Value, Forfeited	174.29
Weighted Average Grant Date Fair Value, outstanding, ending balance	$ 159.74	$ 190.27
Weighted Average Remaining Contractual Term (Years)	1 year 4 months 24 days	1 year 7 months 6 days
Aggregate Grant Date Fair Value, outstanding, beginning balance	$ 472.9
Aggregate Grant Date Fair Value, Granted	210.7
Aggregate Grant Date Fair Value, Vested	(159.6)
Aggregate Grant Date Fair Value, Forfeited	(31)
Aggregate Grant Date Fair Value, outstanding, ending balance	$ 493	$ 472.9

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares (Detail) - Non-qualified Options [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding, Beginning Balance	6.3
Options, vested and expected to vest, Beginning Balance	6.3
Options, Granted	0.3
Options, Exercised	(0.9)
Options, Cancelled	(0.2)
Options, Outstanding, Ending Balance	5.5	6.3
Options, vested and expected to vest, Ending Balance	5.5	6.3
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 122.74
Weighted Average Exercise Price, vested and expected to vest, Beginning Balance	122.74
Weighted Average Exercise Price, Granted	140.56
Weighted Average Exercise Price, Exercised	99.71
Weighted Average Exercise Price, Cancelled	224.58
Weighted Average Exercise Price, Outstanding, Ending Balance	127.27	$ 122.74
Weighted Average Exercise Price, vested and expected to vest, Ending Balance	$ 127.27	$ 122.74
Weighted Average Remaining Contractual Term (Years), Outstanding	3 years 10 months 24 days	4 years 4 months 24 days
Weighted Average Remaining Contractual Term (Years), vested and expected to vest	3 years 10 months 24 days	4 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding	$ 352.9	$ 69
Aggregate Intrinsic Value, vested and expected to vest	$ 352.9	$ 69

Pension and Other Postretirem_3

Pension and Other Postretirement Benefit Plans - Summary of Net Periodic (Benefit) of Defined Benefit Plans for Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Service cost	$ 1.2	$ 2.8	$ 5.5
Interest cost	39.6	38.1	40.7
Expected return on plan assets	(56.3)	(63.8)	(54.5)
Settlement	(0.6)	(0.6)	(0.1)
Net periodic (benefit)	$ (16.1)	$ (23.5)	$ (8.4)

Pension and Other Postretirem_4

Pension and Other Postretirement Benefit Plans - Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Change in Plan Assets
Fair value of plan assets at beginning of year	$ 1,129.6	$ 1,235.2
Employer contribution	12.3	14.8
(Loss) / gain on plan assets	221.3	(53.6)
Benefits paid	(38.6)	(41.1)
Settlements		(2.9)
Effects of exchange rate changes and other	(2.9)	(22.8)
Fair value of plan assets at end of year	1,321.7	1,129.6	$ 1,235.2
Change in Benefit Obligation
Benefit obligation at beginning of the year	1,227.2	1,330
Service cost	1.2	2.8	5.5
Interest cost	39.6	38.1	40.7
Actuarial (gain) / loss	143.5	(74.5)
Settlements and other		(2.9)
Benefits paid	(38.6)	(41.1)
Effects of exchange rate changes and other	(5.7)	(25.2)
Fair value of plan assets at end of year	1,321.7	1,129.6	1,235.2
Benefit obligation at end of year	1,367.2	1,227.2	$ 1,330
Funded status at end of year	$ (45.5)	$ (97.6)

Pension and Other Postretirem_5

Pension and Other Postretirement Benefit Plans - Schedule of Funded Status Amount in Consolidated Balance Sheet (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Amounts Recognized In Balance Sheet [Abstract]
Noncurrent assets	$ 57.1	$ 27.6
Current liabilities	(0.9)	(0.9)
Noncurrent liabilities	(101.7)	(124.3)
Funded status at end of year	$ (45.5)	$ (97.6)

Pension and Other Postretirem_6

Pension and Other Postretirement Benefit Plans - Schedule of Fair Values of Pension Plan Assets by Asset Category (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	$ 1,321.7	$ 1,129.6	$ 1,235.2
Investment Funds [Member] | Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	345.2	275.7
Investment Funds [Member] | Equity Securities [Member] | U.S. Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	30.6	20.6
Investment Funds [Member] | Equity Securities [Member] | International Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	249.1	205.3
Investment Funds [Member] | Equity Securities [Member] | Other Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	65.5	49.8
Investment Funds [Member] | Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	969.4	850.2
Investment Funds [Member] | Debt Securities [Member] | U.S. Treasury Bonds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	46.2	63
Investment Funds [Member] | Debt Securities [Member] | Bonds and Bond Funds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	923.2	787.2
Other Investments [Member] | Other [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	7.1	3.7
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	345.2	275.7
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	345.2	275.7
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member] | U.S. Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	30.6	20.6
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member] | International Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	249.1	205.3
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member] | Other Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	65.5	49.8
Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	976.5	853.9
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	969.4	850.2
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member] | U.S. Treasury Bonds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	46.2	63
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member] | Bonds and Bond Funds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	923.2	787.2
Significant Other Observable Inputs (Level 2) [Member] | Other Investments [Member] | Other [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	$ 7.1	$ 3.7

Pension and Other Postretirem_7

Pension and Other Postretirement Benefit Plans - Schedule of Allocated Target Investment Portfolio of Pension Plans for Continuing Operations (Detail)	Dec. 31, 2019	Dec. 31, 2018
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	22.40%	26.00%
Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	74.30%	70.60%
Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	3.30%	3.40%

Pension and Other Postretirem_8

Pension and Other Postretirement Benefit Plans - Additional Information (Detail) - Continuing Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2020
Savings Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 150.4	$ 128.9	$ 89.1
Scenario, Forecast [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions to pension plans in next fiscal year				$ 8.5

Pension and Other Postretirem_9

Pension and Other Postretirement Benefit Plans - Schedule of Expected Benefit Payments of Pension Plans (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Estimated Future Benefit Payments [Abstract]
2020	$ 38.6
2021	40.9
2022	43.1
2023	45.2
2024	47.1
Thereafter	1,152.3
Total liability	$ 1,367.2	$ 1,227.2	$ 1,330

Pension and Other Postretire_10

Pension and Other Postretirement Benefit Plans - Schedule of Defined Benefit Plans with Accumulated Benefit Obligation in Excess of Plan Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets [Abstract]
Projected benefit obligations	$ 1,367.2	$ 1,227.2
Accumulated benefit obligations	1,362.6	1,223.5
Plan assets	$ 1,321.7	$ 1,129.6

Pension and Other Postretire_11

Pension and Other Postretirement Benefit Plans - Schedule of Balances Recognized within Accumulated Other Comprehensive Income / (Loss) Excluding the Impact of Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income [Abstract]
Beginning balance	$ 13.6	$ 58.2
Net actuarial gain (loss)	20.3	(44.6)
Ending Balance	$ 33.9	$ 13.6

Pension and Other Postretire_12

Pension and Other Postretirement Benefit Plans - Weighted Average Assumptions Used to Calculate Projected Benefit Obligations and Net Periodic Benefit Cost (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Benefit Obligation [Abstract]
Projected benefit obligations, Discount rate	2.40%	3.30%
Projected benefit obligations, Salary growth rate	3.00%	3.00%
Net periodic benefit cost, Discount Rate	3.30%	2.90%
Net periodic benefit cost, Expected rate of return on plan assets	5.10%	5.20%
Net periodic benefit cost, Salary growth rate	3.00%	3.00%

Pension and Other Postretire_13

Pension and Other Postretirement Benefit Plans - Schedule of Accumulated Benefit Obligation for Defined Benefit Plans (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Actuarial charge	$ (143.5)	$ 74.5
Benefits paid	(38.6)	(41.1)
Allergan and Forest Acquisitions [Member] | Other Benefit Obligation [Member]
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Accumulated benefit obligation, Beginning balance	42.2	46.8
Interest cost	1.7	1.6
Actuarial charge	2.1	(2.6)
Benefits paid	(3.6)	(3.6)
Accumulated benefit obligation, Ending balance	$ 42.4	$ 42.2

Other Income _ (Expense), Net -

Other Income / (Expense), Net - Components of Other (Expense) / Income, Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Non Operating Income Expense [Line Items]
Sale of businesses		$ 182.6
Other-than-temporary impairments			$ (26.1)
Dividend income			85.2
Naurex recovery			20
Other (expense) / income, net	$ 33	(2.4)	5
Other income / (expense), net	32.8	256.7	(3,437.3)
Teva [Member]
Other Non Operating Income Expense [Line Items]
Net income impact of other-than-temporary loss on investment		60.9	(3,269.3)
Forward sale of shares			(62.9)
Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Debt extinguishment costs			(161.6)
Other Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Debt extinguishment costs	$ (0.2)	$ 15.6	$ (27.6)

Other Income _ (Expense), Net_2

Other Income / (Expense), Net - Additional Information (Detail) shares in Millions, $ in Millions	Aug. 02, 2016shares	Aug. 28, 2015	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)Product	Dec. 31, 2017USD ($)
Other Non Operating Income Expense [Line Items]
Net gain on sale of dermatology product				$ 129.6
Number of dermatology products sold | Product				5
Gain(loss) on sale of business				$ 182.6
Other-than-temporary impairment charges on other equity and cost investments					$ 26.1
Dividend income					85.2
Mark to market gains (loss) on equity securities			$ 7.7	(13.6)
Naurex, Inc. [Member]
Other Non Operating Income Expense [Line Items]
Business acquisition date		Aug. 28, 2015
Amount received from purchase price reduction					20
Teva [Member]
Other Non Operating Income Expense [Line Items]
Ordinary shares received from divestiture of businesses | shares	100.3
Dividend income					85.2
Other Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Gain (loss) on extinguishment of debt				15.6
Other income (expenses), net discount received upon repurchase				45.6
Redeemable premium interest				30
Senior Notes [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount				3,939.1
Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Early repayment of senior notes					2,843.3
Gain (loss) on extinguishment of debt					(161.6)
Make-whole premium					170.5
Other Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Early repayment of senior notes					750
Gain (loss) on extinguishment of debt			$ (0.2)	15.6	(27.6)
Make-whole premium					$ 35.1
Non-Strategic Asset Group [Member]
Other Non Operating Income Expense [Line Items]
Asset held-for-sale in cash				55
Asset held-for-sale in deferred consideration				20
Gain(loss) on sale of business				$ 53

Other Income _ (Expense), Net_3

Other Income / (Expense), Net - Summary of Redeemed and Retired Senior Notes (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount	$ 249.8
Cash Paid for Retirement	249.8
Remaining Value at December 31, 2019	8,424.9
3.000% notes due March 12, 2020 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount	180.7
Cash Paid for Retirement	180.7
Remaining Value at December 31, 2019	2,526
3.450% notes due March 15, 2022 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount	62.3
Cash Paid for Retirement	62.3
Remaining Value at December 31, 2019	2,878.2
3.800% notes due March 15, 2025 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount	6.8
Cash Paid for Retirement	6.8
Remaining Value at December 31, 2019	$ 3,020.7

Other Income _ (Expense), Net_4

Other Income / (Expense), Net - Summary of Redeemed and Retired Senior Notes (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2019
3.000% notes due March 12, 2020 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate	3.00%
Senior notes, maturity date	2020
3.450% notes due March 15, 2022 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate	3.45%
Senior notes, maturity date	2022
3.800% notes due March 15, 2025 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate	3.80%
Senior notes, maturity date	2025

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 455.2	$ 303.2
Work-in-process	246.2	145.7
Finished goods	581.7	520.2
Inventory, Gross	1,283.1	969.1
Less: inventory reserves	150	122.2
Total Inventories	$ 1,133.1	$ 846.9

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Cost of sales to Inventory Write-down	$ 160.2	$ 96.4	$ 102.2
Inventory Reserves [Member] | BIOCELL [Member]
Inventory [Line Items]
Cost of sales to Inventory Write-down	42.1
Total charge to cost of sales	$ 68.1

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accrued expenses:
Accrued third-party rebates	$ 2,001.8	$ 1,832.1
Litigation-related reserves and legal fees	1,250.7	92
Accrued payroll and related benefits	830.3	694.3
Accrued returns and other allowances	596.7	527.8
Accrued R&D expenditures	184.8	215.5
Interest payable	189.5	191.4
Royalties payable	216.9	155.1
Accrued pharmaceutical fees	125.9	145.3
Accrued severance, retention and other shutdown costs	12.7	71.6
Accrued non-provision taxes	64.6	68.5
Accrued selling and marketing expenditures	61.3	61.1
Current portion of contingent consideration obligations	12.1	8.3
Dividends payable	1.1	1.4	$ 24.6
Other accrued expenses	409.9	373
Total accrued expenses	5,958.3	4,437.4
Accounts payable	390.4	349.8
Total accounts payable and accrued expenses	$ 6,348.7	$ 4,787.2

Leases - Additional Information

Leases - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Property Subject To Or Available For Operating Lease [Line Items]
Weighted average remaining lease term for operating leases	6 years 7 months 6 days
Weighted average discount rate for operating leases	2.50%
Right-of-Use asset obtained in exchange for operating lease liability	$ 159.9
Cash paid for amounts included in measurement of lease liabilities	137.2
Property Rental Expense [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Rent expenses for operating leases	63.2
Fleet Rental Expense [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Rent expenses for operating leases	$ 41.1
Minimum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms	1 year
Maximum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms	9 years
Real Estate [Member] | Minimum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms	1 year
Real Estate [Member] | Maximum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms	13 years

Leases - Summary of Operating R

Leases - Summary of Operating ROU Assets and liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	$ 490.4	$ 462.1
Lease Liability	570.5	548.6
Current lease liability - operating	124.4
Long-term lease liability - operating	446.1
Real Estate [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	321.2	304.2
Lease Liability	386.9	$ 370.6
Fleet Rental Expense [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	115
Lease Liability	114.9
Other [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	54.2
Lease Liability	$ 68.7

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating lease expense	$ 151.3
Sublease (income)	(14.3)
Net operating lease expense	$ 137

Leases - Schedule of Lease Ex_2

Leases - Schedule of Lease Expense (Detail) (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Short-term and variable lease expenses	$ 9.5

Leases - Schedule of Lease Comm

Leases - Schedule of Lease Commitments (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
2020	$ 131.6
2021	116.6
2022	88.8
2023	58.3
2024	49.7
2025 and after	192.1
Total undiscounted cash flows	637.1
Future interest	(66.6)
Lease Liability	$ 570.5	$ 548.6

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Property Lease Rental Payments under Capital and Operating Leases (Detail) $ in Millions	Dec. 31, 2019USD ($)
Leases [Abstract]
2019	$ 62.5
2020	52.5
2021	47.9
2022	43.3
2023	39
Thereafter	173.8
Total minimum lease payments	$ 419

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Beginning balance	$ 2,565.2
Additions	375.2
Disposals/transfers/other	(81.1)
Currency translation	(4.9)
Ending balance	2,854.4	$ 2,565.2
Accumulated depreciation
Accumulated depreciation, beginning balance	778.2
Additions	204.5	196.3	$ 171.5
Disposals/transfers/impairments/other	(53.3)
Currency translation	(1.6)
Accumulated depreciation, ending balance	927.8	778.2
Property, plant and equipment, net	1,926.5	1,787
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Beginning balance	590.4
Additions	11.5
Disposals/transfers/other	82.5
Currency translation	(2.4)
Ending balance	682	590.4
Accumulated depreciation
Accumulated depreciation, beginning balance	284.2
Additions	67.3
Disposals/transfers/impairments/other	(23.2)
Currency translation	(1)
Accumulated depreciation, ending balance	327.3	284.2
Property, plant and equipment, net	354.7
Research and Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Beginning balance	67.4
Additions	20
Disposals/transfers/other	8.4
Currency translation	1.2
Ending balance	97	67.4
Accumulated depreciation
Accumulated depreciation, beginning balance	46.3
Additions	10.9
Disposals/transfers/impairments/other	(0.1)
Currency translation	0.8
Accumulated depreciation, ending balance	57.9	46.3
Property, plant and equipment, net	39.1
Transportation / Other [Member]
Property Plant And Equipment [Line Items]
Beginning balance	529.6
Additions	25.6
Disposals/transfers/other	89.5
Currency translation	(1.2)
Ending balance	643.5	529.6
Accumulated depreciation
Accumulated depreciation, beginning balance	291.4
Additions	77.8
Disposals/transfers/impairments/other	(9.2)
Currency translation	(0.9)
Accumulated depreciation, ending balance	359.1	291.4
Property, plant and equipment, net	284.4
Land, Buildings and Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Beginning balance	911.1
Additions	38.9
Disposals/transfers/other	41.4
Currency translation	(1.9)
Ending balance	989.5	911.1
Accumulated depreciation
Accumulated depreciation, beginning balance	156.3
Additions	48.5
Disposals/transfers/impairments/other	(20.8)
Currency translation	(0.5)
Accumulated depreciation, ending balance	183.5	156.3
Property, plant and equipment, net	806
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Beginning balance	466.7
Additions	279.2
Disposals/transfers/other	(302.9)
Currency translation	(0.6)
Ending balance	442.4	$ 466.7
Accumulated depreciation
Property, plant and equipment, net	$ 442.4

Prepaid Expenses, Investments_3

Prepaid Expenses, Investments and Other Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expense And Other Assets Current [Abstract]
Prepaid taxes	$ 437.7	$ 403.8
Prepaid insurance	11.5	16.7
Contingent income	83.6	67.7
Sales and marketing	65	41.8
Other	288.6	289.1
Total prepaid expenses and other current assets	$ 886.4	$ 819.1

Prepaid Expenses, Investments_4

Prepaid Expenses, Investments and Other Assets - Marketable Securities, Including Cash and Cash Equivalents, Other Investments and Other Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Total marketable securities	$ 3,411.6	$ 1,026.9
Investments and other assets:
Deferred executive compensation investments	89.2	90.8
Equity method investments	7.6	8.4
Other long-term investments	63.3	37.6
Taxes receivable	41.2	1,674.8
Contingent income	51.8	75.3
Other assets	154.9	83.7
Total investments and other assets	408	1,970.6
Short-term Investments
Schedule Of Available For Sale Securities [Line Items]
Total marketable securities	$ 3,411.6	$ 1,026.9

Prepaid Expenses, Investments_5

Prepaid Expenses, Investments and Other Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Tax refund	$ 1,600
Upfront payment recorded for prepaid asset		$ 125
Future milestone payment		$ 120
Arrangement for diversified brand product, term of contract		5 years
Amount recorded in Prepaid other		$ 39.2
Amount recorded in other Assets		$ 36.7

Goodwill, Product Rights and _3

Goodwill, Product Rights and Other Intangible Assets - Schedule of Goodwill (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Line Items]
Balance as of December 31, 2018		$ 45,913.3	$ 45,913.3	$ 45,913.3
Acquisitions				34.1
Impairments				(3,552.8)	$ (2,841.1)
Foreign exchange and other adjustments				(146.3)
Balance as of December 31, 2019				42,248.3	45,913.3
US Specialized Therapeutics [Member]
Goodwill [Line Items]
Balance as of December 31, 2018		20,675.6	20,675.6	20,675.6
Acquisitions				34.1
Allocation to current segments				(340)
Balance as of December 31, 2019				20,369.7	20,675.6
US General Medicine [Member]
Goodwill [Line Items]
Balance as of December 31, 2018		17,936.6	17,936.6	17,936.6
Impairments	$ (1,085.8)	(2,467)		(3,552.8)
Allocation to current segments			340	340
Balance as of December 31, 2019				14,723.8	17,936.6
International [Member]
Goodwill [Line Items]
Balance as of December 31, 2018		$ 7,301.1	$ 7,301.1	7,301.1
Foreign exchange and other adjustments				(146.3)
Balance as of December 31, 2019				$ 7,154.8	$ 7,301.1

Goodwill, Product Rights and _4

Goodwill, Product Rights and Other Intangible Assets - Additional Information (Detail) $ in Millions	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Sep. 30, 2019USD ($)Segment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Goodwill Product Rights And Other Intangible Assets [Line Items]
Number of reporting units | Segment						5
Goodwill impairments							$ 3,552.8	$ 2,841.1
Goodwill			$ 45,913.3				42,248.3	45,913.3
Gross balance of goodwill			48,771.7				48,659.4	48,771.7
In-process research and development impairments							436	804.6	$ 1,452.3
Net product rights and other intangibles			43,695.4				37,890.6	43,695.4	$ 54,648.3
Generic Entrant [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Impairment of intangible assets							314
Kybella [Member] | Non-Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Impairment of intangible assets			1,643.8
True Tear [Member] | Non-Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Impairment of intangible assets			187.6
Almirall, S.A. [Member] | Non-Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Net product rights and other intangibles			205.4					205.4
Aclaris Therapeutics, Inc [Member] | Non-Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Net product rights and other intangibles			130.5					130.5
Almirall, S.A. and Aclaris Therapeutics, Inc [Member] | Non-Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Impairment of intangible assets								252
IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments							127
IPR&D [Member] | Allergan, Inc. [Member] | Eye care project | Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				$ 20
IPR&D [Member] | Allergan, Inc. [Member] | Eye care project | Annual Testing [Member] | Changes in launch plans
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				164
IPR&D [Member] | Allergan, Inc. [Member] | Eye care project | Annual Testing [Member] | Delay in clinical studies
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				6
IPR&D [Member] | Allergan, Inc. [Member] | Dermatology Project | Annual Testing [Member] | Delay in clinical studies
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				27
IPR&D [Member] | Allergan, Inc. [Member] | CNS [Member] | Annual Testing [Member] | Delay in clinical studies
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				19
IPR&D [Member] | Allergan, Inc. [Member] | Facial Aesthetic Product [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments							133
IPR&D [Member] | Tobira Therapeutics Inc [Member] | GI Project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments							$ 176
IPR&D [Member] | Vitae Pharmaceuticals Inc | Annual Testing [Member] | Delay in clinical studies
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				$ 40
IPR&D [Member] | Vitae Pharmaceuticals Inc | RORyt [Member] | Non-Annual Testing [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments					$ 522
Currently Marketed Products ("CMP") [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Impairment of intangible assets								149.7
Net product rights and other intangibles			849.4					849.4
Minimum [Member] | Discount Rate [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Rate used for goodwill annual impairment test						9.50%	8.50%
Maximum [Member] | Discount Rate [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Rate used for goodwill annual impairment test						11.00%	10.00%
US General Medicine [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Goodwill Re-Allocated Amount						$ 340	$ 340
Goodwill impairments	$ 1,085.8	$ 2,467					3,552.8
Goodwill			$ 17,936.6				$ 14,723.8	$ 17,936.6
U S Specialized Therapeutics Segment
Goodwill Product Rights And Other Intangible Assets [Line Items]
Goodwill	9,824.8
U S Medical Aesthetics Reporting Unit
Goodwill Product Rights And Other Intangible Assets [Line Items]
Goodwill	$ 7,698.8

Goodwill, Product Rights and _5

Goodwill, Product Rights and Other Intangible Assets - Schedule of Cost Basis on Product Rights and Other Intangible Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, gross, Amortization	$ (5,856.6)	$ (6,552.3)	$ (7,197.1)
Intangibles with indefinite lives, Impairments	(436)	(804.6)	(1,452.3)
Product rights and other intangibles	37,890.6	43,695.4	54,648.3
Balance as of December 31, 2017	37,890.6	43,695.4	54,648.3
IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Impairments	(127)
Cost Basis [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	70,925.1	74,582.5
Intangibles with definite lives, Additions	178.4	49
Intangibles with definite lives, Impairments	0	0
Intangible assets, gross, Impairments	(436)	(798)
Intangibles with definite lives, IPR&D to CMP Transfers		0
Intangibles with definite lives, Transfers/Held for Sale	1,936.6
Intangibles assets, Transfers/Held for Sale/Other	1,861	(3,419)
Intangibles with definite lives, Divested/Held for Sale/Other		(3,391)
Intangibles assets, gross, Foreign Currency Translation	(132.6)	(315.4)
Intangibles with definite lives, Foreign Currency Translation	(132.6)	(315.4)
Intangibles with definite lives, Ending balance	72,907.5	70,925.1	74,582.5
Intangibles with indefinite lives, Beginning balance	5,048.1	5,874.1
Intangibles with indefinite lives, Additions	0
Intangibles with indefinite lives, Impairments	(436)	(798)
Intangibles with indefinite lives, IPR&D to CMP Transfers	0
Intagibles with indefinite lives, Divested/Held for Sale	(75.6)
Intangibles with indefinite lives, Divested/Held for Sale/Other		(28)
Intangibles with indefinite lives, Foreign Currency Translation	0
Intangibles with indefinite lives, Ending balance	4,536.5	5,048.1	5,874.1
Intangible assets, gross, Beginning balance	75,973.2	80,456.6
Intangible assets, gross, Additions	178.4	49
Intangible assets, IPR&D to CMP Transfers		0
Intangible assets, gross, Ending balance	77,444	75,973.2	80,456.6
Cost Basis [Member] | Product Rights and Other Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	70,235.1	73,892.5
Intangibles with definite lives, Additions	178.4	49
Intangibles with definite lives, Impairments		0
Intangibles with definite lives, IPR&D to CMP Transfers		0
Intangibles with definite lives, Transfers/Held for Sale	1,936.6
Intangibles with definite lives, Divested/Held for Sale/Other		(3,391)
Intangibles with definite lives, Foreign Currency Translation	(132.6)	(315.4)
Intangibles with definite lives, Ending balance	72,217.5	70,235.1	73,892.5
Cost Basis [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	690	690
Intangibles with definite lives, Additions		0
Intangibles with definite lives, Impairments		0
Intangibles with definite lives, IPR&D to CMP Transfers		0
Intangibles with definite lives, Divested/Held for Sale/Other		0
Intangibles with definite lives, Foreign Currency Translation		0
Intangibles with definite lives, Ending balance	690	690	690
Cost Basis [Member] | IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Beginning balance	5,048.1	5,874.1
Intangibles with indefinite lives, Impairments	(436)	(798)
Intagibles with indefinite lives, Divested/Held for Sale	(75.6)
Intangibles with indefinite lives, Divested/Held for Sale/Other		(28)
Intangibles with indefinite lives, Ending balance	4,536.5	5,048.1	5,874.1
Accumulated Amortization
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(32,277.8)	(25,808.3)
Intangible assets, gross, Amortization	(5,856.6)	(6,552.3)
Intangibles with definite lives, Impairments	(443.6)	(2,239.9)
Intangible assets, gross, Impairments	(443.6)	(2,239.9)
Intangibles assets, Transfers/Held for Sale/Other	(1,011.4)	2,233.4
Intangibles with definite lives, Divested/Held for Sale/Other		2,233.4
Intangibles assets, gross, Foreign Currency Translation	36	89.3
Intangibles with definite lives, Foreign Currency Translation	36	89.3
Intangible assets, Accumulated Amortization, Ending balance	(39,553.4)	(32,277.8)	(25,808.3)
Intangibles with indefinite lives, Divested/Held for Sale/Other	(1,011.4)
Accumulated Amortization | Product Rights and Other Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(31,985)	(25,593.6)
Intangible assets, gross, Amortization	(5,776.7)	(6,474.2)
Intangibles with definite lives, Impairments	(443.6)	(2,239.9)
Intangibles with definite lives, Divested/Held for Sale/Other		2,233.4
Intangibles with definite lives, Foreign Currency Translation	36	89.3
Intangible assets, Accumulated Amortization, Ending balance	(39,180.7)	(31,985)	(25,593.6)
Intangibles with indefinite lives, Divested/Held for Sale/Other	(1,011.4)
Accumulated Amortization | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(292.8)	(214.7)
Intangible assets, gross, Amortization	(79.9)	(78.1)
Intangibles with definite lives, Impairments		0
Intangibles with definite lives, Divested/Held for Sale/Other		0
Intangibles with definite lives, Foreign Currency Translation		0
Intangible assets, Accumulated Amortization, Ending balance	$ (372.7)	$ (292.8)	$ (214.7)

Goodwill, Product Rights and _6

Goodwill, Product Rights and Other Intangible Assets - Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles (Detail) - Product Rights and Other Related Intangibles [Member] $ in Millions	Dec. 31, 2019USD ($)
Finite Lived Intangible Assets [Line Items]
2020	$ 5,565.8
2021	4,590.7
2022	4,197.8
2023	3,741.7
2024	$ 2,864.8

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt and Capital Leases (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 22,666.6	$ 23,813.1
Unamortized premium	39.9	64.3
Unamortized discount	(55.4)	(64.5)
Total Senior Notes Net	22,651.1	23,812.9
Senior Notes, Fair Market Value	23,679.1	23,303.3
Debt Issuance Costs	(74.7)	(92.1)
Total Other Borrowings	(2.1)	(22.8)
Total Indebtedness	22,649	23,797.7
Capital Leases [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		7.6
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	501	501.9
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	$ 501	$ 501.9
Issuance Date	Mar. 4, 2015
Interest Payments	Quarterly
Acquisition Date		Mar. 4, 2015
Euro Denominated Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 4,148.9	$ 5,045.6
Senior Notes, Fair Market Value	4,370.7	4,951.9
Euro Denominated Notes [Member] | Notes Due November 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	784.9	802.7
Senior Notes, Fair Market Value	$ 784.4	$ 791.3
Issuance Date	Nov. 15, 2018
Interest Payments	Quarterly
Acquisition Date		Nov. 15, 2018
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		$ 802.7
Senior Notes, Fair Market Value		$ 794.9
Issuance Date	May 26, 2017
Interest Payments	Quarterly
Acquisition Date		May 26, 2017
Euro Denominated Notes [Member] | 0.500% Notes Due June 1, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 841	$ 860
Senior Notes, Fair Market Value	$ 846.7	$ 849.7
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date		May 26, 2017
Euro Denominated Notes [Member] | 1.250% Notes Due June 1, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 784.9	$ 802.7
Senior Notes, Fair Market Value	$ 817.7	$ 775.5
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date		May 26, 2017
Euro Denominated Notes [Member] | 1.500% Notes Due November 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 560.7	$ 573.4
Senior Notes, Fair Market Value	$ 589.8	$ 572.4
Issuance Date	Nov. 15, 2018
Interest Payments	Annually
Acquisition Date		Nov. 15, 2018
Euro Denominated Notes [Member] | 2.625% Notes Due November 15, 2028 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 560.7	$ 573.4
Senior Notes, Fair Market Value	$ 648.2	$ 573.4
Issuance Date	Nov. 15, 2018
Interest Payments	Annually
Acquisition Date		Nov. 15, 2018
Euro Denominated Notes [Member] | 2.125% Notes Due June 1, 2029 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 616.7	$ 630.7
Senior Notes, Fair Market Value	$ 683.9	$ 594.7
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date		May 26, 2017
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 18,017.7	$ 18,267.5
Senior Notes, Fair Market Value	18,807.4	17,849.5
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	2,526	2,706.7
Senior Notes, Fair Market Value	$ 2,529.5	$ 2,694.8
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 4, 2015
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 650	$ 650
Senior Notes, Fair Market Value	$ 654.7	$ 648.7
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 17, 2015
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 450	$ 450
Senior Notes, Fair Market Value	$ 463.4	$ 459.4
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date		Jul. 1, 2014
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,200	$ 1,200
Senior Notes, Fair Market Value	$ 1,262.9	$ 1,234.8
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date		Jul. 1, 2014
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 2,878.2	$ 2,940.5
Senior Notes, Fair Market Value	$ 2,945.1	$ 2,891
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 4, 2015
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,700	$ 1,700
Senior Notes, Fair Market Value	$ 1,739.1	$ 1,652.2
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date		Oct. 2, 2012
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 350	$ 350
Senior Notes, Fair Market Value	$ 352.7	$ 332.8
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 17, 2015
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,036.7	$ 1,036.7
Senior Notes, Fair Market Value	$ 1,089.9	$ 1,021
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date		Jun. 10, 2014
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 3,020.7	$ 3,027.5
Senior Notes, Fair Market Value	$ 3,172.4	$ 2,956
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 4, 2015
Fixed Rate Notes [Member] | 4.550% Notes Due March 15, 2035 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,789	$ 1,789
Senior Notes, Fair Market Value	$ 1,953.4	$ 1,690.7
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 4, 2015
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 456.7	$ 456.7
Senior Notes, Fair Market Value	$ 482.8	$ 412.4
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date		Oct. 2, 2012
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,079.4	$ 1,079.4
Senior Notes, Fair Market Value	$ 1,192.8	$ 1,019.1
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date		Jun. 10, 2014
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 881	$ 881
Senior Notes, Fair Market Value	$ 968.7	$ 836.6
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date		Mar. 4, 2015
Other [Member]
Debt Instrument [Line Items]
Total Other Borrowings	$ 72.6	$ 69.3

Long-Term Debt - Schedule of _2

Long-Term Debt - Schedule of Long-Term Debt and Capital Leases (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.00%
3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.45%
3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.80%
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2020	Mar. 12, 2020
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Percentage of margin	1.255%	1.255%
Debt instrument variable rate basis	three month USD LIBOR	three month USD LIBOR
Interest payment terms	Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum	Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2020	Mar. 12, 2020
Senior notes, interest rate	3.00%	3.00%
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Sep. 15, 2020	Sep. 15, 2020
Senior notes, interest rate	3.375%	3.375%
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Feb. 15, 2021	Feb. 15, 2021
Senior notes, interest rate	4.875%	4.875%
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Dec. 15, 2021	Dec. 15, 2021
Senior notes, interest rate	5.00%	5.00%
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2022	Mar. 15, 2022
Senior notes, interest rate	3.45%	3.45%
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2022	Oct. 1, 2022
Senior notes, interest rate	3.25%	3.25%
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2023	Mar. 15, 2023
Senior notes, interest rate	2.80%	2.80%
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2024	Jun. 15, 2024
Senior notes, interest rate	3.85%	3.85%
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2025	Mar. 15, 2025
Senior notes, interest rate	3.80%	3.80%
Fixed Rate Notes [Member] | 4.550% Notes Due March 15, 2035 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2035	Mar. 15, 2035
Senior notes, interest rate	4.55%	4.55%
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2042	Oct. 1, 2042
Senior notes, interest rate	4.625%	4.625%
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2044	Jun. 15, 2044
Senior notes, interest rate	4.85%	4.85%
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2045	Mar. 15, 2045
Senior notes, interest rate	4.75%	4.75%
Euro Denominated Notes [Member] | 0.500% Notes Due June 1, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2021	Jun. 1, 2021
Senior notes, interest rate	0.50%	0.50%
Euro Denominated Notes [Member] | 1.500% Notes Due November 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Nov. 15, 2023	Nov. 15, 2023
Senior notes, interest rate	1.50%	1.50%
Euro Denominated Notes [Member] | 1.250% Notes Due June 1, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2024	Jun. 1, 2024
Senior notes, interest rate	1.25%	1.25%
Euro Denominated Notes [Member] | 2.625% Notes Due November 15, 2028 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Nov. 15, 2028	Nov. 15, 2028
Senior notes, interest rate	2.625%	2.625%
Euro Denominated Notes [Member] | 2.125% Notes Due June 1, 2029 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2029	Jun. 1, 2029
Senior notes, interest rate	2.125%	2.125%
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.35%	0.35%
Debt instrument variable rate basis	three month EURIBOR	three month EURIBOR
Interest payment terms	Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum	Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum
Euro Denominated Notes [Member] | Notes Due November 15, 2020 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.35%	0.35%
Debt instrument variable rate basis	three month EURIBOR	three month EURIBOR
Interest payment terms	Interest on the 2020 floating rate notes is the three month EURIBOR plus 0.350% per annum	Interest on the 2020 floating rate notes is the three month EURIBOR plus 0.350% per annum

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Debt instrument, repurchase amount		$ 3,893.5
Income/ expenses net		15.6
Repurchase discount received		45.6
Write off premium and debt fees		30
Senior notes		23,812.9	$ 22,651.1
Repayment of senior notes		3,750
Borrowings [Member]
Debt Instrument [Line Items]
Senior notes		1,700
Senior Notes [Member]
Debt Instrument [Line Items]
Senior notes, repurchase amount		3,939.1	$ 249.8
Margin Loan [Member]
Debt Instrument [Line Items]
Repayments of Debt		459
Revolver Agreement [Member]
Debt Instrument [Line Items]
Revolving credit facility, borrowing amount		700
Revolving credit facility, repayment amount		$ 700
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Repayments of Debt | €	€ 700

Long-Term Debt - Revolving Cred

Long-Term Debt - Revolving Credit Facility - Additional Information (Detail) - Revolver Agreement [Member] - USD ($) $ in Millions	Jun. 14, 2017	Dec. 31, 2019
Line Of Credit Facility [Line Items]
Revolving credit facility, term	5 years
Maximum borrowing capacity	$ 1,500
Ability to increase the revolving credit facility	500
Borrowing capacity	$ 2,000
Customary affirmative covenants		The Revolver Agreement contains customary affirmative covenants for facilities of this type, including, among others, covenants pertaining to the delivery of financial statements, notices of default, maintenance of corporate existence and compliance with laws, as well as customary negative covenants for facilities of this type, including, among others, limitations on secured indebtedness, non-guarantor subsidiary indebtedness, mergers and certain other fundamental changes and passive holding company status. The Revolver Agreement also contains a financial covenant requiring maintenance of a maximum consolidated leverage ratio.
Borrowings outstanding		$ 33.6
Letters of credit outstanding		$ 33.6
Minimum [Member]
Line Of Credit Facility [Line Items]
Credit facility unused portion commitment fee percentage	0.07%
Minimum [Member] | Base Rate [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	0.00%
Minimum [Member] | Eurodollar [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	0.875%
Maximum [Member]
Line Of Credit Facility [Line Items]
Credit facility unused portion commitment fee percentage	0.25%
Maximum [Member] | Base Rate [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	1.00%
Maximum [Member] | Eurodollar [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	2.00%

Long-Term Debt - Schedule of An

Long-Term Debt - Schedule of Annual Debt Maturities of Senior Notes Gross (Detail) $ in Millions	Dec. 31, 2019USD ($)
Debt Disclosure [Abstract]
2020	$ 4,460.9
2021	2,491
2022	4,578.2
2023	910.7
2024	1,821.6
2025 and after	8,404.2
Total senior notes gross	$ 22,666.6

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Other Liabilities Disclosure [Abstract]
Acquisition related contingent consideration liabilities	$ 377.3	$ 336.3
Long-term pension and post retirement liability	144.1	166.5
Legacy Allergan deferred executive compensation	89.2	90.8
Accrued R&D milestone	75	75
Long-term contractual obligations		43.2
Deferred revenue	26.6	36.1
Product warranties	29.2	27.9
Long-term severance and restructuring liabilities	10.8	14.2
Other long-term liabilities	48.7	92
Total other long-term liabilities	$ 800.9	$ 882

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Losses Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Irish	$ (4,756)	$ (4,285.8)	$ (1,139)
Non-Irish	(362.7)	(2,571.1)	(9,247.4)
Income / (loss) before income taxes and noncontrolling interest	$ (5,118.7)	$ (6,856.9)	$ (10,386.4)

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision / (Benefit) for Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current (benefit) / provision:
Current (benefit) / provision, U.S. federal	$ 476.5	$ (1,024.5)	$ 763.1
Current (benefit) / provision, U.S. state	35.6	34.2	(54.8)
Current (benefit) / provision, Non-U.S.	295.2	481.6	410
Total current (benefit) / provision	807.3	(508.7)	1,118.3
Deferred (benefit) / provision:
Deferred (benefit) / provision, U.S. federal	(635.7)	(569.9)	(6,911.9)
Deferred (benefit) / provision, U.S. state	(131.7)	(80.6)	(252.3)
Deferred (benefit) / provision, Non-U.S.	106.5	(611.5)	(624.5)
Total deferred (benefit) / provision	(660.9)	(1,262)	(7,788.7)
Total (benefit) / provision for income taxes	$ 146.4	$ (1,770.7)	$ (6,670.4)

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Irish [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	(12.50%)	(12.50%)	(12.50%)
Earnings subject to U.S. taxes	1.30%	(1.80%)	(17.40%)
Earnings subject to rates different than the statutory rate	(5.30%)	(3.40%)	2.10%
Impact of U.S. tax reform enactment	0.00%	(0.20%)	(27.20%)
Tax reserves and audit outcomes	2.10%	2.60%	0.40%
Non-deductible expenses	12.60%	7.40%	0.20%
Impact of acquisitions and reorganizations	(2.60%)	(15.30%)	(9.30%)
Tax credits and U.S. special deductions	(2.00%)	(0.90%)	(1.50%)
Rate changes	0.30%	2.20%	(1.20%)
Valuation allowances	8.70%	(3.70%)	2.20%
Other	0.30%	(0.20%)	0.00%
Effective income tax rate	2.90%	(25.80%)	(64.20%)
Bermuda [Member] | Warner Chilcott Limited [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	(0.00%)	(0.00%)	(0.00%)
Earnings subject to U.S. taxes	(2.80%)	(10.20%)	(27.40%)
Earnings subject to rates different than the statutory rate	(14.20%)	(8.40%)	(0.90%)
Impact of U.S. tax reform enactment	0.00%	(0.20%)	(27.70%)
Tax reserves and audit outcomes	2.10%	2.60%	0.50%
Non-deductible expenses	13.00%	7.70%	0.20%
Impact of acquisitions and reorganizations	(2.60%)	(16.00%)	(9.50%)
Tax credits and U.S. special deductions	(2.10%)	(1.00%)	(1.50%)
Rate changes	0.30%	2.30%	(1.30%)
Valuation allowances	9.00%	(3.90%)	2.30%
Other	0.30%	(0.10%)	(0.20%)
Effective income tax rate	3.00%	(27.20%)	(65.50%)

Income Taxes - Schedule of Re_2

Income Taxes - Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Effective tax rate	$ 64.5	$ 122.9
Impairment charges	900	3,000
Amortization expense	5,856.6	6,552.3	$ 7,197.1
Impact on effective tax rate	14.1	277.5
Goodwill impairment including asset held for sale	3,600	3,500
Legal settlements	1,100
Tax detriment	581.5	432.9
Income tax benefit related to basis differences in investments	131.2	1,047.8
Change in tax rate amount recorded as detriment	15.1	148
Valuation Allowance on Non U.S. Capital Loss Carryforwards [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Tax benefit amount related to valuation allowance	444.9	$ 254
Non-U.S. [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Impairment charges	2,900
Non-U.S. [Member] | Valuation Allowance on Non U.S. Capital Loss Carryforwards [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Tax benefit amount related to valuation allowance	$ 441.2

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components Company's Net Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Benefits from net operating and capital loss carryforwards	$ 2,105.2	$ 2,145.8
Benefits from tax credit and other carryforwards	440.4	377.6
Differences in financial statement and tax accounting for:
Inventories, receivables and accruals	496.8	231.8
Basis differences in investments	185.5	56.1
Share-based and other compensation	242.8	295.5
Other	183.4	82.4
Total deferred tax asset, gross	3,654.1	3,189.2
Less: Valuation allowance	(2,079.1)	(1,637.9)
Total deferred tax asset, net	1,575	1,551.3
Differences in financial statement and tax accounting for:
Property, equipment and intangible assets	(4,725.2)	(5,487.4)
Basis differences in investments	(525.9)	(499.9)
Other	(110.7)	(2.1)
Total deferred tax liabilities	(5,361.8)	(5,989.4)
Total deferred taxes	$ (3,786.8)	$ (4,438.1)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
Decreased in net deferred tax liabilities	$ 651.3
Valuation allowance	2,079.1	$ 1,637.9
Tax credits	440.4	377.6
Net operating income (losses)	(4,445.3)	(6,247.6)	$ (5,921.2)
Other deferred tax assets	183.4	82.4
Undistributed Earnings of Foreign Subsidiaries	17,000
Deferred tax liabilities repatriation amount	67.7
Unrecognized amount that would favorably affect Company's effective tax rate	965.7
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	218.1	5	38.7
Interest and penalties related to uncertain tax positions recognized in tax expense	27.7	42.3	45.8
Interest and penalties related to tax positions accrued	183	155.2	113.7
Tax benefit on penalties and interest accrued	44.1	35	$ 25.9
Reasonably possible change in unrecognized tax benefits	200
Valuation Allowance on Non U.S. Capital Loss Carryforwards [Member]
Income Tax [Line Items]
Tax benefit amount related to valuation allowance	444.9	$ 254
Tax Valuation Allowance [Member]
Income Tax [Line Items]
Tax credits	56.3
Net operating income (losses)	(1,822.6)
Capital loss carryforwards	115.3
Other deferred tax assets	(84.9)
U.S. [Member]
Income Tax [Line Items]
Tax net operating losses, expire in 2019	1,095.1
Tax credits, expire in 2019	310.2
Net operating loss carryforwards	194.8
Tax credit carryforwards	4.6
U.S. State [Member]
Income Tax [Line Items]
Tax net operating losses, expire in 2019	227.3
Non-U.S. [Member]
Income Tax [Line Items]
Tax net operating losses, expire in 2019	4,819.5
Tax net operating losses, not subject to expiration	4,120.8
Non-U.S. [Member] | Valuation Allowance on Non U.S. Capital Loss Carryforwards [Member]
Income Tax [Line Items]
Tax benefit amount related to valuation allowance	$ 441.2

Income Taxes - Schedule of Re_3

Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 1,186.8	$ 850.3	$ 811.2
Increases for current year tax positions	66.4	164.3	10.1
Increases for prior year tax positions	214.3	193.4	69.2
Increases due to acquisitions	0	0	19.8
Decreases for prior year tax positions	(218.1)	(5)	(38.7)
Settlements	(23.3)	(5.4)	(21.7)
Lapse of applicable statute of limitations	(13.3)	(5.9)	(2.9)
Foreign exchange	1.6		3.3
Foreign exchange		(4.9)
Balance at the end of the year	$ 1,214.4	$ 1,186.8	$ 850.3

Income Taxes - Summary of Acqui

Income Taxes - Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS (Detail) - U.S. Federal Income Tax Authority [Member]	12 Months Ended
	Dec. 31, 2019
Allergan W.C. Holding Inc. [Member]
Income Tax Examination [Line Items]
Tax Years	2013 2014 2015 2016
Warner Chilcott Corporation [Member]
Income Tax Examination [Line Items]
Tax Years	2010 2011 2012 2013
Forest Laboratories, Inc. [Member]
Income Tax Examination [Line Items]
Tax Years	2010 2011 2012 2013 2014
Allergan, Inc. [Member]
Income Tax Examination [Line Items]
Tax Years	2009 2010 2011 2012 2013 2014
Taxable Years, date	Mar. 17, 2015

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($)	Mar. 01, 2018	Feb. 28, 2015	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 29, 2019	Jul. 30, 2018	Sep. 30, 2017
Shareholders Equity [Line Items]
Share repurchase program, Approved amount						$ 2,000,000,000	$ 2,000,000,000	$ 2,000,000,000
Quarterly cash dividends paid			$ 0.74	$ 0.72
Dividends on ordinary shares			$ 974,400,000	$ 980,200,000
Dividends on preferred shares				$ 69,600,000	$ 278,400,000
Convertible Preferred Share, conversion date				Mar. 1, 2018
Convertible Preferred Stock, shares issued upon each share conversion	3.53
Unrealized gain (loss) net of tax included in pension and other post retirement plans			$ 7,900,000	$ 36,900,000
Allergan plc Ordinary Shares [Member]
Shareholders Equity [Line Items]
Convertible Preferred Stock, shares issued upon conversion	17,876,930
Mandatory Convertible Preferred Shares [Member]
Shareholders Equity [Line Items]
Preferred shares, shares issued		5,060,000
Preferred shares, dividend rate percentage		5.50%
Preferred shares, par value		$ 0.0001
Preferred shares, liquidation preference per share		$ 1,000
Mandatory Convertible Preferred Shares [Member] | Allergan, Inc. [Member]
Shareholders Equity [Line Items]
Proceeds from the issuance of Mandatory Convertible Preferred Shares		$ 4,929,700,000
July 30, 2018 Share Repurchase Program [Member]
Shareholders Equity [Line Items]
Number of shares repurchased under program			12,500,000
Additional shares repurchased amount under program			5,300,000
Shares repurchased amount under program			$ 800,000,000
September 25, 2017 Share Repurchase Program [Member]
Shareholders Equity [Line Items]
Number of shares repurchased under program			9,600,000		2,600,000
Shares repurchased amount under program			$ 1,540,000,000		$ 450,000,000

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Movements in Accumulated Other Comprehensive (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	$ 65,131	$ 73,837.1
Implementation of new accounting pronouncements	(22)	361.7
Adjusted Balance	65,109
Balance	58,196.4	65,131
Amounts reclassed, net of tax, upon adoption of ASU 2016-01		(22)
Ending balance		65,109
Foreign Currency Translation Items [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	1,308.3	1,782.7
Adjusted Balance		1,782.7
Other comprehensive gain / (loss) before reclassifications into general and administrative	(151.8)	(474.4)
Balance	1,156.5	1,308.3
Unrealized Gains/(Loss) Net of Tax [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	36.9	138
Implementation of new accounting pronouncements		(63)
Adjusted Balance		75
Other comprehensive gain / (loss) before reclassifications into general and administrative	13.8	(38.1)
Balance	50.7	36.9
Accumulated Other Comprehensive Income / (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	1,345.2	1,920.7
Implementation of new accounting pronouncements		(63)
Adjusted Balance	1,345.2	1,857.7
Other comprehensive gain / (loss) before reclassifications into general and administrative	(138)	(512.5)
Balance	$ 1,207.2	1,345.2
Ending balance		$ 1,345.2

Segments - Additional Informati

Segments - Additional Information (Detail) $ in Millions	Jul. 24, 2019USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)Segment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment										3
Operating (loss)										$ (4,445.3)	$ (6,247.6)	$ (5,921.2)
Net revenues		$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	16,088.9	15,787.4	15,940.7
Cost of sales										$ 2,493.1	$ 2,191.4	$ 2,168
Adjustment [Member]
Segment Reporting Information [Line Items]
Operating (loss)	$ (118)
Net revenues	(37.9)
Cost of sales	68.1
Selling, general and administrative expense	$ 12

Segments - Schedule of Net Reve

Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net revenues		$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Operating expenses:
Cost of sales										2,493.1	2,191.4	2,168
Selling and marketing										3,461.7	3,250.6	3,514.8
General and administrative										2,481.8	1,271.2	1,501.9
Research and development										1,812	2,266.2	2,100.1
Amortization										5,856.6	6,552.3	7,197.1
Goodwill impairments										3,552.8	2,841.1
In-process research and development impairments										436	804.6	1,452.3
Asset sales and impairments, net										440.2	2,857.6	3,927.7
Operating (loss)										(4,445.3)	(6,247.6)	(5,921.2)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues										16,056.9	15,747.9	15,919.3
Operating expenses:
Cost of sales										2,081.3	1,901.4	1,818
Selling and marketing										3,403.3	3,201.6	3,367.4
General and administrative										467.8	503.4	506.1
Segment contribution										$ 10,104.5	$ 10,141.5	$ 10,227.8
Contribution margin										62.90%	64.40%	64.20%
Research and development										$ 1,812	$ 2,266.2	$ 2,100.1
Amortization										5,856.6	6,552.3	7,197.1
Goodwill impairments										3,552.8	2,841.1
In-process research and development impairments										436	804.6	1,452.3
Asset sales and impairments, net										440.2	2,857.6	3,927.7
Operating (loss)										$ (4,445.3)	$ (6,247.6)	$ (5,921.2)
Operating margin										(27.70%)	(39.70%)	(37.20%)
Corporate Non Segment [Member]
Segment Reporting Information [Line Items]
Net revenues										$ 32	$ 39.5	$ 21.4
Operating expenses:
Corporate										2,452.2	1,067.3	1,471.8
US Specialized Therapeutics [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues										6,820	6,920.3	6,803.6
Operating expenses:
Cost of sales										578.2	565.2	495.4
Selling and marketing										1,490.4	1,348.3	1,369.5
General and administrative										190.1	205.3	208.2
Segment contribution										$ 4,561.3	$ 4,801.5	$ 4,730.5
Contribution margin										66.90%	69.40%	69.50%
International [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues										$ 3,402	$ 3,504.7	$ 3,319.5
Operating expenses:
Cost of sales										548.3	537.1	478.7
Selling and marketing										934.7	928.7	913.8
General and administrative										117	141.7	120.6
Segment contribution										$ 1,802	$ 1,897.2	$ 1,806.4
Contribution margin										53.00%	54.10%	54.40%
US General Medicine [Member]
Operating expenses:
Goodwill impairments	$ 1,085.8				$ 2,467					$ 3,552.8
US General Medicine [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues										5,834.9	$ 5,322.9	$ 5,796.2
Operating expenses:
Cost of sales										954.8	799.1	843.9
Selling and marketing										978.2	924.6	1,084.1
General and administrative										160.7	156.4	177.3
Segment contribution										$ 3,741.2	$ 3,442.8	$ 3,690.9
Contribution margin										64.10%	64.70%	63.70%

Segments - Schedule of Net Re_2

Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Corporate Non Segment [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 32	$ 39.5	$ 21.4

Segments - Schedule of Net Re_3

Segments - Schedule of Net Revenue Disaggregated by Geography for International Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Operating Segments [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues									16,056.9	15,747.9	15,919.3
Operating Segments [Member] | International [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues									3,402	3,504.7	3,319.5
Operating Segments [Member] | International [Member] | Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues									1,471.7	1,482.6	1,439.2
Operating Segments [Member] | International [Member] | Asia Pacific, Middle East and Africa [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues									1,075.1	1,089.9	929.9
Operating Segments [Member] | International [Member] | Latin America and Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues									772.9	862.4	863.3
Operating Segments [Member] | International [Member] | Other [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues									$ 82.3	$ 69.8	$ 87.1

Segments - Schedule of Global N

Segments - Schedule of Global Net Revenues for Top Products and Reconciliation of Segment Revenues to Total Net Revenues by Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									16,056.9	15,747.9	15,919.3
Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									6,820	6,920.3	6,803.6
Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									5,834.9	5,322.9	5,796.2
Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3,402	3,504.7	3,319.5
Operating Segments [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3,791.3	3,577.4	3,168.9
Operating Segments [Member] | Botox [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,730.5	2,545.8	2,254.4
Operating Segments [Member] | Botox [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,060.8	1,031.6	914.5
Operating Segments [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,188.6	1,261.5	1,473.6
Operating Segments [Member] | Restasis [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,138.4	1,197	1,412.3
Operating Segments [Member] | Restasis [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									50.2	64.5	61.3
Operating Segments [Member] | Juvederm Collection [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,243.6	1,163	1,041.8
Operating Segments [Member] | Juvederm Collection [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									587.5	548.2	501.1
Operating Segments [Member] | Juvederm Collection [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									656.1	614.8	540.7
Operating Segments [Member] | Linzess/Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									827	785.2	723
Operating Segments [Member] | Linzess/Constella [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									803.2	761.1	701.1
Operating Segments [Member] | Linzess/Constella [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									23.8	24.1	21.9
Operating Segments [Member] | Lumigan/Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									630	684.4	689
Operating Segments [Member] | Lumigan/Ganfort [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									269.2	291.8	317.5
Operating Segments [Member] | Lumigan/Ganfort [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									360.8	392.6	371.5
Operating Segments [Member] | Bystolic/Byvalson [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									602.7	585.8	614.4
Operating Segments [Member] | Bystolic/Byvalson [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									600.6	583.8	612.2
Operating Segments [Member] | Bystolic/Byvalson [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2.1	2	2.2
Operating Segments [Member] | Alphagan/Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									522	551.4	552.4
Operating Segments [Member] | Alphagan/Combigan [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									360	375.4	377.3
Operating Segments [Member] | Alphagan/Combigan [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									162	176	175.1
Operating Segments [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									588.9	527.7	459.3
Operating Segments [Member] | Lo Loestrin [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									588.9	527.7	459.3
Operating Segments [Member] | Vraylar [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									857.5	487.1	287.8
Operating Segments [Member] | Vraylar [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									857.5	487.1	287.8
Operating Segments [Member] | Eye Drops [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									466.2	482.4	480.5
Operating Segments [Member] | Eye Drops [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									230.4	202.7	199.5
Operating Segments [Member] | Eye Drops [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									235.8	279.7	281
Operating Segments [Member] | Alloderm [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									403.8	415.3	328.7
Operating Segments [Member] | Alloderm [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									395.9	407.3	321.2
Operating Segments [Member] | Alloderm [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									7.9	8	7.5
Operating Segments [Member] | Breast Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									255	393.1	399.5
Operating Segments [Member] | Breast Implants [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									254.4	263	242.6
Operating Segments [Member] | Breast Implants [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.6	130.1	156.9
Operating Segments [Member] | Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									423.5	349.6	336.3
Operating Segments [Member] | Viibryd/Fetzima [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									412.1	342.4	333.2
Operating Segments [Member] | Viibryd/Fetzima [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									11.4	7.2	3.1
Operating Segments [Member] | Coolsculpting Consumables [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									261.6	299.5	191.7
Operating Segments [Member] | Coolsculpting Consumables [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									185.3	235.3	150.1
Operating Segments [Member] | Coolsculpting Consumables [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									76.3	64.2	41.6
Operating Segments [Member] | Ozurdex [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									400.1	298.7	311.8
Operating Segments [Member] | Ozurdex [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									125.5	111	98.4
Operating Segments [Member] | Ozurdex [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									274.6	187.7	213.4
Operating Segments [Member] | Zenpep [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									289.2	237.7	212.3
Operating Segments [Member] | Zenpep [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									288	237.3	212.3
Operating Segments [Member] | Zenpep [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1.2	0.4
Operating Segments [Member] | Carafate/Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									215.5	220.6	238.7
Operating Segments [Member] | Carafate/Sulcrate [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									212.5	217.8	235.8
Operating Segments [Member] | Carafate/Sulcrate [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3	2.8	2.9
Operating Segments [Member] | Armour Thyroid [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									218.5	198.8	169.1
Operating Segments [Member] | Armour Thyroid [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									218.5	198.8	169.1
Operating Segments [Member] | Canasa/Salofalk [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									48.3	186.8	181
Operating Segments [Member] | Canasa/Salofalk [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									31.5	169.2	162.7
Operating Segments [Member] | Canasa/Salofalk [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									16.8	17.6	18.3
Operating Segments [Member] | Viberzi [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									189.5	177.8	157.1
Operating Segments [Member] | Viberzi [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									187.9	176.5	156.6
Operating Segments [Member] | Viberzi [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1.6	1.3	0.5
Operating Segments [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									112.8	176.5	245.7
Operating Segments [Member] | Asacol/Delzicol [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									76.7	130.8	195.5
Operating Segments [Member] | Asacol/Delzicol [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									36.1	45.7	50.2
Operating Segments [Member] | Coolsculpting Systems & Add On Applicators [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									105.2	169.6	138.7
Operating Segments [Member] | Coolsculpting Systems & Add On Applicators [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									62.8	126.3	106.6
Operating Segments [Member] | Coolsculpting Systems & Add On Applicators [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									42.4	43.3	32.1
Operating Segments [Member] | Skin Care [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									172.6	154	165.2
Operating Segments [Member] | Skin Care [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									158	138.8	153.2
Operating Segments [Member] | Skin Care [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									14.6	15.2	12
Operating Segments [Member] | Saphris [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									135.3	139.7	155.2
Operating Segments [Member] | Saphris [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									135.3	139.7	155.2
Operating Segments [Member] | Teflaro [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									153	128.3	121.9
Operating Segments [Member] | Teflaro [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									147	128	121.9
Operating Segments [Member] | Teflaro [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									6	0.3
Operating Segments [Member] | Namzaric [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									88.6	115.8	130.8
Operating Segments [Member] | Namzaric [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									88.6	115.8	130.8
Operating Segments [Member] | Avycaz [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									116.7	94.6	61.2
Operating Segments [Member] | Avycaz [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									116.7	94.6	61.2
Operating Segments [Member] | Rapaflo [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									29.5	88.3	115.4
Operating Segments [Member] | Rapaflo [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									23.5	81.9	108.1
Operating Segments [Member] | Rapaflo [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									6	6.4	7.3
Operating Segments [Member] | Savella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									88.5	85	98.2
Operating Segments [Member] | Savella [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									88.5	85	98.2
Operating Segments [Member] | Namenda [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									22.8	71	452.9
Operating Segments [Member] | Namenda [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									22.8	71	452.9
Operating Segments [Member] | Dalvance [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									87.9	58.4	56.3
Operating Segments [Member] | Dalvance [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									81.9	56.1	53.9
Operating Segments [Member] | Dalvance [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									6	2.3	2.4
Operating Segments [Member] | Aczone [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									9.3	55.5	166.8
Operating Segments [Member] | Aczone [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									9.3	55.1	166.3
Operating Segments [Member] | Aczone [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										0.4	0.5
Operating Segments [Member] | Liletta [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									79.1	50.9	37.6
Operating Segments [Member] | Liletta [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									79.1	50.9	37.6
Operating Segments [Member] | Kybella/Belkyra [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									30.7	38.1	56.3
Operating Segments [Member] | Kybella/Belkyra [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									27.4	31.8	49.5
Operating Segments [Member] | Kybella/Belkyra [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3.3	6.3	6.8
Operating Segments [Member] | Other Products Revenues [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,402.1
Operating Segments [Member] | Other Products Revenues [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									261.9
Operating Segments [Member] | Other Products Revenues [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									797.6
Operating Segments [Member] | Other Products Revenues [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									342.6
Operating Segments [Member] | Other [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										1,438.4	1,900.2
Operating Segments [Member] | Other [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										308.9	345.5
Operating Segments [Member] | Other [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										749.3	1,158.9
Operating Segments [Member] | Other [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										380.2	395.8
Corporate Non Segment [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									$ 32	$ 39.5	$ 21.4

Business Restructuring Charge_2

Business Restructuring Charges - Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	$ 85.8	$ 185.9
Charged to expense	8.1	52
Cash payments	(68.3)	(143.9)
Non-cash adjustments	(2.1)	(8.2)
Reserve ending balance	23.5	85.8
Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	1.4	7.3
Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		1
Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	0.7	35.3
General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	6	8.4
Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	71.4	166
Charged to expense	5.8	43.8
Cash payments	(64.8)	(138.4)
Non-cash adjustments	(2.1)
Reserve ending balance	10.3	71.4
Severance and Retention [Member] | Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	1.4	7.3
Severance and Retention [Member] | Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		1
Severance and Retention [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	0.7	31.2
Severance and Retention [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	3.7	4.3
Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		8.2
Non-cash adjustments		(8.2)
Share-Based Compensation [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		4.1
Share-Based Compensation [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		4.1
Other [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	14.4	19.9
Charged to expense	2.3
Cash payments	(3.5)	(5.5)
Reserve ending balance	13.2	$ 14.4
Other [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	$ 2.3

Business Restructuring Charge_3

Business Restructuring Charges - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)Employee	Dec. 31, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Severance and other employee related charges	$ 52
Share based compensation related to business restructuring	8.2	$ 8.2
Severance and other employee related charges incurred	$ 14.1
Selling And Marketing [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee	200

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities - Additional Information (Detail) € in Millions, $ in Millions	1 Months Ended		12 Months Ended
	Jan. 31, 2019USD ($)	Nov. 30, 2018EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Outstanding third-party foreign currency instruments			$ 49.7	$ 42.1
Derivative, Maturity Date		May 31, 2019
Derivative instrument offsetting revaluation impact on variable interest debt | €		€ 700
Designated as Hedging Instrument [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative notional amount			5,000	5,100
Gain on Derivative Used in Net Investment Hedge, Net of Tax			113	144.5
Designated as Hedging Instrument [Member] | Cash Flow Hedge [Member] | Interest Rate Swap [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative notional amount	$ 500
Debt instrument, maturity date	Mar. 12, 2020
Derivative, average interest rate	3.98%
Interest rate swaps fair value			0.8
Unrealized gain (loss) on interest rate swaps			$ 0.8
Foreign Currency Gain [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Loss on derivatives				$ (29.8)
Forward Contract [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Forward contract to buy Euros | €		€ 700

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or Disclosed at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
ASSETS
Deferred executive compensation investments	$ 89.2	$ 90.8
Contingent income	51.8	75.3
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Cash equivalents	1,535.4	207.1
Fair Value, Measurements, Recurring [Member]
ASSETS
Short-term investments	3,411.6	1,026.9
Deferred executive compensation investments	89.2	90.8
Contingent income	51.8	50.3
Investments and other	70.9	46
Total assets	5,158.9	1,421.1
Liabilities:
Deferred executive compensation liabilities	89.2	90.8
Contingent consideration obligations	389.4	344.6
Total liabilities	478.6	435.4
Fair Value, Measurements, Recurring [Member] | Cash Equivalents [Member]
ASSETS
Cash equivalents	1,535.4	207.1
Fair Value, Measurements, Recurring [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Deferred executive compensation investments	77	73.8
Investments and other	38.2	38.5
Total assets	1,650.6	319.4
Liabilities:
Deferred executive compensation liabilities	77	73.8
Total liabilities	77	73.8
Fair Value, Measurements, Recurring [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Cash Equivalents [Member]
ASSETS
Cash equivalents	1,535.4	207.1
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
ASSETS
Short-term investments	3,411.6	1,026.9
Deferred executive compensation investments	12.2	17
Investments and other	32.6	7.5
Total assets	3,456.4	1,051.4
Liabilities:
Deferred executive compensation liabilities	12.2	17
Total liabilities	12.2	17
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
ASSETS
Contingent income	51.8	50.3
Total assets	51.8	50.3
Liabilities:
Contingent consideration obligations	389.4	344.6
Total liabilities	$ 389.4	$ 344.6

Fair Value Measurement - Sche_2

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or Disclosed at Fair Value on Recurring Basis (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities remaining maturity period at the time of acquisition	90 days	90 days

Fair Value Measurement - Invest

Fair Value Measurement - Investments in Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Marketable securities	$ 3,411.6	$ 1,026.9
Level 1 [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,535.4	207.1
Estimated fair value	1,535.4	207.1
Cash & cash equivalents	1,535.4	207.1
Level 1 [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,535.4	207.1
Estimated fair value	1,535.4	207.1
Cash & cash equivalents	1,535.4	207.1
Level 2 [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	3,411.6	1,026.9
Estimated fair value	3,411.6	1,026.9
Marketable securities	3,411.6	1,026.9
Level 2 [Member] | Other Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	3,411.6	1,026.9
Estimated fair value	3,411.6	1,026.9
Marketable securities	$ 3,411.6	$ 1,026.9

Fair Value Measurement - Change

Fair Value Measurement - Change in Fair Value of Contingent Consideration Obligations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 54.1	$ (106.6)	$ (133.2)
Cost of Sales [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	44.6	(111.7)	(183.2)
R&D Expense [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 9.5	$ 5.1	$ 50

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	$ 54.1	$ (106.6)	$ (133.2)
Cost of Sales [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	44.6	(111.7)	(183.2)
R&D Expense [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	$ 9.5	$ 5.1	50
Allergan, Inc. [Member] | Cost of Sales [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income			183.2
Net contingent consideration expense			50
Allergan, Inc. [Member] | R&D Expense [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration expense			$ 50

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) - Contingent Consideration Obligations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 344.6	$ 476.9
Purchases, settlements, and other net	(9.3)	(25.7)
Net accretion and fair value adjustments	54.1	(106.6)
Ending balance	$ 389.4	$ 344.6

Fair Value Measurement - Sche_3

Fair Value Measurement - Schedule of Contingent Consideration Obligations by Acquisitions (Detail) - Contingent Consideration Obligations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Beginning balance	$ 344.6	$ 476.9
Fair Value Adjustments and Accretion	54.1	(106.6)
Payments and Other	(9.3)
Ending balance	389.4	344.6
Tobira [Member]
Business Acquisition [Line Items]
Beginning balance	255
Fair Value Adjustments and Accretion	9.3
Ending balance	264.3	255
Medicines 360 Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	43.1
Fair Value Adjustments and Accretion	43.3
Payments and Other	(6.7)
Ending balance	79.7	43.1
AqueSys Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	5.4
Fair Value Adjustments and Accretion	0.2
Ending balance	5.6	5.4
Oculeve Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	1.7
Ending balance	1.7	1.7
ForSight [Member]
Business Acquisition [Line Items]
Beginning balance	24.1
Fair Value Adjustments and Accretion	0.3
Ending balance	24.4	24.1
Forest Laboratories, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	13.6
Fair Value Adjustments and Accretion	1.2
Payments and Other	(2.3)
Ending balance	12.5	13.6
Other Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	1.7
Fair Value Adjustments and Accretion	(0.2)
Payments and Other	(0.3)
Ending balance	$ 1.2	$ 1.7

Fair Value Measurement - Chan_2

Fair Value Measurement - Changes in Fair Value of Royalty Receivable Recorded in Consolidated Statements of Operations (Detail) - Royalty Receivable [Member] $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2018	$ 50.3
Net transfers in to (out of) Level 3	0
Purchases, settlements, and other net	(1.1)
Net accretion and fair value adjustments	2.6
Balance as of December 31, 2019	$ 51.8

Commitments & Contingencies - A

Commitments & Contingencies - Additional Information (Detail)	Aug. 01, 2018USD ($)	Dec. 31, 2019USD ($)TrademarkLitigationClaimPlaintiffDefendant	Dec. 31, 2019EUR (€)LitigationClaimPlaintiff	Dec. 31, 2018USD ($)
Loss Contingencies [Line Items]
Accrued loss contingencies		$ 1,190,000,000		$ 65,000,000
Accrual for settlements		$ 78,800,000
Sandoz [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Litigation plaintiff preliminary injunction bond amount	$ 157,300,000
Prinston [Member]
Loss Contingencies [Line Items]
Settlement agreement date		June 6, 2019	June 6, 2019
Sun And Sun Certain Affiliates
Loss Contingencies [Line Items]
Dismissal date		Jan. 18, 2018	Jan. 18, 2018
Aurobindo [Member]
Loss Contingencies [Line Items]
Dismissal date		May 7, 2018	May 7, 2018
Mylan [Member]
Loss Contingencies [Line Items]
Dismissal date		Dec. 27, 2018	Dec. 27, 2018
Dermavita Limited Partnership | Minimum [Member]
Loss Contingencies [Line Items]
Liquidated damages for violation of preliminary injunction | €			€ 75,000
Number of trademark opposition and cancellation pending | Trademark		150
Bystolic[Member] | Ajanta [Member]
Loss Contingencies [Line Items]
Settlement agreement date		December 17, 2019	December 17, 2019
Dismissal date		Jan. 2, 2020	Jan. 2, 2020
Juvederm | K B C Media Relations Limited Liability Company
Loss Contingencies [Line Items]
Settlement agreement date		June 2017	June 2017
Loestrin Twenty Four Litigation [Member]
Loss Contingencies [Line Items]
Accrued loss contingencies		$ 302,500,000
Namenda Litigation [Member]
Loss Contingencies [Line Items]
Principle to settle that litigation amount		$ 750,000,000
Celexa/Lexapro [Member]
Loss Contingencies [Line Items]
Settlement agreement date		September 2014	September 2014
Number of lawsuit filed | Litigation		2	2
Warner Chilcott Marketing Practices [Member] | Warner Chilcott Limited [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Claim		1	1
Generic Drug Pricing Securities Litigation [Member] | New Jersey [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Plaintiff		2	2
Prescription Drug Abuse Litigation [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendant cases pending | Defendant		2,000

Commitments & Contingencies -_2

Commitments & Contingencies - Additional Information 1 (Detail)	Dec. 28, 2015Product	Dec. 31, 2019PlaintiffDefendantCasesPatent
Botox [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Product	2
Saint Regis Mohawk Tribe [Member] | Restasis [Member]
Loss Contingencies [Line Items]
Number of patents acquired | Patent		6
Actonel Litigation [Member] | Product Liability Litigation [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendant cases		500
Actonel Litigation [Member] | Product Liability Litigation [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | Plaintiff		2
Actonel Litigation [Member] | Product Liability Litigation [Member] | Pending Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending		3
Breast Implant Litigation | Product Liability Litigation [Member] | Canada [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of plaintiffs		38
Celexa/Lexapro [Member] | Product Liability Litigation [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendant cases | Defendant		150
RepliForm Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending		3
RepliForm Litigation [Member] | Product Liability Litigation [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendant cases		300

Warner Chilcott Limited ("WCL_3

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Balance Sheets (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,503.3		$ 880.4
Marketable securities	3,411.6		1,026.9
Accounts receivable, net	3,192.3		2,868.1
Inventories	1,133.1		846.9
Current assets held for sale			34
Prepaid expenses and other current assets	886.4		819.1
Total current assets	11,126.7		6,475.4
Property, plant and equipment, net	1,926.5		1,787
Right of use asset - operating leases	490.4	$ 462.1
Investments and other assets	408		1,970.6
Non current assets held for sale	31.7		882.2
Deferred tax assets	576.9		1,063.7
Product rights and other intangibles	37,890.6		43,695.4	$ 54,648.3
Goodwill	42,248.3		45,913.3
Total assets	94,699.1		101,787.6
Current liabilities:
Accounts payable and accrued expenses	6,348.7		4,787.2
Income taxes payable	65.1		72.4
Current portion of long-term debt and capital leases	4,532.5		868.3
Current portion of lease liability - operating	124.4
Total current liabilities	11,070.7		5,727.9
Long-term debt and capital leases	18,116.5		22,929.4
Lease liability - operating	446.1
Other long-term liabilities	800.9		882
Other taxes payable	1,704.8		1,615.5
Deferred tax liabilities	4,363.7		5,501.8
Total liabilities	36,502.7		36,656.6
Total equity / (deficit)	58,196.4		65,131	73,837.1	$ 76,200.5
Total liabilities and equity	94,699.1		101,787.6
Warner Chilcott Limited Parent Guarantor [Member]
Current assets:
Cash and cash equivalents	0.1		0.1	0.1	0.1
Total current assets	0.1		0.1
Investment in subsidiaries	55,891.8		62,940.2
Total assets	55,891.9		62,940.3
Current liabilities:
Total equity / (deficit)	55,891.9		62,940.3
Total liabilities and equity	55,891.9		62,940.3
Allergan Capital S.a.r.l. (Guarantor) [Member]
Current assets:
Cash and cash equivalents	1.6		1.8	593.1	513.9
Marketable securities			489.9
Intercompany receivables	6,508		3,534.7
Total current assets	6,509.6		4,026.4
Investment in subsidiaries	76,855.8		73,846
Non current intercompany receivables			28,239.4
Deferred tax assets	49.6		43.6
Total assets	83,415		106,155.4
Current liabilities:
Accounts payable and accrued expenses	0.1		0.1
Intercompany payables	3,544.4		14,315
Total current liabilities	3,544.5		14,315.1
Long-term intercompany payables			18,597.4
Total liabilities	3,544.5		32,912.5
Total equity / (deficit)	79,870.5		73,242.9
Total liabilities and equity	83,415		106,155.4
Allergan Funding SCS (Issuer) [Member]
Current assets:
Cash and cash equivalents	0.1		0.8	0.1
Intercompany receivables	154		961
Total current assets	154.1		961.8
Investment in subsidiaries	21,016.7		22,656.5
Non current intercompany receivables			18,090.2
Total assets	21,170.8		41,708.5
Current liabilities:
Accounts payable and accrued expenses	155.2		156.3
Intercompany payables	930.6		21.7
Income taxes payable	2.4
Current portion of long-term debt and capital leases	3,008.2		779.6
Total current liabilities	4,096.4		957.6
Long-term debt and capital leases	14,742.1		18,090.2
Total liabilities	18,838.5		19,047.8
Total equity / (deficit)	2,332.3		22,660.7
Total liabilities and equity	21,170.8		41,708.5
Allergan Finance LLC (Issuer and Guarantor) [Member]
Current assets:
Intercompany receivables	40.5		16.7
Prepaid expenses and other current assets	33.3		33.3
Total current assets	73.8		50
Investment in subsidiaries	83,155.2		86,628.2
Total assets	83,229		86,678.2
Current liabilities:
Accounts payable and accrued expenses	97.3		92.9
Intercompany payables	10,455.1		10,442.6
Total current liabilities	10,552.4		10,535.5
Long-term debt and capital leases	2,142.8		2,135.9
Long-term intercompany payables	1,156.6		1,076.8
Total liabilities	13,851.8		13,748.2
Total equity / (deficit)	69,377.2		72,930
Total liabilities and equity	83,229		86,678.2
Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	2,495.3		875.9	1,223	1,199.2
Marketable securities	3,411.6		537
Accounts receivable, net	3,192.3		2,868.1
Receivables from Parents	409.3		640.9
Inventories	1,133.1		846.9
Intercompany receivables	14,930.1		24,779.3
Current assets held for sale			34
Prepaid expenses and other current assets	853.1		785.4
Total current assets	26,424.8		31,367.5
Property, plant and equipment, net	1,926.5		1,787
Right of use asset - operating leases	490.4
Investments and other assets	408		1,970.6
Non current intercompany receivables	1,156.6		19,674.2
Non current assets held for sale	31.7		882.2
Deferred tax assets	527.3		1,020.1
Product rights and other intangibles	37,890.6		43,695.4
Goodwill	42,248.3		45,913.3
Total assets	111,104.2		146,310.3
Current liabilities:
Accounts payable and accrued expenses	6,094.4		4,538.1
Intercompany payables	6,702.5		4,512.4
Payables to Parents	2,715.5		2,829.2
Income taxes payable	62.7		72.4
Current portion of long-term debt and capital leases	1,524.3		88.7
Current portion of lease liability - operating	124.4
Total current liabilities	17,223.8		12,040.8
Long-term debt and capital leases	1,231.6		2,703.3
Lease liability - operating	446.1
Other long-term liabilities	801.4		882
Long-term intercompany payables			46,329.6
Other taxes payable	1,698.6		1,615.5
Deferred tax liabilities	4,363.2		5,501.8
Total liabilities	25,764.7		69,073
Total equity / (deficit)	85,339.5		77,237.3
Total liabilities and equity	111,104.2		146,310.3
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	2,497.1		878.6	1,816.3	1,713.2
Marketable securities	3,411.6		1,026.9
Accounts receivable, net	3,192.3		2,868.1
Receivables from Parents	409.3		640.9
Inventories	1,133.1		846.9
Current assets held for sale			34
Prepaid expenses and other current assets	886.4		818.7
Total current assets	11,529.8		7,114.1
Property, plant and equipment, net	1,926.5		1,787
Right of use asset - operating leases	490.4
Investments and other assets	408		1,970.6
Non current assets held for sale	31.7		882.2
Deferred tax assets	576.9		1,063.7
Product rights and other intangibles	37,890.6		43,695.4
Goodwill	42,248.3		45,913.3
Total assets	95,102.2		102,426.3
Current liabilities:
Accounts payable and accrued expenses	6,347		4,787.4
Payables to Parents	2,715.5		2,829.2
Income taxes payable	65.1		72.4
Current portion of long-term debt and capital leases	4,532.5		868.3
Current portion of lease liability - operating	124.4
Total current liabilities	13,784.5		8,557.3
Long-term debt and capital leases	18,116.5		22,929.4
Lease liability - operating	446.1
Other long-term liabilities	801.4		882
Other taxes payable	1,698.6		1,615.5
Deferred tax liabilities	4,363.2		5,501.8
Total liabilities	39,210.3		39,486
Total equity / (deficit)	55,891.9		62,940.3	$ 81,282.2	$ 88,093.5
Total liabilities and equity	95,102.2		102,426.3
Eliminations [Member]
Current assets:
Intercompany receivables	(21,632.6)		(29,291.7)
Total current assets	(21,632.6)		(29,291.7)
Investment in subsidiaries	(236,919.5)		(246,070.9)
Non current intercompany receivables	(1,156.6)		(66,003.8)
Total assets	(259,708.7)		(341,366.4)
Current liabilities:
Intercompany payables	(21,632.6)		(29,291.7)
Total current liabilities	(21,632.6)		(29,291.7)
Long-term intercompany payables	(1,156.6)		(66,003.8)
Total liabilities	(22,789.2)		(95,295.5)
Total equity / (deficit)	(236,919.5)		(246,070.9)
Total liabilities and equity	$ (259,708.7)		$ (341,366.4)

Warner Chilcott Limited ("WCL_4

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Operations and Comprehensive (Loss) / Income (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Income Statements Captions [Line Items]
Net revenues	$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									2,493.1	2,191.4	2,168
Research and development									1,812	2,266.2	2,100.1
Selling and marketing									3,461.7	3,250.6	3,514.8
Amortization									5,856.6	6,552.3	7,197.1
Goodwill impairments									3,552.8	2,841.1
Asset sales and impairments, net									440.2	2,857.6	3,927.7
Total operating expenses									20,534.2	22,035	21,861.9
Operating (loss)									(4,445.3)	(6,247.6)	(5,921.2)
Other income / (expense), net									32.8	256.7	(3,437.3)
Total other income (expense), net									(673.4)	(609.3)	(4,465.2)
Income / (loss) before income taxes and noncontrolling interest									(5,118.7)	(6,856.9)	(10,386.4)
(Benefit) / provision for income taxes									146.4	(1,770.7)	(6,670.4)
Net income / (loss) from continuing operations, net of tax									(5,265.1)	(5,086.2)	(3,716)
(Loss) / income from discontinued operations, net of tax											(402.9)
Net (loss) / income	$ (317.3)	$ (785.6)	$ (1,754.9)	$ (2,407.3)	$ (4,295.9)	$ (36.3)	$ (470.1)	$ (283.9)	(5,265.1)	(5,086.2)	(4,118.9)
(Income) attributable to noncontrolling interest									(5.9)	(10.2)	(6.6)
Other comprehensive (loss) / income, net of tax									(138)	(512.5)	2,959.1
Warner Chilcott Limited Parent Guarantor [Member]
Operating expenses:
Losses / (earnings) of equity interest subsidiaries									5,120	4,772.1	3,927.3
Net income / (loss) from continuing operations, net of tax									(5,120)	(4,772.1)	(3,927.3)
Net (loss) / income									(5,120)	(4,772.1)	(3,927.3)
Net (loss) / income attributable to members									(5,120)	(4,772.1)	(3,927.3)
Other comprehensive (loss) / income, net of tax									(138)	(512.5)	2,959.1
Comprehensive (loss) / income attributable to members									(5,258)	(5,284.6)	(968.2)
Allergan Capital S.a.r.l. (Guarantor) [Member]
Operating expenses:
Interest income / (expense), net									3.8	1,101.1	845.5
Total other income (expense), net									3.8	1,101.1	845.5
Income / (loss) before income taxes and noncontrolling interest									3.8	1,101.1	845.5
(Benefit) / provision for income taxes									1.8	(23.8)	5
Losses / (earnings) of equity interest subsidiaries									5,070	5,719.1	4,517.5
Net income / (loss) from continuing operations, net of tax									(5,068)	(4,594.2)	(3,677)
Net (loss) / income									(5,068)	(4,594.2)	(3,677)
Net (loss) / income attributable to members									(5,068)	(4,594.2)	(3,677)
Other comprehensive (loss) / income, net of tax									(400)	(599.3)	3,001.5
Comprehensive (loss) / income attributable to members									(5,468)	(5,193.5)	(675.5)
Allergan Funding SCS (Issuer) [Member]
Operating expenses:
General and administrative											8.6
Total operating expenses											8.6
Operating (loss)											(8.6)
Interest income / (expense), net									(598.3)	(8.8)	116.6
Other income / (expense), net									(0.1)	15.6	(110.4)
Total other income (expense), net									(598.4)	6.8	6.2
Income / (loss) before income taxes and noncontrolling interest									(598.4)	6.8	(2.4)
(Benefit) / provision for income taxes										3.5	0.3
Losses / (earnings) of equity interest subsidiaries									533.6	280.7	1,958.1
Net income / (loss) from continuing operations, net of tax									(1,132)	(277.4)	(1,960.8)
Net (loss) / income									(1,132)	(277.4)	(1,960.8)
Net (loss) / income attributable to members									(1,132)	(277.4)	(1,960.8)
Other comprehensive (loss) / income, net of tax									(1,106.2)	587.2	(643.8)
Comprehensive (loss) / income attributable to members									(2,238.2)	309.8	(2,604.6)
Allergan Finance LLC (Issuer and Guarantor) [Member]
Operating expenses:
General and administrative											1.1
Total operating expenses											1.1
Operating (loss)											(1.1)
Interest income / (expense), net									(79.8)	(82.8)	(131.2)
Other income / (expense), net											(66.7)
Total other income (expense), net									(79.8)	(82.8)	(197.9)
Income / (loss) before income taxes and noncontrolling interest									(79.8)	(82.8)	(199)
(Benefit) / provision for income taxes										(50.7)	(177.3)
Losses / (earnings) of equity interest subsidiaries									(251.3)	250.1	752.7
Net income / (loss) from continuing operations, net of tax									171.5	(282.2)	(774.4)
Net (loss) / income									171.5	(282.2)	(774.4)
Net (loss) / income attributable to members									171.5	(282.2)	(774.4)
Other comprehensive (loss) / income, net of tax									(3,724.3)	2,013	(2,203.7)
Comprehensive (loss) / income attributable to members									(3,552.8)	1,730.8	(2,978.1)
Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Net revenues									16,088.9	15,787.4	15,940.7
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									2,493.1	2,191.4	2,168
Research and development									1,812	2,266.2	2,100.1
Selling and marketing									3,461.7	3,250.6	3,514.8
General and administrative									2,330.8	1,177.5	1,392.6
Amortization									5,856.6	6,552.3	7,197.1
Goodwill impairments									3,552.8	2,841.1
In-process research and development impairments									436	804.6	1,452.3
Asset sales and impairments, net									440.2	2,857.6	3,927.7
Total operating expenses									20,383.2	21,941.3	21,752.6
Operating (loss)									(4,294.3)	(6,153.9)	(5,811.9)
Interest income / (expense), net									(31.9)	(1,650.6)	(1,760.2)
Other income / (expense), net									32.9	241.1	(3,260.2)
Total other income (expense), net									1	(1,409.5)	(5,020.4)
Income / (loss) before income taxes and noncontrolling interest									(4,293.3)	(7,563.4)	(10,832.3)
(Benefit) / provision for income taxes									144.6	(1,705.4)	(6,498.4)
Net income / (loss) from continuing operations, net of tax									(4,437.9)	(5,858)	(4,333.9)
(Loss) / income from discontinued operations, net of tax											(402.9)
Net (loss) / income									(4,437.9)	(5,858)	(4,736.8)
(Income) attributable to noncontrolling interest									(5.9)	(10.2)	(6.6)
Net (loss) / income attributable to members									(4,443.8)	(5,868.2)	(4,743.4)
Other comprehensive (loss) / income, net of tax									(138)	(512.5)	2,959.1
Comprehensive (loss) / income attributable to members									(4,581.8)	(6,380.7)	(1,784.3)
Warner Chilcott Limited [Member]
Condensed Income Statements Captions [Line Items]
Net revenues									16,088.9	15,787.4	15,940.7
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									2,493.1	2,191.4	2,168
Research and development									1,812	2,266.2	2,100.1
Selling and marketing									3,461.7	3,250.6	3,514.8
General and administrative									2,330.8	1,177.5	1,402.3
Amortization									5,856.6	6,552.3	7,197.1
Goodwill impairments									3,552.8	2,841.1
In-process research and development impairments									436	804.6	1,452.3
Asset sales and impairments, net									440.2	2,857.6	3,927.7
Total operating expenses									20,383.2	21,941.3	21,762.3
Operating (loss)									(4,294.3)	(6,153.9)	(5,821.6)
Interest income / (expense), net									(706.2)	(641.1)	(929.3)
Other income / (expense), net									32.8	256.7	(3,437.3)
Total other income (expense), net									(673.4)	(384.4)	(4,366.6)
Income / (loss) before income taxes and noncontrolling interest									(4,967.7)	(6,538.3)	(10,188.2)
(Benefit) / provision for income taxes									146.4	(1,776.4)	(6,670.4)
Net income / (loss) from continuing operations, net of tax									(5,114.1)	(4,761.9)	(3,517.8)
(Loss) / income from discontinued operations, net of tax											(402.9)
Net (loss) / income									(5,114.1)	(4,761.9)	(3,920.7)
(Income) attributable to noncontrolling interest									(5.9)	(10.2)	(6.6)
Net (loss) / income attributable to members									(5,120)	(4,772.1)	(3,927.3)
Other comprehensive (loss) / income, net of tax									(138)	(512.5)	2,959.1
Comprehensive (loss) / income attributable to members									(5,258)	(5,284.6)	(968.2)
Eliminations [Member]
Operating expenses:
Losses / (earnings) of equity interest subsidiaries									(10,472.3)	(11,022)	(11,155.6)
Net income / (loss) from continuing operations, net of tax									10,472.3	11,022	11,155.6
Net (loss) / income									10,472.3	11,022	11,155.6
Net (loss) / income attributable to members									10,472.3	11,022	11,155.6
Other comprehensive (loss) / income, net of tax									5,368.5	(1,488.4)	(3,113.1)
Comprehensive (loss) / income attributable to members									$ 15,840.8	$ 9,533.6	$ 8,042.5

Warner Chilcott Limited ("WCL_5

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities:
Net (loss) / income	$ (317.3)	$ (785.6)	$ (1,754.9)	$ (2,407.3)	$ (4,295.9)	$ (36.3)	$ (470.1)	$ (283.9)	$ (5,265.1)	$ (5,086.2)	$ (4,118.9)
Depreciation									204.5	196.3	171.5
Provision for inventory reserve									160.2	96.4	102.2
Share-based compensation									214.3	239.8	293.3
Deferred income tax benefit									(660.9)	(1,255.7)	(7,783.1)
Goodwill impairments									3,552.8	2,841.1
In-process research and development impairments									436	804.6	1,452.3
Loss on asset sales and impairments, net									440.2	2,857.6	3,927.7
Non-cash extinguishment of debt									0.2	30	(15.7)
Amortization of deferred financing costs									17.5	22.6	27.8
Amortization of right of use assets									130.9
Contingent consideration adjustments, including accretion									54.1	(106.5)	(133.2)
Other, net									(5.5)	29	(37)
(Gain) loss on sale of Teva securities, net										(60.9)	62.9
Gain on sale of businesses										(182.6)
Cash (discount) / charge related to extinguishment of debt										(45.6)	205.6
Charge to settle Teva related matters											387.4
Amortization of inventory step-up											131.7
Net cash provided by operating activities									7,238.7	5,640.1	6,079
Net (loss) / income	(317.3)	$ (785.6)	$ (1,754.9)	(2,407.3)	(4,295.9)	$ (36.3)	$ (470.1)	(283.9)	(5,265.1)	(5,086.2)	(4,118.9)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									7,238.7	5,640.1	6,079
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(375.2)	(253.5)	(349.9)
Additions to product rights and other intangibles									(58.3)		(614.3)
Additions to investments									(3,938)	(2,471.7)	(9,783.8)
Proceeds from sale of investments and other assets									1,569.6	6,259.3	15,153.3
Acquisitions of businesses, net of cash acquired									(80.6)		(5,290.4)
Proceeds from sales of property, plant and equipment									23.7	30.4	7.1
Net cash provided by / (used in) investing activities									(2,858.8)	3,098.5	(878)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									11.9	2,657	3,550
Payments on debt, including capital lease obligations and credit facility									(1,044.9)	(8,804.5)	(6,413.6)
Debt issuance and other financing costs										(10.4)	(20.6)
Payments of contingent consideration and other financing									(9.3)	(30.9)	(511.6)
Net cash (used in) financing activities									(2,766.1)	(9,680.1)	(5,129.2)
Cash charge related to extinguishment of debt											(205.6)
Effect of currency exchange rate changes on cash and cash equivalents									9.1	4.7	21.4
Cash and cash equivalents at beginning of period				880.4					880.4
Cash and cash equivalents at end of period	2,503.3				880.4				2,503.3	880.4
Warner Chilcott Limited Parent Guarantor [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(5,120)	(4,772.1)	(3,927.3)
Losses / (earnings) of equity interest subsidiaries									5,120	4,772.1	3,927.3
Dividends from subsidiaries									1,774.3	4,075.6	1,668.2
Net cash provided by operating activities									1,774.3	4,075.6	1,668.2
Net (loss) / income									(5,120)	(4,772.1)	(3,927.3)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									1,774.3	4,075.6	1,668.2
Cash Flows From Financing Activities:
Dividend to Parents									(1,774.3)	(4,075.6)	(1,668.2)
Net cash (used in) financing activities									(1,774.3)	(4,075.6)	(1,668.2)
Cash and cash equivalents at beginning of period				0.1				0.1	0.1	0.1	0.1
Cash and cash equivalents at end of period	0.1				0.1				0.1	0.1	0.1
Allergan Capital S.a.r.l. (Guarantor) [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(5,068)	(4,594.2)	(3,677)
Losses / (earnings) of equity interest subsidiaries									5,070	5,719.1	4,517.5
Other, net											(10)
Changes in assets and liabilities (net of effects of acquisitions)									(291.6)	(1,626.3)	(4,228.1)
Net cash provided by operating activities									(289.6)	(501.4)	(3,397.6)
Net (loss) / income									(5,068)	(4,594.2)	(3,677)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									(289.6)	(501.4)	(3,397.6)
Cash Flows From Investing Activities:
Additions to investments									(100)	(889.9)	(4,389.6)
Proceeds from sale of investments and other assets									389.4	800	7,866.4
Net cash provided by / (used in) investing activities									289.4	(89.9)	3,476.8
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility										700
Payments on debt, including capital lease obligations and credit facility										(700)
Net (decrease) / increase in cash and cash equivalents									(0.2)	(591.3)	79.2
Cash and cash equivalents at beginning of period				1.8				593.1	1.8	593.1	513.9
Cash and cash equivalents at end of period	1.6				1.8				1.6	1.8	593.1
Allergan Funding SCS (Issuer) [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(1,132)	(277.4)	(1,960.8)
Losses / (earnings) of equity interest subsidiaries									533.6	280.7	1,958.1
Non-cash extinguishment of debt										30	17.6
Amortization of deferred financing costs									15.9	21	23.3
Other, net									(5.2)	(5.6)
Changes in assets and liabilities (net of effects of acquisitions)									1,618.6	5,482	(241.5)
Cash (discount) / charge related to extinguishment of debt										(45.6)	91.6
Net cash provided by operating activities									1,030.9	5,485.1	(111.7)
Net (loss) / income									(1,132)	(277.4)	(1,960.8)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									1,030.9	5,485.1	(111.7)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility										1,919.7	3,020.9
Payments on debt, including capital lease obligations and credit facility									(1,031.6)	(7,393.7)	(2,800)
Debt issuance and other financing costs										(10.4)	(17.5)
Net cash (used in) financing activities									(1,031.6)	(5,484.4)	111.8
Cash charge related to extinguishment of debt											(91.6)
Net (decrease) / increase in cash and cash equivalents									(0.7)	0.7	0.1
Cash and cash equivalents at beginning of period				0.8				0.1	0.8	0.1
Cash and cash equivalents at end of period	0.1				0.8				0.1	0.8	0.1
Non-Guarantors [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(4,437.9)	(5,858)	(4,736.8)
Depreciation									204.5	196.3	171.5
Amortization									5,856.6	6,552.3	7,197.1
Provision for inventory reserve									160.2	96.4	102.2
Share-based compensation									214.3	239.8	293.3
Deferred income tax benefit									(660.9)	(1,255.7)	(7,783.1)
Goodwill impairments									3,552.8	2,841.1
In-process research and development impairments									436	804.6	1,452.3
Loss on asset sales and impairments, net									440.2	2,857.6	3,927.7
Non-cash extinguishment of debt									0.2		(45.5)
Amortization of right of use assets									130.9
Contingent consideration adjustments, including accretion									54.1	(106.5)	(133.2)
Other, net									1.4	36.3	(27)
Changes in assets and liabilities (net of effects of acquisitions)									591.1	(5,152.4)	3,207.3
(Gain) loss on sale of Teva securities, net										(60.9)
Gain on sale of businesses										(182.6)
Cash (discount) / charge related to extinguishment of debt											61.1
Net income impact of other-than-temporary loss on investment in Teva securities											3,273.5
Charge to settle Teva related matters											387.4
Loss on forward sale of investment											62.9
Amortization of inventory step-up											131.7
Net cash provided by operating activities									6,543.5	1,008.3	7,542.4
Net (loss) / income									(4,437.9)	(5,858)	(4,736.8)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									6,543.5	1,008.3	7,542.4
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(375.2)	(253.5)	(349.9)
Additions to product rights and other intangibles									(58.3)		(614.3)
Additions to investments									(3,838)	(1,581.8)	(5,394.2)
Proceeds from sale of investments and other assets									1,180.2	5,459.3	7,286.9
Payments to settle Teva related matters										(466)
Acquisitions of businesses, net of cash acquired									(80.6)		(5,290.4)
Proceeds from sales of property, plant and equipment									23.7	30.4	7.1
Net cash provided by / (used in) investing activities									(3,148.2)	3,188.4	(4,354.8)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									11.9	37.3	529.1
Payments on debt, including capital lease obligations and credit facility									(13.3)	(710.8)	(1,470.3)
Debt issuance and other financing costs											(3.1)
Payments of contingent consideration and other financing									(9.3)	(30.9)	(511.6)
Dividend to Parents									(1,774.3)	(4,075.6)	(1,668.2)
Net cash (used in) financing activities									(1,785)	(4,548.5)	(3,185.2)
Proceeds from forward sale of Teva securities										465.5
Payments to settle Teva related matters										(234)
Cash charge related to extinguishment of debt											(61.1)
Effect of currency exchange rate changes on cash and cash equivalents									9.1	4.7	21.4
Net (decrease) / increase in cash and cash equivalents									1,619.4	(347.1)	23.8
Cash and cash equivalents at beginning of period				875.9				1,223	875.9	1,223	1,199.2
Cash and cash equivalents at end of period	2,495.3				875.9				2,495.3	875.9	1,223
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(5,114.1)	(4,761.9)	(3,920.7)
Depreciation									204.5	196.3	171.5
Amortization									5,856.6	6,552.3	7,197.1
Provision for inventory reserve									160.2	96.4	102.2
Share-based compensation									214.3	239.8	293.3
Deferred income tax benefit									(660.9)	(1,255.7)	(7,783.1)
Goodwill impairments									3,552.8	2,841.1
In-process research and development impairments									436	804.6	1,452.3
Loss on asset sales and impairments, net									440.2	2,857.6	3,927.7
Non-cash extinguishment of debt									0.2	30	(15.7)
Amortization of deferred financing costs									17.5	22.6	27.8
Amortization of right of use assets									130.9
Contingent consideration adjustments, including accretion									54.1	(106.5)	(133.2)
Other, net									(5.5)	29	(37)
Changes in assets and liabilities (net of effects of acquisitions)									1,998	(1,264.5)	886
(Gain) loss on sale of Teva securities, net										(60.9)	62.9
Gain on sale of businesses										(182.6)
Cash (discount) / charge related to extinguishment of debt										(45.6)	205.6
Net income impact of other-than-temporary loss on investment in Teva securities											3,273.5
Charge to settle Teva related matters											387.4
Loss on forward sale of investment											62.9
Amortization of inventory step-up											131.7
Net cash provided by operating activities									7,284.8	5,992	6,229.3
Net (loss) / income									(5,114.1)	(4,761.9)	(3,920.7)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									7,284.8	5,992	6,229.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(375.2)	(253.5)	(349.9)
Additions to product rights and other intangibles									(58.3)		(614.3)
Additions to investments									(3,938)	(2,471.7)	(9,783.8)
Proceeds from sale of investments and other assets									1,569.6	6,259.3	15,153.3
Payments to settle Teva related matters										(466)
Acquisitions of businesses, net of cash acquired									(80.6)		(5,290.4)
Proceeds from sales of property, plant and equipment									23.7	30.4	7.1
Net cash provided by / (used in) investing activities									(2,858.8)	3,098.5	(878)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									11.9	2,657	3,550
Payments on debt, including capital lease obligations and credit facility									(1,044.9)	(8,804.5)	(6,413.6)
Debt issuance and other financing costs										(10.4)	(20.6)
Payments of contingent consideration and other financing									(9.3)	(30.9)	(511.6)
Dividend to Parents									(1,774.3)	(4,075.6)	(1,668.2)
Net cash (used in) financing activities									(2,816.6)	(10,032.9)	(5,269.6)
Proceeds from forward sale of Teva securities										465.5
Payments to settle Teva related matters										(234)
Cash charge related to extinguishment of debt											(205.6)
Effect of currency exchange rate changes on cash and cash equivalents									9.1	4.7	21.4
Net (decrease) / increase in cash and cash equivalents									1,618.5	(937.7)	103.1
Cash and cash equivalents at beginning of period				$ 878.6				$ 1,816.3	878.6	1,816.3	1,713.2
Cash and cash equivalents at end of period	$ 2,497.1				$ 878.6				2,497.1	878.6	1,816.3
Allergan Finance LLC (Issuer and Guarantor) [Member]
Cash Flows From Operating Activities:
Net (loss) / income									171.5	(282.2)	(774.4)
Losses / (earnings) of equity interest subsidiaries									(251.3)	250.1	752.7
Non-cash extinguishment of debt											12.2
Amortization of deferred financing costs									1.6	1.6	4.5
Other, net									(1.7)	(1.7)
Changes in assets and liabilities (net of effects of acquisitions)									79.9	32.2	2,148.3
Cash (discount) / charge related to extinguishment of debt											52.9
Net cash provided by operating activities											2,196.2
Net (loss) / income									171.5	(282.2)	(774.4)
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities											2,196.2
Cash Flows From Financing Activities:
Payments on debt, including capital lease obligations and credit facility											(2,143.3)
Net cash (used in) financing activities											(2,196.2)
Cash charge related to extinguishment of debt											(52.9)
Eliminations [Member]
Cash Flows From Operating Activities:
Net (loss) / income									10,472.3	11,022	11,155.6
Losses / (earnings) of equity interest subsidiaries									(10,472.3)	(11,022)	(11,155.6)
Dividends from subsidiaries									(1,774.3)	(4,075.6)	(1,668.2)
Net cash provided by operating activities									(1,774.3)	(4,075.6)	(1,668.2)
Net (loss) / income									10,472.3	11,022	11,155.6
Reconciliation to net cash provided by operating activities:
Net cash provided by operating activities									(1,774.3)	(4,075.6)	(1,668.2)
Cash Flows From Financing Activities:
Dividend to Parents									1,774.3	4,075.6	1,668.2
Net cash (used in) financing activities									$ 1,774.3	$ 4,075.6	$ 1,668.2

Compensation - Schedule of Comp

Compensation - Schedule of Compensation Charges (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Compensation Related Costs [Line Items]
Wages and salaries	$ 2,193.2	$ 1,994.9	$ 1,892.8
Share-based compensation	214.3	239.8	308
Retirement plans	136	107	82.7
Social welfare (taxes)	143.3	163.1	150.4
Other benefits	152.5	175.2	265.1
Continuing Operations [Member]
Compensation Related Costs [Line Items]
Total compensation charges	$ 2,839.3	$ 2,680	$ 2,699

Concentration - Additional Info

Concentration - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019CustomerManufacturer	Dec. 31, 2018Customer
Concentration Risk [Line Items]
Number of customer outside the U.S and Canada in relation to 10% global sales	0
Percentage of gross accounts receivable due from largest customers	66.00%	62.00%
Number of largest customers	3	3
Concentration risk, supplier	No third party manufacturer accounted for 10% or more of the Company’s products sold based on third-party revenues for the year ended December 31, 2019.
Number of manufacturers accounted more than 10% of company's product sold | Manufacturer	0
U.S. and Canada [Member]
Concentration Risk [Line Items]
Percentage of other individual customers in relation to net revenues	10.00%
Percentage of individual customers in relation to global sales	10.00%
Customer Concentration Risk [Member] | Revenues [Member] | Minimum [Member]
Concentration Risk [Line Items]
Concentration risk percentage	10.00%

Concentration - Schedule of Con

Concentration - Schedule of Concentration on Revenues (Detail) - U.S. and Canada [Member] - Revenues [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
McKesson Corporation [Member]
Concentration Risk [Line Items]
Concentration risk percentage	25.00%	25.00%	23.00%
Cardinal Health, Inc. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24.00%	23.00%	19.00%
AmerisourceBergen Corporation [Member]
Concentration Risk [Line Items]
Concentration risk percentage	22.00%	22.00%	19.00%

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Valuation And Qualifying Accounts [Abstract]
Allowance for doubtful accounts, Balance at beginning of period	$ 101.7	$ 93	$ 75.7
Allowance for doubtful accounts, Charged to costs and expenses	35.8	18.5	11.6
Allowance for doubtful accounts, Deductions/ Write-offs	(26.7)	(9.8)	(1.7)
Allowance for doubtful accounts, Other			7.4
Allowance for doubtful accounts, Balance at end of period	110.8	101.7	93
Tax valuation allowance, Balance at beginning of period	1,637.9	403.8	183.9
Tax valuation allowance, Charged to costs and expenses	443.4	1,237.9	230.1
Tax valuation allowance, Other	(2.2)	(3.8)	(10.2)
Tax valuation allowance, Balance at end of period	$ 2,079.1	$ 1,637.9	$ 403.8

Supplementary Data - Quarterly

Supplementary Data - Quarterly Consolidated Financial Data and Market Price Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Selected Quarterly Financial Information [Abstract]
Net revenues	$ 4,351	$ 4,050.7	$ 4,090.1	$ 3,597.1	$ 4,079.7	$ 3,911.4	$ 4,124.2	$ 3,672.1	$ 16,088.9	$ 15,787.4	$ 15,940.7
Net (loss) / income	$ (317.3)	$ (785.6)	$ (1,754.9)	$ (2,407.3)	$ (4,295.9)	$ (36.3)	$ (470.1)	$ (283.9)	$ (5,265.1)	$ (5,086.2)	$ (4,118.9)
Basic earnings per share	$ (0.97)	$ (2.40)	$ (5.37)	$ (7.25)	$ (12.83)	$ (0.11)	$ (1.39)	$ (0.99)	$ (16.02)	$ (15.26)	$ (13.19)
Diluted earnings per share	(0.97)	(2.40)	(5.37)	(7.25)	(12.83)	(0.11)	(1.39)	(0.99)	$ (16.02)	$ (15.26)	$ (13.19)
Market price per share:
High	191.58	169.61	167.43	160.79	193.46	192.51	175.19	188.15
Low	$ 165.40	$ 156.34	$ 115.73	$ 132.09	$ 129.82	$ 167.21	$ 143.80	$ 144.02